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Uronic acids are an important class of monosaccharides and are defined as aldohexoses that 
have their primary alcohol oxidized to a carboxylic acid.1,2 Polysaccharides containing uronic 
acid entities are widely spread in Nature and display an array of physical properties and 
biological functions. A well known class of polysaccharides are the glycosaminoglycans 
(GAGs), which are composed of uronic acids linked to 2-acetamido-2-deoxyglycosides in an 
alternating fashion.3,4 Perhaps the best known member of the GAG-family is heparin, 
containing both D-glucuronic acid and L-iduronic acid moieties, that are interspaced with N-
acetyl-D-glucosamine residues.5 Other GAGs are the hyaluronan6 (assembled of D-glucuronic 
acid and N-acetyl-D-glucosamine) and the chondroitin7 (D-glucuronic acid and N-acetyl-D-
galactosamine) polysaccharides. A structurally and functionally distinct class of 
polysaccharides are the so-called homoglycuronans, which contain only uronic acid residues. 
Examples are alginate8 (composed of D-mannuronic acid and L-guluronic acid) and pectin9,10 







The structural complexity of uronic acid containing polysaccharides, combined with their 
diverse biological properties, has inspired many research groups to study their chemical 
synthesis. In general, the aim of these studies is the development of methodologies to 
introduce the required interglycosidic linkages and to apply these to construct 
oligosaccharides of a defined length and substitution pattern. These in turn are used in 
structure-function studies to determine the structural features that are at the basis of their 
biological properties. The potential of this general strategy is best illustrated by the extensive 
work on heparan sulfate, which led to the identification of a unique pentasaccharide sequence, 
which is at the basis of the anti-blood coagulation properties that characterize the natural 
polysaccharide.3b,11 Ensuing combined efforts at the Organon (Van Boeckel and coworkers) 
and Sanofi laboratories (Petitou and coworkers) led to the development of a closely related 
pentasaccharide as a drug (Arixtra®) for the treatment of thrombotic disease. 
In this Chapter some general strategies for the synthesis of uronic acid containing 
oligosaccharides are discussed. The focus is on the preparation and incorporation of the 
uronic acid building blocks.12 Two distinct strategies can be recognized. In most literature 
examples a target oligosaccharide is assembled from aldose building blocks, after which the 
appropriate primary hydroxyls are oxidized to carboxylates prior to or after global 
deprotection (post-glycosidation oxidation). The alternative general strategy entails the use of 
uronic acid building blocks in the glycosylation scheme (pre-glycosidation oxidation). 
Examples of both strategies will be presented, with a focus on the advantages and 




The most frequently used method for the construction of acidic oligosaccharides is the 
initial construction of the oligosaccharide followed by oxidation of (specific) primary 
hydroxyl groups to the desired carboxylic acid functionality. Following this post-
glycosidation approach, Ogawa and coworkers investigated the synthesis of α-(1→4)-
dodecagalactosiduronic acid extracted from plant cell wall isolates (Scheme 1).13,14,15 Starting 
from the fluoride donors 1 and 3 and acceptor 2, dodecasaccharide 4 was assembled in a 
straightforward manner using the Mukaiyama coupling conditions (SnCl2, AgClO4).16 All 
glycosylation reactions proceeded predominantly α-stereoselective, which was attributed to 
attack of the acceptor nucleophile from the α-side and coordination of the diethyl ether 
solvent shielding the β-face. 17,18 The secondary alcohol groups were masked as benzyl ethers 
whereas the primary positions destined for oxidation were capped with acetyl groups. After 
construction of dodecasaccharide 4, selective liberation of the primary hydroxyl groups by 
treatment with base gave dodeca-ol 5 in good yield. Swern oxidation19,20 of dodecasaccharide 







NaClO2 in water afforded expected dodecacarboxylic acid 6 in 50% overall yield. 





























































































More recently, the group of Madsen published a procedure towards defined tri- and 
hexasaccharide fragments of the homogalacturonans.21 Here, orthogonality between the 
primary and secondary alcohol positions was conferred by application of para-
methoxyphenyl (pMP) and benzyl protective groups. For the oxidation of all primary 
positions the two-step Dess-Martin periodinane22/NaClO2 protocol was employed. Compared 
to the Swern/NaClO2 protocol used by the group of Ogawa, lower oxidation efficiencies were 
found especially in the case of larger oligosaccharides. 
In a related study to elucidate the cleavage pattern of pectic enzymes, the group of Madsen 
embarked on the synthesis of defined, partly methyl-esterified fragments of the 
homogalacturonan polysaccharide.23 This pectic polysaccharide forms the primary cell wall 
matrix of all land plants and contributes to both the physical integrity and physiological status 
of the cell walls.24 Homogalacturonan is thought to be deposited in cell walls in a highly 
methyl-esterified form but can subsequently be de-esterified by pectin methyl esterases. 
Hence, the functionality of the pectin polysaccharide is largely determined by the pattern and 
degree of methyl esterification of the galacturonic acid backbone. In order to be able to 
introduce a partial methyl-esterification pattern in synthetic pectin oligosaccharides, the 
protective group strategy was slightly expanded. Acetyl protective groups were installed on 
the hydroxyl groups to be converted to methyl esters and para-methoxyphenyl protective 







the acetyl and para-methoxyphenyl protection along the oligosaccharide backbone all the 
different partly methyl-esterified oligosaccharides can in theory be obtained. A typical 
example is depicted in Scheme 2 and commences with trisaccharide 8, which was synthesized 
in a straightforward manner using the n-pentenyl glycosylation technique. After de-
acetylation under standard conditions (8 → 9) the two-step Dess-Martin periodinane/NaClO2 
oxidation protocol was applied. Reaction of the intermediate carboxylic acid with 
trimethylsilyldiazomethane afforded methyl ester 10. Subsequent cleavage of both para-
methoxyphenyl ethers (11) and oxidation of the residual primary alcohol positions yielded 
trisaccharide 12 bearing orthogonally functionalized carboxylate groups. Final de-benzylation 
under standard conditions provided target trisaccharide 13. By applying the same orthogonal 







































































Chromium based oxidation methods such as the strongly acidic Jones reagent26 and the 
milder pyridinium dichromate27 (Collins reagent, PDC) and pyridinium chlorochromate28 
(PCC) reagents have also found application in carbohydrate chemistry. Depending on the 
reaction conditions, either the carboxylic acids or the corresponding carboxylic esters are 
isolated. Disadvantages of these chromium based oxidations are purification problems and 
restricted choice of protective groups.29 A typical example on the use of PDC comes from the 
group of Vliegenthart and Kamerling in their synthesis of a pentasaccharide fragment (17) of 
the gut-associated circulating anodic antigen (CAA, Scheme 3).30 After complete assembly of 
pentasaccharide fragment 14 using trichloroacetimidate chemistry,31 the C6-OH levulinoyl 
protective groups on both glucose residues were selectively cleaved giving compound 15. 
Subsequent oxidation using the chromium(VI) oxidant system (PDC, Ac2O, cat. pyridine) 
gave uronic acid 16. Acetic anhydride is added to facilitate cleavage of chromium(VI) from 
the intermediate ester, thereby accelerating the reaction.32 Global deprotection yielded 







fragments of pentasaccharide 17 several other oxidation protocols (including PCC, Jones and 



























































































En route to the preparation of a pentasaccharide hapten of the Mycobacterium avium 
serovar 19, the group of Lipták explored the synthesis of uronates 20 and 23 (Scheme 4.).34 
Regioselective de-acetylation of the L-manno containing disaccharide 18 proceeded in good 
yield giving compound 19, whereas subjection of L-talo equipped disaccharide 21 to the same 
conditions gave diol 22.35 Jones oxidation of the primary alcohol in disaccharide 19 afforded 
the intermediate glucuronide, which was transformed into the the methyl ester (20) by 
treatment with an ethereal diazomethane solution. In order to achieve oxidation of diol 22, the 
















1) CrO3, 3.5M H2SO4
acetone












































co-oxidant, which reacts in situ with potassium bromide to generate the more reactive sodium 
hypobromite.37 Ensuing addition of methyl iodide and N,N-dimethylformamide (DMF) to the 







choice for a different oxidation method was guided by the presence of the unprotected 
secondary C2’ hydroxyl group, which could also be oxidized using chromium(VI)-based 
oxidants.38 
The finding that TEMPO is able to selectively oxidize primary hydroxyl functions in the 
presence of secondary hydroxyl groups has led to numerous applications of this reagent in 
oligosaccharide synthesis.36,39,40-48 Protective group manipulations to discriminate between 
primary and secondary hydroxyl groups have therefore become obsolete and orthogonality 
between the oxidized and the non-oxidized C6 positions is more easily attained. Depending 
on the amount of primary oxidant (co-oxidant) added and the reaction medium (anhydrous or 
aqueous) the oxidation reaction can be stopped at the aldehyde or carboxylic acid stage 
(Figure 1). Many primary oxidant systems have been reported including electro-oxidation,41 
m-chloroperbenzoic acid,42 high-valent metal salts,43 sodium bromite,44 sodium or calcium 
hypochlorite,37,40a,45 hypervalent iodine(III) salts,46,47 and trichloroisocyanuric acid.48 The 
actual oxidizing species in all these reagent combinations is the N-oxoammonium 
intermediate 24 generated in situ from reaction between TEMPO and the primary co-oxidant 
(Figure 1).36,49 Anhydrous conditions give rise to the aldehyde whereas in the presence of 
water, the aldehyde is hydrated, allowing further oxidation to the carboxylic acid. Van 
Bekkum and coworkers postulated the formation of reaction intermediates 26 and/or 27 








































En route towards synthetic fragments of the heparin polysaccharide, the group of Boons 
used TEMPO/NaOCl as a regioselective oxidation procedure (Scheme 5).51 Using 
trichloroacetimidate based glycosylation strategies trisaccharide 28 was obtained in good 
yields. In compound 28 the primary hydroxyl group in the glucosamine residues is protected 
as the tert-butyldiphenylsilyl (TBDPS)-ether. Oxidation of the two C6-OH functions (29) 
followed by desilylation gave target trisaccharide 30. It was reported that best selectivities 





















































As part of the construction of oligomeric structures corresponding to the capsular 
polysaccharide Streptococcus pneumoniae type 3, the group of Oscarson explored the 
synthesis of dimer 32 (Scheme 6).52 TEMPO-oxidation of the C6’ hydroxyl function of 
minimally protected disaccharide 31 gave target uronate 32 in only a moderate yield of 33%. 
As a side-product, substantial amounts of tri-uronate species 33 resulting from oxidative 
cleavage of the trans-diaxial diol (C2-OH C3-OH) system in compound 31 was isolated. 
Variation of the reaction conditions, such as other solvents and different pH-values met with 
similar failure. The unwanted side reaction was prevented by oxidizing partially protected 
disaccharide residues under biphasic dichloromethane (DCM)/H2O-conditions45a (see below) 













NaBr, NaOH, 4M HCl
H2O, pH = 10

























The group of Field studied the oxidation of di- (34), tri- (36) and tetrasaccharide (38) 
fragments of a rhamnogalacturonan-II polysaccharide using the TEMPO/NaOCl/KBr-reagent 
combination (Scheme 7).53 The presence of solely oxidized and/or deoxygenated C6 
functionalities allows the oxidation of completely unprotected precursors 34, 36 and 38. The 
yield of the reactions decreased with the increasing complexity of the oxidation targets. This 
trend can be explained by the increased steric bulk, which is found to be an important factor 
in oxidation reactions under alkaline conditions (see Figure 1).36,40 
Anelli and coworkers reported biphasic DCM/H2O as a highly suitable medium for 
TEMPO/NaOCl-mediated oxidations of partially protected oligosaccharides.45a It was 
revealed that under standard conditions, initial oxidation to the aldehyde is rather slow. 
Addition of the quaternary ammonium salt tetra-butylammonium bromide (TBABr) as a 
































































conditions, such as aqueous NaHCO3, increases both reactivity and selectivity for primary 
alcohols (see Figure 1.).50a Flitsch and coworkers applied this method for the first time on 
protected monosaccharide residues.45b Petillo and coworkers reported on the NaOBr-mediated 
oxidation of the partly protected trisaccharide 40 en route to hyaluronan oligosaccharide 41 
using the biphasic DCM/H2O-system (Scheme 8).54 Another example of this biphasic 
TEMPO-oxidation protocol is given by Litjens et al. in the synthesis of the repeating unit 



































40 41  
 
Recently, Huang and coworkers reported a two-step oxidation procedure for a partially 
protected hexasaccharadic hyaluronan fragment.56 Initial conversion of the substrate to the 
aldehyde using the TEMPO/NaOCl reagent combination is followed by further oxidation with 
sodium chlorite (NaClO2) to the corresponding uronic acid derivative. Increased lipophilicity 
of the substrate reduces the hydration rate of the intermediate aldehyde and thereby decreases 
the efficiency of the overall oxidation. This procedure, and in particular the use of NaClO2 in 
combination with tBuOH, is claimed to be less sensitive to changes in the hydrophobicity of 














In pre-glycosidation oxidation strategies, suitably protected donor and/or acceptor 
glycuronates are employed in the construction of acidic oligosaccharides. The presence of the 
electron withdrawing ester function make these uronic acids less reactive compared to their 
non-oxidized counterparts. Donor uronic acid derivatives that have found application in 
oligosaccharide synthesis over the years include anomeric bromides,57 fluorides,58 
orthoesters,59 trichloroacetimidates,60 n-pentenyl glycosides,61 and 1-thioglycosides.56  
The group of Ogawa investigated the glycosylation properties of protected galacturonic acid 
fluorides in the synthesis of truncated pectic polysaccharides (Scheme 10).58 Fluoride donor 
45 and acceptor allyl uronate 44 were synthesized from substrate 42 (Scheme 9). Jones 
oxidation not only led to a sluggish and incomplete reaction but also to migration of the 
chloroacetyl group to the thermodynamically favored C6 position. Catalytic oxidation using 
Pt/NaHCO3/H2O resulted in incomplete reactions. Swern oxidation of compound 42 followed 
by Jones oxidation of the intermediate aldehyde and subsequent treatment with ethereal 
diazomethane afforded uronic acid derivative 43 in a yield of 72%. Exchange of the anomeric 
allyl group (43) for a fluoride afforded uronate donor 45. Galacturonate acceptor 44 was 
obtained by treatment of fully protected compound 43 with thiourea. Takeda and coworkers 
also encountered problems during the synthesis of OH4-unprotected galacturonates and 
therefore opted for the post-glycosidation oxidation strategy in their synthesis of a pectic 





























EtOH, 70%  
 
Subjection of uronic acids 45 and 44 to Mukaiyama conditions (SnCl2, AgClO4)16 did not 
result in a productive glycosylation reaction, most probably due to the deactivating influence 
of the remotely attached uronic acid esters (Scheme 10). Indeed, application of galactosyl 
fluoride 46 as a more reactive donor gave α-linked disaccharide 48 in a yield of 42%. The 
yield was further improved by using non-oxidized, acetyl protected acceptor 47 instead, 
giving α-linked disaccharide 49 in 83% yield. From these results it can be concluded that the 
use of anomeric fluorides in combination with the Mukaiyama activation conditions is less 







Vogel and coworkers investigated the trityl-cyanoethylidene glycosidation method63,64 for 
the construction of acidic oligosaccharides.65 This method proved to be successful in the 
synthesis of β-(1→2)- and β-(1→3)-linked digalacturonic acid residues. The construction 
however, of the demanding β-(1→4)-linked dimers resulted in complex reaction mixtures 














































49: R=CH2OAc (83%)  
 
Westman and coworkers reported on the use of anomeric bromides and 1-thioglycuronides in 
the synthesis of defined fragments of a known glycosaminoglycan tetrasaccharide.67 In order 
to minimize protective group manipulations a block type synthesis strategy was chosen in 
combination with an orthogonal12e glycosylation strategy. Starting from peracetylated methyl 
glucuronate 50 the corresponding iduronic acid68 donor 51 was obtained using a radical 
initiated epimerization around C5 (Scheme 11).57a,b Iduronic acid 51 was then converted into 
bromide donor 52 upon treatment with a hydrogen bromide (HBr)-solution in acetic acid. 
Thio donor 54 was obtained by oxidation of compound 53 with PDC and acetic anhydride in a 
mixture of tert-butanol and DCM.69 In this process, the intermediate aldehyde is trapped by 
tert-butanol to give the tert-butyl hemiacetal, which is further oxidized to give tert-butyl 
uronate 54. No oxidation of the thiophenyl function to the corresponding sulfoxide or sulfone 
is reported. In an orthogonal glycosylation strategy, iduronic acid bromide 52 was condensed 
with ethylthio glucosazide 55 giving 1-thiodisaccharide 57 in a yield of 60%. The 1-
thioglucuronide 54 was glycosylated with acceptor 56 under the agency of 
dimethyl(methylthio)sulfonium triflate (DMTST) giving compound 58.70 The synthesis of 
tetrasaccharide 60 was completed by oxidative cleavage of the para-methoxybenzyl (pMB) 
group (58 → 59) and DMTST-mediated coupling between thiodisaccharide 57 and 
glucuronide acceptor 59. This approach highlights the usefulness of the stable 1-

























































































50: R1=COOMe, R2=H, R3=OAc
51: R1=H, R2=COOMe, R3=OAc





Another successful application of 1-thioglycuronic acid esters in acidic oligosaccharide 
synthesis was published by the group of Robert-Baudouy in their synthesis of defined 
fragments of the pectic polysaccharide.71,72 Chemoselective oxidation of the partially 
protected 1-thioglycoside 61 was accomplished using the PDC/Ac2O/tert-BuOH oxidation 
system (Scheme 12.). Exchange of the acid labile tert-butyl ester in compound 62 for either a 
benzyl or a methyl ester yielded galacturonates 63 and 64. The benzyl and methyl esters were 
introduced under acidic conditions to prevent putative β-elimination or epimerization 
reactions, which were earlier observed by the groups of Sinaÿ73 and Vogel.73,74,75 Direct 
application of the tert-butyl ester functionalized glycosides sometimes resulted in 
compromized coupling efficiencies due to the increased steric bulk.76 It was found that 
application of the N-iodosuccinimide (NIS)/trifluoromethanesulfonic acid (TfOH) activator 
system77 is successful in the α-stereoselective glycosidation of these deactivated galacturonate 















































Sinaÿ and coworkers published a study in which the glycosylation properties of n-pentenyl 
70, trichloroacetimidate 71, and 1-thio (75 + 76) and functionalized iduronic acid donors were 
compared (Scheme 13).61 Starting from 6-O-tert-butyldimethylsilyl protected 67 and 68, 
uronic acid esters 69 and 70 were obtained using Jones reagent (CrO3, 3.5M H2SO4) and 
subsequent methylation. Disaccharides could also be oxidized by this one-pot silyl 
cleavage/oxidation protocol although the yields dropped slightly.71 After oxidation, 1-O-
acetyl derivative 69 was transformed into the corresponding trichloroacetimidate donor 71 via 
a known sequence of reactions (α-Ac → α-Br → α/β-OH → α/β-OC(NH)CCl3). Jones 
oxidation of the corresponding 6-O-TBDMS functionalized phenylthio residue 72 proceeded 
less straightforward and, along with the desired 1-thio-α-L-iduronic acid ester 75 (26%), 
considerable amounts of sulfoxide and sulfone were isolated (together ~50%).78 Acidic 
cleavage of the silyl group (72 → 73) and oxidation using the milder pyridinium dichromate 
(PDC) gave a substantially improved yield of 1-thio iduronic acids 75 and 76 (both 52%). 
Table 1 summarizes the glycosidations performed with the donors 70 and 71. It can be 
concluded that trichloroacetimidate 71 and n-pentenyl glycoside 70 are equally efficient in 
glycosylating acceptors 78 and 79. On the other hand, the corresponding 1-thioiduronates 75 
and 76 did not yield the expected disaccharides using DMTST70 as activator.79 Closer 
inspection revealed that thiophenyl donor 75 was completely inert for DMTST activation 





























































The groups of Garegg and Oscarson investigated the use of 1-thioglycuronides in their 
study towards the synthesis of naturally occurring acidic polysaccharides isolated from 
Streptococcus pneumoniae and Cryptococcus neoformans.80 In agreement with the 




































































































and peracetyl methyl (β-D-glucopyranoside) uronate resulted in a moderate yield and low 
stereoselectivity. It was therefore decided to examine direct oxidation of suitably protected 
ethyl 1-thioglycoside 84 (Scheme 14). Oxidation was accomplished using a two-step 
oxidation protocol comprising first Pfitzner-Moffat oxidation82 of alcohol 84 to the 
intermediate aldehyde and ensuing treatment with excess PDC giving donor 86 in a yield of 
71%. In the same way, 2-O-acyl donor 87 was prepared from compound 85. Furthermore, 
basic hydrolysis of the 2-O-acetate (87 → 88) and reprotection yielded donor species 89, 90 
and 91. The glycosylation properties of donor 86, having a C2 benzyl group and donors 87, 
89, 90 and 91, having a C2 acyl group were investigated using acceptors 92 and 93 and 
DMTST as system. DMTST-mediated coupling of tri-O-benzyl 1-thioglucuronide 86 with 
acceptors 92 and 93 afforded the corresponding disaccharides 94 and 99 as anomeric 
mixtures. In a later study by the same group it was found that 2-O-benzylated 1-
thioglucuronide donors are sensitive to changes in reaction conditions, such as different 
promoter systems, different protective groups, and application of a participating solvent.83 







selectivity using tribenzylated donor 86 in methyl triflate-mediated glycosylations.84 On the 
other hand, glycosylations using 2-O-acylated donors 87 and 91 proved problematic whereas 

























99: R=Bn (69%, α/β=2/1)
100: R=Ac (33%, β)
101: R=Bz (69%, β)
102: R=MBz (60%, β)























94: R=Bn (76%, α/β=2/1)
95: R=Ac (25%, β)
96: R=Bz (68%, β)
97: R=MBz (65%, β)









































Van der Marel and coworkers recently published on the use of the TEMPO/ 
[bis(acetoxy)iodo]benzene (BAIB) reagent combination for the efficient oxidation of 
variously functionalized 1-thioglycosides (Figure 2).85,86 Both the starting glycoside (glucose, 
glucosamine, galactose, and idose) and the nature of the protective groups (benzyl, benzoyl, 
isopropylidene, tert-butyldimethylsilyl, azide, and phthalimide) can be varied without major 
implications on the outcome of the oxidation step. Furthermore, the mild oxidation conditions 
allow the presence of unprotected secondary hydroxyl functions and various substituted 1-thio 















































conditions afforded the corresponding uronic acids 10585 whereas 3,6-unprotected 
thioglycosides 107 resulted in a tandem oxidation/lactonization process giving the 
corresponding 6,3-lactones 108.86 Methyl ester 106 was obtained upon treatment of uronic 
acid 105 with ethereal diazomethane, and acidic cleavage of lactone 108 in MeOH gave 
methyl ester 109. In a related study using the TEMPO/NaClO2 oxidation system, Huang and 












a: R = piperidino (BSP)




The donor and acceptor properties of uronates 106 and 108 were investigated using the BSP 
(110a)/Tf2O87 or Ph2SO (110b)/Tf2O88 activator system (Figure 3). It was assumed that the 
electrophilic nature of these activator systems was sufficient to overcome the reduced 
nucleophilicity at the anomeric centre due to the remotely attached carboxyl function. Indeed, 
both activator systems proved successful in the glycosidation of oxidized gluco- and  
galactopyranosides, although activation had to be performed at slightly higher temperature    
(-40°C – -50°C) compared to the standard procedure. 
Comparison of the methyl uronate 112 and lactone 115 shows the latter to be more α-
selective in glycosidation reactions with the same acceptor molecule 113 (Table 2, entries 1 
and 2). Even fully acylated donor 117 was efficiently glycosidated with acceptor 113 under 
the agency of the BSP/Tf2O reagent combination (entry 3). Illustrative in this respect are the 
examples published by the groups of Garegg and Oscarson who had to install at least two 
activating benzyl functions or a 3,4-tetraisopropyldisiloxyl group at the thioglucuronate 
donors (for instance 89, Scheme 14.) to obtain sufficient activation with DMTST (see Scheme 
14).80 N-(benzyloxycarbonyl)-protected glucosamine 119 was efficiently employed as 
acceptor nucleophile giving, with full α-selectivity, disaccharide 120 (entry 4). This reaction 
proceeded slower than the other glycosidations, possibly due to reduced reactivity of the 
acceptor alcohol via intramolecular H-bonding.89 Glycosidations using the 1-thiomannuronic 
acid ester donors (e.g. 121) have different outcomes compared to their 1-thioglucuronic and 
galacturonic acid ester congeners (entry 5). The gluco- and galacto-configured uronate donors 
show preference for α-product formation, almost all the mannuronic acid derivatives 


























































































































a isolated yields b 2.5 equiv. TTBP c 1 equiv. TTBP d anomeric ratios were determined by 1H NMR spectroscopy. 
 
Crich91 and Bols,92 it is assumed that the strong electron-withdrawing nature of the remotely 
attached carboxyl group combined with the enlarged anomeric effect in the manno-series 
dictates the reaction towards the β-product. 
Scheme 15 displays the synthetic strategy for the assembly of the protected carbohydrate 
motif GlcpNAcα(1→4)-GlcpAα(1→2)Galf (127) present in the capsular polysaccharide of 
the Fungus Fusarium sp. M7-1.93 Activation of hemiacetal donor 123 with diphenylsulfonium 
bistriflate 111b in the presence of tri-tert-butylpyrimidine (TTBP)94 as a base and subsequent 
treatment with uronic acid acceptor 124 gave the α-linked thiodisaccharide 125 as the sole 
product in 67% yield (Scheme 3). In the second glycosylation event, disaccharide 125 was 







galactono-1,4-lactone 126 to give trisaccharide 127 as an anomeric mixture (α/β = 4/1) in a 
yield of 35%. Based on a related iterative, chemoselective glycosylation approach, Codée et 
al. described a modular synthesis approach towards a defined heparin pentasaccharide starting 




























































Scheme 16 depicts the strategy for the first synthesis of alginate trisaccharide 134.90 The 
synthesis starts from the non-reducing end monosaccharide 128 and makes use of levulinoyl 
groups as temporary protection. Unmasking of the Lev-group in disaccharide 130 afforded the 
new acceptor 131 which was condensed with donor 128 to give trisaccharide 132 in 50% 
yield. Global deprotection afforded alginate trisaccharide 133, which was recently reported as 
a potential ligand for Toll-like receptors 2 and 4. In the same way, 1-thio functionalized 
mannosaziduronic acid showed promise as donor and acceptor glycosides in carbohydrate 




















































132 : R1=Bn, R2=Lev, R3=Me, R4=N3



























This Chapter reviews the developments in the synthesis of acidic oligosaccharides. Both 
approaches for the introduction of uronic acid residues (that is, oxidation prior to or post 
glycosylation) in acidic oligosaccharides are discussed and typical examples are presented. It 
can be concluded that the post-glycosylation strategy requires an additional protective group 
manipulation and risks of losing valuable oligosaccharide compound during oxidation. The 
pre-glycosylation protocol avoids these difficulties although the reactivity at the anomeric 
centre is impaired compared to the non-oxidized counterparts. In general, the advent of 
TEMPO as oxidizing reagent largely stimulated the development of new and efficient ways 
for the synthesis of acidic oligosaccharides. In comparison to the other, more robust oxidation 
methods, the applied protective group pattern is only minimally restricted allowing the 
oxidation of partially or completely deprotected carbohydrate structures. Furthermore, it has 
inspired the development of techniques to employ oxidized monosaccharide residues as 
building blocks in acidic oligosaccharide synthesis. Especially, application of the versatile 
thiogluronic acid esters holds promise in the synthesis of complex acidic oligosaccharides. 
 
References and Notes 
 
1  Lindberg, B.; Kenne, L. The Polysaccharides, Aspinall G.O. ed., Academic Press, New York, 1985. 
2  Lindberg, B. Adv. Carbohydr. Chem. Biochem. 1990, 48, 279–318. 
3  (a) Thunberg, L.; Bäckstrom, G.; Lindahl, U. Carbohydr. Res. 1982, 100, 393–410 (b) Petitou, M.; Van 
 Boeckel, C.A.A. Angew. Chem. Int. Ed. 2004, 43, 3118–3133. 
4  (a) Lindahl, U.; Kusche-Gullberg, M.; Kjellén, L. J. Biol. Chem. 1998, 273, 24979–24982 (b) Esko, J.D.; 
 Lindahl, U. J. Clin. Invest., 2001, 108, 169–173. 
5  (a) Capila, I.; Linhardt, R.J. Angew. Chem. Int. Ed. 2002, 41, 391–412 (b) Hacker, U.; Nybakken, K.; 
 Perimon, N. Nat. Rev. Mol. Cell Biol. 2005, 6, 530–541. 
6  Laurent, T.C.; Fraser, J.R.E. FASEB J. 1992, 6, 2397–2404. 
7  Gama, C.I.; Tully, S.E.; Sotogaku, N.; Clark, P.M.; Rawat, M.; Vaidehi, N.; Goddard, W.A.; Nishi, A.; 
 Hsieh-Wilson, L.C. Nat. Chem. Biol. 2006, 2, 467–473. 
8  Moe, S.T.; Draget, K.I.; Skjak-Braek, G.; and Smidsrød, O. In Food Polysaccharides and Their 
 Applications, Stephen A.M. ed., Marcel Dekker, Inc., New York, 1995, 245–286.  
9  Mohnen, D. In Comprehensive Natural Products Chemistry, Barton, D. Nakanishi, K.; Meth-Noho, O. eds, 
 Elsevier Science Publishers BV, Amsterdam, 1999, Vol 3, 497–527. 
10 Modifications bearing rhamnose residues are known: Ridley, B.L.; O’Neill, M.A.; Mohnen, D.A. 
 Phytochemistry 2001, 57, 929–967. 
11  Bauer, K.A.; Hawkins, D.W.; Peters, P.C.; Petitou, M.; Herbert, J.-M.; Van Boeckel, C.A.A. Cardiovasc. 
 Drug Rev. 2002, 20, 37–52. 
12  See for reviews on the introduction of glycosidic linkages: (a) Paulsen, H. Angew. Chem. Int. Ed. Engl. 1982, 
 21, 155–224 (b) Boons, G.-J. Tetrahedron 1996, 52, 1095–1121 (c) Garegg, P.J. Adv. Chem. Biochem. 1997, 








 R.E.J.N.; Van den Bos, L.J.; Overkleeft, H.S.; Van der Marel, G.A. Chem. Soc. Rev. 2005, 34, 769–782 (f) 
 Demchenko, A.V. Lett. Org. Chem. 2005, 2, 580–589.  
13  Nakahara, Y.; Ogawa, T. Tetrahedron Lett. 1989, 30, 87–90. 
14  Other studies of the group of Ogawa on the synthesis of α-(1→4)-linked homogalacturonans: (a) 
 Nakahara, Y.; Ogawa, T. Carbohydr. Res. 1987, 167, C1–C7 (b) Nakahara, Y.; Ogawa, T. Carbohydr. Res. 
 1989, 194, 95–114 (c) Nakahara, Y.; Ogawa, T. Carbohydr. Res. 1990, 200, 363–375 (d) Nakahara, Y.; 
 Ogawa, T. Carbohydr. Res. 1990, 205, 147–159. 
15  Hahn, M.G.; Darvill, A.G.; Albersheim, P. Plant Physiol. 1981, 68, 1161–1169. 
16  Mukaiyama, T.; Murai, Y.; Shoda, S. Chem. Lett. 1981, 431–432. 
17  Nakahara, Y.; Ogawa, T. Tetrahedron Lett. 1987, 28, 2731–2734.  
18  Ethers are known to be participating solvents: (a) Demchenko, A.V.; Stauch, T.; Boons, G.-J. Synlett 1997, 
 818–820 (b) Demchenko, A.V.; Rousson, E.; Boons, G.-J. Tetrahedron Lett. 1999, 40, 6532–6526. 
19  For a comprehensive review on activated dimethylsulfoxide see: Mancuso, A.J.; Swern, D. Synthesis 1981, 
 165–185. Selected examples: (a) Omura, K.; Swern, D. Tetrahedron 1978, 34, 1651–1660 (b) Slaghek, T.M.; 
 Nakahara, Y.; Ogawa, T. Tetrahedron Lett. 1992, 33, 4971–4974 (c) Slaghek, T.M.; Nakahara, Y.; Ogawa, 
 T.; Kamerling, J.P.; Vliegenthart, J.F.G. Carbohydr. Res., 1994, 255, 61–85 (d) Slaghek, T.M.; Hyppönen, 
 T.K.; Ogawa, T.; Kamerling, J.P.; Vliegenthart, J.F.G. Tetrahedron Lett. 1993, 34, 7939–7942 (e) Slaghek, 
 T.M.; Hyppönen, T.K.; Ogawa, T.; Kamerling, J.P.; Vliegenthart, J.F.G. Tetrahedron Asymm. 1994, 5, 
 2291–2301 (f) Lucas, R.; Hamza, D.; Lubineau, A.; Bonnaffé, D. Eur. J. Org. Chem. 2004, 2107–2117.  
20  Failed oxidations using this protocol have also been published: Halkes, K.M.; Slaghek, T.M.; Hyppönen, 
 T.K.; Kruiskamp, P.H.; Ogawa, T.; Kamerling, J.P.; Vliegenthart, J.F.G. Carbohydr. Res. 1998, 309, 161–
 174. 
21  Clausen, M.H.; Madsen, R. Carbohydr. Res. 2004, 339, 2159–2169. 
22  (a) Dess, D.B.; Martin, J.C. J. Am. Chem. Soc. 1991, 113, 7277–7287 (b) Chambers, D.J.; Evans, G.R.; 
 Fairbanks, A.J. Tetrahedron 2005, 61, 7184–7192. 
23  Clausen, M.H.; Jørgensen, M.R.; Thorsen, J.; Madsen, R. J. Chem. Soc., Perkin Trans. 1 2001, 543–551.  
24  Willats, W.G.T.; Orfila, C.; Limberg, G.; Buchholt, H.C.; Van Alebeek, G.-J.W.M.; Voragen, A.G.J.; 
 Marcus, S.E.; Christensen, T.M.I.E.; Mikkelsen, J.D.; Murray, B.S.; Knox, J.P. J. Biol. Chem. 2001, 276, 
 19404–19413. 
25 Clausen, M.H.; Madsen, R. Chem. Eur. J. 2003, 9, 3821–3832. 
26  Bowden, K.; Heilbron, I. M.; Jones, E. R. H. J. Chem. Soc. 1946, 39–45. Selected examples of the use of the 
 Jones reagent system in oligosaccharide systems: (a) Kováč, P. Carbohydr. Res. 1973, 31, 323–330 (b) 
 Jacquinet, J.-C.; Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Torri, G.; Sinaÿ, P. Carbohydr. Res. 
 1984, 130, 221–241 (c) Betanelli, V.I.; Ott, A.Y.; Brukhova, O.V.; Kochetkov, N.K. Carbohydr. Res. 1988, 
 179, 37–50 (d) Carter, M.B.; Petillo, P.A.; Anderson, L.; Lerner, L.E. Carbohydr. Res. 1994, 258, 299–306 
 (e) La Ferla, B.; Lay, L.; Guerrini, M.; Poletti, L.; Panza, L.; Russo, G. Tetrahedron, 1999, 55, 9867–9880 
 (f) Mukhopadhay, B.; Roy, N. Carbohydr. Res. 2003, 338, 589–596. 
27  (a) Coates, W.M.; Corrigan, J.R. Chem. Ind. 1969, 44, 1594–1595 (b) Corey, E.J.; Schmidt, G. Tetrahedron 
 Lett. 1979, 20, 399–402. 
28  Piancatelli, G.; Screttri, A.; D’Auria, M. Synthesis 1982, 245–258. 
29  Palmacci, E.R.; Seeberger, P.H. Tetrahedron 2004, 60, 7755–7766. 
30  Vermeer, H.J.; Halkes, K.M.; Van Kuik, J.A.; Kamerling, J.P.; Vliegenthart, J.F.G. J. Chem. Soc., Perkin 
 Trans. 1 2000, 2249–2263.  








32  Garegg, P.J.; Samuelsson, B. Carbohydr. Res. 1978, 67, 267–270. 
33  Halkes, K.M.; Vermeer, H.J.; Slaghek, T.M.; Van Hooft, P.A.V.; Loof, A.; Kamerling, J.P.; Vliegenthart, 
 J.F.G. Carbohydr. Res. 1998, 309, 175–188. 
34  Fekete, A.; Gyergyói, K.; Köver, K.E.; Bajza, I.; Lipták, A. Carbohydr. Res. 2006, 341, 1312–1321. 
35  (a) Szurmai, Z.; Lipták, A.; Carbohydr. Res. 1982, 107, 33–41 (b) Szurmai, Z.; Lipták, A.; Snatzke, G. 
 Carbohydr. Res. 1990, 200, 201–208. 
36  De Nooy, A.E.J.; Besemer, A.C.; Van Bekkum, H. Synthesis 1996, 1153–1174. 
37  Anelli, P.L.; Biffi, C.; Montanari, F.; Quici, S. J. Org. Chem. 1987, 52, 2559-2562. 
38  Jones oxidiation protocol: (a) Assarsson; Theander, O. Acta Chem. Scand. 1958, 1507–1509. Methods based 
 on PDC-mediated oxidation of C2 position: (b) Wood, W.W.; Rashid, A. Tetrahedron Lett. 1987, 28, 1933–
 1936 (c) Rashid, A.; Taylor, G.M.; Wood, W.W.; Alker, D. J. Chem. Soc., Perkin Trans. 1 1990, 1289–1296 
 (d) Perez-Perez, M.-J.; Camarasa, M.-J.; Diaz-Ortiz, A.; Felix, A.S.; De las Heras, F.G. Carbohydr. Res. 
 1991, 216, 399–411 (e) Lichtenthaler, F.W.; Immel, S.; Pokinskyj, P. Liebigs Ann. Chem. 1995, 1939–1948 
 (f) Hiraoka, S.; Yamazaki, T.; Kitazume, T. Synlett 1997, 669–670. 
39  Maruyama, M.; Takeda, T.; Shimizu, N.; Hada, N.; Yamada, H. Carbohydr. Res. 2003, 325, 83–92. 
40  (a) De Nooy, A.E.J.; Besemer, A.C.; Van Bekkum, H. Carbohydr. Res. 1995, 269, 89–98 (b) Söderman, P.; 
 Widmalm, G. Eur. J. Org. Chem. 2001, 3453–3456. 
41  (a) Semmelhack, M.F.; Chou, C.S.; Cortes, D.A. J. Am. Chem. Soc. 1983, 105, 4492–4494 (b) Inokuchi, 
 T.; Matsumoto, S.; Torii, S. J. Org. Chem. 1991, 56, 2416–2421 (c) For a review, see: Yamaguchi, M.; 
 Miyazawa, T.; Takata, Y.; Endo, T. Pure Appl. Chem. 1990, 62, 217–222 (d) Kashiwagi, Y.; Yanagisawa, 
 Y.; Kurashima, F.; Anzai, J.; Osa, T.; Bobbit, J. M. Chem. Commun. 1996, 2745–2746. 
42  (a) Cella, J.A.; Kelley, J.A.; Kenhan, E.F. J. Org. Chem. 1975, 40, 1860–1862 (b) Ganem, B. J. Org. Chem. 
 1975, 40, 1998–2000 (c) Cella, J.A.; McGrath, J.P.; Kelley, J.A.; El Soukkary, O.; Hilpert, L. J. Org. Chem. 
 1977, 42, 2077–2080. 
43  (a) Miyazawa, T.; Endo, T. J. Mol. Catal. 1985, 31, 217–220. (b) Miyazawa, T.; Endo, T. J. Mol. Catal. 
 1985, 32, 357–360. (c) Semmelhack, M.F.; Schmid, C.R.; Cortes, D.A.; Chou, C.S. J. Am. Chem. Soc. 1984, 
 106, 3374–3376. 
44  Inokuchi, T.; Matsumoto, S.; Nishiyama, T.; Torii, S. J. Org. Chem. 1990, 55, 462–466.  
45  (a) Anelli, P.L.; Banfi, S.; Montanari, F.; Quici, S. J. Org. Chem. 1989, 54, 2970–2972 (b) Siedlecka, R.; 
 Skarzewski, J.; Mlochowski, J. Tetrahedron Lett. 1990, 31, 2177–2180 (b) Davis, N.J.; Flitsch, S.L. 
 Tetrahedron Lett. 1993, 34, 1181–1184. 
46  (a) Spyroudis, S.; Varvoglis, A. Synthesis 1975, 445–447 (b) Narasaka, K.; Morikawa, A.; Saigo, K.; 
 Mukaiyama, T. Bull. Chem. Soc. Jpn. 1977, 50, 2773–2776 (c) Muller, P.; Godoy, J. Tetrahedron Lett. 1981, 
 22, 2361–2364 (d) Muller, P.; Godoy, J.; Helv. Chim. Acta 1983, 66, 1790–1795 (d) Togo, H.; Aoki, M.; 
 Kuramochi, T.; Yokoyama, M. J. Chem. Soc., Perkin Trans. 1 1993, 2417–2427 (e) Magnus, P.; Lacour, J.; 
 Evans, P.A.; Roe, M.B.; Hulme, C. J. Am. Chem. Soc. 1996, 118, 3406–3418.  
47  See for the use of [bis(acetoxy)iodo]benzene (BAIB): Epp, J.B.; Widlanski, T.S. J. Org. Chem. 1999, 64, 
 293–295. 
48  De Luca, L.; Giacomelli, G.; Masala, S.; Porcheddu, A. J. Org. Chem. 2003, 68, 4999–5001. Unpredictable 
 outcomes were reported by Chambers et al. (see ref 22b). 
49  Bragd, P.L.; Van Bekkum, H.; Besemer, A.C. Topics in Catalysis, 2004, 27, 49–66. 
50  Despite extensive studies, the exact mechanism is still unclear: (a) Semmelhack, M.F.; Schmid, C.R.;  Cortés, 
 D.A. Tetrahedron Lett. 1986, 27, 1119–1122 (b) Ma, Z.; Bobbitt, J.M. J. Org. Chem. 1991, 56, 6110–6114 








51  Haller, M.; Boons, G.-J. J. Chem. Soc., Perkin Trans. 1 2001, 814–822. 
52  Garegg, P.J.; Oscarson, S.; Tedebark, U. J. Carbohydr. Chem. 1998, 17, 587–594. 
53  Chauvin, A.-L.; Nepogodiev, S.A.; Field, R.A. J. Org. Chem. 2005, 70, 960–966. 
54  Yeung, B.K.S.; Hill, D.C.; Janicka, M.; Petillo, P.A. Org. Lett. 2000, 2, 1279–1282. 
55  Litjens, R.E.J.N.; Den Heeten, R.; Timmer, M.S.M.; Overkleeft, H.S.; Van der Marel, G.A. Chem. Eur. J. 
 2005, 11, 1010–1016. 
56  Huang, L.; Teumelsan, N.; Huang, X. Chem. Eur. J. 2006, 12, 5246–5252. 
57  (a) Chiba, T.; Sinaÿ, P. Carbohydr. Res. 1986, 151, 379–389 (b) Chiba, T.; Jacquinet, J.-C.; Sinaÿ, P.; 
 Petitou, M.; Choay, J. Carbohydr. Res. 1988, 174, 253–264 (c) Schmidt, R.R.; Rücker, E. Tetrahedron Lett. 
 1980, 21, 1421–1424. 
58  Nakahara, Y.; Ogawa, T. Carbohydr. Res. 1988, 173, 306–315. 
59  (a) Jacquinet, J.-C.; Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Torri, G.; Sinaÿ, P. Carbohydr. 
 Res. 1984, 130, 221–241 (b) Sinaÿ, P.; Jacquinet, J.-C.; Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, 
 J.; Torri, G. Carbohydr. Res. 1984, 132, C5–C9 (c) Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; 
 Jacquinet, J.-C.; Sinaÿ, P.; Torri, G. Carbohydr. Res. 1987, 167, 67–75.  
60  (a) Schmidt, R.R.; Grundler, G. Synthesis 1981, 885–887 (b) Marra, A.; Dong, X.; Petitou, M.; Sinaÿ, P. 
 Carbohydr. Res. 1989, 195, 39–50 (c) Hada, N.; Ogino, T.; Yamada, H.; Takeda, T. Carbohydr. Res. 2001, 
 334, 7–17. 
61  Tabeur, C.; Machetto, F.; Mallet, J.-M.; Duchaussoy, P.; Petitou, M.; Sinaÿ, P. Carbohydr. Res. 1996, 281, 
 253–276. 
62  Maruyama, M.; Takeda, T.; Shimizu, N.; Hada, N.; Yamada, H. Carbohydr. Res. 2000, 325, 83–92. 
63 Kochetkov, N.K. Tetrahedron 1987, 43, 2389–2436.  
64 Vogel, C.; Steffan, W.; Ott, A.Y.; Betanelli, V.I. Carbohydr. Res. 1992, 237, 115–129.  
65  Steffan, W.; Vogel, C.; Kristen, H. Carbohydr. Res. 1990, 204, 109–120. 
66  Partial epimerization around the anomeric centre of the acceptor occurred, which is earlier observed using 
 this glycosylation method: Kitov, P.I.; Tsvetkov, Y.E.; Bachinowski, L.V.; Kochetkov, N.K. Bioorg. Khim. 
 1989, 15, 1416–1422. 
67  Nilsson, M.; Svahn, C.M.; Westman, J. Carbohydr. Res. 1993, 246, 161–172. 
68  Throughout the text, glycosides having the ido-configuration are depicted in the 1C4 conformation. For more 
 details see Codée, J.D.C. Thesis Leiden University 2004.  
69  This is a modified version of the Corey-conditions: Corey, E.J.; Samuelsson, B. J. Org. Chem. 1984, 49, 
 4735–4735. 
70  The authors mentioned that no acid scavenger was added to the reaction mixture. DMTST-mediated 
 glycosylations are usually performed without adding base, even in the presence of acid labile protective 
 groups. Original article: Fügedi, P.; Garegg, P. Carbohydr. Res. 1986, 149, C9–C12. 
71  Magaud, D.; Grandjean, C.; Doutheau, A.; Anker, D.; Shevchik, V.; Cotte-Pattat, N.; Robert-Baudouy, J. 
 Carbohydr. Res.; 2000, 314, 189–199. 
72  Initially it was established that coupling between two D-galacturonic acid esters could not be effected using 
 bromide, trichloroacetimidate and n-pentenyl functionalized donors. 
73  Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Sinaÿ, P.; Jacquinet, J.-C.; Torri, G. Carbohydr. Res. 
 1986, 147, 221–236 
74  Pews-Davtyan, A.; Pirojan, A.; Shaljyan, I.; Awetissjan, A.A.; Reinke, H.; Vogel, C. J. Carbohydr. Chem. 
 2003, 22, 939–962. See also: (a) Lönn, H.; Lönngren, J.; Thompson, J.L. Carbohydr. Res. 1984, 132, 39–44 








75  Elimination is also found in the degradation of uronic acid containing polysaccharides: Lindberg, B.; 
 Lönngren, J.; Thompson, J.L. Carbohydr. Res. 1973, 28, 351–357. 
76  Magaud, D.; Grandjean, C.; Doutheau, A.; Anker, D.; Shevchik, V.; Cotte-Pattat, N.; Robert-Baudouy, J. 
 Tetrahedron Lett. 1997, 38, 241–244. 
77  Konradsson, P.; Udodong, U.E.; Fraser-Reid, B. Tetrahedron Lett. 1990, 31, 4313–4316. 
78  Better results were obtained using sonicated Jones oxidation: Allanson, N.M.; Liu, D; Chi, F.; Jain, R.K.; 
 Chen, A.; Ghosh, M.; Hong, L.; Sofia, M.J. Tetrahedron Lett. 1998, 39, 1889–1892. 
79  The authors also tried the rather unknown tris(4-bromophenyl) ammoniumyl hexachloroantimonate without 
 success: Marra, A.; Mallet, J.-M.; Amatore, C.; Sinaÿ, P. Synlett 1990, 572–574. 
80  Garegg, P.J., Olsson, L.; Oscarson, S. J. Org. Chem. 1995, 60, 2200–2204. 
81  (a) Nakano, T.; Ito, Y.; Ogawa, T. Tetrahedron Lett. 1990, 31, 1597–1600 (b) Goto, F.; Ogawa, T. 
 Tetrahedron Lett. 1992, 33, 5099–5102. 
82  Pfitzner, K.E.; Moffat, J.G. J. Am. Chem. Soc. 1965, 87, 5661–5670. 
83  Oscarson, S.; Svahnberg, P. J. Chem. Soc., Perkin Trans. 1 2001, 873–879. 
84  Misra, A.K.; Roy, N. Carbohydr. Res. 1995, 278, 103–111. 
85  Van den Bos, L.J.; Codée, J.D.C.; Van der Toorn, J.C.; Boltje, T.J.; Van Boom, J.H.; Overkleeft, H.S.; Van 
 der Marel, G.A. Org. Lett. 2004, 6, 2165–2168. 
86  Van den Bos, L.J.; Litjens, R.E.J.N.; Van den Berg, R.J.B.H.N.; Overkleeft, H.S.; Van der Marel, G.A. Org. 
 Lett. 2005, 7, 2007–2010. 
87  (a) Crich, D.; Sun, S. J. Org. Chem. 1997, 62, 1198–1199 (b) Crich, D.; Smith, M. J. Am. Chem. Soc. 2001, 
 123, 9015–9020 (c) Crich, D.; Li, W.; Li, H. J. Am. Chem. Soc. 2004, 126, 15081–15086. 
88  (a) Garcia, B.A.; Gin, D.Y. J. Am. Chem. Soc. 2000, 122, 4269–4279 (b) Codée, J.D.C.; Litjens, R.E.J.N.; 
 Den Heeten, R.; Overkleeft, H.S.; Van Boom, J.H.; Van der Marel, G.A. Org. Lett. 2003, 5, 1519–1522. 
89  Crich, D.; Dudkin, V. J. Am. Chem. Soc. 2001, 123, 6819–6825.  
90  Van den Bos, L.J.; Dinkelaar, J.; Overkleeft, H.S.; Van der Marel, G.A. J. Am. Chem. Soc. 2006, 128, 
 13066–13067. 
91  (a) Crich, D.; Sun, S.; Brunckova, J. J. Org. Chem. 1996, 61, 605–615. (b) Crich, D.; Sun, S. J. Org. Chem. 
 1996, 61, 4506–4507 
92  Jensen, H.H.; Nordstrøm, L.U.; Bols, M. J. Am. Chem. Soc. 2004, 126, 9205–9213. 
93  (a) Iwahara, S.; Suemori, N.; Ramli, N.; Takegawa, K. Biosci. Biotech. Biochem. 1995, 59, 1082–1085 (b) 
 Jikibara, T.; Takegawa, K.; Iwahara, S. J. Biochem. 1992, 111, 225–229. 
94  Crich, D.; Smith, M.; Yao, Q.; Picione, J. Synthesis 2001, 323–326. 
95  Codée, J.D.C.; Stubba, B.; Schiattarella, M.; Overkleeft, H.S.; Van Boeckel, C.A.A.; Van Boom, J.H.; Van 
 der Marel, G.A. J. Am. Chem. Soc. 2005, 127, 3767–3773. 
96  Van den Bos, L.J.; Duivenvoorden, B.A.; De Koning, M.C.; Filippov, D.V.; Overkleeft, H.S.; Van der 

















Abstract: Partially protected thioglycuronic acids are prepared efficiently by chemo- and 
regioselective oxidation of the corresponding thioglycosides using the TEMPO/BAIB reagent 
combination. After esterification, the thioglycuronic acids proved to be useful as both donor and 







Uronic acids are present in a wide array of biologically relevant oligosaccharides, 
polysaccharides and glycoconjugates.2 As a result, flexible and straightforward synthesis 
routes towards these important molecules should have major impact on research in 
glycobiology. Although it is well established that thioglycosides are versatile synthons en 
route towards such carbohydrate targets,3 approaches utilizing thioglycuronic acids are scarce. 
This can be explained by the lack of efficient synthetic protocols for the preparation of 
suitably protected thioglycuronides.4 In addition, thioglycuronic acids have been shown to be 
rather poor glycosyl donors, generally requiring the presence of activating protective groups.  
As part of a program directed towards the development of efficient methodologies for the 
preparation of biologically relevant oligosaccharides,5 Codée et al. recently reported a novel 
sequential glycosylation strategy (Figure 1, route A).6 The method is based on Ph2SO 







thioglycoside 2 to afford the corresponding thiodisaccharide. In the next glycosylation event 
(II) successive treatment of the intermediate thio function with sulfonium triflate species 7a 
or 7b, generated in situ from BSP (6a)/Tf2O8 or Ph2SO (6b)/Tf2O9 (see insert in Figure 1), 
followed by addition of a suitably protected nucleophile 3 afforded the desired trisaccharide. 
The potency of the novel activator systems 7a and 7b in these syntheses encouraged us to use 
the highly unreactive thioglycuronides in the aforementioned glycosylation sequence. This 































R = Et or Ph


















a: R = piperidino (BSP)













This Chapter describes the 2,2,6,6-tetramethyl-1-piperidinyloxyl free radical 
(TEMPO)/[bis(acetoxy)iodo]benzene (BAIB)-mediated chemo- and regioselective oxidation 
of readily available partially protected thioglycosides 4 as a powerful means to obtain the 
corresponding thioglycuronic acids (Figure 1, route B).10,11 After esterification of the 
carboxylate functions, these partially-protected thioglycuronides 5 can be incorporated in the 
chemoselective glycosylation strategy, in the same way as key building block 2, to furnish 
acidic oligosaccharides. 
 
Results and Discussion 
 
Piancatelli and coworkers recently reported the oxidation of primary alcohols into their 
corresponding aldehydes using catalytic TEMPO and an equimolar amount of BAIB as co-
oxidant.10 Interestingly, this oxidation protocol could also be applied to alcohols containing 
sulfo- and selenoethers. In this Chapter, application of this reagent combination for the 
selective oxidation of suitably protected thioglycosides to the corresponding thioglycuronic 
acids is established. As the initial research objective, the compatibility of the TEMPO/BAIB 







2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside (8)12 with a catalytic amount of TEMPO and 
excess BAIB in a mixture of dichloromethane (DCM) and water (2:1), followed by 
methylation of carboxylate 10 using freshly prepared diazomethane, afforded thioglucuronide 
12 in a rewarding yield of 88% over the two steps. It should be noted that careful monitoring 
of the reaction mixture by TLC and timely quenching with an aqueous thiosulfate solution 
adequately suppresses unwanted over-oxidation to the sulfoxide and/or sulfone. Following the 
same sequence of reactions, ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside (9)12 was 
converted into methyl ester 13 in 85% yield (based on 9), demonstrating the excellent chemo- 





















8: R = Bn
9: R = H
10: R = Bn
11: R = H
12: R = Bn
13: R = H
a b
 
Reagents and conditions: (a) TEMPO, BAIB, DCM, H2O, 10: 88%, 11: 92% (b) CH2N2, DMF, 12: quant., 13: 
92%. 
 
The results of the TEMPO/BAIB oxidation of a variety of thioglycosides and one 
selenoglycoside are summarized in Table 1. Phenyl 2,3,4-tri-O-benzoyl-1-seleno-α-D-
galactopyranoside (14) was readily transformed into methyl galacturonate 16, via acid 15 
(entry 1). In the same way, subjection of isopropylidene-protected mannoside 17 and 
benzylated galactoside 2013 to the two-step procedure produced esters 19 and 22 in good yield 
(entry 2 and 3). Entries 4-10 further demonstrate the selectivity of this method for the 
oxidation of primary alcohols in the presence of both a thio-functionality and a secondary 
alcohol. Both S-phenyl- and S-ethylthioglycosides can be employed, as illustrated by the 
equally efficient transformation of 2314 and 2415 into 26 and 28, respectively. Furthermore, 
both the starting glycoside (glucose, glucosamine, galactose, and idose) and the nature of the 
protective groups (benzyl, benzoyl, isopropylidene, tert-butyldimethylsilyl, azide, and 
phthalimide) can be readily varied without major implications on the outcome of the 
oxidation step (all yields are within the range of 60-90%). 
As the next research objective, the applicability of the obtained thioglycuronates in 
sulfonium triflate-mediated glycosylation reactions was established. The reactivity of these 
thioglycuronic acids towards various activating systems is considerably reduced compared to 
the corresponding thioglycosides due to the electron withdrawing effect of the carboxyl 
function. It was reasoned that the sulfonium triflate activators 7a and 7b would be sufficiently 








Table 1.  
 
entry substrate product entry substrate product 
















15: R = H (61%)a,c











33: R = H (67%)a,c

















18: R = H (quant.)a,c
















36: R = H (85%)a,c




















21: R = Ha



















39: R = H (88%)a,c








23: R = Et










25: R1=Et, R2=H (76%)a,c
26: R1=Et, R2=Me (83%)b,c
27: R1=Ph, R2=H (81%)a,c









42: R = H (85%)a,c
























30: R = Ha









45: R = H (84%)a,c








a TEMPO, BAIB, DCM/H2O (2/1). b CH2N2, DMF. c isolated yields. d over 2 reaction steps. 
 
donor 47 with 7b showed nice activation of the donor glycoside. Compared to the standard 
conditions reported by the Crich laboratory, higher activation temperatures and longer 
activation times were needed.16 Addition of primary alcohol acceptor 4817 to the reaction 
mixture afforded disaccharide 49 as an anomeric mixture (α/β = 1/3) in 71% yield (Table 2., 
entry 1). Decrease in the reactivity of the acceptor nucleophile, as in 50, leads to an increase 
in the formation of the α-product (entry 2). This trend was further pronounced when 
galacturonic acid ester 52 was subjected to Ph2SO/Tf2O-mediated glycosylation with 
acceptors 48 and 50 to give disaccharides 53 and 54 in good yields (entry 3 and 4). The 
BSP/Tf2O reagent combination is equally efficient in the activation and glycosidation of 
donor 52 with deactivated acceptor 55, despite the slightly lower reactivity of BSP due to its 
stabilizing nitrogen lone pair (entry 5).9,18 Even the highly “disarmed”, fully acylated donor 
57 was smoothly activated by the BSP/Tf2O activator system affording disaccharide 58 in 







of Oscarson who had to install at least two activating benzyl functions or a 3,4-
tetraisopropyldisiloxyl group at the thioglucuronate donors to obtain sufficient activation with 
dimethyl(methylthio)sulfonium triflate (DMTST).4,19 
 
Table 2.  






































































































































Since the results in Table 2. demonstrate that 1-thioglycuronates can be readily applied as 
donors in the sulfonium activator-mediated disaccharide synthesis, attention was focused on 
the implementation of 1-thioglucuronic acid ester 13 in the sequential chemoselective 
synthesis of trisaccharide 62. This protected carbohydrate corresponds to the (→2)-α-D-
GlcpNAc-(1→4)-α-D-GlcpA-α-(1→2)-β-D-Galf-(1→) trisaccharide present in the capsular 
polysaccharide of the Fungus Fusarium sp. M7-1.20 Activation of hemiacetal donor 5921 with 
diphenylsulfonium bistriflate 7b  followed by treatment with uronic acid acceptor 13 gave the 
α-linked thiodisaccharide 60 as the sole product in a gratifying yield of 67% (Scheme 3). Tri-
tert-butylpyrimidine (TTBP) was used as acid scavenger.22 In the second glycosylation event, 
60 was smoothly activated under the agency of BSP/Tf2O and condensed with partially 
protected galactono-1,4-lactone 6123 to give the desired trisaccharide 62 as an anomeric 
mixture (α/β = 4/1) in 35% yield. Despite several attempts, the yield for this reaction could 























































Reagents and conditions: (a) 59, Ph2SO, Tf2O, TTBP, DCM, -60°C then 13, 67% (b) 60, BSP, Tf2O, TTBP, 




This Chapter presents a novel and efficient strategy for the regio- and chemoselective 
oxidation of thioglycosides to the corresponding thioglycuronides. In turn, these 
thioglycuronides proved to be useful as both acceptors and donors in the synthesis of acidic 
oligosaccharides as demonstrated by the assembly of trisaccharide 62. Further, the 
electrophilic Ph2SO/Tf2O and BSP/Tf2O activator systems proved capable in activating even 
highly deactivated 1-thioglycuronides. This approach nicely complements contemporary 
synthetic efforts towards uronic acid containing oligosaccharides, which are often based on 
the introduction of the carboxylate functions after oligosaccharide assembly. The efficiency of 







their reduced reactivity compared to the parent thioglycosides. The yields observed in the 
examples presented here are in the range of 35–80%. However, the partial loss in 





General Procedures: 1H and 13C NMR spectra were recorded on a Jeol JNM-FX-200 (200/50.1 MHz), a Bruker 
AV-400 (400/100 MHz) and a Brüker DMX-600 (600/150 MHz) spectrometer. Chemical shifts are given in ppm 
(δ) relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. All given 13C spectra 
are proton decoupled. Mass spectra were recorded with PE/SCIEX API 165 with electronspray interface and Q-
Star Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured on a Propol automatic 
polarimeter. IR-spectra were recorded on a Shimadzu FTIR-8300. Melting points were measured on a Büchi 
Schmelzpunktbestimmungsapparat nach dr. Tottoli (+ pat 320.388) and were uncorrected. Traces of water in the 
donor and acceptor glycosides, Ph2SO, BSP and TTBP were removed by co-evaporation with toluene. BSP8 and 
TTBP22 were synthesised as described by Crich et al. Dichloromethane (DCM, Baker p.a.) was boiled under 
reflux over P2O5 for 2h and distilled immediately prior to use. Trifluoromethanesulfonic anhydride was distilled 
from P2O5. Molecular sieves 3Å were flame dried before use. Solvents used for flash chromatography and TLC 
were of technical grade and distilled before use. Flash chromatography was performed on Baker silica gel (0.063 
– 0.200 mm). TLC-analysis was conducted on DC-fertigfolien (Schleicher & Schuell, F1500, LS254) with 
detection by UV-absorption (254 nm) where applicable and by spraying with 20% sulfuric acid in ethanol 
followed by charring at ~150°C or by spraying with a solution of (NH4)6Mo7O24·H2O (25 g/L) and 
(NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulfuric acid in ethanol followed by charring at ~150°C.  
 
General Procedure for the TEMPO/BAIB-Mediated Oxidation: To a vigorously stirred solution of 0.3 mmol 
thioglycoside in 1 mL DCM and 0.5 mL H2O was added 0.06 mmol TEMPO (0.2 equiv.) and 0.75 mmol BAIB 
(2.5 equiv.). Stirring was allowed until TLC indicated complete conversion of the starting material to a lower 
running spot (~45 min). The reaction mixture was quenched by the addition of 10 mL Na2S2O3 solution (10% in 
H2O) and 10 mL NaHCO3 (sat., aq.). The mixture was then extracted twice with EtOAc (10 mL) and the 
combined organic phase was dried (MgSO4), filtered and concentrated. Flash column chromatography using 
EtOAc/petroleum ether/AcOH afforded the pure glycuronic acids. 
 
N.B.: NMR-spectra of the various unprotected carboxylic acids sometimes showed low intensity of the C-5 
signals. In all cases, the intensity of the peak was restored after methylation of the carboxylate group. 
 
General Procedure for the Esterification using Diazomethane: A solution of 0.2 mmol thio uronic acid in 1 
mL DMF was treated with a freshly prepared ethereal solution of diazomethane24 (~0.03 M) until the evolution 
of gas ceased [CAUTION: diazomethane is highly explosive]. The reaction mixture was then treated with 1 mL 









General Procedure for Glycosylations using BSP/Tf2O or Ph2SO/Tf2O: A solution of donor (1 equiv), 
benzenesulfinylpiperidine (1.3 equiv.) or diphenyl sulfoxide (1.3 equiv.) and tri-tert-butylpyrimidine (2.5 equiv.) 
in DCM (0.05M) was stirred over activated MS3Å for 30 min. The mixture was cooled to -60°C before triflic 
acid anhydride (1.3 equiv.) was added. The mixture was allowed to warm to -40°C in 15min followed by 
addition of acceptor (1.5 equiv.) in DCM (0.15M). Stirring was continued and the reaction mixture was allowed 
to warm to 0°C. The reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was 
extracted twice with EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under 
reduced pressure. Flash chromatography (EtOAc/PE) and removal of the eluent afforded the corresponding 
coupled disaccharides.  
 
Ethyl 2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranosiduronic acid (10): TLC: 50% EtOAc/PE 
(5% AcOH); MP: 125°C; [α]D22: -22° (c = 1, CHCl3); IR (neat, cm-1): 1074, 1454, 1726; 1H 
NMR (400 MHz, MeOD) δ = 1.25 (t, 3H, J = 7.4 Hz, CH3 SEt), 2.62 – 2.75 (m, 2H, CH2 
SEt), 3.39 (t, 1H, J = 9.2 Hz, H-2), 3.67 (t, 1H, J = 8.7 Hz, H-3), 3.75 (t, 1H, J = 9.2 Hz, H-4), 3.93 (d, 1H, J = 
9.6 Hz, H-5), 4.59 (d, 1H, J = 10.0 Hz, H-1), 4.62 – 4.86 (m, 6H, 3xCH2Ph), 7.22 – 7.31 (m, 15H, H Arom); 13C 
NMR (100 MHz, MeOD) δ = 15.6 (CH3 SEt), 25.8 (CH2 SEt), 75.9 (CH2 Bn), 76.2 (CH2 Bn), 76.7 (CH2 Bn), 
79.0 (C-5), 81.0 (C-4), 82.5 (C-2), 86.6 (C-1), 86.7 (C-3), 128.6 – 129.3 (CH Arom), 139.3 (Cq Bn), 139.5 (Cq 
Bn), 139.8 (Cq Bn), 172.0 (C=O COOH); HRMS: [M+NH4]+ calcd for C29H36O6SN 509.19924, found 
509.19894. 
 
Ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranosiduronic acid (11): TLC: 50% EtOAc/PE 
(5% AcOH); [α]D22: -24° (c = 1, CHCl3); IR (neat, cm-1): 1085, 1251, 1712, 1776, 3386; 1H 
NMR (400 MHz, MeOD) δ = 1.23 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.59 – 2.74 (m, 2H, CH2 
SEt), 3.51 (t, 1H, J = 9.4 Hz, H-2), 3.51 (t, 1H, J = 8.8 Hz, H-3), 3.75 (t, 1H, J = 9.2 Hz, H-4), 3.81 (d, 1H, J = 
9.6 Hz, H-5), 4.52 (d, 1H, J = 9.6 Hz, H-1), 4.62 (d, 1H, J = 10.4 Hz, CHHPh), 4.75 (d, 1H, J = 11.2 Hz, 
CHHPh), 4.78 (d, 1H, J = 10.8 Hz, CHHPh), 4.90 (d, 1H, J = 10.8 Hz, CHHPh), 7.06 – 7.31 (m, 10H, H Arom); 
13C NMR (100 MHz, MeOD) δ = 15.5 (CH3 SEt), 25.6 (CH2 SEt), 73.3 (C-5), 76.2 (CH2 Bn), 76.5 (CH2 Bn), 
80.0 (C-4), 82.0 (C-2), 86.4 (C-1), 87.0 (C-3), 128.5 – 129.9 (CH Arom), 139.4 (Cq Bn), 140.0 (Cq Bn), 172.2 
(C=O COOMe); HRMS: [M+NH4]+ calcd for C22H30O6SN 436.1788, found 436.1793. 
 
Methyl (ethyl 2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside) uronate (12): TLC: 25% 
EtOAc/PE; MP: 125°C; [α]D22: -10° (c = 1, CHCl3); IR (neat, cm-1): 1026, 1074, 1284, 
1745; 1H NMR (400 MHz, CDCl3) δ = 1.30 (t, 3H, CH3 SEt), 2.75 (m, 2H, CH2 SEt), 3.47 
(t, 1H, J = 9.2 Hz, H-2), 3.69 (t, 1H, J = 8.8 Hz, H-3), 3.75 (t, 1H, J = 9.2 Hz, H-4), 3.89 (d, 1H, J = 9.6 Hz, H-
5), 4.50 (d, 1H, J = 9.6 Hz, H-1), 4.61 (d, 1H, J = 10.8 Hz, CHHPh), 4.73 (d, 1H, J = 10.4 Hz, CHHPh), 4.77 (d, 
1H, J = 10.8 Hz, CHHPh), 4.84 (d, 1H, J = 10.8 Hz, CHHPh), 4.90 (d, 1H, J = 11.2 Hz, CHHPh), 4.92 (d, 1H, J 
= 10.0 Hz, CHHPh), 7.29 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 14.9 (CH3 SEt), 25.0 (CH2 SEt), 
52.3 (CH3 COOMe), 75.0 (CH2 Bn), 75.4 (CH2 Bn), 76.0 (CH2 Bn), 78.1 (C-5), 81.2 (C-4), 81.2 (C-2), 85.8 (C-
1 and C-3), 127.8 – 128.4 (CH Arom), 137.8 (Cq Bn), 138.2 (Cq Bn), 168.7 (C=O COOMe); HRMS: [M+NH4]+ 
calcd for C30H38O6SN 540.2414, found 540.2422. 
  
Methyl (ethyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside) uronate (13): TLC 50% 
EtOAc/PE; [α]D22: -30° (c = 1, CHCl3); IR (neat, cm-1): 1026, 1062, 1174, 1209, 1357, 1438, 
1454, 1496, 1747, 2329, 2866; 1H NMR (400 MHz, CDCl3) δ = 1.32 (t, 3H, J = 7.6 Hz, CH3 































3), 3.80 (s, 3H, CH3 COOMe), 3.83 (s, 1H, H-5), 3.90 (t, 1H, J = 9.4 Hz, H-4), 4.52 (d, 1H, J = 9.6 Hz, H-1), 
4.75 (d, 1H, J = 10.0 Hz, CHHPh), 4.88 (s, 2H, CH2 Bn), 4.89 (d, 1H, J = 11.2 Hz, CHHPh), 7.13 – 7.35 (m, 
10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 15.0 (CH3 SEt), 25.2 (CH2 SEt), 52.7 (CH3 COOMe), 71.9 (C-
4), 75.5 (CH2 Bn), 76.2 (CH2 Bn), 77.6 (C-5), 80.6 (C-2), 85.1 (C-3), 85.9 (C-1), 126.6 – 128.8 (CH Arom), 
137.8 (Cq Bn), 138.4 (Cq Bn), 169.6 (C=O COOMe); HRMS: [M+NH4]+ calcd for C23H28O6S 450.1945, found 
450.1930. 
 
Phenyl 2,3,4-tri-O-benzoyl-1-seleno-α-D-galactopyranosiduronic acid (15): TLC: 50% 
EtOAc/PE (5% AcOH); IR (neat, cm-1): 1026, 1068, 1091, 1178, 1211, 1257, 1315, 1450, 
1583, 1600, 1724; 1H NMR (400 MHz, MeOD) δ = 4.89 (s, 1H, H-5), 5.44 (d, 1H, J = 10.0 Hz, 
H-1), 5.66 (t, 1H, J = 9.8 Hz, H-2), 5.74 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H-3), 6.21 (d, 1H, J = 
2.4 Hz, H-4), 7.08 – 7.96 (m, 20H, H Arom); 13C NMR (100 MHz, MeOD) δ = 69.8 (C-2), 71.1 (C-4), 74.0 (C-
3), 77.5 (C-5), 80.9 (C-1), 127.2 (Cq SePh), 129.1 – 137.7 (CH Arom), 130.2 (Cq Bz), 130.5 (Cq Bz), 130.6 (Cq 
Bz), 166.6 (C=O Bz or COOH), 169.5 (C=O Bz or COOH); HRMS: [M+NH4]+ calcd for C33H30O9SeN 
664.1080, found 664.1098. 
 
Methyl (phenyl 2,3,4-tri-O-benzoyl-1-seleno-α-D-galactopyranoside) uronate (16): TLC: 30% 
EtOAc/PE; IR (neat, cm-1): 1001, 1024, 1066, 1091, 1178, 1211, 1257, 1438, 1450, 1600, 
1726; 1H NMR (400 MHz, CDCl3) δ = 4.63 (s, 1H, H-5), 5.20 (d, 1H, J = 9.6 Hz, H-1), 5.58 
(dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H-3), 5.73 (t, 1H, J = 9.8 Hz, H-2), 6.18 (dd, 1H, J = 2.8 Hz, J 
= 0.8 Hz, H-4), 7.20 – 7.99 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.6 (CH3 COOMe), 68.0 (C-
3), 69.2 (C-4), 72.4 (C-2), 76.8 (C-5), 80.2 (C-1), 125.7 (Cq SePh), 128.2 – 136.7 (CH Arom), 128.8 (Cq Bz), 
164.9 (C=O Bz or COOMe), 165.4 (C=O Bz or COOMe), 166.1 (C=O Bz or COOMe); HRMS: [M+NH4]+ calcd 
for C34H32O9SeN 678.1237, found 678.1235. 
 
Phenyl 4-O-benzyl-2,3-O-isopropylidene-1-thio-α-D-mannopyraniduronic acid (18): TLC: 
50% EtOAc/PE (5% AcOH); [α]D22: +104° (c = 1, CHCl3); 1H NMR (400 MHz, MeOD) δ = 
1.33 (s, 3H, CH3 isoprop), 1.42 (s, 3H, CH3 isoprop), 3.97 (dd, 1H, J = 7.4 Hz, J = 6.0 Hz, J = 
5.6 Hz, H-4), 4.26 (dd, 1H, J = 5.4 Hz, J = 3.6 Hz, H-2), 4.32 (t, 1H, J = 5.6 Hz, H-3), 4.59 (d, 1H, J = 7.2 Hz, 
H-5), 4.67 (d, 1H, J = 11.6 Hz, CHHPh), 4.75 (d, 1H, J = 11.6 Hz, CHHPh), 5.68 (d, 1H, J = 3.2 Hz, H-1), 7.07 
– 7.55 (m, 10H, H Arom); 13C NMR (100 MHz, MeOD) δ = 26.5 (CH3 isoprop), 28.1 (CH3 isoprop), 71.9 (C-5), 
73.7 (CH2 Bn), 76.1 (C-2), 77.2 (C-4), 77.9 (C-3), 84.7 (C-1), 111.0 (Cq isoprop), 128.8 – 133.0 (CH Arom), 
134.3 (Cq SPh), 139.1 (Cq Bn), 172.3 (C=O); HRMS: [M+NH4]+ calcd for C22H28O6SN 434.1632, found 
434.1695. 
 
Methyl (phenyl 4-O-benzyl-2,3-O-isopropylidene-1-thio-α-D-mannopyranoside) uronate (19): 
TLC: 30% EtOAc/PE; [α]D 22: +43° (c = 0.6, CHCl3); IR (neat, cm-1): 1043, 1093, 1234, 1735; 
1H NMR (400 MHz, CDCl3) δ = 1.29 (s, 3H, CH3 isoprop), 1.42 (s, 3H, CH3 isoprop), 3.63 (s, 
3H, CH3 COOMe), 3.90 (dd, 1H, J = 7.8 Hz, J = 6.0 Hz, H-4), 4.22 (dd, 1H, J = 5.6 Hz, J = 3.6 Hz, H-2), 4.27 (t, 
1H, J = 5.8 Hz, H-3), 4.56 (d, 1H, J = 8.4 Hz, H-5), 4.59 (d, 1H, J = 12.4 Hz, CHHPh), 4.72 (d, 1H, J = 11.2 Hz, 
CHHPh), 5.60 (d, 1H, J = 3.6 Hz, H-1), 7.17 – 7.47 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 26.1 
(CH3 isoprop), 27.7 (CH3 isoprop), 52.3 (CH3 COOMe), 70.7 (C-5), 72.9 (CH2 Bn), 75.0 (C-2), 76.0 (C-4), 76.7 
(C-3), 83.7 (C-1), 110.0 (Cq isoprop), 127.6 – 131.9 (CH Arom), 132.8 (Cq SPh), 137.5 (Cq Bn), 169.4 (C=O); 






























Phenyl 2,3,4-tri-O-benzyl-1-thio-β-D-galactopyranosiduronic acid (21): Experimental data 
were in full accord with reported literature data.25 
 
 
Methyl (phenyl 2,3,4-tri-O-benzyl-1-thio-β-D-galactopyranoside) uronate (22): Experimental 
data were in full accord with literature.25 ESI: 588.2 [M+NH4]+; HRMS: [M+NH4]+ calcd for 
C34H38O6SN 588.24144, found 588.24011. 
 
Ethyl 2,3-di-O-benzoyl-1-thio-β-D-glucopyranosiduronic acid (25): TLC: 50% EtOAc/PE 
(5% AcOH); IR (neat, cm-1): 1072, 1272, 1450, 1604, 1720; 1H NMR (400 MHz, MeOD) δ 
= 1.22 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.67 – 2.77 (m, 2H, CH2 SEt), 4.07 (t, 1H, J = 9.4 Hz, 
H-4), 4.13 (d, 1H, J = 10.0 Hz, H-5), 4.93 (d, 1H, J = 9.2 Hz, H-1), 5.35 (t, 1H, J = 9.8 Hz, H-2), 5.62 (t, 1H, J = 
9.2 Hz, H-3), 7.09 – 7.92 (m, 10H, H Arom); 13C NMR (100 MHz, MeOD) δ = 15.3 (CH3 SEt), 25.0 (CH2 SEt), 
71.0 (C-4), 71.8 (C-2), 77.4 (C-3), 80.1 (C-5), 84.7 (C-1), 128.9 – 134.3 (CH Arom), 129.7 (Cq Bz), 130.2 (Cq 
Bz), 166.5 (C=O Bz or COOH), 167.2 (C=O Bz or COOH); HRMS: [M+H]+ calcd for C22H23O8S 469.09276, 
found 469.09314. 
 
Methyl (ethyl 2,3-di-O-benzoyl-1-thio-β-D-glucopyranoside) uronate (26): TLC: 30% 
EtOAc/PE; [α]D22: +63° (c = 1, CHCl3); IR (neat, cm-1): 1066, 1272, 1724, 3471; 1H NMR 
(400 MHz, CDCl3): δ = 1.20 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.72 (m, 2H, CH2 SEt), 3.82 (s, 
3H, CH3 COOMe), 4.14 (d, 1H, J = 10.0 Hz, H-5), 4.21 (t, 1H, J = 9.2 Hz, H-4), 4.80 (d, 1H, J = 10.0 Hz, H-1), 
5.46 (t, 1H, J = 9.8 Hz, H-2), 5.62 (t, 1H, J = 9.2 Hz, H-3), 7.28 – 7.96 (m, 10H, H Arom); 13C NMR (100 MHz, 
CDCl3): δ = 14.6 (CH3 SEt), 24.3 (CH2 SEt), 52.7 (CH3 COOMe), 69.8 (C-2), 70.3 (C-4), 76.0 (C-3), 78.3 (C-5), 
84.2 (C-1), 128.2 – 133.2 (CH Arom), 129.0 (Cq Bz), 165.2 (C=O Bz or COOMe), 166.3 (C=O Bz or COOMe), 
168.7 (C=O Bz or COOMe); HRMS: [M+NH4]+ calcd for C23H28O8SN 483.10841, found 483.10828. 
 
Phenyl 2,3-di-O-benzoyl-1-thio-α-D-glucopyranosiduronic acid (27): TLC: EtOAc (2% 
AcOH); [α]D22: +61° (c = 1; CHCl3); IR (neat, cm-1): 707, 1066, 1271, 1712; 1H NMR (400 
MHz, MeOD): δ = 4.12 (t, 1H, J = 9.4 Hz, H-4), 5.26 (d,1H, J = 10.0 Hz, H-5), 5.29 (t, 1H, 
J = 10.0 Hz, H-1), 5.37 (t, 1H, J = 9.4 Hz, H-2), 5.74 (t, 1H, J = 9.2 Hz, H-3), 7.21 – 8.06 (m, 15H, H Arom); 
13C NMR (100 MHz, MeOD): δ = 70.1 (C-4), 70.9 (C-2), 76.6 (C-3), 78.9 (C-5), 86.1 (C-1), 128.1 – 133.5 (CH 
Arom), 129.2 (Cq Bz), 132.2 (Cq SPh), 165.5 (C=O Bz), 166.3 (C=O Bz), 170.4 (C=O COOH); HRMS: [M+H]+ 
calcd for C26H23O8S 469.09276, found 469.09314. 
 
Methyl (phenyl 2,3-di-O-benzoyl-1-thio-β-D-glucopyranoside) uronate (28): TLC: 30% 
EtOAc/PE; [α]D22: +63° (c = 1, CHCl3); IR (neat, cm-1): 707, 1066, 1272, 1724, 3471; 1H 
NMR (400 MHz, CDCl3) δ = 3.52 (bs, 1H, OH), 3.87 (s, 3H, CH3 COOMe), 4.13 (d, 1H, J 
= 9.6 Hz, H-5), 4.18 (t, 1H, J = 9.2 Hz, H-4), 4.99 (d, 1H, J = 10.0 Hz, H-1), 5.41 (t, 1H, J = 9.8 Hz, H-2), 5.58 
(t, 1H, J = 9.0 Hz, H-3), 7.26 – 8.02 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 53.0 (CH3 COOMe), 
69.7 (C-4), 70.3 (C-2), 76.2 (C-3), 78.0 (C-5), 86.9 (C-1), 128.4 – 133.4 (CH Arom), 128.9 (Cq Bz), 129.0 (Cq 
Bz), 131.9 (Cq SPh), 165.0 (C=O Bz or COOMe), 166.5 (C=O Bz or COOMe), 168.8 (C=O Bz or COOMe); 














































 Methyl (phenyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside) uronate (31): TLC: 25% 
EtOAc/PE; [α]D22: -54° (c = 1.8, CHCl3); IR (neat, cm-1): 694, 734, 979, 1026, 1141, 1203, 
1355, 1436, 1759; 1H NMR (600 MHz, CDCl3) δ = 2.95 (bs, 1H, OH-4), 3.40 (dd, 1H, J = 
9.9 Hz, J = 9.0 Hz, J = 8.4 Hz, H-2), 3.51 (t, 1H, J = 9.0 Hz, J = 8.4 Hz, H-3), 3.73 (s, 3H, CH3 COOMe), 3.76 
(d, 1H, J = 9.6 Hz, H-5), 3.82 (t, 1H, J = 9.6 Hz, J = 9.0 Hz, H-4), 4.61 (d, 1H, J = 9.6 Hz, H-1), 4.67 (d, 1H, J = 
10.2 Hz, CHHPh), 4.78 (s, 2H, CH2 Bn), 4.80 (d, 1H, J = 10.2 Hz, CHHPh), 7.16 – 7.48 (m, 15H, H Arom); 13C 
NMR (150 MHz, CDCl3) δ = 52.7 (CH3 COOMe), 71.7 (C-4), 75.5 (CH2 Bn), 75.6 (CH2 Bn), 77.7 (C-5), 79.6 
(C-2), 85.1 (C-3), 88.3 (C-1), 127.1 – 132.6 (CH Arom), 133.1 (Cq SPh), 137.7 (Cq Bn), 138.2 (Cq Bn), 169.5 




acid (33): TLC: EtOAc (5% AcOH); [α]D22: +39.6° (c = 1, CHCl3); IR (neat, cm-1): 1085, 
1251, 1386, 1593, 1712, 1776, 3386; 1H NMR (400 MHz, CDCl3) δ =  -0.19 (s, 3H, CH3 
TBDMS), 0.14 (s, 3H, CH3 TBDMS), 0.66 (s, 9H, tBu TBDMS), 3.65 (t, 1H, J = 9.2 Hz, H-4), 3.93 (d, 1H, J = 
10.0 Hz, H-5), 4.26 (t, 1H, J = 10.2 Hz, H-2), 4.49 (t, 1H, J = 9.2 Hz, H-3), 5.65 (d, 1H, J = 10.4 Hz, H-1), 7.22 
– 7.93 (m, 9H, H Arom); 13C NMR (100 MHz, CDCl3) δ = -5.0 (CH3 TBDMS), -3.4 (CH3 TBDMS), 18.7 (Cq 
tBu TBDMS), 26.2 (tBu TBDMS), 57.6 (C-2), 74.8 (C-4), 75.1 (C-3), 81.0 (C-5), 85.8 (C-1), 124.3 – 135.8 (CH 
Arom), 132.9 (Cq SPh), 134.2 (Cq NPhth), 169.0 (C=O NPhth), 169.7 (C=O NPhth), 177.2 (C=O COOH); 
HRMS: [M+NH4]+ calcd for C26H35O7N2SSi 547.1929, found 547.1987. 
 
Methyl (phenyl 3-O-tert-butyldimethylsilyl-2-deoxy-2-phtalimido-1-thio-β-D-glucopyran-
oside) uronate 34: : TLC: 50% EtOAc/PE (5% AcOH); [α]D22: +93.2° (c = 1, CHCl3); IR 
(neat, cm-1): 1110, 1384, 1710; 1H NMR (400 MHz, CDCl3) δ = -0.30 (s, 3H, CH3 
TBDMS), 0.02 (s, 3H, CH3 TBDMS), 0.61 (s, 9H, tBu TBDMS), 3.10 (bs, 1H, OH), 3.76 (dd, 1H, J = 11.0 Hz, J 
= 8.4 Hz, J = 5.6 Hz, H-4), 3.81 (s, 3H, CH3 COOMe), 4.02 (d, 1H, J = 10.0 Hz, H-5), 4.24 (t, 1H, J = 10.2 Hz, 
H-2), 4.43 (dd, 1H, J = 9.6 Hz, J = 8.4 Hz, H-3), 5.55 (d, 1H, J = 10.8 Hz, H-1), 7.13 – 7.84 (m, 10H, H Arom); 
13C NMR (100 MHz, CDCl3) δ = -5.3 (CH3 TBDMS), -4.1 (CH3 TBDMS), 17.8 (Cq tBu TBDMS), 25.5 (tBu 
TBDMS), 52.8 (CH3 COOMe), 55.6 (C-2), 72.9 (C-3), 73.1 (C-4), 77.7 (C-5), 84.5 (C-1), 123.2 – 134.2 (CH 
Arom), 131.7 (Cq SPh), 132.1 (Cq Phth), 169.7 (C=O NPhth or COOMe); ESI-MS: 566.2 [M+Na]+. 
 
Phenyl 2,3-di-O-benzyl-1-thio-β-D-galactopyranosiduronic acid (36): TLC: 50% EtOAc/PE 
(5% AcOH); [α]D22: -11° (c = 0.8, CHCl3); IR (neat, cm-1): 1027, 1086, 1725; 1H NMR (400 
MHz, CDCl3) δ = 3.62 (dd, 1H, J = 8.8 Hz, J = 2.8 Hz, H-3), 3.74 (t, 1H, J = 9.4 Hz, H-2), 
4.06 (s, 3H, H-5), 4.43 (bs, 1H, H-4), 4.64 (d, 1H, J = 9.6 Hz, H-1), 4.65 (d, 1H, J = 11.6 Hz, CHHPh), 4.73 (d, 
1H, J = 11.2 Hz, CHHPh), 4.75 (d, 1H, J = 10.0 Hz, CHHPh), 4.82 (d, 1H, J = 10.4 Hz, CHHPh), 5.57 (bs, 1H, 
COOH), 7.12 – 7.58 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 67.4 (C-4), 72.2 (CH2 Bn), 75.8 (CH2 
Bn), 76.2 (C-2), 76.6 (C-5), 81.5 (C-3), 87.8 (C-1), 127.9 – 132.6 (CH Arom), 132.9 (Cq SPh), 137.2 (Cq Bn), 
137.9 (Cq Bn), 169.9 (C=O COOH); HRMS: [M+Na]+ calcd for C26H26O6SNa 467.15229, found 467.15396 
 
Methyl (phenyl 2,3-di-O-benzyl-1-thio-β-D-galactopyranoside) uronate (37): TLC: 50% 
EtOAc/PE; [α]D22: -8° (c = 0.6, CHCl3); IR (neat, cm-1): 1026, 1083, 1716; 1H NMR (400 
MHz, CDCl3) δ = 2.49 (s, 1H, OH), 3.63 (dd, 1H, J = 8.8 Hz, J = 3.2 Hz, H-3), 3.77 (t, 1H, J 
= 9.0 Hz, H-2), 3.84 (s, 3H, CH3 COOMe), 4.07 (s, 1H, H-5), 4.39 (s, 1H, H-4), 4.59 (d, 1H, J = 10.0 Hz, H-1), 



































CHHPh), 7.13 – 8.01 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.7 (CH3 COOMe), 67.8 (C-4), 72.2 
(CH2 Bn), 75.8 (CH2 Bn), 76.3 (C-2), 76.7 (C-5), 81.7 (C-3), 87.8 (C-1), 127.8 – 132.8 (CH Arom), 133.1 (Cq 
SPh), 137.2 (Cq Bn), 138.0 (Cq Bn), 168.2 (C=O); HRMS: [M+H]+ calcd for C27H29O6S 503.14972, found 
503.14988. 
 
Ethyl 2-azido-3-O-benzoyl-2-deoxy-1-thio-β-D-glucopyranosiduronic acid (39): TLC: 50% 
EtOAc/PE (5% AcOH); [α]D22: -1° (c = 1, CHCl3); IR (neat, cm-1): 1026, 1068, 1116, 1261, 
1421, 1716, 2108; 1H NMR (400 MHz, MeOD) δ = 1.31 (t, 3H, J = 7.0 Hz, CH3 SEt), 2.79 
(m, 2H, CH2 SEt), 3.67 (t, 1H, J = 10.0 Hz, H-2), 3.91 (t, 1H, J = 9.4 Hz, H-4), 3.98 (d, 1H, J = 9.6 Hz, H-5), 
4.69 (d, 1H, J = 10.4 Hz, H-1), 5.25 (t, 1H, J = 9.4 Hz, H-3), 7.47 – 8.11 (m, 5H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 15.5 (CH3 SEt), 25.5 (CH2 SEt), 65.1 (C-2), 71.2 (C-4), 77.9 (C-3), 80.1 (C-5), 85.7 (C-1), 129.6 – 
134.5 (CH Arom), 167.3 (C=O Bz), 172.0 (C=O COOH); HRMS: [M+H]+ calcd for C15H18N3O6S 368.09108, 
found 368.09232. 
 
Methyl (ethyl 2-azido-3-O-benzoyl-2-deoxy-1-thio-β-D-glucopyranoside) uronate (40): 
TLC: 30% EtOAc/PE; [α]D22: -2° (c = 0.8, CHCl3); IR (neat, cm-1): 1091, 1211, 1265, 1450, 
1732, 2110; 1H NMR (400 MHz, CDCl3) δ = 1.36 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.82 (m, 2H. 
CH2 SEt), 3.62 (t, 1H, J = 10.0 Hz, H-2), 3.82 (s, 3H, CH3 COOMe), 4.00 (d, 1H, J = 9.6 Hz, H-5), 4.05 (t, 1H, J 
= 9.4 Hz, H-4), 4.55 (d, 1H, J = 10.0 Hz, H-1), 5.26 (t, 1H, J = 9.6 Hz, J = 9.2 Hz, H-3), 7.45 – 8.10 (m, 5H, H 
Arom); 13C NMR (100 MHz, CDCl3) δ = 14.9 (CH3 SEt), 25.2 (CH2 SEt), 52.9 (CH3 COOMe), 63.6 (C-2), 70.2 
(C-4), 76.7 (C-3), 78.1 (C-5), 85.2 (C-1), 128.5 – 133.6 (CH Arom), 129.1 (Cq Bz), 166.4 (C=O Bz or COOMe), 
168.7 (C=O Bz or COOMe); ESI-MS: 404.1 [M+Na]+. 
 
Phenyl 2-O-benzoyl-3-O-benzyl-1-thio-β-D-galactopyranosiduronic acid (42): TLC: 50% 
EtOAc/PE (5% AcOH); [α]D22: +53° (c = 1, CHCl3); IR (neat, cm-1): 1026, 1068, 1091, 
1263, 1431, 1600, 1720; 1H NMR (400 MHz, MeOD) δ = 3.80 (d, 1H, J = 9.6 Hz, H-3), 4.21 
(s, 1H, H-5), 4.53 (d, 1H, J = 12.4 Hz, CHHPh), 4.54 (s, 1H, H-4), 4.64 (d, 1H, J = 12.4 Hz, CHHPh), 4.90 (d, 
1H, J = 8.4 Hz, H-1), 5.49 (t, 1H, J = 9.8 Hz, H-2), 7.00 – 7.93 (m, 15H, H Arom); 13C NMR (100 MHz, MeOD) 
δ = 67.0 (C-4), 69.7 (C-2), 70.5 (CH2 Bn), 78.1 (C-5), 79.4 (C-3), 86.6 (C-1), 127.1 – 133.0 (CH Arom), 129.8 
(Cq SPh), 133.9 (Cq Bz), 137.8 (Cq Bn), 165.6 (C=O Bz or COOH); ESI-MS: 503.3 [M+Na]+. 
 
Methyl (phenyl 2-O-benzoyl-3-O-benzyl-1-thio-β-D-galactopyranoside) uronate (43): TLC: 
50% EtOAc/PE; [α]D22: +29° (c = 1, CHCl3); IR (neat, cm-1): 1213, 1265, 1662, 1726, 1760; 
1H NMR (400 MHz, CDCl3) δ = 3.74 (dd, 1H, J = 9.2 Hz, J = 2.8 Hz, H-3), 3.84 (s, 3H, CH3 
COOMe), 4.18 (s, 1H, H-5), 4.50 (d, 1H, J = 12.0 Hz, CHHPh), 4.51 (s, 1H, H-4), 4.67 (d, 1H, J = 12.4 Hz, 
CHHPh), 4.74 (d, 1H, J = 10.4 Hz, H-1), 5.52 (t, 1H, J = 9.2 Hz, H-2), 7.02 – 8.02 (m, 15H, H Arom); 13C NMR 
(100 MHz, CDCl3) δ = 52.6 (CH3 COOMe), 67.3 (C-4), 68.9 (C-2), 71.2 (CH2 Bn), 77.0 (C-5), 78.3 (C-3), 86.6 
(C-1), 127.8 – 133.1 (CH Arom), 129.6 (Cq SPh), 132.4 (Cq Bz), 136.6 (Cq Bn), 165.1 (C=O Bz or COOMe), 
167.9 (C=O Bz or COOMe); HRMS: [M+H]+ calcd for C27H27O7S 512.1738, found 512.1797. 
 
Ethyl 2-O-benzoyl-3-O-benzyl-1-thio-α/β-L-idopyranosiduronic acid (45): TLC: 50% 
EtOAc/PE (5% AcOH); %); IR (neat, cm-1) 1066, 1716; α-anomer: 1H NMR (400 MHz, 
MeOD): δ = 1.27 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.68 (m, 2H, CH2 SEt), 3.87 (s, 1H, H-3), 
4.14 (m, 1H, H-4), 4.68 (d, 1H, J = 12.0 Hz, CHHPh), 4.80 (d, 1H, J = 12.0 Hz, CHHPh), 5.08 (s, 1H, H-5), 5.26 



































SEt), 27.3 (CH2 SEt), 69.0 (C-4), 70.2 (C-5), 71.0 (C-2), 73.4 (CH2 Bn), 76.8 (C-3), 84.0 (C-1), 128.7 – 134.4 
(CH Arom), 130.8 (Cq Bz), 138.9 (Cq Bn), 166.9 (C=O Bz or COOMe), 173.2 (C=O Bz or COOMe); β-anomer: 
1H NMR (400 MHz, CDCl3): δ = 1.30 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.78 (m, 2H, CH2 SEt), 3.82 (s, 1H, H-3), 
4.08 (m, 1H, H-4), 4.57 (s, 1H, H-5), 4.76 (d, 1H, J = 12.0 Hz, CHHPh), 4.81 (d, 1H, J = 12.0 Hz, CHHPh), 5.21 
(s, 1H, H-1), 5.22 (s, 1H, H-2), 7.12 – 8.17 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 15.5 (CH3 
SEt), 26.4 (CH2 SEt), 67.8 (C-4), 71.3 (C-2), 73.4 (CH2 Bn), 76.4 (C-3), 77.2 (C-5), 83.0 (C-1), 128.7 – 134.4 
(CH Arom), 130.7 (Cq Bz) 139.0 (Cq Bn), 167.3 (C=O Bz or COOMe), 172.4 (C=O Bz or COOMe); HRMS: 
[M+NH4]+ calcd for C22H28O7SN 450.1581, found 450.1568. 
 
Methyl (ethyl 2-O-benzoyl-3-O-benzyl-1-thio-α/β-L-idopyranoside) uronate (46): TLC: 
50% EtOAc/PE; IR (neat, cm-1): 1091, 1720, 1760; α-anomer: 1H NMR (400 MHz, CDCl3) 
δ = 1.30 (t, 3H, J = 7.6 Hz, CH3 SEt), 2.66 (m, 2H, CH2 SEt), 2.93 (bd, 1H, J = 11.2 Hz, 
OH), 3.79 (s, 3H, CH3 COOMe), 3.88 (s, 1H, H-3), 4.10 (m, 1H, H-4), 4.63 (d, 1H, J = 12.0 Hz, CHHPh), 4.83 
(d, 1H, J = 12.0 Hz, CHHPh), 5.28 (s, 1H, H-5), 5.32 (s, 1H, H-2), 5.56 (s, 1H, H-1), 7.12 – 8.00 (m, 10H, H 
Arom); 13C NMR (100 MHz, CDCl3): δ = 14.8 (CH3 SEt), 26.7 (CH2 SEt), 52.1 (CH3 COOMe), 68.1 (C-4), 68.3 
(C-5), 69.5 (C-2), 72.0 (CH2 Bn), 73.6 (C-3), 83.0 (C-1), 127.5 – 133.4 (CH Arom), 128.8 (Cq Bz), 136.9 (Cq 
Bn), 164.7 (C=O Bz or COOMe), 169.6 (C=O Bz or COOMe); β-anomer: 1H NMR (400 MHz, CDCl3): δ = 1.30 
(t, 3H, J = 7.6 Hz, CH3 SEt), 2.75 (m, 2H, CH2 SEt), 2.87 (bd, 1H, J = 11.6 Hz, OH), 3.79 (s, 3H, CH3 COOMe), 
3.99 (s, 1H, H-3), 4.06 (m, 1H, H-4), 4.60 (s, 1H, H-5), 4.72 (d, 1H, J = 12.0 Hz, CHHPh), 4.80 (d, 1H, J = 11.6 
Hz, CHHPh), 5.15 (s, 1H, H-1), 5.28 (s, 1H, H-2), 7.12 – 8.00 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): 
δ = 14.7 (CH3 SEt), 25.6 (CH2 SEt), 52.1 (CH3 COOMe), 67.3 (C-4), 69.9 (C-2), 72.4 (CH2 Bn), 74.2 (C-3), 76.0 
(C-5), 81.9 (C-1), 127.5 – 133.4 (CH Arom), 128.7 (Cq Bz), 136.9 (Cq Bn), 165.1 (C=O Bz or COOMe), 168.7 
(C=O Bz or COOMe); HRMS: [M+NH4]+ calcd for C23H30O7SN 464.1737, found 464.1739. 
 
 Methyl (phenyl 4-O-acetyl-2,3-di-O-benzyl-1-thio-β-D-galactopyranoside) uronate (47): 
TLC: 25% EtOAc/PE; [α]D22: -60° (c = 2.5, CHCl3); IR (neat, cm-1): 694, 734, 979, 1026, 
1141, 1203, 1355, 1436, 1759; 1H NMR (600 MHz, CDCl3) δ = 1.85 (s, 3H, CH3 Ac), 3.46 
(dd, 1H, J = 9.6 Hz, J = 9.0 Hz, H-2), 3.62 (t, 1H, J = 9.6 Hz, J = 9.0 Hz, H-3), 3.66 (s, 3H, CH3 COOMe), 3.82 
(d, 1H, J = 9.6 Hz, H-5), 4.57 (d, 1H, J = 9.6 Hz, H-1), 4.60 (d, 1H, J = 10.2 Hz, CHHPh), 4.62 (d, 1H, J = 10.2 
Hz, CHHPh), 4.72 (d, 1H, J = 10.2 Hz, CHHPh), 4.78 (d, 1H, J = 10.2 Hz, CHHPh), 5.06 (t, 1H, J = 9.6 Hz, H-
4), 7.15 – 7.50 (m, 15H, H Arom); 13C NMR (150 MHz, CDCl3) δ = 20.6 (CH3 Ac), 52.6 (CH3 COOMe), 70.8 
(C-4), 72.9 (C-5), 75.5 (CH2 Bn), 76.2 (C-2), 83.1 (C-3), 87.6 (C-1) 127.4 – 132.6 (CH Arom), 132.5 (Cq SPh), 
137.6 (Cq Bn), 137.8 (Cq Bn), 167.5 (C=O Ac or COOMe), 139.5 (C=O Ac or COOMe); ESI-MS: 545.2 
[M+Na]+; HRMS: [M+Na]+ calcd for C29H30O7SNa 545.16045, found 545.16022. 
 
Methyl 2,3,4-tri-O-benzyl-6-O-(methyl (4-acetyl-2,3-di-O-benzyl-α/β-D-gluco-
pyranoside) uronate)-α-D-glucopyranoside (49): Donor 47 was glycosylated 
with acceptor 4817 in the same way as described in the general procedure using 
Ph2SO/Tf2O delivering the title compound 49 as a colorless oil. TLC: 25% 
EtOAc/PE; IR (neat, cm-1): 694, 734, 979, 1026, 1141, 1203, 1355, 1436, 1759; β-anomer: 1H NMR (400 MHz, 
CDCl3) δ = 1.91 (s, 3H, CH3 Ac), 3.31 (s, 3H, CH3 OMe), 3.45 (t, 1H, J= 10.0 Hz, H-4), 3.49 (dd, 1H, J = 10.0 
Hz, J = 3.5 Hz, H-2), 3.54 (dd, 1H, J = 9.5 Hz, J = 7.5 Hz, H-2’), 3.58 – 3.62 (m, 2H, H-6, H-3’), 3.74 (s, 3H, 
CH3 COOMe), 3.79 (d, 1H, J = 10.0 Hz, H-5’), 3.80 (m, 1H, H-5), 3.99 (t, 1H, J = 9.5 Hz, H-3), 4.13 (d, 1H, J = 
11.0 Hz, H-6), 4.48 – 4.98 (m, 10H, 5xCH2Ph), 4.36 (d, 1H, J = 7.5 Hz, H-1’), 4.58 (d, 1H, J = 3.5 Hz, H-1), 




























52.6 (CH3 COOMe), 55.1 (CH3 OMe), 68.6 (C-6), 70.2 (C-5’), 71.0 (C-4’), 72.7 (C-5), 73.3 (CH2 Bn), 74.8 
(CH2 Bn), 75.0 (CH2 Bn), 75.1 (CH2 Bn), 75.6 (CH2 Bn), 77.9 (C-4), 79.8 (C-2), 81.1 (C-2’ or C-3’), 81.2 (C-3’ 
or C-2’), 81.8 (C-3), 97.9 (C-1), 103.6 (C-1’), 127.5 – 128.4 (CH Arom), 137.9 (2xCq Bn), 138.0 (Cq Bn), 138.2 
(Cq Bn), 138.7 (Cq Bn), 167.8 (C=O Ac or COOMe), 169.6 (C=O Ac or COOMe); ESI: 894.5 [M+NH4]+; 




Donor 47 was glycosylated with acceptor 50 in the same way as described in 
the general procedure using Ph2SO/Tf2O delivering the title compound 51 as a 
colorless oil. TLC: 25% EtOAc/PE; IR (neat, cm-1): 694, 734, 979, 1026, 1141, 
1203, 1355, 1436, 1759; α-anomer: 1H NMR (400 MHz, CDCl3) δ = 1.87 (s, 3H, CH3 Ac), 3.51 – 3.53 (m, 1H, 
H-5), 3.63 – 3.65 (m, 4H, H-2, CH3 pMP), 3.76 (s, 3H, CH3 COOMe), 4.05 (dd, 1H, J = 7.6 Hz, J = 2.4 Hz, H-
3), 4.05 (t, 1H, J = 7.6 Hz, H-3’), 4.10 (d, 1H, J = 10.0 Hz, H-6), 4.17 (t, 1H, J = 7.6 Hz, H-2), 4.32 – 4.39 (m, 
2H, H-4, H-6), 4.49 (d, 1H, J = 8.4 Hz, H-5’), 4.61 – 5.19 (m, 6H, 3xCH2Ph), 4.92 (d, 1H, J = 7.6 Hz, H-1), 5.01 
(t, 1H, J = 7.6 Hz, H-4’), 5.63 (s, 1H, CHPh), 6.81 (d, 2H, J = 9.0 Hz, 2xCH pMP), 7.03 (d, 2H, J = 9.0 Hz, 
2xCH pMP), 7.07 – 7.61 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.5 (CH3 Ac), 52.5 (CH3 pMP), 
55.6 (CH3 COOMe), 66.7 (C-5), 68.2 (C-5’), 69.0 (C-6), 74.5 (C-4’), 74.9 (CH2 Bn), 75.1 (CH2 Bn), 75.3 (CH2 
Bn), 75.5 (C-4), 75.9 (C-3), 77.3 (C-3’), 78.0 (C-2’), 79.0 (C-2), 92.4 (C-1’), 100.7 (CHPh), 103.2 (C-1), 114.4 
(CH pMP), 119.6 (CH pMP), 126.2 – 129.7 (CH Arom), 137.5 (Cq Bn), 137.9 (Cq Bn), 138.2 (Cq Bn), 151.4 (Cq 
pMP), 155.3 (Cq pMP), 168.1 (C=O COOMe or Ac), 169.7 (C=O Ac or COOMe); ESI: 894.5 [M+NH4]+; 
HRMS: [M+NH4]+ calcd for C50H56O14N 894.36953, found 894.36334. 
 
Methyl (phenyl 4-O-acetyl-2,3-di-O-benzyl-1-thio-β-D-galactopyranoside) uronate (52): A 
solution of 734 mg compound 37 (1.53 mmol) in 5 mL pyridine and 2 mL Ac2O was stirred 
for 3h before 5 mL MeOH was added. The reaction mixture was concentrated under reduced 
pressure and several times co-evaporated with toluene. Flash column chromatography using EtOAc/petroleum 
ether afforded 798 mg of the title compound 52 (1.53 mmol, quant) as a colorless oil. TLC: 25% EtOAc/PE; 
[α]D22: -32° (c = 1, CHCl3); IR (neat, cm-1): 1230, 1749; 1H NMR (400 MHz, CDCl3) δ = 2.11 (s, 3H, CH3 Ac), 
3.67 (m, 2H, H-2, H-5), 3.78 (s, 3H, CH3 COOMe), 4.52 (d, 1H, J = 11.2 Hz, CHHPh), 4.63 (d, 1H, J = 9.6 Hz, 
H-1), 4.74 (d, 1H, J = 10.4 Hz, CHHPh), 4.75 (d, 1H, J = 10.0 Hz, CHHPh), 4.77 (d, 1H, J = 10.0 Hz, CHHPh), 
5.82 (d, 1H, J = 1.2 Hz, H-4), 7.25 – 7.40 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.8 (CH3 Ac), 
52.6 (CH3 COOMe), 67.6 (C-4), 72.0 (CH2 Bn), 75.6 (C-3), 76.1 (CH2 Bn), 76.7 (C-2 or C-5), 80.6 (C-5 or C-2), 
87.8 (C-1), 127.8 – 128.8 (CH Arom), 137.2 (Cq Bn), 138.0 (Cq Bn), 167.0 (C=O Ac or COOMe), 169.9 (C=O 
Ac or COOMe); HRMS: [M+H]+ calcd for C29H31O7S 523.17850, found 523.18024 
 
Methyl 2,3,4-tri-O-benzyl-6-O-(methyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-
galacto-pyranosyluronate)-α-D-glucopyranoside (53): Donor 52 was glycosylated 
with acceptor 4817 in the same way as described in the general procedure using 
Ph2SO/Tf2O delivering the title compound 53 as a colorless oil. TLC: 25% 
EtOAc/PE; IR (neat, cm-1): 694, 734, 979, 1026, 1141, 1203, 1355, 1436, 1759; β-anomer: 1H NMR (400 MHz, 
CDCl3) δ = 2.08 (s, 3H, CH3 Ac), 3.29 (s, 3H, CH3 OMe), 3.48 (m, 2H, H-2, H-4), 3.55 (dd, 1H, J = 9.6 Hz, J = 
3.6 Hz, H-3’), 3.64 – 3.70 (m, 2H, H-5 and H-2’), 3.74 (s, 3H, CH3 COOMe), 3.79 – 3.85 (m, 1H, H-6), 4.00 (m, 
2H, H-3, H-5’), 4.23 (d, 1H, J = 9.6 Hz, H-6), 4.29 (d, 1H, J = 8.0 Hz, H-1’), 4.48 – 4.98 (m, 10H, 5xCH2Ph), 

































MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.4 (CH3 COOMe), 54.9 (CH3 OMe), 67.0 (C-4’), 68.8 (C-6), 69.9 (C-5), 
72.0 (CH2 Bn), 72.4 (C-5’), 73.2 (CH2 Bn), 74.7 (CH2 Bn), 75.6 (CH2 Bn), 75.7 (CH2 Bn), 77.9 (C-2 or C-4), 
78.0 (C-2’), 78.6 (C-3’), 79.8 (C-4 or C-2), 81.9 (C-3), 97.9 (C-1), 103.7 (C-1’), 127.4 – 128.4 (CH Arom), 
137.5 (Cq Bn), 138.0 (Cq Bn), 138.4 (Cq Bn), 138.7 (Cq Bn), 138.8 (Cq Bn), 167.2 (C=O Ac or COOMe), 169.9 




di-O-benzyl-α-D-galactopyranosyluronate)-β-D-galactopyranoside (54): Donor 52 
was glycosylated with acceptor 50 in the same way as described in the general 
procedure using Ph2SO/Tf2O delivering the title compound 54 as a colorless oil. 
TLC: 25% EtOAc/PE; IR (neat, cm-1): 694, 734, 979, 1026, 1141, 1203, 1355, 
1436, 1759; 1H NMR (400 MHz, CDCl3) δ = 2.02 (s, 3H, CH3 Ac), 3.47 (s, 1H, H-5), 3.58 (s, 3H, CH3 OMe), 
3.76 (s, 3H, CH3 COOMe), 3.83 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H-2’), 3.86 (dd, 1H, J = 10.0 Hz, J = 3.6 Hz, H-
3), 3.95 (dd, 1H, J = 10.0 Hz, J = 3.32 Hz, H-3’), 4.08 (d, 1H, J = 11.2 Hz, H-6), 4.13 (dd, 1H, J = 10.0 Hz, J = 
8.0 Hz, H-2), 4.33 (d, 1H, J = 3.2 Hz, H-4), 4.36 (d, 1H, J = 11.6 Hz, H-6), 4.50 (d, 1H, J = 11.2 Hz, CHHPh), 
4.54 (d, 1H, J = 12.0 Hz, CHHPh), 4.63 (d, 1H, J = 11.6 Hz, CHHPh), 4.70 (d, 2H, J = 10.8 Hz, 2xCHHPh), 
4.75 (d, 1H, J = 1.2 Hz, H-5’), 4.90 (d, 1H, J = 8.0 Hz, H-1), 5.06 (d, 1H, J = 10.8 Hz, CHHPh), 5.24 (d, 1H, J = 
3.6 Hz, H-1’), 5.52 (d, 1H, J = 2.0 Hz, H-4’), 5.57 (s, 1H, CHPh), 6.82 (d, 2H, J = 9.0 Hz, 2xCH pMP), 7.03 (d, 
2H, J = 9.0 Hz, 2xCH pMP), 7.07 – 7.28 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.7 (CH3 Ac), 
52.2 (CH3 OMe), 55.6 (CH3 COOMe), 66.3 (C-5), 68.9 (C-4’), 68.8 (C-5’), 69.2 (C-6), 71.4 (C-4), 72.2 (CH2 
Bn), 72.6 (CH2 Bn), 74.0 (C-3), 74.4 (C-2’), 75.0 (C-3’), 75.4 (CH2 Bn), 76.8 (C-2), 93.4 (C-1’), 101.3 (CHPh), 
103.2 (C-1), 107.4 (CH Arom pMP), 119.6 (CH Arom pMP), 123.8 – 128.9 (CH Arom), 137.5 (Cq Bn), 137.9 
(Cq Bn), 138.2 (Cq Bn), 138.2 (Cq Bn), 151.4 (Cq pMP), 155.3 (Cq pMP), 168.1 (C=O COOMe or Ac), 169.7 
(C=O Ac or COOMe); ESI: 899.6 [M+Na]+; HRMS: [M+Na]+ calcd for C50H52O14Na 899.32493, found 
899.31935. 
 
Methyl (4-methoxyphenyl 2,4-di-O-benzyl-3-O-(methyl 4-O-acetyl-2,3-di-O-ben-
zyl-α-D-galactopyranosyluronate)-β-D-galactopyranoside) uronate (56): Donor 52 
was glycosylated with acceptor 55 in the same way as described in the general 
procedure using BSP/Tf2O delivering 51 mg (0.056 mmol, 57%) of the title 
compound 56 as a colorless oil. TLC: 20% EtOAc/toluene; [α]D22: +68° (c = 1, CHCl3); IR (neat, cm-1): 1026, 
1089, 1215, 1506, 1747; 1H NMR (400 MHz, CDCl3) δ = 2.01 (s, 3H, CH3 Ac), 3.58 (s, 3H, CH3 COOMe), 3.67 
(s, 3H, CH3 COOMe), 3.76 (s, 3H, CH3 pMP), 3.89 (m, 2H, H-3, H-2’), 3.96 (dd, 1H, J = 10.0 Hz, J = 3.2 Hz, 
H-3’), 4.12 (t, 2H, J = 8.8 Hz, H-2, H-5), 4.28 (s, 1H, H-4), 4.42 (d, 1H, J = 11.2 Hz, CHHPh), 4.50 (d, 1H, J = 
11.2 Hz, CHHPh), 4.63 (d, 1H, J = 11.8 Hz, CHHPh), 4.64 (d, 1H, J = 11.4 Hz, CHHPh), 4.72 (d, 1H, J = 11.2 
Hz, CHHPh), 4.80 (d, 1H, J = 7.6 Hz, H-1), 4.84 (d, 1H, J = 11.2 Hz, CHHPh), 4.90 (d, 1H, J = 1.2 Hz, H-5’), 
5.04 (d, 1H, J = 11.6 Hz, CHHPh), 5.08 (d, 1H, J = 11.2 Hz, CHHPh), 5.27 (d, 1H, J = 3.2 Hz, H-1’), 5.50 (bs, 
1H, H-4’), 6.77 – 7.43 (m, 24H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.1 (CH3 COOMe), 
52.4 (CH3 COOMe), 55.6 (CH3 pMP), 68.6 (C-4’), 69.0 (C-5’), 71.9 (CH2 Bn), 73.9 (C-4), 74.0 (C-5), 74.4 (C-3 
or C-2’), 74.7 (CH2 Bn), 74.9 (CH2 Bn), 75.4 (CH2 Bn), 75.6 (C-3’), 76.4 (C-2’ or C-3), 76.9 (C-2), 95.3 (C-1’), 
103.3 (C-1), 114.4 (CH Arom pMP), 118.8 (CH Arom pMP), 127.2 – 128.5 (CH Arom), 137.7 (Cq Bn), 137.9 
(Cq Bn), 138.3 (Cq Bn), 151.3 (Cq pMP), 155.4 (Cq pMP), 168.0 (C=O Ac or COOMe), 168.1 (C=O Ac or 































Methyl (phenyl 4-O-acetyl-2,3-di-O-benzoyl-1-thio-β-D-glucopyranoside) uronate (57): A 
solution of 138 mg compound 28 (0.3 mmol) in 2 mL pyridine and 0.7 mL Ac2O was 
stirred for 3h before 3 mL MeOH was added. The reaction mixture was concentrated under 
reduced pressure and several times co-evaporated with toluene. Flash column chromatography using 
EtOAc/petroleum ether afforded 153 mg of the title compound 57 (0.3 mmol, quant.) as a colorless oil. TLC: 
25% EtOAc/PE; MP: 178°C; [α]D22: +59° (c = 1, CHCl3); IR (neat, cm-1): 1066, 1093, 1226, 1257, 1708; 1H 
NMR (400 MHz, CDCl3) δ = 1.94 (s, 3H, CH3 Ac), 3.80 (s, 3H, CH3 COOMe), 4.23 (d, 1H, J = 10.0 Hz, H-5), 
5.99 (d, 1H, J = 10.0 Hz, H-1), 5.40 (t, 1H, J = 10.0 Hz, H-2), 5.45 (t, 1H, J = 10.2 Hz, H-4), 5.73 (t, 1H, J = 9.4 
Hz, H-3), 7.31 – 7.96 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.4 (CH3 Ac), 52.9 (CH3 COOMe), 
69.4 (C-4), 69.9 (C-2), 73.6 (C-3), 76.4 (C-5), 86.5 (C-1), 128.4 – 133.4 (CH Arom), 128.5 (Cq SPh), 131.3 (Cq 
Bz), 164.8 (C=O Ac, Bz or COOMe), 165.5 (C=O Ac, Bz or COOMe), 166.9 (C=O Ac, Bz or COOMe); 
HRMS: [M+H]+ calcd for C29H27O9S 551.13703, found 551.13885. 
 
Methyl 2,3,4-tri-O-benzyl-6-O-(methyl 4-O-acetyl-2,3-di-O-benzoyl-β-D-gluco-
pyranosyluronate)-α-D-glucopyranoside (58): Donor 57 was glycosylated with 
acceptor 4817 in the same way as described in the general procedure using 
BSP/Tf2O delivering 57 mg of the title compound 58 (0.063 mmol, 63%). NB: In 
this case TTBP was excluded from the reaction mixture to prevent ortho-ester formation. TLC: 20% 
EtOAc/toluene; MP: 168°C (decomp.); [α]D22: +40° (c = 1, CHCl3); IR (neat, cm-1): 1024, 1066, 1091, 1220, 
1276, 1730; 1H NMR (400 MHz, CDCl3) δ = 1.94 (s, 3H, CH3 Ac), 3.18 (s, 3H, CH3 OMe), 3.35 (m, 1H, J = 9.2 
Hz, H-4), 3.40 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H-2), 3.69 (m, 2H, H-5, H-6), 3.76 (s, 3H, CH3 COOMe), 4.00 (t, 
J = 9.6 Hz, 1H, H-3), 4.14 (m, 2H, H-5’, H-6), 4.31 (d, 1H, J = 11.2 Hz, CHHPh), 4.47 (d, 1H, J = 3.6 Hz, H-1), 
4.56 (d, 1H, J = 8.4 Hz, CHHPh), 4.58 (d, 1H, J = 9.6 Hz, CHHPh), 4.68 (d, 2H, J = 10.8 Hz, 2xCHHPh), 4.74 
(d, 1H, J = 6.8 Hz, H-1’), 4.90 (d, 1H, J = 10.8 Hz, CHHPh), 5.45 – 5.51 (m, 2H, J = 9.6 Hz, J = 6.4 Hz, H-2’, 
H-4’), 5.68 (t, 1H, J = 9.4 Hz, H-3’), 7.08 – 7.91 (m, 25H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.4 (CH3 
Ac), 52.8 (CH3 COOMe), 54.9 (CH3 OMe), 68.5 (C-6), 69.3 (C-2’ or C-4’), 69.5 (C-5), 71.4 (C-4’ or C-2’), 72.2 
(C-3’), 72.7 (C-5’), 73.2 (CH2 Bn), 74.6 (CH2 Bn), 75.4 (CH2 Bn), 77.4 (C-4), 79.7 (C-2), 81.8 (C-3), 97.8 (C-1), 
101.1 (C-1’), 127.4 – 133.4 (CH Arom), 128.3 (Cq Bz), 129.0 (Cq Bz), 138.1 (Cq Bn), 138.7 (Cq Bn), 163.2 
(C=O Bz or Ac or COOMe), 164.7 (C=O Bz or Ac or COOMe), 165.6 (C=O Bz or Ac or COOMe), 167.1 (C=O 




α-D-glucopyranosyl)-1-thio-β-D-glucopyranoside) uronate (60): A solution of 128 
mg donor 59 (0.3 mmol), 170 mg diphenylsulfoxide (0.84 mmol, 2.5 equiv.) and 
223 mg tri-tert-butylpyrimidine (0.9 mmol, 3 equiv.) in 3 mL DCM was stirred 
over 100 mg activated MS3Å for 30 min. The mixture was cooled to -60°C before 
69 µL triflic acid anhydride (0.42 mmol, 1.4 equiv.) was added. The mixture was allowed to warm to -40°C in 
1h followed by addition of 173 mg acceptor 13 (0.4 mmol, 1.5 equiv.) in 1 mL DCM. Stirring was continued and 
the reaction mixture was allowed to warm to 0°C. Subsequently 0.16 mL triethylamine was added to the reaction 
mixture. Flash chromatography (10% EtOAc/PE) and removal of the eluent afforded 169 mg of the title 
compound 60 (0.2 mmol, 67%) as a colorless oil. TLC: 20% EtOAc/toluene; [α]D22: +15° (c = 1, CHCl3); IR 
(neat, cm-1): 1028, 1074, 1209, 1236, 1361, 1444, 1741, 2108; 1H NMR (400 MHz, CDCl3) δ = 1.23 (t, 3H, J = 
7.6 Hz, CH3 SEt), 2.01 (s, 3H, CH3 Ac), 2.73 – 2.78 (m, 2H, CH2 SEt), 3.50 (t, 1H, J = 9.2 Hz, H-2), 3.52 (t, 1H, 


































3.88 (t, 1H, J = 9.2 Hz, H-3’), 3.91 (d, 1H, J = 9.6 Hz, H-5), 4.13 (t, 1H, J = 9.4 Hz, H-4), 4.28 (bs, 2H, H-6’), 
4.51 (t, 2H, J = 9.4 Hz, H-1, CHHPh), 4.65 (d, 1H, J = 10.0 Hz, CHHPh), 4.80 (d, 1H, J = 11.2 Hz, CHHPh), 
4.86 (s, 2H, CH2 Bn), 4.90 (d, 1H, J = 10.8 Hz, CHHPh), 4.93 (d, 1H, J = 10.4 Hz, CHHPh), 5.03 (d, 1H, J = 
10.8 Hz, CHHPh), 5.53 (d, 1H, J = 3.6 Hz, H-1’), 7.24 – 7.71 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ 
= 14.8 (CH3 SEt), 20.8 (CH3 Ac), 25.0 (CH2 SEt), 52.7 (CH3 COOMe), 62.1 (C-6’), 63.2 (C-2’), 69.6 (C-5’), 
74.9 (CH2 Bn), 75.1 (C-4), 75.1 (CH2 Bn), 75.2 (CH2 Bn), 75.4 (CH2 Bn), 77.4 (C-4’), 77.8 (C-5), 80.0 (C-3’), 
81.2 (C-2), 85.5 (C-3), 85.6 (C-1), 97.7 (C-1’); 124.7 – 131.0 (CH Arom), 137.5 (Cq Bn), 138.1 (Cq Bn), 168.3 
(C=O Ac or COOMe), 170.6 (C=O Ac or COOMe), ESI-MS: 864.4 [M+Na]+. 
 
 3-O-Benzoyl-5,6-O-isopropylidene-D-galactono-1,4-lactone (61): Commercially available 
D-galactono-1,4-lactone (910 mg, 5 mmol) was suspended in 25 mL acetone before 572 mg 
dimethoxypropane (5.5 mmol, 1.1 equiv.) and a catalytic amount of pTsOH were added. 
The mixture was stirred overnight, neutralized with 5 mL NEt3 and concentrated under 
reduced pressure. The crude oil was dissolved in 25 mL DCM and cooled to 0°C. Subsequently 408 mg 
imidazole (6 mmol, 1.2 equiv.) and 830 mg TBDMSCl (5.5 mmol, 1.1 equiv.) were added. The mixture was 
stirred for 15 min and filtered over a plug of silica gel. The filtrate was concentrated under reduced pressure. The 
crude oil was dissolved in 25 mL pyridine and cooled to 0°C before 0.58 mL BzCl (5 mmol, 1 equiv.) was 
added. The reaction mixture was allowed to stir overnight followed by the addition of 1 mL MeOH. The mixture 
was concentrated and filtered over a short plug of silica gel. Evaporation of the solvent yielded the completely 
protected intermediate. This was dissolved in 20 mL THF and treated with 0.29 mL AcOH and 5 mL TBAF (5 
mmol, 1 equiv.) for 6 h. The reaction mixture was diluted with EtOAc and washed with NaHCO3 (sat. aq.) and 
brine. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column 
chromatography, using EtOAc/petroleum ether afforded 656 mg of the title compound 61 (2.10 mmol, 62% over 
the 4 steps) as a colorless oil. TLC: 40% EtOAc/toluene; [α]D22: +24° (c = 1, CHCl3); IR (neat, cm-1): 636, 694, 
756, 889, 912, 1008, 1029, 1157, 1271, 1444, 1488, 1728, 1793; 1H NMR (400 MHz, CDCl3) δ = 1.58 (s, 3H, 
CH3 isoprop), 1.60 (s, 3H, CH3 isoprop), 3.94 (d, 1H, J = 8.4 Hz, OH-2), 4.05 (t, 1H, J = 6.8 Hz, H-6), 4.19 (dd, 
1H, J = 8.4 Hz, J = 6.7 Hz, H-6), 4.51 – 4.57 (m, 3H, H-2, H-4, H-5), 5.42 (t, 1H, J = 3.2 Hz, H-3), 7.42 – 7.86 
(m, 5H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 25.5 (CH3 isoprop), 25.6 (CH3 isoprop), 65.2 (C-6), 71.9 (C-
2), 74.7 (C-5), 77.9 (C-3), 79.7 (C-4), 111.1 (Cq isoprop), 128.7 – 134.1 (CH Arom), 172.3 (C=O lactone); ESI-





















benzyl-α-D-glucopyranosyluronate)-5,6-O-isopropylidene-D-galactono-1,4-lactone (62): Donor 60 was 
glycosylated with acceptor 61 in the same way as described in the general procedure using BSP/Tf2O delivering 
38 mg of the title compound 62 (0.035 mmol, 35%) as a colorless oil (α/β = 4/1). TLC: 20% EtOAc/toluene; IR 
(neat, cm-1): 1174, 1296, 1676, 1743, 2106; α-anomer: 1H NMR (600 MHz, CDCl3) δ = 1.41 (s, 3H, CH3 
isoprop), 1.43 (s, 3H, CH3 isoprop), 2.00 (s, 3H, CH3 Ac), 3.19 (dd, 1H, J = 10.4 Hz, J = 3.7 Hz, H-2”), 3.44 – 
3.45 (m, 2H, H-4”, H-5”), 3.45 (s, 3H, CH3 COOMe), 3.66 (t, 1H, J = 8.2 Hz, H-2’), 3.68 – 3.71 (m, 2H, J = 9.5 













1H, J = 9.1 Hz, H-3’), 4.11 – 4.14 (m, 2H, H-6, H-6”), 4.20 – 4.23 (m, 2H, H-5’, H-6”), 4.43 (dd, 1H, J = 5.9 
Hz, J = 2.9 Hz, H-4), 4.51 (d, 1H, J = 10.9 Hz, CHHPh), 4.56 (dt, 1H, J = 6.7 Hz, J = 2.8 Hz, H-5), 4.65 (d, 1H, 
J = 11.3 Hz, CHHPh), 4.71 (d, 1H, J = 10.5 Hz, CHHPh), 4.73 (d, 1H, J = 10.5 Hz, CHHPh), 4.79 (d, 1H, J = 
10.9 Hz, CHHPh), 4.81 (d, 1H, J = 6.7 Hz, H-2), 4.82 (d, 1H, J = 10.3 Hz, CHHPh), 4.84 (d, 1H, J = 11.0 Hz, 
CHHPh), 5.08 (d, 1H, J = 10.6 Hz, CHHPh), 5.52 (d, 1H, J = 3.7 Hz, H-1”), 5.61 (d, 1H, J = 3.5 Hz, H-1’), 5.89 
(t, 1H, J = 6.5 Hz, H-3”), 7.23 – 8.09 (m, 25H, H Arom); 13C NMR (150 MHz, CDCl3) δ = 20.8 (CH3 Ac), 25.4 
(CH3 isoprop), 25.9 (CH3 isoprop), 52.4 (CH3 COOMe), 62.2 (C-6”), 63.1 (C-2”), 65.1 (C-6), 69.5 (C-5’’), 70.5 
(C-5’), 72.4 (CH2 Bn), 74.3 (C-3), 74.6 (C-2, C-5), 74.8 (CH2 Bn), 74.9 (C-4’), 75.2 (CH2 Bn), 75.4 (CH2 Bn), 
77.4 (C-4”), 78.6 (C-2’), 80.0 (C-4), 80.7 (C-3”), 81.0 (C-3’), 96.1 (C-1’), 97.9 (C-1”), 110.7 (Cq isoprop), 125.2 
– 134.0 (CH Arom), 137.2 (Cq Bn), 137.6 (Cq Bn), 138.1 (Cq Bn), 138.4 (Cq Bn), 165.4 (C=O Ac, Bz or 
COOMe), 169.1 (C=O Ac, Bz or COOMe), 170.7 (C=O Ac, Bz or COOMe); HRMS: [M+H]+ calcd for 
C59H64O18N3 1119.44449, found 1119.44702. 
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Abstract: The chemo- and regioselective TEMPO/BAIB-mediated oxidation of 2,6- and 3,6-
dihydroxy 1-thio glycopyranosides to the corresponding 1-thio uronic acid lactones is described. 
These locked 1-thio glycuronides can directly be used as donors in glycosidation reactions using the 
Ph2SO/Tf2O reagent system. Alternatively, selective opening of the lactone bridge liberates a hydroxyl 






The 2,2,6,6-tetramethylpiperidinyloxy free radical 1 (TEMPO, Figure 1A) is a versatile and 
often applied reagent for the selective oxidation of primary hydroxyl functions.2 The active 
species in this reaction is believed to be the N-oxoammonium salt 2, generated in situ from 
the reaction between TEMPO (1) and any of a number of co-oxidants, including m-
chloroperoxybenzoic acid,3 calcium or sodium hypochlorite4 and several hypervalent 
iodine(III) species.5 Recently, it was reported that the combination of TEMPO and 
[bis(acetoxy)iodo]benzene (BAIB) enabled the chemo- and regioselective oxidation of 
primary alcohols into the corresponding aldehydes6 or carboxylic acids.7 The Forsyth group 
used the same reagent combination for the synthesis of δ-lactones from the corresponding 1,5-
diol systems having a primary and a secondary hydroxyl function.8 Studies on this process 
revealed the formation of a lactol intermediate via selective oxidation of the primary hydroxyl 
function followed by nucleophilic attack of the secondary alcohol on the resulting aldehyde. 







Chapter 2 describes the application of the TEMPO/BAIB reagent system in the chemo- and 
regioselective oxidation of a variety of 4,6-dihydroxy 1-thioglycosides (3, Figure 1B).10,11 The 
1-thio uronic esters 5, obtained by treatment of 4 with diazomethane, proved to be valuable 
building blocks in oligosaccharide synthesis. In an extension of this method for the selective 
oxidation of 4,6-dihydroxy 1-thioglycosides, this Chapter outlines the tandem oxidation-
lactonization process of a variety of 2,6- and 3,6-dihydroxy 1-thioglycosides and application 








































Results and Discussion 
 
In a first attempt to induce lactone formation, phenyl 2,4-di-O-benzyl-1-thio-β-D-
galactopyranoside (6)12 was treated with 0.2 equiv. TEMPO and 2.5 equiv. BAIB in 
anhydrous DCM (Table 1, entry 1). The expected 6,3-lactone13 7 was obtained in 54% yield 
along with a considerable amount of sulfoxide and sulfone by-products. Changing the 
reaction medium to the biphasic DCM/H2O system led to the rapid and efficient 
transformation of diol 6 into lactone 7 (75% yield) with only trace amounts of the side 
products formed. Subjection of ethyl 3,4-di-O-benzyl-1-thio-α-D-mannopyranoside (9), which 
has a 2,6-cis diol configuration, to the latter oxidation conditions afforded lactone product 10 
in 77% yield (entry 2). Similarly, glycopyranosides 12 and 15 were converted into lactones 13 
and 16 (entries 3 and 4). The relatively poor yield of lactone 16 is likely due to the change 
from the “all equatorial” 4C1 conformation of compound 15 into its 1C4 conformation in which 
all substituents are axially oriented. As a final example, compound 18 containing an anomeric 
hydroxyl group was converted into the corresponding 6,1-lactone 19, albeit in moderate yield 
(27%).  
The next objective was to find suitable conditions for selective opening of the lactone 
bridge, liberating the hydroxyl function for potential functionalization in ensuing 







reflux furnished the corresponding transesterified products 11 and 14 (entries 2 and 3) in a 
quantitative yield. As exemplified in entry 3, the relatively labile acetyl group is stable with 
respect to the cleavage conditions of the lactone bridge.14 The lactone function in compounds 
7 and 16 (entry 1 and 4) proved to be stable to these conditions.15 However, stirring 7 and 16 
in methanol containing a catalytic amount of p-toluenesulfonic acid delivered the desired 
esters 8 and 17 in a quantitative yield.  
The conformationally locked lactones 7, 10, 13, and 16 have potential for stereoselective 
glycosylation reactions.16 It is now well established that the conformation of donor glycosides 
plays a pivotal role in governing both reactivity and anomeric selectivity in glycosidations.17  
 
Table 1.  






















































































































27%c --- --- 
 
a isolated yields. b 0.2 equiv. TEMPO, 2.5 equiv. BAIB, DCM. c 0.2 equiv. TEMPO, 2.5 equiv. BAIB, 







For example, Fraser-Reid and coworkers reported that benzylidene protected glycosides are 
less reactive than their benzylated counterparts.18 This difference in reactivity was attributed 
to so-called “torsional disarmament” and has shown promise in increasing anomeric 
selectivities.19 On the other hand, it has been stated that in glycosylation events torsional 
effects are, in general, overruled by the electronic effects exerted by the ring substituents.20 
However, Bols and coworkers demonstrated that in the case of 1C4 locked methyl 3,6-
anhydro-β-D-glycosides, the reactivity of the anomeric function is influenced by electronic 
effects originating from the orientation of the remaining hydroxyl substituents.21 Chapter 2 
describes the decreased nucleophilicity of the sulfur atom at the anomeric centre due to the 
remotely attached carboxylic ester at the C6 position.10 The intrinsic low reactivity of the  
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1-thio methyl uronates was overcome by activation with the highly electrophilic Ph2SO/Tf2O 
reagent combination at slightly elevated temperature (-40°C) compared to the standard 
activation temperature (-60°C).22 Galactosyl donor 7 was chosen as a model compound to 
determine the influence of the bridged lactone function in glycosidation reactions (Table 2). 
Treatment of lactone 7 with 1.3 equiv. Ph2SO, 1.3 equiv. Tf2O and 2.5 equiv. TTBP23 at         
-50°C gave full activation within 15 min. Addition of acceptor 20,24 bearing a primary 
hydroxyl group afforded disaccharide 21 in good yield (entry 1). The heteronuclear coupling 
constant between C1 and H1 (so-called 13C-GATED experiment) revealed the presence of an 
α-interglycosidic linkage. Treatment of an activated mixture of donor 7 with acceptor 22 
afforded disaccharide 23 in near quantitative yield, again fully α-selective (entry 2).25 
Analogously, methyl uronate 24 was applied as acceptor species in the Ph2SO/Tf2O-mediated 
glycosidation involving donor 7, resulting in α-selective formation of disaccharide 25 (entry 
3). Changing the acceptor towards N-(benzyloxycarbonyl)-protected glucosamine 26 also 
delivered the corresponding disaccharide 27 as a single diastereomer (entry 4). This reaction 
proceeded slower than the other glycosidations, probably due to reduced reactivity of the 
acceptor alcohol acting as an intramolecular H-bond acceptor.26 The amount of base (tri-tert-
butylpyrimidine, TTBP)27 used in this condensation was reduced to one equivalent with 
respect to the amount of Tf2O to circumvent possible side-reactions involving the nucleophilic 
N-atom.28 Performing the reaction in the absence of base gave no significant improvement in 
yield. Upon addition of galactopyranose 28 to the activated mixture of donor 7, Ph2SO and 
Tf2O, a 4/1 mixture of α- and β-disaccharide 29 was formed (entry 5). The reduced 
stereoselectivity may be related to the steric environment of the OH4 group in acceptor 28, 

























































Having established that locked 1-thio uronic acid lactones can be used as donors in 
glycosylation reactions it was decided to explore their acceptor properties after the opening of 
the lactone bridge. Disaccharide 27 was taken as a model compound towards the synthesis of 
nonnatural trisaccharide 32 (Scheme 1). Treatment of benzylated lactone 27 with potassium 
tert-butoxide in MeOH under strictly anhydrous conditions afforded the desired acceptor 30 
in a yield of 82%. Pre-activation of 2-O-acylated donor 31 using diphenylsulfonium bistriflate 
at -60°C in DCM followed by addition of acceptor 30 afforded trisaccharide 32 in 63% yield. 





This Chapter describes an efficient synthetic route for locked 1-thio 6,2- and 6,3-lactones 
and their implementation as both donor and acceptor in Ph2SO/Tf2O-mediated coupling 
reactions. Compared to the open-form galacturonic acid esters decribed in Chapter 2, the 
galacto-6,3-lactones possess higher reactivity and superior stereoselectivity in glycosylation. 
Application of these lactones in oligosaccharide synthesis is shown for the synthesis of 
trisaccharide 32 requiring only a minimal number of protective group manipulations at the 




General Procedures: 1H and 13C NMR spectra were recorded on a Brüker DPX-300 (300/75 MHz), Brüker AV-
400 (400/100 MHz) and a Brüker DMX-600 (600/150 MHz) spectrometer. Chemical shifts (δ) are given in ppm 
relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. All given 13C spectra are 
proton decoupled. Mass spectra were recorded with PE/SCIEX API 165 with electronspray interface and Q-Star 
Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured on a Propol automatic polarimeter. 
IR-spectra were recorded on a Shimadzu FTIR-8300. Traces of water in the donor and acceptor glycosides, 
diphenylsulfoxide and TTBP were removed by co-evaporation with toluene. TTBP27 was synthesised as 
described by Crich et al. Dichloromethane (DCM, Baker p.a.) was boiled under reflux over P2O5 for 2h and 
distilled immediately prior to use. Trifluoromethanesulfonic anhydride was distilled from P2O5. Molecular sieves 
3Å were flame dried before use. Solvents used for flash chromatography and TLC were of technical grade and 
distilled before use. Flash chromatography was performed on Fluka silica gel 60 (0.04 – 0.063 mm). TLC-
analysis was conducted on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm) 
where applicable and by spraying with 20% sulfuric acid in ethanol followed by charring at ~150°C or by 
spraying with a solution of (NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulfuric acid 








General Procedure for the TEMPO/BAIB-Mediated Tandem Oxidation/Lactonization: To a vigorously 
stirred solution of 0.3 mmol thioglycoside in 1 mL DCM and 0.5 mL H2O was added 0.06 mmol TEMPO (0.2 
equiv.) and 0.75 mmol BAIB (2.5 equiv.). Stirring was allowed until TLC indicated complete conversion of the 
starting material to a higher running spot (~15min). The reaction mixture was quenched by the addition of 10 mL 
Na2S2O3 solution (10% in H2O) and 10 mL NaHCO3 (sat., aq.). The mixture was then extracted twice with 
EtOAc (10 mL) and the combined organic phase was dried (MgSO4), filtered and concentrated. Flash column 
chromatography using EtOAc/petroleum ether afforded the pure lactones. 
 
General Procedure for Glycosidations using Ph2SO/Tf2O: A solution of lactone (1 equiv), diphenyl sulfoxide 
(1.3 equiv.) and tri-tert-butylpyrimidine (2.5 equiv.) in DCM (0.05M) was stirred over activated MS3Å for 30 
min. The mixture was cooled to -60°C before triflic acid anhydride (1.3 equiv.) was added. The mixture was 
allowed to warm to -50°C in 15min followed by addition of acceptor (1.5 equiv.) in DCM (0.15M). Stirring was 
continued and the reaction mixture was allowed to warm to 0°C. The reaction mixture was diluted with EtOAc 
and washed with water. The aqueous phase was extracted twice with EtOAc. The combined organic phase was 
dried (MgSO4), filtered and concentrated under reduced pressure. Flash chromatography (EtOAc/PE) and 
removal of the eluent afforded the corresponding coupled products.  
 
Phenyl 2,4-di-O-benzyl-1-thio-β-D-galactopyranosidurono-6,3-lactone (7): Diol 6 was conver-
ted according to the general procedure delivering lactone 7 in 75% yield as a colorless oil. 
TLC: 20% EtOAc/PE; [α]D22: -95° (c = 0.5, CHCl3); IR (neat, cm-1): 979, 1026, 1060, 1097, 
1151, 1365, 1454, 1799, 2869, 3030; 1H NMR (400 MHz, CDCl3) δ = 4.02 (s, 1H, H-4), 4.23 
(d, 1H, J = 4.8 Hz, H-2), 4.36 (s, 1H, H-5), 4.48 (d, 1H, J = 11.8 Hz, CHHPh), 4.51 (s, 2H, CH2Ph), 4.56 (d, 1H, 
J = 11.8 Hz, CHHPh), 4.79 (d, 1H, J = 4.4 Hz, H-3), 5.40 (s, 1H, H-1), 7.14 – 7.43 (m, 15H, H Arom); 13C NMR 
(100 MHz, CDCl3) δ = 70.6 (C-4), 71.1 (CH2 Bn), 72.7 (CH2 Bn), 75.7 (C-5), 78.4 (C-2), 78.6 (C-3), 85.6 (C-1), 
127.6 – 132.4 (CH Arom), 133.5 (Cq SPh), 136.4 (Cq Bn), 136.5 (Cq Bn), 172.5 (C=O); 13C-GATED (125 MHz, 
CDCl3): 85.6 (J = 168 Hz, C-1); HRMS: [M+NH4]+ calcd for C26H28O5SN 466.16882, found 466.16946. 
 
Methyl (phenyl 2,4-di-O-benzyl-1-thio-β-D-galactopyranoside) uronate (8): Compound 7 was 
suspended in MeOH and a catalytic amount TsOH was added. The mixture was stirred for 3h 
until TLC-analysis indicated complete conversion. The reaction mixture was neutralized by 
adding 0.1 mL Et3N, followed by concentration under reduced pressure. Flash chromatography and removal of 
the eluent afforded the title compound 8 (quant.) as a colorless oil. TLC: 20% EtOAc/PE; IR (neat, cm-1): 1026, 
1103, 1348, 1438, 1735, 2858; 1H NMR (400 MHz, CDCl3) δ = 2.26 (d, 1H, J = 4.8 Hz, OH-3), 3.70 (t, 1H, J = 
8.8 Hz, H-2), 3.73 (m, 4H, H-3 and CH3 COOMe), 4.10 (s, 1H, H-5), 4.23 (d, 1H, J = 1.2 Hz, H-4), 4.57 (d, 1H, 
J = 8.8 Hz, H-1), 4.63 (d, 2H, J = 11.2 Hz, 2xCHHPh), 4.70 (d, 1H, J = 11.2 Hz, CHHPh), 4.91 (d, 1H, J = 11.2 
Hz, CHHPh), 7.24 – 7.66 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.4 (CH3 COOMe), 74.8 (CH2 
Bn), 75.3 (CH2 Bn), 75.3 (C-3), 77.0 (C-5), 77.3 (C-4), 77.5 (C-2), 87.5 (C-1), 127.6 – 132.3 (CH Arom), 133.5 
(Cq SPh), 137.9 (Cq Bn), 138.0 (Cq Bn), 168.4 (C=O); HRMS: [M+Na]+ calcd for C27H28O6SNa 503.14988, 
found 503.15082. 
 
Ethyl 3,4-di-O-benzyl-1-thio-α-D-mannopyranosidurono-6,2-lactone (10): Diol 9 was converted 
according to the general procedure delivering lactone 10 in 77% yield as a colorless oil. TLC: 
20% EtOAc/PE; [α]D22: +152° (c = 1.7, CHCl3); IR (neat, cm-1): 981, 1064, 1188, 1352, 1454, 
1672, 1778, 2871, 3031, 3192; 1H NMR (300 MHz, CDCl3) δ = 1.34 (t, 3H, J = 7.4 Hz, CH3 
























1H, H-5), 4.50 (d, 1H, J = 12.4 Hz, CHHPh), 4.61 (d, 1H, J = 11.2 Hz, CHHPh), 4.65 (d, 1H, J = 12.4 Hz, 
CHHPh), 4.85 (s, 1H, H-2), 5.27 (d, 1H, J = 2.6 Hz, H-1), 7.30 – 7.36 (m, 10H, H Arom); 13C NMR (75 MHz, 
CDCl3) δ = 16.1 (CH3 SEt), 25.8 (CH2 SEt), 71.8 (CH2 Bn), 71.9 (CH2 Bn), 72.9, 76.3, 77.9, 80.6 (C-2, C-3, C-
4, C-5), 81.6 (C-1), 128.7 – 129.4 (CH Arom), 137.6 (Cq Bn), 137.7 (Cq Bn), 168.8 (C=O); 13C-GATED (75 
MHz, CDCl3): 81.6 (J = 169 Hz, C-1); HRMS: [M+NH4]+ calcd for C22H28O5SN 418.16827, found 418.16864. 
 
Methyl (ethyl 3,4-di-O-benzyl-1-thio-α-D-mannopyranoside) uronate (11): Compound 10 was 
suspended in MeOH and stirred at reflux temperature for 5h after which TLC-analysis 
indicated complete conversion. Removal of the methanol under reduced pressure and co-
evaporation of the residual oil using chloroform afforded the title compound 11 (quant.) as a light yellow oil. 
TLC: 20% EtOAc/PE; [α]D22: +72° (c = 1, CHCl3); IR (neat, cm-1): 702, 732, 1033, 1087, 1234, 1373, 1735; 1H 
NMR (400 MHz, CDCl3) δ = 1.31 (t, 3H, J = 7.4 Hz, CH3 SEt), 2.71 (m, 2H, CH2 SEt), 3.64 (s, 3H, CH3 
COOMe), 3.84 (dd, 1H, J = 7.0 Hz, J = 3.0 Hz, H-3), 4.00 (dd, 1H, J = 5.2, J = 3.0 Hz, H-2), 4.16 (t, 1H, J = 7.0 
Hz, J = 6.2 Hz, H-4), 4.56 (d, 1H, J = 6.2 Hz, H-5), 4.61 (s, 2H, CH2Ph), 4.64 (d, 1H, J = 11.6 Hz, CHHPh), 
4.68 (d, 1H, J = 11.6 Hz, CHHPh), 5.35 (d, 1H, J = 5.2 Hz, H-1); 7.24 – 7.35 (m, 10H, H Arom); 13C NMR (100 
MHz, CDCl3) δ = 14.9 (CH3 SEt), 25.5 (CH2 SEt), 52.2 (CH3 COOMe), 68.3 (C-2), 71.8 (C-5), 72.5 (CH2 Bn), 
73.7 (CH2 Bn), 75.4 (C-4), 78.6 (C-3), 84.5 (C-1), 127.7 – 128.5 (CH Arom), 137.3 (Cq Bn), 137.7 (Cq Bn), 
169.7 (C=O); HRMS: [M+NH4]+ calcd for C23H32O6SN 450.19503, found 450.19748. 
 
Ethyl 2-O-acetyl-4-O-benzyl-1-thio-α-D-mannopyranosidurono-6,3-lactone (13): Diol 12 was 
converted according to the general procedure delivering lactone 13 in 72% yield as a colorless 
oil. TLC: 20% EtOAc/PE; [α]D22: +40° (c = 0.5, CHCl3); IR (neat, cm-1): 948, 1012, 1058, 1161, 
1224, 1373, 1456, 1741, 1799, 2873; 1H NMR (400 MHz, CDCl3) δ = 1.25 (t, 3H, J = 7.2 Hz, 
CH3 SEt), 2.13 (s, 3H, CH3 Ac), 2.71 (m, 2H, CH2 SEt), 4.07 (dd, 1H, J = 5.9 Hz, J = 2.8 Hz, H-4), 4.28 (dd, 1H, 
J = 2.8 Hz, J = 1.0 Hz, H-5), 4.63 (d, 1H, J = 11.8 Hz, CHHPh), 4.69 (d, 1H, J = 9.2 Hz, H-1), 4.75 (d, 1H, J = 
11.8 Hz, CHHPh), 4.79 (dt, 1H, J = 5.9 Hz, J = 1.2 Hz, J = 1.0 Hz, H-3), 5.40 (dd, 1H, J = 1.2 Hz, H-2), 7.26 – 
7.40 (m, 5H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 14.8 (CH3 SEt), 20.8 (CH3 Ac), 23.9 (CH2 SEt), 67.3 
(C-2), 72.0 (CH2 Bn), 72.1 (C-5), 74.8 (C-4), 77.5 (C-3), 80.3 (C-1), 128.1 – 128.7 (CH Arom), 136.0 (Cq Bn), 
169.5 (C=O Ac or lactone), 169.6 (C=O lactone or Ac); HRMS: [M+NH4]+ calcd for C17H24O6SN 370.13243, 
found 370.12914. 
 
Methyl (ethyl 2-O-acetyl-4-O-benzyl-1-thio-α-D-mannopyranoside) uronate (14): Compound 
14 was obtained in an analogous way as described for compound 11. TLC: 20% EtOAc/PE; 
[α]D22: +35° (c = 0.6, CHCl3); IR (neat, cm-1): 1035, 1091, 1232, 1373, 1438, 1739, 2858; 1H 
NMR (400 MHz, CDCl3) δ = 1.30 (t, 1H, J = 7.6 Hz, CH3 SEt), 2.16 (s, 3H, CH3 Ac), 2.65 (m, 2H, CH2 SEt), 
3.78 (s, 3H, CH3 COOMe), 3.98 (t, 1H, J = 8.8 Hz, H-4), 4.08 (dd, 1H, J = 8.8 Hz, J = 8.4 Hz, J = 3.3 Hz, H-3), 
4.58 (d, 1H, J = 8.4 Hz, H-5), 4.68 (d, 1H, J = 11.2 Hz, CHHPh), 4.72 (d, 1H, J = 11.2 Hz, CHHPh), 5.20 (t, 1H, 
J = 3.3, J = 2.8 Hz, H-2), 5.40 (d, 1H, J = 2.8 Hz, H-1), 7.26 – 7.37 (m, 5H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 14.8 (CH3 SEt), 22.4 (CH3 Ac), 25.1 (CH2 SEt), 52.5 (CH3 COOMe), 70.1 (C-3), 71.3 (C-5), 72.8 
(C-2), 74.5 (CH2 Bn), 77.4 (C-4), 81.9 (C-1), 127.8 – 128.5 (CH Arom), 137.8 (Cq Bn), 169.8 (C=O Ac or 
lactone), 170.5 (C=O lactone or Ac); HRMS: [M+NH4]+ calcd for C18H28O7SN 402.15865, found 402.16217. 
 
Phenyl 2,4-di-O-benzyl-1-thio-β-D-glucopyranosidurono-6,3-lactone (16): Diol 15 was converted 
according to the general procedure delivering lactone 16 in 51% yield as a colorless oil. TLC: 



























1637, 1801, 3006, 3223; 1H NMR (400 MHz, CDCl3) δ = 3.83 (d, 1H, J = 5.4 Hz, H-2), 4.06 (t, 1H, J = 3.2 Hz, 
J = 2.4 Hz, J = 1.0 Hz, H-4), 4.10 (d, 1H, J = 2.4 Hz, H-5), 4.56 (d, 1H, J = 11.6 Hz, CHHPh), 4.60 (d, 1H, J = 
11.6 Hz, CHHPh), 4.64 (dd, 1H, J = 3.2 Hz, J = 1.0 Hz, H-3), 4.68 (d, 1H, J = 11.6 Hz, CHHPh), 4.70 (d, 1H, J 
= 11.6 Hz, CHHPh), 5.61 (d, 1H, J = 5.4 Hz, H-1), 7.19 – 7.43 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) 
δ = 69.7 (C-5), 72.2 (CH2 Bn), 73.4 (CH2 Bn), 74.5 (C-4), 74.7 (C-3), 76.9 (C-2), 84.4 (C-1), 128.0 – 133.2 (CH 
Arom), 132.3 (Cq SPh), 136.3 (Cq Bn), 137.0 (Cq Bn), 170.5 (C=O); HRMS: [M+NH4]+ calcd for C26H28O5SN 
466.16882, found 466.17197. 
 
Methyl (phenyl 2,4-di-O-benzyl-1-thio-β-D-glucopyranoside) uronate (17): Compound 17 
was obtained in an analogous way as described for compound 8. TLC: 20% EtOAc/PE; IR 
(neat, cm-1): 1026, 1074, 1207, 1438, 1747, 2920; 1H NMR (400 MHz, CDCl3) δ = 3.92 
(dd, 1H, J = 9.6 Hz, J = 8.8 Hz, H-2), 3.72 (t, 1H, J = 9.2 Hz, J = 8.8 Hz, H-4), 3.75 (s, 3H, CH3 COOMe), 3.78 
(t, 1H, J = 9.2 Hz, J = 8.8 Hz, H-3), 3.91 (d, 1H, J = 9.2 Hz, H-5), 4.63 (d, 1H, J = 11.2 Hz, CHHPh), 4.66 (d, 
1H, J = 9.6 Hz, H-1), 4.68 (d, 1H, J = 10.4 Hz, CHHPh), 4.76 (d, 1H, J = 11.2 Hz, CHHPh), 4.96 (d, 1H, J = 
10.4 Hz, CHHPh), 7.25 – 7.55 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.5 (CH3 COOMe), 74.8 
(CH2 Bn), 75.2 (CH2 Bn), 77.6 (C-5), 77.7 (C-3), 78.6 (C-4), 80.0 (C-2), 88.0 (C-1), 127.8 – 132.0 (CH Arom), 
137.4 (2xCq Bn), 170.9 (C=O COOMe); HRMS: [M+NH4]+ calcd for C27H32O6SN 498.19503, found 498.19424. 
 
2,3,4-Tri-O-benzyl-β-D-glucopyranosidurono-6,1-lactone (19): Diol 18 was converted according 
to the general procedure delivering lactone 19 in 27% yield as a colorless oil. TLC: 20% 
EtOAc/PE; [α]D22: -5° (c = 0.2, CHCl3); IR (neat, cm-1): 912, 1043, 1068, 1178, 1454, 1807, 2866, 
3340; 1H NMR (400 MHz, CDCl3) δ = 3.50 (s, 1H, H-2), 3.63 (s, 1H, H-4 or H-3), 3.68 (t, 1H, J = 
1.6 Hz, H-3 or H-4), 4.26 (d, 1H, J = 12.4 Hz, CHHPh), 4.40 (d, 1H, J = 12.4 Hz, CHHPh), 4.47 (d, 1H, J = 12.4 
Hz, CHHPh), 4.54 (d, 1H, J = 12.4 Hz, CHHPh), 4.59 (d, 1H, J = 12.4 Hz, CHHPh), 4.64 (d, 1H, J = 12.4 Hz, 
CHHPh), 5.79 (s, 1H, H-1), 7.15 – 7.36 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 71.6 (CH2 Bn), 
72.0 (CH2 Bn), 72.1 (C-5), 72.4 (C-4 or C-3), 72.4 (CH2 Bn), 73.0 (C-2), 75.0 (C-3 or C-4), 102.5 (C-1), 127.7 – 




6,3-lactone)-α-D-glucopyranoside (21): Donor 7 was glycosylated with 
acceptor 20 in the same way as described in the general procedure delivering 
the title compound 21 as a colorless oil. TLC: 30% EtOAc/PE; IR (neat, cm-1): 
694, 734, 979, 1026, 1141, 1203, 1355, 1436, 1759; 1H NMR (400 MHz, CDCl3) δ = 3.22 (s, 3H, CH3 OMe), 
3.42 (dd, 1H, J = 10.0 Hz, J = 3.5 Hz, H-2), 3.54 (t, 1H, J = 9.5 Hz, H-4), 3.68 (d, 1H, J = 11.0 Hz, H-6), 3.73 
(d, 1H, J = 9.5 Hz, H-5), 3.97 (t, 1H, J = 9.5 Hz, H-3), 4.00 (bs, 1H, H-2’), 4.11 (s, 1H, H-4’), 4.19 (dd, 1H, J = 
11.0 Hz, J = 3.5 Hz, H-6), 4.44 (s, 1H, H-5’), 4.54 (s, 1H, H-1), 4.55 (s, 2H, CH2Ph), 4.57 (d, 1H, J = 12.5 Hz, 
CHHPh), 4.62 (d, 1H, J = 12.0 Hz, CHHPh), 4.65 (d, 1H, J = 10.0 Hz, CHHPh), 4.69 (d, 1H, J = 5.0 Hz, H-3’), 
4.76 (d, 1H, J = 10.5 Hz, CHHPh), 4.79 (d, 1H, J = 12.0 Hz, CHHPh), 4.83 (d, 1H, J = 11.0 Hz, CHHPh), 4.89 
(s, 1H, H-1’), 4.90 (d, 1H, J = 12.5 Hz, CHHPh), 4.96 (d, 1H, J = 11.0 Hz, CHHPh), 7.24 – 7.65 (m, 25H, H 
Arom); 13C NMR (100 MHz, CDCl3) δ = 55.1 (CH3 OMe), 68.5 (C-6), 69.8 (C-5), 71.6 (CH2 Bn), 73.3 (CH2 
Bn), 74.2 (CH2 Bn), 74.4 (C-2’), 75.1 (CH2 Bn), 76.0 (C-5’), 77.7 (C-4), 79.9 (C-2), 80.2 (C-3’), 81.7 (C-3), 98.0 
(C-1), 98.8 (C-1’), 124.7 – 130.9 (CH Arom), 136.7 (Cq Bn), 137.5 (Cq Bn), 138.0 (Cq Bn), 138.1 (Cq Bn), 138.7 
(Cq Bn), 171.6 (C=O lactone); 13C-GATED (125 MHz, CDCl3): 98.0 (JC1,H1 = 161 Hz, C-1), 102.4 (JC1’,H1’ = 163 




























6,3-lactone)-α-D-glucopyranoside (23): Donor 7 was glycosylated with 
acceptor 22 in the same way as described in the general procedure delivering 
the title compound 23 as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: +82°    
(c = 1, CHCl3); IR (neat, cm-1): 925, 1028, 1159, 1217, 1367, 1454, 1747, 1799, 2920; 1H NMR (400 MHz, 
CDCl3) δ = 1.94 (s, 6H, 2xCH3 Ac), 2.00 (s, 3H, CH3 Ac), 3.28 (s, 3H, CH3 OMe), 3.62 (d, 1H, J = 11.6 Hz, H-
6), 3.84 (bd, 1H, J = 10.4 Hz, H-5), 3.89 – 3.94 (m, 2H, H-6 and H-2’), 4.05 (s, 1H, H-4’), 4.44 (s, 1H, H-5’), 
4.51 (s, 2H, CH2Ph), 4.53 (d, 1H, J = 12.0 Hz, CHHPh), 4.62 (d, 1H, J = 4.0 Hz, H-3’), 4.74 (dd, 1H, J = 10.2 
Hz, J = 3.6 Hz, H-2), 4.81 (s, 1H, H-1’), 4.83 (d, 1H, J = 3.2 Hz, H-1), 4.86 (d, 1H, J = 12.0 Hz, CHHPh), 5.04 
(t, 1H, J = 9.6 Hz, H-4), 5.38 (t, 1H, J = 10.2 Hz, J = 9.6 Hz, H-3), 7.19 – 7.48 (m, 10H, H Arom); 13C NMR 
(100 MHz, CDCl3) δ = 20.6 (3xCH3 Ac), 55.4 (CH3 OMe), 67.8 (C-6), 68.3 (C-4), 68.6 (C-5), 70.4 (C-3), 70.7 
(C-2), 71.6 (CH2 Bn), 72.0 (C-4’), 74.2 (CH2 Bn), 74.3 (C-2’), 75.5 (C-5’), 80.3 (C-3’), 96.7 (C-1), 98.9 (C-1’), 
127.8 – 128.6 (CH Arom), 136.8 (Cq Bn), 137.5 (Cq Bn), 169.3 (C=O Ac or lactone), 170.1 (C=O Ac or lactone), 
170.1 (C=O Ac or lactone), 171.7 (C=O Ac or lactone); 13C-GATED (100 MHz, CDCl3): 96.7 (JC1,H1 = 169 Hz, 
C-1), 98.9 (JC1’,H1’ = 158 Hz, C-1’); HRMS: [M+NH4]+ calcd for C33H42O14N 676.26053, found 676.26440. 
 
Methyl (methyl 2,3-di-O-benzyl-4-O-(2,4-di-O-benzyl-α-D-galactopyranosyl-
urono-6,3-lactone)-α-D-glucopyranoside) uronate (25): Donor 7 was glycosylated 
with acceptor 24 in the same way as described in the general procedure delivering 
the title compound 25 as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: +6° (c = 
0.5, CHCl3); IR (neat, cm-1): 915, 1030, 1057, 1080, 1219, 1360, 1450, 1504, 1730, 1809, 2925; 1H NMR (400 
MHz, CDCl3) δ = 3.39 (s, 3H, CH3 OMe), 3.53 (dd, 1H, J = 5.0 Hz, J = 2.4 Hz, H-2’), 3.56 (dd, 1H, J = 6.5 Hz, 
J = 3.2 Hz, H-2), 3.67 (s, 3H, CH3 COOMe), 3.87 (m, 1H, J = 2.5 Hz, H-3, H-5), 4.00 (s, 1H, H-4’), 4.15 (dd, 
1H, J = 7.3 Hz, J = 2.5 Hz, H-4), 4.30 (d, 1H, J = 11.9 Hz, CHHPh), 4.34 (s, 1H, H-5’), 4.51 (s, 2H, CH2 Bn), 
4.54 (dd, 1H, J = 5.0 Hz, J = 1.6 Hz, H-3’), 4.59 (d, 1H, J = 11.7 Hz, CHHPh), 4.60 (s, 1H, H-1), 4.61 (d, 1H, J 
= 12.0 Hz, CHHPh), 4.72 (d, 1H, J = 11.9 Hz, CHHPh), 4.75 (d, 1H, J = 12.0 Hz, CHHPh), 4.99 (d, 1H, J = 11.7 
Hz, CHHPh), 5.03 (d, 1H, J = 2.4 Hz, H-1’), 7.18 – 7.35 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 
52.3 (CH3 COOMe), 55.8 (CH3 OMe), 70.3 (C-4’), 71.3 (CH2 Bn), 71.9 (C-4), 74.2 (CH2 Bn), 74.3 (C-2’), 74.4 
(CH2 Bn), 74.5 (CH2 Bn), 75.4 (C-5’), 78.2 (C-5 or C-3), 79.2 (C-2), 80.4 (C-3 or C-5), 98.4 (C-1), 99.1 (C-1’), 
127.3 – 128.6 (CH Arom), 137.6 (Cq Bn), 138.6 (Cq Bn), 168.9 (C=O COOMe), 172.6 (C=O lactone); 13C-
GATED (100 MHz, CDCl3): 98.4 (JC1,H1 = 169 Hz, C-1), 99.1 (JC1’,H1’ = 164 Hz, C-1’); HRMS: [M+NH4]+ calcd 




Donor 7 was glycosylated with acceptor 26 in the same way as described in the 
general procedure delivering the title compound 27 as a colorless oil. N.B.: The 
amount of TTBP added to the reaction mixture was 1 equiv. with respect to the amount of Tf2O. TLC: 30% 
EtOAc/PE; [α]D22: +31° (c = 1, CHCl3); IR (neat, cm-1): 912, 1028, 1102, 1153, 1211, 1356, 1401, 1724, 1753; 
1H NMR (400 MHz, CDCl3) δ = 3.36 (s, 3H, CH3 OMe), 3.47 (d, 1H, J = 2.8 Hz, H-2’), 3.61 (t, 1H, J = 8.8 Hz, 
H-3), 3.63 – 3.75 (m, 2H, H-5 and H-6), 3.78 (t, 1H, J = 8.8 Hz, H-4), 3.89 (d, 1H, J = 10.8 Hz. H-6), 3.99 (s, 
1H, H-4’), 4.12 (t, 1H, J = 10.0 Hz, J = 8.0 Hz, H-2), 4.28 (s, 1H, H-5’), 4.37 (d, 1H, J = 12.0 Hz, CHHPh), 4.44 
(d, 1H, J = 11.6 Hz, CHHPh), 4.49 (s, 1H, H-3’), 4.51 (d, 1H, J = 10.8 Hz, CHHPh), 4.60 (d, 1H, J = 11.6 Hz, 
CHHPh), 4.65 (d, 1H, J = 12.0 Hz, CHHPh), 4.67 (s, 1H, H-1), 4.72 (d, 1H, J = 10.8 Hz, CHHPh), 5.00 (d, 1H, J 





































– 7.65 (m, 25H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 54.6 (C-2), 55.0 (CH3 OMe), 66.8 (C-6), 69.9 (C-4), 
71.2 (CH2 Cbz), 71.8 (C-4’), 73.4 (CH2 Bn), 74.4 (CH2 Bn), 74.8 (C-5’), 75.6 (C-2’), 79.6 (C-3’), 81.4 (C-3), 
98.9 (C-1), 101.3 (C-1’), 126.8 – 130.9 (CH Arom), 136.7 (Cq Bn), 137.7 (Cq Bn), 137.8 (Cq Bn), 138.3 (Cq Bn), 
155.6 (C=O Cbz), 171.1 (C=O lactone); HRMS: [M+Na]+ calcd for C49H55N2O12 868.33035, found 868.33606. 
 
Methyl (para-methoxyphenyl 2,3-di-O-benzyl-4-O-(2,4-di-O-benzyl-α/β-D-
galactopyranosylurono-6,3-lactone)-α-D-galactopyranoside) uronate (29): Donor 7 
was glycosylated with acceptor 28 in the same way as described in the general 
procedure delivering title compound 29 as a colorless oil. The anomers were 
separated with flash chromatography. TLC: 30% EtOAc/PE; α-anomer: [α]D22:      
-30° (c = 1, CHCl3); IR (neat, cm-1): 910, 1028, 1058, 1080, 1217, 1363, 1454, 1506, 1735, 1809, 2922; 1H NMR 
(400 MHz, CDCl3) δ = 3.58 (dd, 1H, J = 8.8 Hz, J = 4.6 Hz, J = 3.2 Hz, H-3), 3.74 (s, 3H, CH3 OMe or 
COOMe), 3.75 (s, 3H, CH3 COOMe or OMe), 3.91 (dd, 1H, J = 8.8 Hz, J = 1.6 Hz, H-2), 3.93 (s, 1H, H-2’), 
4.05 (s, 1H, H-5), 4.12 (s, 1H, H-4’), 4.50 (d, 1H, J = 11.6 Hz, CHHPh), 4.54 (s, 1H, H-4), 4.56 (d, 1H, J = 11.6 
Hz, CHHPh), 4.58 (s, 1H, H-5’), 4.62 (d, 1H, J = 12.0 Hz, CHHPh), 4.67 (d, 1H, J = 11.6 Hz, CHHPh), 4.70 (s, 
1H, H-3’), 4.78 (d, 1H, J = 10.8 Hz, CHHPh), 4.80 (s, 1H, H-1’), 4.81 (d, 1H, J = 8.8 Hz, H-1), 4.85 (d, 1H, J = 
12.0 Hz, CHHPh), 4.86 (d, 1H, J = 11.6 Hz, CHHPh), 5.02 (d, 1H, J = 10.8 Hz, CHHPh), 6.78 (d, 2H, J = 9.0 
Hz, 2xH pMP Arom), 7.03 (d, 2H, J = 9.0 Hz, 2xH pMP Arom), 7.23 – 7.42 (m, 20H, H Arom); 13C NMR (100 
MHz, CDCl3) δ = 51.7 (CH3 OMe or COOMe), 53.9 (CH3 COOMe or OMe), 69.6 (CH2 Bn), 71.3 (C-4), 71.6 
(C-5), 74.2 (CH2 Bn), 74.6 (C-2’), 75.6 (CH2 Bn), 75.7 (C-5’), 75.8 (C-4), 78.0 (C-2), 78.8 (C-3), 80.4 (C-3’), 
99.1 (C-1’), 102.5 (C-1), 107.4 (CH pMP Arom), 119.6 (CH pMP Arom), 123.8 – 124.4 (CH Arom), 137.8 (Cq 
Bn), 137.9 (Cq Bn), 138.4 (Cq Bn), 138.8 (Cq Bn), 151.7 (Cq pMP), 155.6 (Cq pMP), 167.9 (C=O lactone), 173.7 
(C=O COOMe); 13C-GATED (100 MHz, CDCl3): 99.1 (JC1’,H1’ = 160 Hz, C-1’), 102.5 (JC1,H1 = 159 Hz, C-1); 
HRMS: [M+NH4]+ calcd for C48H48O13 850.34387, found 850.34180. β-anomer: [α]D22: +15° (c = 1, CHCl3); IR 
(neat, cm-1): 910, 1028, 1058, 1080, 1217, 1363, 1454, 1506, 1735, 1809, 2922; 1H NMR (400 MHz, CDCl3) δ = 
3.67 (dd, 1H, J = 9.8 Hz, J = 2.4 Hz, H-3), 3.82 (s, 3H, CH3 COOMe or OMe), 3.97 (s, 3H, CH3 OMe or 
COOMe), 3.98 (dd, 1H, J = 7.6 Hz, J = 2.4 Hz, H-2), 4.04 (s, 1H, H-4’), 4.08 (s, 1H, H-5’), 4.11 (d, 1H, J = 4.8 
Hz, H-2’), 4.23 (d, 1H, J = 12.0 Hz, CHHPh), 4.34 (s, 1H, H-5’), 4.39 (d, 1H, J = 12.0 Hz, CHHPh), 4.61 (s, 2H, 
CH2 Bn), 4.66 (s, 1H, H-4), 4.68 (d, 1H, J = 4.8 Hz, H-3’), 4.81 (s, 2H, CH2 Bn), 4.86 (d, 1H, J = 7.6 Hz, H-1), 
4.90 (d, 1H, J = 10.8 Hz, CHHPh), 5.07 (d, 1H, J = 10.8 Hz, CHHPh), 5.60 (s, 1H, H-1’), 6.87 (d, 2H, J = 9.2 
Hz, 2xH pMP Arom), 7.15 (d, 2H, J = 9.2 Hz, 2xH pMP Arom), 7.30 – 7.43 (m, 20H, H Arom); 13C NMR (100 
MHz, CDCl3) δ = 52.9 (CH3 OMe or COOMe), 55.6 (CH3 COOMe or OMe), 70.7 (C-4’), 71.2 (CH2 Bn), 72.2 
(CH2 Bn), 73.3 (C-5), 73.5 (C-4), 74.0 (CH2 Bn), 75.1 (CH2 Bn), 75.9 (C-5’), 77.5 (C-2), 78.1 (C-2’), 78.5 (C-
3’), 81.5 (C-3), 100.5 (C-1’), 103.5 (C-1), 114.4 (CH pMP Arom), 119.08 (CH pMP Arom), 127.6 – 128.6 (CH 
Arom), 136.8 (Cq Bn), 137.1 (Cq Bn), 137.3 (Cq Bn), 138.1 (Cq Bn), 151.4 (Cq pMP), 155.5 (Cq pMP), 166.9 
(C=O lactone), 172.0 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 100.5 (JC1’,H1’ = 174 Hz, C-1’), 103.5 
(JC1,H1 = 159 Hz, C-1); HRMS: [M+NH4]+ calcd for C48H52O13N 850.34387, found 850.33893. 
 
Methyl (2-(N-benzyloxycarbonyl)-amino-3,6-di-O-benzyl-2-deoxy-4-O-(methyl 2,4-
di-O-benzyl-α-D-galactopyranosyluronate)-α-D-glucopyranoside (30): Lactone 27 was 
dissolved in anhydrous methanol before a catalytic amount KOtBu (10 mol%) was 
added. Stirring was continued for 4h before the mixture was neutralized with 
Amberlite IR-120 H+-resin. After filtration and purification by flash chromatography 
title compound 30 was isolated as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: +94° (c = 1, CHCl3); IR (neat, 




























OMe), 3.43 (s, 3H, CH3 COOMe), 3.61 (d, 1H, J = 9.6 Hz, H-6), 3.77 – 3.80 (m, 3H, H-4, H-5 and H-2’), 3.85 
(d, 1H, J = 9.6 Hz, H-6), 4.01 (dd, 1H, J = 10.0 Hz, J = 3.0 Hz, H-3’), 4.12 – 4.16 (m, 2H, H-2 and H-4’), 4.18 
(t, 1H, J = 9.6 Hz, H-3), 4.34 (d, 1H, J = 12.0 Hz, CHHPh), 4.46 (s, 1H, H-5’), 4.52 (d, 1H, J = 11.6 Hz, 
CHHPh), 4.55 (d, 1H, J = 12.0 Hz, CHHPh), 4.56 (s, 2H, CH2 Bn), 4.58 (d, 1H, J = 11.6 Hz, CHHPh), 4.67 (d, 
1H, J = 11.2 Hz, CHHPh), 4.70 (s, 1H, H-1), 4.72 (d, 1H, J = 11.2 Hz, CHHPh), 4.94 (d, 1H, J = 10.0 Hz, NH), 
4.98 (d, 1H, J = 12.4 Hz, CHHPh), 5.03 (d, 1H, J = 12.4 Hz, CHHPh), 5.77 (d, 1H, J = 3.2 Hz, H-1’), 7.18 – 
7.34 (m, 25H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.0 (CH3 COOMe), 53.9 (C-2), 55.1 (CH3 OMe), 
66.9 (CH2 Bn), 68.8 (CH2 Bn), 69.4 (C-3’), 70.2 (C-4, C-5 or C-2’), 70.9 (C-5’), 72.1 (CH2 Cbz), 72.3 (C-4’), 
72.8 (CH2 Bn), 73.3 (CH2 Bn), 74.9 (CH2 Bn), 75.6 (C-4, C-5 or C-2’), 77.8 (C-3), 80.7 (C-4, C-5 or C-2’), 96.6 
(C-1’), 98.7 (C-1), 126.8 – 128.4 (CH Arom), 137.5 (Cq Bn), 137.9 (Cq Bn), 138.0 (Cq Bn), 155.7 (C=O Cbz), 
168.9 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 96.6 (JC1’,H1’ = 170 Hz, C-1’), 98.7 (JC1,H1 = 172 Hz, C-



















glucopyranoside (32): A solution of 63 mg donor 31 (0.1 mmol) and 26 mg diphenylsulfoxide (0.13 mmol, 1.3 
equiv.) in 3 mL DCM was stirred over activated MS3Å for 30 min. The mixture was cooled to -60°C before 21 
µL triflic acid anhydride (0.13 mmol, 1.3 equiv.) was added. The mixture was allowed to warm to -40°C in 1h 
followed by addition of 87 mg acceptor 30 (0.1 mmol, 1.0 equiv.) in 1 mL DCM. Stirring was continued and the 
reaction mixture was allowed to warm to -15°C. The reaction mixture was diluted with EtOAc and washed with 
water. The aqueous phase was extracted twice with EtOAc. The combined organic phase was dried (MgSO4), 
filtered and concentrated under reduced pressure. Flash chromatography (EtOAc/PE) and removal of the eluent 
afforded 88 mg of the title compound 32 (0.063 mmol, 63%) as a light yellow oil. TLC: 30% EtOAc/PE; [α]D22: 
+35° (c = 1, CHCl3); IR (neat, cm-1): 912, 1102, 1153, 1211, 1401, 1724, 1753; 1H NMR (600 MHz, CDCl3) δ = 
-0.13 (s, 3H, CH3 TBDMS), -0.07 (s, 3H, CH3 TBDMS), 0.69 (s, 9H, tBu TBDMS), 2.19 (s, 3H, CH3 Ac), 3.31 
(s, 3H, CH3 COOMe), 3.34 (s, 3H, CH3 OMe), 3.51 (d, 1H, J = 10.9 Hz, H-6), 3.60 (t, 2H, J = 10.2 Hz, J = 9.3 
Hz, H-4 and H-5), 3.73 (d, 1H, J = 11.0 Hz, H-6), 3.83 (dd, 1H, J = 8.6 Hz, J = 3.1 Hz, H-2’), 3.91 (m, 2H, H-3’’ 
and H-5’’), 4.02 (t, 1H, J = 9.3 Hz, H-2), 4.07 (t, 1H, J = 9.3 Hz, H-3), 4.10 (d, 1H, J = 12.8 Hz, CHHPh), 4.21 
(dd, 1H, J = 10.3 Hz, J = 2.6 Hz, H-3’), 4.30 (d, 1H, J = 12.8 Hz, CHHPh), 4.32 (s, 1H, H-4’), 4.36 (s, 1H, H-
5’), 4.40 (dd, 1H, J = 11.2 Hz, J = 5.5 Hz, H-6’’), 4.41 (d, 1H, J = 12.1 Hz, CHHPh), 4.43 (d, 1H, J = 12.1 Hz, 
CHHPh), 4.46 (d, 1H, J = 12.1 Hz, CHHPh), 4.52 (dd, 1H, J = 11.2 Hz, J = 7.0 Hz, H-6’’), 4.63 (d, 1H, J = 11.8 
Hz, CHHPh), 4.65 (d, 1H, J = 12.1 Hz, CHHPh), 4.66 (s, 1H, H-1), 4.77 (d, 1H, J = 9.9 Hz, NH), 4.89 (d, 1H, J 
= 8.0 Hz, H-1’’), 4.95 (s, 2H, CH2 Bn), 4.99 (d, 1H, J = 11.8 Hz, CHHPh), 4.31 (d, 1H, J = 3.1 Hz, H-1’), 5.40 
(s, 1H, H-4’’), 5.54 (t, 1H, J = 8.1 Hz, H-2’’), 6.92 – 8.08 (m, 35H, H Arom); 13C NMR (150 MHz, CDCl3) δ =   
-4.8 (2xCH3 TBDMS), 17.6 (Cq tBu TBDMS), 20.9 (CH3 Ac), 25.2 (tBu TBDMS), 51.8 (CH3 OMe), 54.0 (C-2), 
55.1 (CH3 COOMe), 62.4 (C-6’’), 66.8 (CH2 Bn), 68.6 (C-6), 70.2 (C-4’’), 70.5 (C-5), 71.0 (C-3’’ and C-5’’), 
71.3 (C-3’), 72.6 (C-2’’), 72.8 (CH2 Cbz), 73.1 (CH2 Bn), 73.5 (CH2 Bn), 74.3 (C-3), 74.7 (CH2 Bn), 75.1 (C-
2’), 75.2 (C-3), 77.8 (C-3’’), 80.0 (C-4), 97.8 (C-1’), 98.6 (C-1), 101.7 (C-1’’), 127.1 – 133.3 (CH Arom), 128.6 
(Cq Bz), 129.5 (Cq Bz), 133.2 (Cq Bn), 138.2 (Cq Bn), 138.4 (Cq Bn), 138.5 (Cq Bn), 155.7 (C=O Cbz), 165.0 







Ac or COOMe); 13C-GATED (150 MHz, CDCl3): 97.8 (JC1’,H1’ = 172 Hz, C-1’), 98.6 (JC1,H1 = 169 Hz, C-1), 
101.7 (JC1’’,H1’’ = 159 Hz, C-1’’); HRMS: [M+Na]+ calcd for C78H89NO21SiNa 1426.52575, found 1426.53050. 
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Abstract: A facile route of synthesis towards β-linked mannuronic acid oligomers using the 
corresponding 1-thiomannuronic acid esters is presented. Activator systems used are the Ph2SO/Tf2O 
and NIS/TMSOTf reagent combinations. The presence of the remotely attached carboxylic ester 







Alginates are naturally occurring, linear polysaccharides composed of (1,4)-linked β-D-
mannuronic acid and α-L-guluronic acid residues.2 They are produced by brown seaweeds of 
which three main polymer substructures have been reported, one containing mainly β-D-
mannuronic acid residues, one containing mainly α-L-guluronic acid residues and a third 
composed of alternating sequences of β-D-mannuronic and α-L-guluronic acid. The D-
mannuronic and L-guluronic residues are C5 epimers and possess different conformations: D-
mannuronic acid adopts the 4C1 conformation and L-guluronic acid the 1C4 conformation. Due 
to their polyanionic character, alginates have found wide and diverse applications as 
thickening and gel-forming agents in food industry.3  
Recently, it was discovered that mixtures of alginate oligomers have immunomodulating 
properties by binding to Toll-like receptors (TLRs) 2 and 4.4 TLRs are key players in 







and instigate activation of inflammatory and antimicrobial innate immune responses. 
Additionally, recognition of microbial products by TLRs expressed on dendritic cells triggers 
functional maturation of dendritic cells and leads to initiation of antigen-specific adaptive 
immune responses. The availability of well-defined fragments of alginates and functionalized 
derivatives thereof would be highly useful in studying the mechanism of TLR-mediated 
recognition and ensuing signal transduction. To date, however, no synthesis of alginate 
oligomers has been reported. 
Both β-D-mannuronic and α-L-guluronic acid oligomers have a 1,2-cis relationship, which 
is difficult to attain in a stereocontrolled manner. The group of Crich has found an elegant 
solution for the introduction of the similarly challenging β-D-mannoside linkage by 
application of 2,3-di-O-benzyl-4,6-O-benzylidene protected 1-sulfoxide and 1-thiomannoside 
donors. 6,7 Upon activation of these donors, the 4,6-O-benzylidene moiety destabilizes the 
mannosyl oxacarbenium ion relative to the covalent α-mannosyl triflate intermediate.8 The 
latter is thought to undergo an SN2-type displacement with the incoming acceptor. The 
stereochemical influence of the benzylidene function was initially attributed to torsional 
effects, which prevents oxocarbenium ion formation at the anomeric center.6,9 Recently, 
however, Bols and coworkers showed that electronic effects are equally important for the 
observed high β-stereoselectivities.10,11 They found that the cyclic acetal locks the C5-C6 
bond of the mannoside donor in the unfavorable tg conformation. The importance of 
electronic effects in β-mannoside synthesis is also highlighted by the application of 
compounds with non-participating, powerfully electron-withdrawing protective groups at the 
C2 position in combination with a good leaving group at C1 leading to good β-selectivities.12 
In Chapter 2, an efficient route to suitably protected uronic acid donors by the application of 
2,2,6,6-tetramethylpiperidinyloxy free radical (TEMPO)/[bis(acetoxy)iodo]benzene (BAIB) 
as a regio- and chemoselective oxidation system was disclosed.13 The presence of an electron-
withdrawing carboxyl moiety at C5 makes uronic acid donors highly inreactive. A study 
towards the glycosylation properties of protected 1-thio glucuronic and galacturonic acid 
donors showed that these donors could be applied in sequential glycosylation strategies using 
sulfonium ion-based promoter systems.14 In this Chapter, it is demonstrated that 1-thio 
mannuronic acid esters are viable starting compounds for the construction of β-(1→4)-linked 
mannuronic acid oligomers. 
 
Results and Discussion 
 
Thiomannuronic acid derivatives 6, 8 and 11 were selected as model compounds to 
investigate their glycosylation properties in terms of yield and stereoselectivity (Scheme 1). 







benzylated derivatives 215 and 3.16 Compound 9 was readily obtained from phenyl 1-thio-α-D-
galactopyranoside (1) according to a procedure described by Kong and coworkers.17 
Regioselective protection of the C6 and C3 positions as silyl-ethers was followed by 
benzylation of the residual C2 and C4 positions using BnBr and NaH. Removal of the TBS-
ether functionalities gave the desired phenyl 2,4-di-O-benzyl-1-thio-α-D-mannopyranoside 
(9) in 30% yield. Contrary to what is reported by Kong and coworkers, also some 3,4-di-O-
benzylated product was isolated. The next step was oxidation of substrates 2, 3 and 9 using 
the TEMPO/BAIB reagent system.13 In the case of compounds 2 and 3, the corresponding 
uronic acids were obtained (4 and 7, respectively), which were methylated using MeI/K2CO3 
to give uronic ester donors 5 and 8. Acetylation of compound 5 using Ac2O/pyridine afforded 
donor 6. The 3,6-unprotected diol in compound 9 underwent tandem oxidation/lactonization 
affording lactone 10.14a,b Acidic opening of the lactone 10 using Amberlite H+/MeOH 























































from 9 from 2
from 3
 
Reagents and conditions: (a) for compound 2: see ref 15, for compound 3: see ref 16 (b) TEMPO, BAIB, 
DCM/H2O (2/1), 4: 87%, 7: 89%, 10: 63% (c) MeI, K2CO3, DMF, 5: 95%, 8: 93% (d) Ac2O, pyridine, quant. (e) 
1) TBDMSCl, Imidazole, DMF, 2) BnBr, NaH, DMF, 3) TsOH, MeOH, reflux, 30% (over 3 steps) (f) 1) 
Amberlite IR120 H+, MeOH, 2) Ac2O, pyridine, 81% (2 steps). 
 
With these donor building blocks in hand, the next objective was to determine their 
glycosylation properties in terms of yield and stereoselectivity (Table 1). Pre-activation of 4-
O-acetyl donor 6 using diphenylsulfonium bistriflate, generated in situ at -50°C, and 
subsequent slow addition of acceptor 12 afforded β-linked disaccharide 13 (1JC,H = 156 Hz)18 
in 81% yield. Condensation of the 3-O-acetyl donor 11 with acceptor 12 led to α-dimer 14 
(1JC,H = 175 Hz), whereas condensation of tri-O-benzyl donor 8 with the sterically more 
demanding acceptor 15 furnished β-dimer 16 (1JC,H = 159 Hz).19 The stereochemical outcome 








Table 1.  





























































































































































a isolated yields. b anomeric ratios were determined by 1H NMR spectroscopy. 
 
6-membered transition state, thereby preventing β-side attack.20 The glycosylation properties 
of 4-O-acetyl donor 6 were further evaluated by executing condensation reactions with the 
less reactive and therefore more α-directing glycosyl acceptors 15, 18 and 20.21 The 
condensations of 6 with 15 and 18 led to the isolation of β-disaccharides 17 (69%) and 19 







the glycosylation protocol did not lead to a productive coupling, indicating that the reactivity 
of the acceptor plays a decisive role on the outcome of a glycosylation reaction.12c  
The finding that the introduction of 1,2-cis-equatorial glycosidic linkages can be 
accomplished with different types of donors and promotor systems led us to explore 
NIS/TMSOTf-mediated glycosylation reactions.22,23 In a first attempt, a mixture of donor 6, 
acceptor 12 and NIS in DCM was cooled to -40°C and a catalytic amount of TMSOTf was 
added affording β-disaccharide 13 in 91% yield. In another experiment, donor 6 was pre-
activated with NIS and an equimolar amount of TMSOTf.23 However, no complete activation 
of donor 6 could be achieved as monitored by TLC. After addition of acceptor 12, the β-
linked disaccharide 13 was isolated in the same yield (91%). These results suggest that, 
contrary to the Ph2SO/Tf2O conditions, the donor is not transformed into a α-triflate 
intermediate. Possibly, direct SN2-type displacement of the initially formed iodosulfonium 
species is at the basis of the observed β-selectivities in the NIS/TMSOTf-mediated 
glycosylation reactions. The standard NIS/TMSOTf protocol was also applied for the 
condensation of donor 6 and benzylidene-protected acceptor 15 to give β-linked disaccharide 
16 in 58% yield. Partial cleavage of the acid labile benzylidene functionality, observed by 
TLC-analysis, may explain this moderate yield. Finally, the earlier unproductive coupling of 
acceptor 20 with donor 6 was executed using NIS/TMSOTf. Disaccharide 21 was isolated in 
excellent yield as an anomeric mixture (α/β = 1/2), probably as a result of the sterical bias in 


































































Reagents and conditions: (a) Lev2O, pyridine, 86% (b) 6, Ph2SO, Tf2O, TTBP, DCM, -75°C then 3-
azidopropanol, (α/β = 1/5), 80% (c) NaOMe, MeOH, 60% (d) 22, 24, NIS, TMSOTf, DCM, -40°C, 78% (α/β = 
0/1) (e) NH2NH2·H2O, pyridine, AcOH, 95% (f) 22, 26, NIS, TMSOTf, DCM, -40°C, 50% (α/β = 1/>10) (g) 1) 








The stage was now set for the assembly of the spacer containing mannuronic acid 
trisaccharide 28 using the NIS/TMSOTf activation system (Scheme 2). Levulinoylation of 
compound 5 using Lev2O in pyridine afforded donor 22 in excellent yield. The requisite 
acceptor 24 was synthesized under Ph2SO/Tf2O-mediated conditions from donor 6 with 3-
azidopropanol affording fully protected dimer 23 in 80% yield as an inseparable mixture of 
anomeric (α/β = 1/5).24 Ensuing basic hydrolysis of the acetate ester using NaOMe in MeOH 
delivered the target β-linked acceptor 24 in 60% yield. It was found that hydrolysis of the β-
anomer 23β occurred much faster than hydrolysis of the corresponding α-oriented anomer 
23α, resulting in facile separation of the anomers. Donor 22 and acceptor 24 were subjected 
to the NIS/TMSOTf-mediated condensation giving β-linked disaccharide 25 in 78% yield. 
Standard deprotection of the levulinoyl group using hydrazine hydrate yielded acceptor 
disaccharide 26 which was subjected to the same coupling cycle to give trisaccharide 27 in 
50% yield. Global deprotection of the mannuronic acid trisaccharide 27 was accomplished via 
levulinoyl cleavage, hydrolysis of the methyl ester and final reduction of the azide and benzyl 





This Chapter describes a facile synthesis route towards β-1,4-mannuronic acid containing di- 
and trimers. The carboxylic ester function in the mannuronic acid donors sufficiently 
influences the electronic environment around the anomeric centre to allow good to excellent 
β-selectivities in Ph2SO/Tf2O and NIS/TMSOTf-mediated glycosylation events. This strategy 
is a valuable asset for future assembly of alginate oligomers, which may facilitate further 




General Procedures: 1H and 13C NMR spectra were recorded on a Brüker DMX-400 and a Brüker AV-400 
(400/100 MHz), Brüker AV500 (500/125 MHz) and a Brüker DMX-600 (600/150 MHz) spectrometer. Chemical 
shifts (δ) are given in ppm relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. 
All given 13C spectra are proton decoupled. Mass spectra were recorded with PE/SCIEX API 165 with 
electronspray interface and Q-Star Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured 
on a Propol automatic polarimeter. IR-spectra were recorded on a Shimadzu FTIR-8300. Traces of water in the 
donor and acceptor glycosides, diphenylsulfoxide and TTBP were removed by co-evaporation with toluene. 
TTBP was synthesized as described by Crich et al.25 Dichloromethane (DCM, Baker p.a.) was boiled under 
reflux over P2O5 for 2h and distilled prior to use. Trifluoromethanesulfonic anhydride was distilled from P2O5. 







quality. Flash chromatography was performed on Fluka silica gel 60 (0.04 – 0.063 mm). TLC-analysis was 
conducted on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm) were 
applicable and by spraying with 20% sulfuric acid in ethanol followed by charring at ~150°C or by spraying with 
a solution of (NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulfuric acid in water 
followed by charring at ~150°C. All reactions were performed under an inert atmosphere of Argon unless stated 
otherwise.  
 
N.B.: NMR-spectra of the various uronates showed low intensity of the 13C signals, probably due to 
conformational equilibria. 
 
General Procedure for the TEMPO/BAIB-Mediated Oxidation: To a vigorously stirred solution of 0.3 mmol 
thioglycoside in 1 mL DCM and 0.5 mL H2O was added 0.06 mmol TEMPO (0.2 equiv.) and 0.75 mmol BAIB 
(2.5 equiv.). Stirring was allowed until TLC indicated complete conversion of the starting material to a lower 
running spot (~45min). The reaction mixture was quenched by the addition of 10 mL Na2S2O3 solution (10% in 
H2O) and 10 mL NaHCO3 (sat. aq.). The mixture was then extracted twice with EtOAc (10 mL) and the 
combined organic phase was dried (MgSO4), filtered and concentrated. Flash column chromatography using 
EtOAc/petroleum ether (for the uronic acids 2% (v/v) AcOH is used) afforded the pure oxidized products. 
 
General Procedure for Glycosidations using Ph2SO/Tf2O: A solution of 1-thio mannopyranoside uronic acid 
ester (1 equiv.), diphenyl sulfoxide (1.3 equiv.) and tri-tert-butylpyrimidine (2.5 equiv.) in DCM (0.05M) was 
stirred over activated MS3Å for 30min. The mixture was cooled to -60°C before triflic acid anhydride (1.3 
equiv.) was added. The mixture was allowed to warm to -45°C in 15min followed by addition of acceptor (1.5 
equiv.) in DCM (0.15M). Stirring was continued and the reaction mixture was allowed to warm to rT. The 
reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was extracted twice with 
EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. 
Flash chromatography (EtOAc/PE) and removal of the eluent afforded the corresponding disaccharides.  
 
General Procedure for Glycosidations using NIS/TMSOTf:  
Method A (pre-mixing donor and acceptor): A solution of 1-thio mannopyranoside uronic acid ester (1 equiv.) 
and acceptor (1.5 equiv.) in DCM (0.05M) was stirred over activated MS3Å for 30min before N-
iodosuccinimide (1.3 equiv.) was added. The mixture was cooled to -40°C followed by the addition of 
trimethylsilyl trifluoromethanesulfonate (0.1 equiv.). Stirring was continued and the reaction mixture was 
allowed to warm to rT. When TLC-analysis indicated complete reaction, triethylamine (5 equiv.) was added. The 
reaction mixture was diluted with EtOAc and washed with Na2S2O3 (10% in H2O). The aqueous phase was 
extracted twice with EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under 
reduced pressure. Flash chromatography (EtOAc/PE) and removal of the eluent afforded the corresponding 
disaccharides. 
 
Method B (pre-activation using NIS and equimolar TMSOTf): A solution of 1-thio mannopyranoside uronic 
acid ester (1 equiv.) in DCM (0.05M) was stirred over activated MS3Å for 30min before N-iodosuccinimide (1.3 
equiv.) was added. The mixture was cooled to -40°C before trimethylsilyl trifluoromethanesulfonate (1.3 equiv.) 
was added. The mixture was allowed to warm to -30°C in 15min followed by addition of acceptor (1.5 equiv.) in 
DCM (0.15M). Stirring was continued and the reaction mixture was allowed to warm to rT. When TLC-analysis 







and washed with Na2S2O3 (10% in H2O). The aqueous phase was extracted twice with EtOAc. The combined 
organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash chromatography 
(EtOAc/PE) and removal of the eluent afforded the corresponding disaccharides. 
 
Phenyl 2,3-di-O-benzyl-1-thio-α-D-mannopyranosiduronic acid (4): Diol 215 was converted 
according to the general procedure delivering 1-thio mannuronic acid 4 in 87% yield as a 
colorless oil. TLC: 50% EtOAc/PE (5% AcOH); [α]D22: +16° (c = 0.4, CHCl3); 1H NMR (500 
MHz, MeOD) δ = 3.72 (dd, 1H, J = 8.0 Hz, J = 3.0 Hz, H-3), 3.94 (t, 1H, J = 3.5 Hz, H-2), 4.26 (dd, 1H, J = 8.0 
Hz, J = 7.5 Hz, H-4), 4.43 (d, 1H, J = 7.0 Hz, H-5), 4.56 (d, 1H, J = 10.5 Hz, CHHPh), 4.60 (d, 1H, J = 10.5 Hz, 
CHHPh), 4.63 (d, 1H, J = 10.5 Hz, CHHPh), 4.71 (d, 1H, J = 10.5 Hz, CHHPh), 5.61 (d, 1H, J = 3.5 Hz, H-1), 
7.27 – 7.59 (m, 15H, H Arom); 13C NMR (100 MHz, MeOD) δ = 69.3 (C-4), 73.2 (CH2 Bn), 73.5 (CH2 Bn), 
75.5 (C-5), 76.8 (C-2), 79.0 (C-3), 86.2 (C-1), 128.4 – 135.2 (CH Arom), 139.3 (Cq Bn), 139.5 (Cq Bn), 172.5 
(C=O COOMe); 13C-GATED (125 MHz, MeOD): 86.2 (J = 167 Hz, C-1); HRMS: [M+Na]+ calcd for 
C26H26O6SNa 489.13423, found 489.13446. 
 
Methyl (phenyl 2,3-di-O-benzyl-1-thio-α-D-mannopyranoside) uronate (5): To a stirred 
solution of 965 mg compound 4 (2.1 mmol) in 10 mL DMF was added 0.3 mL MeI (5 mmol, 
2.5 equiv.) and 200 mg K2CO3 (excess). The solution was stirred overnight and quenched by 
the addition of 2 mL MeOH. The reaction mixture was taken up in EtOAc and washed with H2O. The aqueous 
phase was extracted with EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated 
under reduced pressure. Flash column chromatography (EtOAc/PE) afforded 0.96 g of the title compound 5 (1.9 
mmol, 95%) as a colorless oil. TLC: 35% EtOAc/PE; [α]D22: +40° (c = 1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
= 2.98 (s, 1H, OH-4), 3.71 (dd, 1H, J = 7.2 Hz, J = 2.4 Hz, H-3), 3.78 (s, 3H, CH3 COOMe), 3.95 (t, 1H, J = 2.4 
Hz, J = 1.6 Hz, H-2), 4.38 (t, 1H, J = 7.2 Hz, H-4), 4.57 (d, 1H, J = 9.6 Hz, CHHPh), 4.60 (d, 1H, J = 9.6 Hz, 
CHHPh), 4.61 (s, 1H, H-5), 4.66 (d, 1H, J = 9.6 Hz, CHHPh), 4.69 (d, 1H, J = 9.6 Hz, CHHPh), 5.61 (d, 1H, J = 
1.6 Hz, H-1), 7.24 – 7.45 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.6 (CH3 COOMe), 68.5 (C-4), 
72.3 (CH2 Bn), 72.5 (CH2 Bn), 72.6 (C-5), 75.7 (C-2), 78.1 (C-3), 86.2 (C-1), 127.6 – 131.5 (CH Arom), 133.7 
(Cq SPh), 137.6 (Cq Bn), 137.9 (Cq Bn), 170.3 (C=O COOMe); HRMS: [M+Na]+ calcd for C27H28O6SNa 
503.14988, found 503.14992. 
 
Methyl (phenyl 4-O-acetyl-2,3-di-O-benzyl-1-thio-α-D-mannopyranoside) uronate (6): 
Compound 5 (0.96 g, 1.9 mmol) was treated with 3 mL pyridine/Ac2O (3:1) solution for 8h 
followed by the addition 2 mL MeOH. The reaction mixture was taken up in EtOAc and 
washed with 2M HCl and saturated aq. NaHCO3. The organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure. Flash column chromatography (EtOAc/PE) afforded 1.04 g of the title 
compound 6 (1.9 mmol, quant.) as a colorless oil. TLC: 25% EtOAc/PE; [α]D22: +28° (c = 1, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ = 2.03 (s, 3H, CH3 Ac), 3.60 (s, 3H, CH3 COOMe), 3.75 (d, 1H, J = 5.0 Hz, H-2), 3.80 (dd, 
1H, J = 6.0 Hz, J = 2.8 Hz, H-3), 4.49 (d, 1H, J = 11.9 Hz, CHHPh), 4.54 (d, 1H, J = 4.5 Hz, H-5), 4.57 (d, 1H, J 
= 12.1 Hz, CHHPh), 4.61 (d, 1H, J = 12.1 Hz, CHHPh), 4.63 (d, 1H, J = 11.9 Hz, CHHPh), 5.55 (t, 1H, J = 6.0 
Hz, J = 4.5 Hz, H-4), 5.77 (d, 1H, J = 7.0 Hz, H-1), 7.22 – 7.59 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) 
δ = 20.8 (CH3 Ac), 52.4 (CH3 COOMe), 69.4 (C-4), 72.4 (CH2 Bn), 72.7 (C-5), 73.1 (C-2, C-3), 82.9 (C-1), 
126.7 – 131.3 (CH Arom), 133.6 (Cq SPh), 137.3 (Cq Bn), 137.4 (Cq Bn), 168.4 (C=O Ac or COOMe), 169.6 
(C=O COOMe or Ac); 13C-GATED (100 MHz, CDCl3): 82.9 (J = 168 Hz, C-1); HRMS: [M+NH4]+ calcd for 

























Phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranosiduronic acid (7): Compound 316 was 
converted according to the general procedure delivering title compound 7 in 68% yield as a 
colorless oil. TLC: 25% EtOAc/PE; [α]D22: +34° (c = 1, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ = 3.81 (dd, 1H, J = 6.8 Hz, J = 2.8 Hz, H-3), 3.91 (dd, 1H, J = 5.2 Hz, J = 2.8 Hz, H-2), 4.23 (t, 1H, J = 6.8 
Hz, H-4), 4.52 (d, 1H, J = 12.0 Hz, CHHPh), 4.54 (d, 1H, J = 12.0 Hz, CHHPh), 4.57 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.64 (d, 1H, J = 6.8 Hz, H-5), 4.65 – 4.73 (m, 3H, 2xCHHPh, CHHPh), 5.67 (d, 1H, J = 5.2 Hz, H-1), 
7.22 – 7.51 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3)26 δ = 72.0, 72.3 (CH2 Bn), 72.3 (CH2 Bn), 74.9, 
75.7 127.4 – 131.5 (CH Arom), 133.5 (Cq SPh), 137.5 (Cq Bn), 137.7 (Cq Bn), 172.4 (C=O COOH); HRMS: 
[M+Na]+ calcd for C33H32O6SNa 579.18118 found 579.18222. 
 
Methyl (phenyl 2,3,4-tri-O-benzyl-1-thio-α-D-mannopyranoside) uronate (8): To a stirred 
solution of 373 mg compound 7 (0.67 mmol) in 2.2 mL DMF was added 92 µL MeI (1.5 
mmol, 2 equiv.) and 200 mg K2CO3 (excess). The solution was stirred overnight and quenched 
by the addition of 2 mL MeOH. The reaction mixture was diluted with EtOAc and washed with H2O. The 
aqueous phase was extracted with EtOAc. The combined organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure. Flash column chromatography (EtOAc/PE) afforded 355 mg of the title 
compound 8 (0.62 mmol, 92%) as a colorless oil. TLC: 25% EtOAc/PE; 1H NMR (400 MHz, CDCl3) δ = 3.46 
(s, 3H, CH3 COOMe), 3.81 (dd, 1H, J = 7.0 Hz, J = 2.8 Hz, H-3), 3.89 (dd, 1H, J = 5.2 Hz, J = 2.8 Hz, H-2), 
4.26 (t, 1H, J = 7.0 Hz, J = 6.2 Hz, H-4), 4.52 (d, 1H, J = 12.0 Hz, CHHPh), 4.55 (s, 2H, CH2 Bn), 4.63 (d, 1H, J 
= 6.2 Hz, H-5), 4.64 – 4.69 (m, 3H, 2xCHHPh, CHHPh), 5.67 (d, 1H, J = 5.2 Hz, H-1), 7.23 – 7.53 (m, 20H, H 
Arom); 13C NMR (100 MHz, CDCl3) δ = 52.2 (CH3 COOMe), 72.1 (CH2 Bn), 72.4 (CH2 Bn), 72.9 (C-5), 73.7 
(CH2 Bn), 74.9 (C-2), 75.6 (C-4), 77.1 (C-3), 84.7 (C-1), 127.2 – 131.4 (CH Arom), 134.9 (Cq SPh), 137.8 (2xCq 
Bn), 137.9 (Cq Bn), 169.2 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 84.7 (J = 163 Hz, C-1); HRMS: 
[M+Na]+ calcd for C34H34O6SNa 593.19683 found 593.19780. 
 
Phenyl 2,4-di-O-benzyl-α-D-mannopyranoside (9): To a cooled solution (0°C) of 2.71 g 
compound 1 (10.0 mmol) in 50 mL DMF was added 3.24 g TBSCl (21.5 mmol, 2.15 equiv.) 
and 3.18 g imidazole (21.5 mmol, 2.15 equiv.). The mixture was allowed to warm to room 
temperature. After stirring for 8 h the reaction was quenched with MeOH, taken up in EtOAc and washed with 
H2O. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
product was filtered through a plug of silica gel using (10% EtOAc/PE) as the eluent. After evaporation the 
product was dissolved in 50 mL DMF and cooled to 0°C before 3 mL BnBr (25 mmol, 2.5 equiv.) and 1 g NaH 
(60% in min. oil, 25 mmol, 2.5 equiv.) were added. The mixture was allowed to stir for 12h and the reaction was 
quenched by MeOH, taken up in Et2O and washed with H2O. The organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure. The oily substance was suspended in 50 mL MeOH and a catalytic amount 
of TsOH was added. The mixture was refluxed until TLC indicated complete conversion. After addition of 5 mL 
NEt3 the reaction mixture was concentrated under reduced pressure. Flash chromatography afforded 1.35 g of the 
title compound 9 (2.98 mmol, 30%) as a colorless oil. TLC: 50% EtOAc/PE; [α]D22: +59° (c = 1, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ = 1.84 (bs, 1H, OH-6), 2.42 (d, 1H, J = 7.6 Hz, OH-3), 3.74 (t, 1H, J = 9.6 Hz, H-4), 
3.78 – 3.85 (m, 2H, H-6), 4.00 (bs, 2H, H-2, H-3), 4.12 (dt, 1H, J = 4.0 Hz, J = 3.2 Hz, H-5), 4.56 (d, 1H, J = 
11.6 Hz, CHHPh), 4.67 (d, 1H, J = 11.6 Hz, CHHPh), 4.75 (d, 1H, J = 11.6 Hz, CHHPh), 4.93 (d, 1H, J = 11.6 
Hz, CHHPh), 5.57 (s, 1H, H-1), 7.24 – 7.48 (m, 15H, H Arom); 13C NMR (150 MHz, CDCl3) δ = 62.1 (C-6), 
72.2 (C-2 or C-3), 72.4 (C-5), 72.5 (CH2 Bn), 74.9 (CH2 Bn), 76.4 (C-4), 79.7 (C-3 or C-2), 85.1 (C-1), 127.4 – 
131.9 (CH Arom), 133.6 (Cq SPh), 137.2 (Cq Bn), 138.1 (Cq Bn); 13C-GATED (150 MHz, CDCl3): 85.1 (J = 165 

























Phenyl 2,4-di-O-benzyl-1-thio-α-D-mannopyranosidurono-6,3-lactone (10): Diol 9 was 
converted according to the general procedure delivering 1-thio mannuronic acid lactone 10 in 
63% yield as a colorless oil. TLC: 25% EtOAc/PE; 1H NMR (500 MHz, CDCl3) δ = 3.94 (dd, 
1H, J = 9.0 Hz, J = 1.0 Hz, H-2), 4.03 (dd, 1H, J = 6.0 Hz, J = 3.0 Hz, H-4), 4.35 (d, 1H, J = 
2.5 Hz, H-5), 4.44 (d, 1H, J = 11.5 Hz, CHHPh), 4.58 (d, 1H, J = 11.5 Hz, CHHPh), 4.66 (d, 1H, J = 11.5 Hz, 
CHHPh), 4.70 (d, 1H, J = 6.0 Hz, H-3), 4.78 (d, 1H, J = 11.5 Hz, CHHPh), 5.00 (d, 1H, J = 9.0 Hz, H-1), 7.24 – 
7.65 (m, 15H, H Arom); 13C NMR (125 MHz, CDCl3) δ = 71.7 (CH2 Bn), 72.0 (C-5), 72.9 (CH2 Bn), 73.1 (C-2), 
74.9 (C-4), 77.8 (C-3), 84.3 (C-1), 127.8 – 132.4 (CH Arom), 132.1 (Cq SPh), 136.3 (Cq Bn), 137.2 (Cq Bn), 
169.6 (C=O lactone); 13C-GATED (125 MHz, CDCl3): 84.3 (J = 158 Hz, C-1); HRMS: [M+H]+ calcd for 
C26H25O5S 448.13444, found 448.19671. 
 
Methyl (phenyl 3-O-acetyl-2,4-di-O-benzyl-1-thio-α-D-mannopyranoside) uronate (11): 
Compound 10 (170 mg, 0.37 mmol) was dissolved in MeOH and, after addition of 200 mg 
Amberlite IR120 H+ resin, heated under reflux. After 4h, TLC analysis indicated complete 
conversion of starting material into a lower running product. The reaction mixture was filtered and concentrated 
under reduced pressure. The product was treated with 5 mL pyridine/Ac2O (3:1) for 8h followed by addition of 
MeOH. The reaction mixture was diluted with EtOAc and washed with 2M HCl and sat. NaHCO3. The organic 
phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography 
(EtOAc/PE) afforded 156 mg of the title compound 11 (0.3 mmol, 81%) as a colorless oil. TLC: 25% 
EtOAc/PE; [α]D22: +29° (c = 1.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 1.97 (s, 3H, CH3 Ac), 3.72 (CH3 
COOMe), 3.99 (dd, 1H, J = 5.1 Hz, J = 3.1 Hz, H-2), 4.25 (t, 1H, J = 6.9 Hz, H-4), 4.48 (d, 1H, J = 11.8 Hz, 
CHHPh), 4.59 (d, 1H, J = 11.8 Hz, CHHPh), 4.61 (d, 1H, J = 11.4 Hz, CHHPh), 4.67 (d, 1H, J = 11.4 Hz, 
CHHPh), 4.68 (d, 1H, J = 6.9 Hz, H-5), 5.25 (dd, 1H, J = 7.3 Hz, J = 3.1 Hz, H-3), 5.58 (d, 1H, J = 5.1 Hz, H-1), 
7.24 – 7.56 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.8 (CH3 Ac), 52.4 (CH3 COOMe), 70.9 (C-
3), 72.3 (CH2 Bn), 72.7 (C-5), 73.8 (CH2 Bn), 74.6 (C-2), 75.0 (C-4), 84.1 (C-1), 127.5 – 131.7 (CH Arom), 
133.3 (Cq SPh), 137.3 (Cq Bn), 137.6 (Cq Bn), 169.4 (C=O Ac or COOMe), 169.7 (C=O COOMe or Ac); 13C-




pyranosyluronate)-α-D-glucopyranoside (13): Donor 6 was glycosylated with 
acceptor 12 in the same way as described in the general procedure (Ph2SO/Tf2O) 
delivering the title compound 13 as a colorless oil. TLC: 30% EtOAc/PE; [α]D22:   
-11° (c = 0.6, CHCl3); 1H NMR (500 MHz, CDCl3) δ = 2.02 (s, 3H, CH3 Ac), 3.31 (s, 3H, CH3 OMe), 3.37 (dd, 
1H, J = 9.5 Hz, J = 2.5 Hz, H-3’), 3.41 (m, 2H, H-4 and H-6), 3.50 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, H-2), 3.71 (s, 
4H, H-2’ and CH3 COOMe), 3.75 (s, 1H, H-5’), 3.79 (bt, 1H, J = 8.0 Hz, J = 6.0 Hz, H-5), 4.01 (t, 1H, J = 9.5 
Hz, H-3), 4.12 (bs, 2H, H-1’ and H-6), 4.36 (d, 1H, J = 12.5 Hz, CHHPh), 4.47 (d, 1H, J = 12.5 Hz, CHHPh), 
4.49 (d, 1H, J = 12.5 Hz, CHHPh), 4.56 (d, 1H, J = 3.5 Hz, H-1), 4.66 (d, 1H, J = 12.0 Hz, CHHPh), 4.75 (d, 
1H, J = 11.5 Hz, CHHPh), 4.79 (d, 1H, J = 12.0 Hz, CHHPh), 4.81 (d, 1H, J = 11.5 Hz, CHHPh), 4.84 (d, 1H, J 
= 10.5 Hz, CHHPh), 4.90 (d, 1H. J = 12.5 Hz, CHHPh), 5.01 (d, 1H, J = 10.5 Hz, CHHPh), 5.48 (t, 1H, J = 9.5 
Hz, H-4’), 7.18 – 7.37 (m, 25H H Arom); 13C NMR (125 MHz, CDCl3) δ = 20.8 (CH3 Ac), 48.5 (CH3 COOMe), 
52.5 (CH3 OMe), 68.8 (C-6), 68.9 (C-4’), 69.7 (C-5), 71.5 (CH2 Bn), 72.9 (C-2’), 73.3 (CH2 Bn), 73.6 (CH2 Bn), 
73.7 (C-5’), 74.7 (CH2 Bn), 75.7 (CH2 Bn), 77.6 (C-4), 78.2 (C-3’), 79.8 (C-2), 82.1 (C-3), 97.8 (C-1), 101.6 (C-



























COOMe), 169.5 (C=O Ac or COOMe); 13C-GATED (125 MHz, CDCl3): 97.8 (JC1,H1 = 169 Hz, C-1), 101.6 
(JC1’,H1’ = 156 Hz, C-1’); HRMS: [M+NH4]+ calcd for C51H60O13N 894.40647, found 894.40531. 
 
N.B.: Conclusive evidence for the β-orientation was gained by reducing both ester functions after which the 
heteronuclear coupling constant was determined at 1JC1’,H1’ = 153 Hz. 
 
Methyl (2,3,4-tri-O-benzyl-6-O-(methyl 4-O-acetyl-2,3-di-O-benzyl-α-D-manno-
pyranosyluronate)-α-D-glucopyranoside (14): Donor 11 was glycosylated with 
acceptor 12 in the same way as described in the general procedure (Ph2SO/Tf2O) 
delivering the title compound 14 as a colorless oil. TLC: 30% EtOAc/PE; 1H NMR 
(400 MHz, CDCl3) δ = 1.96 (s, 3H, CH3 Ac), 3.36 (s, 3H, CH3 OMe), 3.48 (t, 1H, J 
= 9.2 Hz, H-4), 3.50 (dd, 1H, J = 9.6 Hz, J = 3.6 Hz, H-2), 3.68 (s, 3H, CH3 COOMe), 3.71 – 3.77 (m, 2H, H-5, 
H-6), 3.86 (t, 1H, J = 3.0 Hz, H-2’), 3.90 (dd, 1H, J = 11.1 Hz, J = 4.8 Hz, H-6), 3.99 (t, 1H, J = 9.6 Hz, J = 9.2 
Hz, H-3), 4.19 (t, 1H, J = 8.7 Hz, H-4’), 4.29 (d, 1H, J = 8.7 Hz, H-5’), 4.53 (d, 1H, J = 12.3 Hz, CHHPh), 4.56 
(d, 1H, J = 3.6 Hz, H-1), 4.61 (d, 1H, J = 10.9 Hz, CHHPh), 4.63 (d, 1H, J = 12.0 Hz, CHHPh), 4.65 (s, 2H, CH2 
Bn), 4.67 (d, 1H, J = 12.3 CHHPh), 4.78 (d, 1H, J = 12.0 Hz, CHHPh), 4.82 (d, 1H, J = 10.9 Hz, CHHPh), 4.92 
(d, 1H, J = 10.9 Hz, CHHPh), 4.99 (d, 1H, J = 11.1 Hz, CHHPh), 5.00 (s, 1H, H-1’), 5.24 (dd, 1H, J = 8.6 Hz, J 
= 3.2 Hz, H-3’), 7.23 – 7.38 (m, 25H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.9 (CH3 Ac), 52.3 (CH3 
OMe), 55.1 (CH3 COOMe), 66.7 (C-6), 69.8 (C-5), 71.5 (C-5’), 72.5 (C-3’), 72.9 (CH2 Bn), 73.3 (CH2 Bn), 74.3 
(CH2 Bn), 74.8 (C-4’), 75.0 (CH2 Bn), 75.0 (C-2’), 75.7 (CH2 Bn), 77.6 (C-4), 79.9 (C-2), 82.1 (C-3), 97.8 (C-1), 
98.5 (C-1’); 127.5 – 129.1 (CH Arom), 137.7 (Cq Bn), 137.9 (Cq Bn), 138.1 (Cq Bn), 138.6 (Cq Bn), 169.6 (C=O 
COOMe or Ac), 169.9 (C=O Ac or COOMe); 13C-GATED (100 MHz, CDCl3): 97.8 (JC1,H1 = 166 Hz, C-1), 98.5 
(JC1’,H1’ = 170 Hz, C-1’); HRMS: [M+NH4]+ calcd for C51H60O13N 894.40647, found 894.40545. 
 
para-Methoxyphenyl (2-O-benzyl-4,6-O-benzylidene-3-O-(methyl 2,3,4-tri-O-
benzyl-β-D-mannopyranosyluronate)-β-D-galactopyranoside (16): Donor 8 was 
glycosylated with acceptor 15 in the same way as described in the general 
procedure (Ph2SO/Tf2O) delivering the title compound 16 as a colorless oil. 
TLC: 30% EtOAc/PE; [α]D22: -4° (c = 0.5, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ = 3.16 (dd, 1H, J = 9.6 Hz, J = 2.9 Hz, H-3’), 3.56 (s, 1H, H-5), 3.63 (d, 1H, J = 2.8 Hz, H-2’), 3.72 (s, 
3H, CH3 COOMe or OMe), 3.73 (d, 1H, J = 9.2 Hz, H-5’), 3.79 (s, 3H, CH3 COOMe or OMe), 3.84 (dd, 1H, J = 
9.9 Hz, J = 3.4 Hz, H-3), 4.08 (dd, 1H, J = 9.9 Hz, J = 7.6 Hz, H-2), 4.09 (dd, 1H, J = 12.3 Hz, J = 1.7 Hz, H-6), 
4.18 (t, 1H, J = 9.7 Hz, H-4’), 4.28 (d, 1H, J = 11.6 Hz, CHHPh), 4.30 (d, 1H, J = 11.3 Hz, CHHPh), 4.36 (d, 
1H, J = 12.3 Hz, H-6), 4.37 (d, 1H, J = 11.6 Hz, CHHPh), 4.39 (d, 1H, J = 3.4 Hz, H-4), 4.61 (d, 1H, J = 10.7 
Hz, CHHPh), 4.71 (s, 1H, H-1’), 4.85 (d, 1H, J = 10.7 CHHPh), 4.91 (d, 1H, J = 7.6 Hz, H-1), 4.93 (s, 2H, CH2 
Bn), 4.96 (d, 1H, J = 11.6 Hz, CHHPh), 5.62 (s, 1H, CHPh), 6.84 (d, 2H, J = 9.0 Hz, H Arom pMP), 7.05 (d, 2H, 
J = 9.0 Hz, H Arom pMP), 7.10 – 7.60 (m, 25H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.3 (CH3 OMe), 
55.6 (CH3 COOMe), 66.7 (C-5), 68.9 (C-6), 71.8 (CH2 Bn), 71.9 (C-2’), 73.4 (CH2 Bn), 75.2 (2xCH2 Bn), 75.3 
(C-5’), 75.7 (C-4’), 75.8 (C-4), 77.7 (C-3), 79.0 (C-2), 82.0 (C-3’), 100.8 (CHPh), 103.2 (C-1 and C-1’), 114.5 
(CH Arom pMP), 118.9 (CH Arom pMP), 126.3 – 128.7 (CH Arom), 137.9 (Cq Bn), 138.1 (Cq Bn), 138.3 (Cq 
Bn), 138.4 (Cq Bn), 151.5 (Cq pMP), 155.4 (Cq pMP), 168.7 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 
103.2 (JC1’,H1’ = 159 Hz, C-1’), 103.2 (JC1,H1 = 159 Hz, C-1); HRMS: [M+Na]+ calcd for C55H56O13Na 































Donor 6 was glycosylated with acceptor 15 in the same way as described in the 
general procedure (Ph2SO/Tf2O and NIS/TMSOTf) delivering the title 
compound 17 as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: -28° (c = 0.8, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ = 1.97 (s, 3H, CH3 Ac), 3.12 (dd, 1H, J = 9.8 Hz, J = 2.8 Hz, H-3’), 3.53 (s, 1H, H-5), 3.65 (d, 1H, J = 
2.7 Hz, H-2’), 3.70 (d, 1H, J = 9.7 Hz, H-5’), 3.72 (s, 3H, CH3 COOMe or OMe), 3.78 (s, 3H, CH3 OMe or 
COOMe), 3.83 (dd, 1H, J = 9.9 Hz, J = 3.4 Hz, H-3), 4.07 (t, 1H, J = 9.9 Hz, H-2), 4.10 (m, 1H, H-6), 4.18 (d, 
1H, J = 12.1 Hz, CHHPh), 4.30 (d, 1H, J = 12.4 Hz, CHHPh), 4.37 (m, 3H, H-6, 2xCHHPh), 4.42 (d, 1H, J = 3.4 
Hz, H-4), 4.70 (s, 1H, H-1’), 4.88 (d, 1H, J = 11.3 Hz, CHHPh), 4.90 (s, 1H, H-1), 4.95 (d, 1H, J = 11.3 Hz, 
CHHPh), 5.45 (t, 1H, J = 9.7 Hz, H-4’), 5.64 (s, 1H, CHPh), 6.84 (d, 2H, J = 9.0 Hz, H Arom pMP), 7.07 (d, 2H, 
J = 9.0 Hz, H Arom pMP), 7.10 – 7.60 (m, 20H, H Arom); 13C NMR (125 MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.5 
(CH3 OMe), 55.6 (CH3 COOMe), 66.7 (C-5), 68.7 (C-4’), 68.9 (C-6), 71.6 (C-2’), 68.9 (CH2 Bn), 73.4 (CH2 
Bn), 73.5 (C-5’), 75.2 (CH2 Bn), 75.7 (C-4), 77.7 (C-3), 79.0 (C-2, C-3’), 100.8 (CHPh), 102.5 (C-1’), 103.1 (C-
1), 114.5 (CH Arom pMP), 118.8 (CH Arom pMP), 126.3 – 128.8 (CH Arom), 137.7 (Cq Bn), 137.9 (Cq Bn), 
138.2 (Cq Bn), 138.5 (Cq Bn), 151.4 (Cq pMP), 155.4 (Cq pMP), 167.9 (C=O Ac or COOMe), 169.5 (C=O 
COOMe or Ac); 13C-GATED (125 MHz, CDCl3): 102.5 (JC1’,H1’ = 164 Hz, C-1’), 103.1 (JC1,H1 = 158 Hz, C-1); 
HRMS: [M+NH4]+ calcd for C50H56O14N 894.37008, found 894.36879. 
 
1,2;5,6-Di-O-isopropylidene-3-O-(methyl 4-O-acetyl-2,3-di-O-benzyl-β-D-manno-
pyranosyluronate)-α-D-glucopyranose (19): Donor 6 was glycosylated with 
acceptor 18 in the same way as described in the general procedure (Ph2SO/Tf2O) 
delivering the title compound 19 as a colorless oil. TLC: 30% EtOAc/PE; [α]D22:    
-34° (c = 0.7, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 1.22 (s, 3H, CH3 isoprop), 
1.24 (s, 3H, CH3 isoprop), 1.35 (s, 3H, CH3 isoprop), 1.49 (s, 3H, CH3 isoprop), 
1.96 (s, 3H, CH3 Ac), 3.42 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H-3’), 3.65 (s, 3H, CH3 COOMe), 3.76 (d, 1H, J = 
9.2 Hz, H-2’), 3.77 (d, 1H, J = 3.2 Hz, H-5’), 3.97 (dd, 1H, J = 8.4 Hz, J = 6.0 Hz, H-6), 4.09 (dd, 1H, J = 8.4 
Hz, J = 6.8 Hz, H-6), 4.18 (d, 1H, J = 3.2 Hz, H-3), 4.25 (dd, 1H, J = 4.9 Hz, J = 3.2 Hz, H-4), 4.33 (d, 1H, J = 
12.0 Hz, CHHPh), 4.34 (d, 1H, J = 4.0 Hz, H-2), 4.39 (d, 1H, J = 12.0 Hz, CHHPh), 4.45 (dd, 1H, J = 11.2 Hz, J 
= 1.6 Hz, H-5), 4.46 (s, 1H, H-1’), 4.67 (d, 1H, J = 12.0 Hz, CHHPh), 4.76 (d, 1H, J = 12.4 Hz, CHHPh), 5.43 
(t, 1H, J = 9.6 Hz, H-4’), 5.82 (d, 1H, J = 3.6 Hz, H-1), 7.15 – 7.32 (m, 10H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 20.8 (CH3 Ac), 20.0 (CH3 isoprop), 26.3 (CH3 isoprop), 26.5 (CH3 isoprop), 26.7 (CH3 isoprop), 
52.6 (CH3 COOMe), 65.9 (C-6), 68.6 (C-3’), 71.8 (CH2 Bn), 73.3 (C-5’), 73.5, 73.6 (C-2’ and C-5), 73.9 (CH2 
Bn), 78.2 (C-4’), 80.5 (C-4), 81.8 (C-3), 83.0 (C-2), 99.8 (C-1’), 104.9 (C-1), 108.4 (Cq isoprop), 111.9 (Cq 
isoprop), 127.5 – 128.4 (CH Arom), 137.6 (Cq Bn), 137.9 (Cq Bn), 167.7 (C=O Ac or COOMe), 169.5 (C=O Ac 
or COOMe); 13C-GATED (100 MHz, CDCl3): 99.8 (JC1’,H1’ = 157 Hz, C-1’), 104.9 (JC1,H1 = 181 Hz, C-1); 
HRMS: [M+H]+ calcd for C35H45O13 673.28547 found 673.28598. 
 
para-Methoxyphenyl (methyl 2,3-di-O-benzyl-4-O-(methyl 4-O-acetyl-2,3-di-
O-benzyl-α/β-D-mannopyranosyluronate)-β-D-galactopyranoside) uronate (21): 
Donor 6 was glycosylated with acceptor 20 in the same way as described in the 
general procedure (NIS/TMSOTf) delivering the title compound 21 as a 
colorless oil. TLC: 30% EtOAc/PE; α-anomer: [α]D22: +2° (c = 0.3, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ = 2.03 (s, 3H, CH3 Ac), 3.53 (dd, 1H, J = 7.3 Hz, J = 3.1 Hz, H-3), 3.54 (s, 3H, CH3 








































3.91 (dd, 1H, J = 9.8 Hz, J = 7.8 Hz, H-2), 4.09 (s, 1H, H-5), 4.53 (d, 1H, J = 12.3 Hz, CHHPh), 4.54 (d, 1H, J = 
1.1 Hz, H-4), 4.61 (d, 1H, J = 12.3 Hz, CHHPh), 4.62 (d, 1H, J = 11.7 Hz, CHHPh), 4.65 (d, 1H, J = 10.9 Hz, 
CHHPh), 4.68 (d, 1H, J = 8.1 Hz, H-5’), 4.76 (d, 1H, J = 12.6 Hz, CHHPh), 4.80 (d, 1H, J = 7.7 Hz, H-1’), 4.83 
(d, 1H, J = 12.6 Hz, CHHPh), 4.91 (d, 1H, J = 10.9 Hz, CHHPh), 5.01 (d, 1H, J = 10.9 Hz, CHHPh), 5.15 (d, 
1H, J = 2.5 Hz, H-1’), 5.49 (t, 1H, J = 8.1 Hz, H-4’), 6.81 (d, 2H, J = 9.1 Hz, CH Arom pMP), 7.07 (d, 2H, J = 
9.1 Hz, CH Arom pMP), 7.24 – 7.40 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.9 (CH3 Ac), 52.3 
(CH3 COOMe), 52.4 (CH3 COOMe), 55.6 (CH3 OMe), 69.3 (C-4’), 71.2 (C-5’), 71.8 (CH2 Bn), 72.6 (CH2 Bn), 
72.8 (CH2 Bn), 73.3 (C-4), 73.6 (C-2’), 75.2 (CH2 Bn), 75.3 (C-5), 76.4 (C-3’), 77.6 (C-2), 78.7 (C-3), 99.8 (C-
1’), 103.1 (C-1), 114.5 (CH Arom pMP), 118.8 (CH Arom pMP), 127.4 – 128.3 (CH Arom), 137.7 (Cq Bn), 
138.0 (Cq Bn), 138.3 (Cq Bn), 151.6 (Cq pMP), 155.5 (Cq pMP), 167.7 (C=O COOMe or Ac), 169.0 (C=O 
COOMe or Ac), 169.9 (C=O COOMe or Ac); 13C-GATED (100 MHz, CDCl3): 99.8 (JC1’,H1’ = 168 Hz, C-1’), 
103.1 (JC1,H1 = 160 Hz, C-1); HRMS: [M+NH4]+ calcd for C51H54O15 924.38010, found 924.38025.  
β-anomer: [α]D22: -34° (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 1.99 (s, 3H, CH3 Ac), 3.24 (dd, 1H, J = 
9.8 Hz, J = 2.8 Hz, H-3’), 3.63 (dd, 1H, J = 9.6 Hz, J = 3.0 Hz, H-3), 3.67 (d, 1H, J = 9.9 Hz, H-5’), 3.72 (s, 3H, 
CH3 COOMe), 3.77 (s, 3H, CH3 OMe), 3.79 (s, 3H, CH3 COOMe), 3.93 (d, 1H, J = 2.9 Hz, H-2’), 3.95 (dd, 1H, 
J = 9.6 Hz, J = 7.7 Hz, H-2), 4.15 (d, 1H, J = 1.1 Hz, H-5), 4.25 (d, 1H, J = 12.3 Hz, CHHPh), 4.86 (d, 1H, J = 
12.3 Hz, CHHPh), 4.53 (dd, 1H, J = 3.0 Hz, J = 1.1 Hz, H-4), 4.62 (d, 1H, J = 11.7 Hz, CHHPh), 4.76 (d, 1H, J 
= 11.7 Hz, CHHPh), 4.77 (d, 1H, J = 2.9 Hz, H-1’), 4.78 (d, 1H, J = 10.9 Hz, CHHPh), 4.84 (d, 1H, J = 7.7 Hz, 
H-1), 4.86 (d, 1H, J = 12.6 Hz, CHHPh), 4.95 (d, 1H, J = 12.6 Hz, CHHPh), 5.05 (d, 1H, J = 10.9 Hz, CHHPh), 
5.41 (t, 1H, J = 9.8 Hz, H-4’), 6.82 (d, 2H, J = 9.1 Hz, CH Arom pMP), 7.10 (d, 2H, J = 9.1 Hz, CH Arom 
pMP), 7.23 – 7.54 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.4 (CH3 COOMe), 
52.6 (CH3 COOMe), 55.6 (CH3 OMe), 68.6 (C-4’), 71.1 (CH2 Bn), 71.7 (C-2’), 73.1 (C-4), 73.3 (CH2 Bn), 73.5 
(CH2 Bn), 73.7 (C-5’), 73.7 (C-5), 75.3 (CH2 Bn), 78.5 (C-2), 78.6 (C-3’), 80.9 (C-3), 101.4 (C-1’), 103.2 (C-1), 
114.5 (CH Arom pMP), 119.3 (CH Arom pMP), 127.3 – 128.8 (CH Arom), 137.7 (Cq Bn), 137.9 (Cq Bn), 138.3 
(Cq Bn), 138.6 (Cq Bn), 151.4 (Cq pMP), 155.6 (Cq pMP), 167.1 (C=O COOMe or Ac), 167.9 (C=O COOMe or 
Ac), 169.6 (C=O COOMe or Ac); 13C-GATED (100 MHz, CDCl3): 101.4 (JC1’,H1’ = 160 Hz, C-1’), 103.2 (JC1,H1 
= 160 Hz, C-1); HRMS: [M+Na]+ calcd for C51H54O15Na 929.33549, found 929.33706. 
 
Methyl (phenyl 4-O-levulinoyl-2,3-di-O-benzyl-1-thio-α-D-mannopyranoside) uronate (22): 
Compound 5 (276 mg g, 0.57 mmol) was dissolved in 5.7 mL pyridine and levulinoyl 
anhydride (0.5M in dioxane, 3.4 mL, 1.7 mmol) was added. The reaction was stirred 
overnight, after which the mixture was diluted with EtOAc, washed with 1M HCl, saturated aqueous NaHCO3 
and brine. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography (20% EtOAc/PE) to yield 330 mg of the title compound 
22 (0.57 mmol, 86%) as a colorless oil. TLC: 30% EtOAc/PE; 1H NMR (400 MHz, CDCl3) δ = 2.17 (s, 3H, CH3 
Lev), 2.52 (m, 2H, CH2 Lev), 2.69 – 2.72 (m, 2H, CH2 Lev), 3.58 (s, 3H, CH3 COOMe), 3.74 (bd, 1H, J = 6.0 
Hz, H-2), 3.86 (dd, 1H, J = 6.0 Hz, J = 2.8 Hz, H-3), 4.53 (d, 1H, J = 12.0 Hz, CHHPh), 4.54 (s, 1H, H-5), 4.56 
(d, 1H, J = 12.8 Hz, CHHPh), 4.61 (d, 1H, J = 12.8 Hz, CHHPh), 4.64 (d, 1H, J = 12.0 Hz, CHHPh), 5.57 (t, 1H, 
J = 5.6 Hz, H-4), 5.78 (d, 1H, J = 7.2 Hz, H-1), 7.21 – 7.60 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 
27.8 (CH2 Lev), 29.7 (CH3 Lev), 37.7 (CH2 Lev), 52.2 (CH3 COOMe), 69.6 (C-4), 72.9 (C-5), 73.8 (C-3), 74.3 
(C-2), 82.9 (C-1), 168.4 (C=O Lev or COOMe), 171.5 (C=O COOMe or Lev), 206.0 (C=O Lev ketone); HRMS: 















3-Azidopropyl (methyl (4-O-acetyl-2,3-di-O-benzyl-β-D-mannopyranoside) 
uronate) (23): A solution of 102 mg donor 6 (0.2 mmol 1 equiv.), 51 mg diphenyl 
sulfoxide (0.25 mmol, 1.3 equiv.) and 124 mg tri-tert-butylpyrimidine (0.5 mmol, 
2.5 equiv.) in 5 mL DCM was stirred over activated MS3Å for 30min. The mixture was cooled to -60°C before 
41 µL triflic acid anhydride (0.25 mmol, 1.3 equiv.) was added. The mixture was allowed to warm to -40°C in 
15min followed by cooling to -80°C.24 At that temperature 30 mg acceptor (0.3 mmol, 1.5 equiv.) in 1 mL DCM 
was added. Stirring was continued and the reaction mixture was allowed to warm to rT followed by addition of 2 
mL pyridine and 1 mL Ac2O. Stirring was continued for a further 10h. After addition of MeOH, the reaction 
mixture was diluted with EtOAc and washed with 1M HCl and NaHCO3 (sat.). The organic phase was dried 
(MgSO4), filtered and concentrated under reduced pressure. Flash chromatography (EtOAc/PE) and removal of 
the eluent afforded 80 mg of title compound 23 (α/β = 1/5, 0.16 mmol, 80%) as a colorless oil. TLC: 50% 
EtOAc/PE; [α]D22: -2° (c = 0.4, CHCl3); IR (neat, cm-1): 1091, 1211, 1265, 1450, 1732, 2110; 1H NMR (400 
MHz, CDCl3) δ = 1.84 – 1.96 (m, 2H, CH2 azidopropyl), 2.02 (s, 3H, CH3 Ac), 3.39 (t, 2H, CH2 azidopropyl), 
3.48 – 3.56 (m, 2H, H-3, CH azidopropyl), 3.72 (s, 3H, CH3 COOMe), 3.85 (d, 1H, J = 9.6 Hz, H-5), 3.89 (d, 
1H, J = 2.0 Hz, H-2), 4.01 – 4.07 (m, 1H, CH2 azidopropyl), 4.38 (d, 1H, J = 12.4 Hz, CHHPh), 4.44 (s, 1H, H-
1), 4.50 (d, 1H, J = 12.4 Hz, CHHPh), 4.80 (d, 1H, J = 12.4 Hz, CHHPh), 4.92 (d, 1H, J = 12.4 Hz, CHHPh), 
5.52 (t, 1H, J = 9.6 Hz, H-4), 7.21 – 7.42 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.8 (CH3 Ac), 
29.0 (CH2 azidopropyl), 48.3 (CH2 azidopropyl), 52.6 (CH3 COOMe), 66.9 (CH2 azidopropyl), 68.9 (C-4), 71.5 
(CH2 Bn), 73.0 (C-2), 73.7 (C-5), 73.8 (CH2 Bn), 78.1 (C-3), 101.5 (C-1), 127.4 – 128.3 (CH Arom), 137.7 (Cq 
Bn), 138.2 (Cq Bn), 167.9 (C=O Ac), 169.6 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 101.5 (J = 154 
Hz, C-1); HRMS: [M+Na]+ calcd for C26H31O8N3Na 536.20034, found 536.20156. 
 
3-Azidopropyl (methyl 2,3-di-O-benzyl-β-D-mannopyranoside) uronate (24): To a 
stirred solution of 80 mg compound 23 (1.6 mmol) in MeOH was added a catalytic 
amount of sodium methoxide (30% wt in MeOH). The mixture was stirred for 6h 
before Amberlite IR120+ resin was added to acidify the solution to pH = 6. Subsequent filtration and 
concentration under reduced pressure afforded the crude product. Flash chromatography (EtOAc/PE) and 
removal of the eluent afforded 44 mg of title compound 24 (β-isomer was selectively hydrolyzed, 60%) as a 
colorless oil. TLC: 50% EtOAc/PE; [α]D22: -21° (c = 0.2, CHCl3); IR (neat, cm-1): 1091, 1211, 1265, 1450, 1732, 
2110; 1H NMR (400 MHz, CDCl3) δ = 1.89 – 2.02 (m, 2H, CH2 azidopropyl), 3.02 (s, 1H, OH-4), 3.39 (dd, 1H, 
J = 9.5 Hz, J = 2.9 Hz, H-3), 3.44 (t, 2H, J = 6.7 Hz, CH2 azidopropyl), 3.57 – 3.66 (m, 1H, CH azidopropyl), 
3.80 (d, 1H, J = 9.6 Hz, H-5), 3.85 (s, 3H, CH3 COOMe), 3.92 (d, 1H, J = 2.7 Hz, H-2), 4.06 – 4.11 (m, 1H, CH 
azidopropyl), 4.34 (t, 1H, J = 9.6 Hz, H-4), 4.47 (s, 1H, H-1), 4.55 (d, 1H, J = 12.0 Hz, CHHPh), 4.61 (d, 1H, J 
= 12.0 Hz, CHHPh), 4.81 (d, 1H, J = 12.4 Hz, CHHPh), 4.97 (d, 1H, J = 12.4 Hz, CHHPh), 7.30 – 7.47 (m, 10H, 
H Arom); 13C NMR (100 MHz, CDCl3) δ = 28.9 (CH2 azidopropyl), 48.2 (CH2 azidopropyl), 52.5 (CH3 
COOMe), 66.8 (CH2 azidopropyl), 68.2 (C-4), 71.7 (CH2 Bn), 73.4 (C-2), 74.1 (CH2 Bn), 74.9 (C-5), 80.2 (C-3), 
101.9 (C-1), 127.4 – 128.3 (CH Arom), 137.7 (Cq Bn), 138.2 (Cq Bn), 169.6 (C=O COOMe); 13C-GATED (100 
MHz, CDCl3): 101.9 (J = 153 Hz, C-1); HRMS: [M+Na]+ calcd for C24H29O7N3Na 494.18977, found 494.19008. 
 
3-Azidopropyl (methyl 2,3-di-O-benzyl-4-O-(methyl 4-O-levulinoyl-
2,3-di-O-benzyl-β-D-mannopyranosyl-uronate)-β-D-mannopyranoside) 
uronate (25): Disaccharide 25 was obtained from donor 22 and 
acceptor 24 according to method A of the general procedure for 
glycosidations using NIS/TMSOTf giving 73 mg title compound 25 (0.078 mmol, 78%) as a colorless oil. TLC: 
































1H NMR (400 MHz, CDCl3) δ = 1.83 – 1.89 (m, 2H, CH2 azidopropyl), 2.14 (CH3 Lev), 2.50 (q, 2H, J = 6.0 Hz, 
CH2 Lev), 2.67 (t, 2H, J = 6.0 Hz, CH2 Lev), 3.34 (t, 1H, J = 6.8 Hz, CH2 azidopropyl), 3.45 (dd, 1H, J = 9.6 Hz, 
J = 2.8 Hz, H-3’), 3.49 – 3.54 (m, 1H, CH azidopropyl), 3.54 (s, 3H, CH3 COOMe), 3.60 (dd, 1H, J = 8.8 Hz, J 
= 3.2 Hz, H-3), 3.62 (s, 3H, CH3 COOMe), 3.68 (d, 1H, J = 10.0 Hz, H-5’), 3.82 (bs, 2H, H-2, H-2’), 3.87 (d, 
1H, J = 8.8 Hz, H-5), 4.98 – 4.02 (m, 1H, CH azidopropyl), 4.39 (t, 1H, J = 8.8 Hz, H-4), 4.42 (d, 1H, J = 12.0 
Hz, CHHPh), 4.46 (s, 1H, H-1), 4.52 (d, 1H, J = 12.0 Hz, CHHPh), 4.56 (d, 1H, J = 12.4 Hz, CHHPh), 4.69 (s, 
1H, H-1’), 4.70 (d, 1H, J = 12.8 Hz, CHHPh), 4.83 (d, 1H, J = 12.4 Hz, CHHPh), 4.78 (d, 1H, J = 12.8 Hz, 
CHHPh), 4.83 (d, 1H, J = 12.0 Hz, CHHPh), 5.42 (t, 1H, J = 9.6 Hz, H-4’), 7.22 – 7.38 (m, 20H, H Arom); 13C 
NMR (100 MHz, CDCl3) δ = 27.8 (CH2 Lev), 29.0 (CH2 azidopropyl), 29.8 (CH3 Lev), 37.7 (CH2 Lev), 48.2 
(CH2 azidopropyl), 52.3 (CH3 COOMe), 66.8 (CH2 azidopropyl), 68.9 (C-4’), 71.7 (CH2 Bn), 72.2 (CH2 Bn), 
73.3 (C-5’), 73.9 (CH2 Bn), 73.9 (C-2 or C-2’), 74.3 (CH2 Bn), 74.3 (C-5), 74.9 (C-2’ or C-2), 77.5 (C-4), 78.5 
(C-3’), 79.3 (C-3), 101.8 (C-1), 102.3 (C-1’), 127.1 – 128.3 (CH Arom), 137.8 (Cq Bn), 138.3 (Cq Bn), 138.6 (Cq 
Bn), 138.6 (Cq Bn), 167.7 (C=O COOMe), 168.6 (C=O COOMe), 171.6 (C=O Lev ester), 206.1 (C=O Lev 
ketone); 13C-GATED (100 MHz, CDCl3): 101.8 (JC1,H1 = 155 Hz, C-1), 102.3 (JC1’,H1’ = 156 Hz, C-1’); HRMS: 
[M+Na]+ calcd for C50H57O15N3Na 962.36819, found 962.36725. 
 
3-Azidopropyl (methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-
β-D-mannopyranosyluronate)-β-D-mannopyranoside) uronate (26): 
Disaccharide 25 (65 mg, 0.069 mmol) was dissolved in a mixture of 
pyridine and acetic acid (1 mL, 4/1 v/v), after which 17 µL hydrazine 
monohydrate (0.35 mmol) was added. The mixture was stirred for 30min and then diluted with EtOAc, washed 
with 2M HCl and satured NaHCO3. The organic phase was dried (MgSO4), filtered and concentrated under 
reduced pressure. Flash column chromatography (EtOAc/hexane) afforded 55 mg of the title compound 26 (0.66 
mmol, 95%) as a colorless oil. TLC: 20% EtOAc/DCM; [α]D22: +35.6° (c = 0.7, CHCl3); IR (neat, cm-1): 1026, 
1053, 1361, 1454, 1496, 1747, 2094, 2869; 1H NMR (400 MHz, CDCl3) δ = 1.82 – 1.94 (m, 2H, CH2 
azidopropyl), 2.94 (bs, 1H, OH-4’), 3.31 (dd, 1H, J = 9.6 Hz, J = 3.8 Hz, H-3’), 3.35 (t, 2H, J = 7.0 Hz, CH2 
azidopropyl), 3.51 – 3.55 (m, 1H, CH azidopropyl), 3.59 (d, 1H, J = 9.6 Hz, H-5’), 3.62 (s, 3H, CH3 COOMe), 
3.64 (s, 3H, CH3 COOMe), 3.65 (dd, 1H, J = 8.8 Hz, J = 2.8 Hz, H-3), 3.83 (d, 1H, J = 2.8 Hz, H-2’), 3.86 (d, 
1H, J = 2.8 Hz, H-2), 3.90 (d, 1H, J = 8.8 Hz. H-5), 4.00 – 4.06 (m, 1H, CH azidopropyl), 4.19 (t, 1H, J = 9.6 
Hz, H-4’), 4.45 (t, 1H, J = 8.6 Hz, H-4), 4.48 (s, 1H, H-1), 4.56 (d, 1H, J = 12.0 Hz, CHHPh), 4.57 (d, 1H, J = 
12.4 Hz, CHHPh), 4.60 (d, 1H, J = 12.4 Hz, CHHPh), 4.68 (d, 1H, J = 12.8 Hz, CHHPh), 4.73 (s, 1H, H-1’), 
4.74 (d, 1H, J = 12.0 Hz, CHHPh), 4.76 (d, 1H, J = 12.0 Hz, CHHPh), 4.78 (d, 1H, J = 12.8 Hz, CHHPh), 4.83 
(d, 1H, J = 12.0 Hz, CHHPh), 7.23 – 7.38 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 29.0 (CH2 
azidopropyl), 48.2 (CH2 azidopropyl), 52.3 (CH3 COOMe), 52.4 (CH3 COOMe), 66.8 (CH2 azidopropyl), 68.1 
(C-4’), 71.8 (CH2 Bn), 72.1 (CH2 Bn), 73.9 (CH2 Bn), 73.9 (C-2), 74.5 (C-5), 74.6 (CH2 Bn), 74.8 (C-5’), 75.2 
(C-2’), 77.2 (C-4), 79.3 (C-5’), 80.4 (C-3’), 101.7 (C-1), 102.4 (C-1’), 127.0 – 128.4 (CH Arom), 137.9 (Cq Bn), 
138.3 (Cq Bn), 138.6 (Cq Bn), 138.8 (Cq Bn), 168.6 (C=O COOMe), 169.8 (C=O COOMe); 13C-GATED (100 

















3-Azidopropyl (methyl 2,3-di-O-benzyl-4-O-(methyl 2,3-di-O-benzyl-4-O-(methyl 4-O-levulinoyl-2,3-di-O-
benzyl-β-D-mannopyranosyluronate)-β-D-mannopyranosyl) uronate)-β-D-mannopyranoside) uronate (27): 


















for glycosidations using NIS/TMSOTf giving 33 mg title compound 27 (α/β = 1/>10), 0.026 mmol, 70%) as a 
colorless oil. TLC: 30% EtOAc/PE; IR (neat, cm-1): 1091, 1211, 1265, 1450, 1732, 2110; 1H NMR (600 MHz, 
CDCl3) δ = 1.82 – 1.90 (m, 2H, CH2 azidopropyl), 2.14 (s, 3H, CH3 Lev), 2.52 (q, 2H, J = 7.2 Hz, J = 6.6 Hz, 
CH2 Lev), 2.67 (t, 2H, J = 6.6 Hz, CH2 Lev), 3.34 (t, 2H, CH2 azidopropyl), 3.41 (dd, 1H, J = 9.6 Hz, J = 2.4 Hz, 
H-3’’), 3.49 (dd, 1H, J = 9.0 Hz, J = 3.3 Hz, H-3), 3.45 (s, 4H, CH azidopropyl and CH3 COOMe), 3.56 – 3.60 
(m, 4H, H-3’ and CH3 COOMe), 3.65 (d, 1H, J = 9.6 Hz, H-5’’), 3.74 (d, 1H, J = 2.4 Hz, H-2), 3.76 (d, 1H, J = 
9.6 Hz, H-5), 3.79 (d, 1H, J = 2.4 Hz, H-2’’), 3.81 (d, 1H, J = 1.8 Hz, H-2’), 3.82 (d, 1H, J = 8.4 Hz, H-5’), 4.00 
– 4.03 (m, 1H, J = 6.1 Hz, J = 5.4 Hz, CH azidopropyl), 4.30 (t, 1H, J = 9.6 Hz, H-4), 4.41 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.42 (t, 1H, J = 9.4 Hz, H-4’), 4.44 (s, 1H, H-1), 4.47 (d, 1H, J = 12.0 Hz, CHHPh), 4.53 (d, 1H, J = 
12.0 Hz, CHHPh), 4.56 (d, 1H, J = 12.0 Hz, CHHPh), 4.59 (s, 1H, H-1’’), 4.60 (d, 1H, J = 12.0 Hz, CHHPh), 
4.65 (d, 1H, J = 12.0 Hz, CHHPh), 4.71 (s, 1H, H-1’), 4.75 (d, 1H, J = 12.0 Hz, CHHPh), 4.77 (d, 1H, J = 12.0 
Hz, CHHPh), 4.79 (d, 1H, J = 12.0 Hz, CHHPh), 4.79 (d, 1H, J = 12.0 Hz, CHHPh), 4.81 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.83 (d, 1H, J = 12.0 Hz, CHHPh), 5.40 (t, 1H, J = 9.6 Hz, H-4’’), 7.16 – 7.36 (m, 30H, H Arom); 13C 
NMR (150 MHz, CDCl3) δ = 27.8 (CH2 Lev), 29.0 (CH2 azidopropyl), 29.8 (CH3 Lev), 37.8 (CH2 Lev), 48.2 
(CH2 azidopropyl), 52.1 (CH3 COOMe), 52.3 (CH3 COOMe), 52.4 (CH3 COOMe), 66.8 (CH2 azidopropyl), 68.9 
(C-4’), 71.6 (CH2 Bn), 72.3 (CH2 Bn), 72.5 (CH2 Bn), 73.3 (C-5’’), 73.8 (CH2 Bn), 74.1 (C-2’), 74.3 (CH2 Bn), 
74.4 (C-5), 74.5 (C-5’), 74.5 (CH2 Bn), 74.9 (C-2’’), 75.9 (C-2), 77.1 (C-4’), 77.7 (C-4’’), 78.4 (C-3’’), 79.3 (C-
3’), 79.6 (C-3), 101.7 (C-1), 102.4 (C-1’’), 102.5 (C-1’), 127.2 – 128.4 (CH Arom), 137.8 (Cq Bn), 138.4 (Cq 
Bn), 138.7 (Cq Bn), 138.7 (Cq Bn), 138.8 (Cq Bn), 167.8 (C=O COOMe or Lev), 168.6 (C=O COOMe or Lev), 
168.6 (C=O COOMe or Lev), 171.6 (C=O COOMe or Lev), 206.2 (C=O Lev ketone); 13C-GATED (150 MHz, 
CDCl3): 101.6 (JC1’,H1’ = 155 Hz, C-1’), 102.4 (JC1,H1 = 158 Hz, C-1), 102.5 (JC1’’,H1’’ = 156 Hz, C-1’’); HRMS: 


















uronic acid (28): Trisaccharide 27 (35mg, 0.027mmol) was dissolved in 0.5 mL pyridine/AcOH (4/1) before 5 
µL N2H4·H2O (0.1mmol) was added. The mixture was allowed to stir for 10min, diluted with EtOAc and 
subsequently washed with 2M HCl and sat NaHCO3. The organic phase is dried (MgSO4), filtered and 
concentrated under reduced pressure. The crude intermediate was dissolved in 1 mL THF/H2O and treated with 
0.15 mL KOH (0.45M) for 1h. The reaction mixture was neutralized with Amberlite IR120 to pH = 3, filtered 
and concentrated under reduced pressure. The residual oil is dissolved in 1 mL MeOH/AcoH (10/1) before 25 
mg Pd/C (10%) is added. The reaction mixture is stirred overnight under an H2-atmosphere followed by 
filtration. Gel filtration (HW-40, 0.15M Et4NOAc in H2O) of the residual oil afforded the desired trisaccharide 
28 (5 mg, 8.3 µmol, 35% over 3 steps) as a white foam. TLC: 50% iPrOH/H2O; 1H NMR (400 MHz, CDCl3) δ = 
1.99 – 2.03 (m, 2H, CH2 spacer), 3.14 – 3.21 (m, 2H, CH2 spacer), 3.38 (s, 1H), 3.67 – 3.70 (m, 2H), 3.74 – 3.78 
(m, 1H), 3.79 – 3.84 (m, 3H), 3.86 – 3.90 (m, 1H), 3.89 – 3.93 (m, 2H), 3.97 – 4.03 (m, 2H), 4.05 – 4.07 (m, 
2H), 4.66 (s, 1H), 4.69 (s, 1H), 4.77 (s, 1H); 13C NMR (100 MHz, CDCl3) δ = 27.5, 38.5, 63.6, 67.8, 68.4, 69.3, 
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Abstract: A study of the glycosylation properties of 1-thiomannosazides with a variety of electron 
withdrawing substituents is presented. The assembly of the fully protected trisaccharide 24, 
corresponding to the repeating unit of the enterobacterial common antigen, using both an orthogonal 







N-Acetyl mannosamine and N-acetyl mannosaminuronic acids are constituents of various 
bacterial capsular polysaccharides and lipopolysaccharides.2 In most cases, these mannoside 
residues are connected to the next monosaccharide residue via a 1,2-cis linkage.3 Viewing 
along the C2-C1 bond shows that in the β-oriented linkage, the O2, O1 and O(ring) atoms are 
in close proximity (Δ2-condition), resulting in increased conformational instability as 
compared to the α-linked glycoside.4 Several methodologies for the synthesis of β-linked 
mannopyranoside residues have been explored.5 These include methods in which the O2 
position of β-D-glucopyranosides is oxidized and reduced6 or displaced in an SN2-type fashion 
by an azido nucleophile.7 Other procedures involve silver silicate-mediated SN2-displacement 
of α-bromides8 or intramolecular aglycon delivery9 as the key step. A breakthrough in this 
field of research was reported by Crich and coworkers who discovered that activation of 4,6-
O-benzylidene protected mannopyranosyl sulfoxide donors with triflic anhydride leads to the 







selectivities are attained using 4,6-O-benzylidene protected 1-thiomannosides in combination 
with benzenesulfenyl triflate11 (PhSOTf) or 1-benzenesulfinyl piperidine (BSP)/triflic 
anhydride (Tf2O) as activation systems.12 The β-directing effect of the 4,6-O-benzylidene 
protective group was initially explained by increased torsional strain.13 Recently, Bols and 
coworkers argued that electronic effects14 have a major influence on the stereochemical 
outcome of glycosylations involving 4,6-O-benzylidene mannoside donors.15 The decisive 
influence of the 4,6-O-benzylidene protection in mannopyranose donors is further 
underscored by several other reports showing that variations in the glycosylation procedures 
and promotor systems only led to minor fluctuations in the stereochemical outcome of the β-
mannosylation reaction.16 Similarly, Litjens et al. observed stereoselective 1,2-cis 
glycosylation of 4,6-O-benzylidene protected 1-thio-α-D-mannosazidopyranoside donors 
using diphenyl sulfoxide (Ph2SO)/Tf2O17 as the activation system.18 
The finding that the stereodirecting effect of a 4,6-O-benzylidene protective group on 
glycosyl transfer is at least partially governed by electronic effects suggests that the 
introduction of sufficiently electron withdrawing functionalities in the mannose core may also 
lead to β-selective mannosylation.19 In fact, Schuerch and coworkers demonstrated in 1980 
that reaction of mannopyranose donors having a strongly electronegative non-participating 
substituent at C2 (such as tosyl) and a reactive, electronegative leaving group at C1 (such as 
tosyl or chloride) results in high β-selectivities.20 Application of this approach is limited by 
the harsh conditions required for removal of the C2-tosyl functionality and the moderate 
selectivities obtained with sterically hindered acceptor nucleophiles. Chapter 4 describes that 
the strong stereodirecting influence of carboxylic acid functionalized 1-thiomannosides favors 
SN2-type displacement of the putative α-triflate intermediate resulting in high to exclusive β-
selectivities.21 In addition to these studies, this Chapter describes the glycosylation properties 
in terms of yield and stereoselectivity of the 1-thio-α-D-mannosazidopyranoside donors 2, 5 
and 8, functionalized with electron-withdrawing substituents at different positions of the 
pyranoside core. Next to the outcome of these studies, their application in the assembly of the 
fully protected repeating unit trisaccharide 24 of the enterobacterial common antigen (ECA) is 
presented. 
 
Results and Discussion 
 
Donor glycosides 2, 5 and 8 were obtained from commercially available D-mannosamine 
hydrochloride 1 as described in Scheme 1. Subjection of 1 to diazo transfer, followed by 
acetylation and finally Lewis acid catalyzed introduction of the anomeric thiophenyl group 
gave tri-O-acetyl mannosazide 2.22 Deacetylation of compound 2 followed by installation of 
the 4,6-O-benzylidene acetal, introduction of the benzyl group at the C3 position and acidic 







O3 benzylated glycoside 5. Chemo- and regioselective oxidation of the diol 4 using the 
TEMPO/BAIB reagent combination23 afforded the corresponding mannosaziduronic acid 6 in 
65% yield. Methylation of the free carboxylic acid in 6 and acetylation of the residual C4 
























7 : R1=Me, R2=H















Reagents and conditions: (a) TsOH, MeOH (b) Ac2O, pyridine, 7: 88% (from 2), 8: quant. (c) TEMPO, BAIB, 
DCM/H2O (4/1), 65% (from 4) (d) MeI, K2CO3, DMF, 71%. 
 
With the target donor mannosides in hand, attention was focused on the investigation of 
their glycosylation properties. Phenyl 2-azido-3-O-benzyl-4,6-di-O-acetyl-2-deoxy-1-thio-α-
D-mannopyranoside (5) was condensed with methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside 
9,24 under the influence of in situ generated diphenylsulfonium bistriflate (Table 1, entry 1). 
2,4,6-Tri-tert-butylpyrimidine (TTBP) was added as acid scavenger.25 Within 15min, the 
temperature was gradually raised to -50°C followed by addition of acceptor 9 and further 
warming of the reaction mixture to room temperature. Disaccharide 10 was isolated in 86% 
yield as an anomeric mixture (α/β = 1/4).26 The outcome of this glycosylation in terms of 
yield and anomeric ratio compares favorably to the condensation of 4,6-O-benzylidene 
protected donor 3 with the same acceptor (entry 2).18a Condensation of di-acetyl donor 7 with 
the secondary alcohol acceptor 12, executed under the conditions described above gave 
disaccharide 13 in good yield and with a slight preference for α-anomer formation (entry 3). 
This decrease in β-selectivity agrees with the reported trend that glycosylation of a specific 
donor with a series of acceptors of decreasing nucleophilicity leads to a change of the 
anomeric ratio in favor of the α-product.27 Next, the reactivity of the mannosazide donor was 
further reduced by replacement of the 3-O-benzyl with the 3-O-acetyl protective group (2). 
Phenyl 2-azido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-α-D-mannopyranoside (2) was effectively 
condensed with the highly reactive 9, the less reactive 15 and the sterically demanding 
acceptor 12 to give disaccharides 14, 16 and 17, respectively (entries 4, 5 and 6). In all cases 
only the α-product was isolated suggesting that the stereochemical outcome of these reactions 
is independent of the reactivity of the acceptor. These results support earlier observations that 
3-O-acyl groups in mannopyranose28 and glucopyranose29 donors are α-directing by 
neighboring group participation, which proceeds via a 6-membered transition state shielding 








Table 1.  
entry donor acceptor activator
 



















































































































































































































8, bearing an electron withdrawing ester moiety at the C5 position was investigated. Coupling 
of donor 8 with primary alcohol 9 gave exclusively β-linked disaccharide 18 in 69% yield. An 
attempt to glycosylate the secondary alcohol acceptor 12 using the same Ph2SO/Tf2O 
activation protocol did not result in satisfactory product formation. Monitoring the reaction by 
TLC analysis showed that the initial pre-activation of donor 8 with Ph2SO/Tf2O proceeded 
uneventfully. Addition of the acceptor and warming of the reaction mixture showed partial 
regeneration of the donor 8 in addition to the formation of several by-products. This 
observation indicates that under Ph2SO/Tf2O activation conditions the donor glycoside is not 
always fully converted into the intermediate α-triflate.31 Changing the activation system to 
NIS/TMSOTf21,32 led to a productive coupling of donor 8 with acceptor 12 affording 
disaccharide 19 in 53% yield as an anomeric mixture (α/β = 1/2). 
Finally, the assembly of fully protected trisaccharide 24 was investigated (Scheme 2). In its 
unprotected form, this trisaccharide [→3)-α-D-Fucp4NAc-(1→4)-β-D-ManpNAcA-(1→4)-α-
D-GlcpNAc-(1→], is the repeating unit of a polysaccharide that constitutes 70% or more of 
the enterobacterial common antigen (ECA).33,34 The route of synthesis to trimer 24 was 
investigated starting from the non-reducing end D-fucose residue and using both a 
chemoselective27a and an orthogonal glycosylation strategy.35 In the chemoselective approach, 
4-azido 1-thiofucose donor 2036 was coupled with 1-thiomannosaziduronic acid ester 7 to 
afford α-linked thiodisaccharide 22 in a yield of 55%.37 The result of this coupling was 
compared with an orthogonal glycosylation strategy in which 1-hydroxyl donor 21 was 
condensed with acceptor 7. To this end, fucose donor 21 was prepared via hydrolysis of the 
thiophenyl function in compound 20 using the NIS/TFA reagent system.38 Activation of 








22: R = β-SPh










































Reagents and conditions: (a) NIS, TFA, DCM/H2O (10/1), 72% (b) 20, Ph2SO, Tf2O, TTBP, DCM, -60°C then 









of acceptor 7 gave α-linked thiodisaccharide 22 in 67% yield. Treatment of a mixture of 1-
thiodisaccharide donor 22 with 1,6-anhydro acceptor 2339 with the NIS/TMSOTf reagent 
combination finally afforded trisaccharide 24 in 65% yield as a separable anomeric mixture of 




This Chapter describes the glycosylation properties of 1-thiomannosazidopyranosides 
bearing electron-withdrawing substituents on different positions of the carbohydrate core. It 
was found that 4,6-di-O-acetyl protection on 1-thiomannosazides sufficiently influences the 
electronic environment around the anomeric centre leading to reasonable β-selectivities. Acyl 
protection at the C3 position always gave exclusive α-glycoside formation. Furthermore, the 





General Procedures: 1H and 13C NMR spectra were recorded on a Brüker DMX-400 and a Brüker AV-400 
(400/100 MHz) and a Brüker AV500 (500/125 MHz) spectrometer. Chemical shifts (δ) are given in ppm relative 
to tetramethylsilane as internal standard. Coupling constants are given in Hz. All given 13C spectra are proton 
decoupled. Mass spectra were recorded with PE/SCIEX API 165 with electronspray interface and Q-Star 
Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured on a Propol automatic polarimeter. 
IR-spectra were recorded on a Shimadzu FTIR-8300. Traces of water in the donor and acceptor glycosides, 
diphenylsulfoxide and TTBP were removed by co-evaporation with toluene. TTBP was synthesized as described 
by Crich et al.25 Dichloromethane (DCM, Baker p.a.) was boiled under reflux over P2O5 for 2h and distilled prior 
to use. Trifluoromethanesulfonic anhydride was distilled from P2O5. Molecular sieves 3Å were flame dried 
before use. Solvents used for flash chromatography and TLC were of technical grade and distilled before use. 
Flash chromatography was performed on Fluka silica gel 60 (0.04 – 0.063 mm). TLC-analysis was conducted on 
DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm) where applicable and by 
spraying with 20% sulfuric acid in ethanol followed by charring at ~150°C or by spraying with a solution of 
(NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulfuric acid in water followed by 
charring at ~150°C.  
 
General Procedure for Glycosidations using Ph2SO/Tf2O: A solution of 1-thio mannopyranoside uronic acid 
ester (1 equiv.), diphenyl sulfoxide (1.3 equiv.) and tri-tert-butylpyrimidine (2.5 equiv.) in DCM (0.05M) was 
stirred over activated MS3Å for 30min. The mixture was cooled to -60°C before triflic acid anhydride (1.3 
equiv.) was added. The mixture was allowed to warm to -50°C in 15min followed by addition of acceptor (1.5 
equiv.) in DCM (0.15M). Stirring was continued and the reaction mixture was allowed to warm to rT. The 







EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. 
Flash chromatography (EtOAc/PE) and removal of the eluent afforded the corresponding disaccharides.  
 
Phenyl 4,6-di-O-acetyl-2-azido-3-O-benzyl-2-deoxy-1-thio-α-D-mannopyranoside (5): Known 
compound 222 (381 mg, 0.9 mmol) was dissolved in 3 mL MeOH and a catalytic amount of 
KOtBu was added. After TLC-analysis indicated complete reaction, the reaction mixture was 
neutralized using Amberlite IR120 H+-form. The reaction mixture was filtered and concentrated under reduced 
pressure. The crude oil was suspended in 3 mL acetonitrile followed by addition of 0.15 mL benzaldehyde 
dimethylacetal (1 mmol, 1.1 equiv.) and a catalytic amount of TsOH. After TLC-analysis indicated complete 
reaction, 1 mL triethylamine was added and the reaction mixture was concentrated under reduced pressure. The 
crude oil is dissolved in 3 mL DMF and cooled to 0°C. Benzylbromide (0.14 mL, 1.2 mmol, 1.3 equiv.) and 48 
mg sodium hydride (1.2 mmol, 1.3 equiv.) were added. After TLC-analysis indicated complete conversion, the 
reaction mixture was dissolved in 50 mL Et2O and washed with water. The organic phase was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude oil was suspended in 10 mL MeOH and a catalytic 
amount of TsOH was added. The reaction mixture was refluxed for 1h followed by the addition of 1 mL 
triethylamine and concentration under reduced pressure. The crude oil was treated with a mixture of 5 mL 
pyridine and 2 mL acetic anhydride. After TLC-analysis indicated complete reaction, the reaction mixture was 
quenched by the addition of 1 mL MeOH, taken up in 50 mL Et2O and washed with water. The organic phase 
was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography using 
EtOAc/petroleum ether afforded 391 mg of the title compound 5 (0.79 mmol, 88% over the 5 steps) as a 
colorless oil. TLC: 50% EtOAc/PE; [α]D22: +12° (c = 0.8, CHCl3); IR (neat, cm-1): 740, 1001, 1118, 1218, 1373, 
2102; 1H NMR (400 MHz, CDCl3) δ = 2.02 (s, 3H, CH3 Ac), 2.03 (s, 3H, CH3 Ac), 3.95 (dd, 1H, J = 9.2 Hz, J = 
3.6 Hz, H-3), 4.05 – 4.09 (m, 2H, J = 2.4 Hz, H-2, H-6), 4.20 (dd, 1H, J = 12.4 Hz, J = 6.0 Hz, H-6), 4.33 – 4.38 
(m, 1H, J = 6.0 Hz, J = 2.4 Hz, H-5), 4.62 (d, 1H, J = 12.0 Hz, CHHPh), 4.70 (d, 1H, J = 12.0 Hz, CHHPh), 5.31 
(t, 1H, J = 9.6 Hz, H-4), 5.48 (d, 1H, J = 1.6 Hz, H-1), 7.26 – 7.55 (m, 10H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 20.7 (CH3 Ac), 20.8 (CH3 Ac), 62.2 (C-2), 62.4 (C-6), 67.6 (C-4), 69.9 (C-5), 72.6 (CH2 Bn), 76.7 
(C-3), 85.9 (C-1), 127.9 – 131.8 (CH Arom), 132.7 (Cq SPh), 137.1 (Cq Bn), 169.5 (C=O Ac), 170.7 (C=O Ac); 
HRMS: [M+Na]+ calcd for C23H25O6N3SNa 494.13563, found 494.13583. 
 
Phenyl 2-azido-3-O-benzyl-2-deoxy-1-thio-α-D-mannopyranosiduronic acid (6): To a 
vigorously stirred solution of 505 mg compound 4 (1.3 mmol) in 10 mL DCM and 2 mL H2O 
were added 41 mg TEMPO (0.26 mmol, 0.2 equiv.) and 966 mg BAIB (3 mmol, 2.5 equiv.). 
Stirring was allowed until TLC indicated complete conversion of the starting material into a lower running 
product. The reaction mixture was quenched by the addition of 25 mL Na2S2O3 solution (10% in H2O). The 
mixture was then extracted twice with 10 mL EtOAc and the combined organic phase was dried (MgSO4), 
filtered and concentrated. Flash column chromatography (EtOAc/PE, 2% (v/v) AcOH) afforded 340 mg of the 
title compound 6 (0.85 mmol, 65%) as a colorless oil. TLC: 50% EtOAc/PE (5% AcOH); 1H NMR (600 MHz, 
CDCl3) δ = 3.90 (dd, 1H, J = 8.4 Hz, J = 3.4 Hz, H-3), 3.99 (s, 1H, H-2), 4.25 (t, 1H, J = 8.6 Hz, H-4), 4.64 (d, 
1H, J = 8.4 Hz, H-5), 4.74 (d, 1H, J = 11.7 Hz, CHHPh), 4.84 (d, 1H, J = 11.7 Hz, CHHPh), 5.51 (d, 1H, J = 3.9 
Hz, H-1), 7.26 – 7.59 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 61.1 (C-2), 68.5 (C-4), 71.8 (C-5), 
73.4 (CH2 Bn), 77.9 (C-3), 85.9 (C-1), 127.9 – 132.2 (CH Arom), 132.1 (Cq SPh), 137.2 (Cq Bn), 172.57 (C=O 
COOH); 13C-GATED (100 MHz, CDCl3): 85.9 (J = 169 Hz, C-1); HRMS: [M+Na]+ calcd for C19H19O5N3SNa 




















Methyl (phenyl 2-azido-3-O-benzyl-2-deoxy-1-thio-α-D-mannopyranoside) uronate (7): To a 
stirred solution of 340 mg compound 6 (0.85 mmol) in 5 mL DMF was added 60 µL MeI (1 
mmol, 1.2 equiv.) and 200 mg K2CO3. The solution was stirred overnight, taken up in EtOAc 
and washed with H2O. The aqueous phase was extracted with EtOAc. The combined organic phase was dried 
(MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography (EtOAc/PE) afforded 
245 mg of the title compound 7 (0.6 mmol, 71%) as a colorless oil. TLC: 50% EtOAc/PE; [α]D22: +69° (c = 1.4, 
CHCl3); IR (neat, cm-1): 740, 1001, 1118, 1218, 1373, 1747, 2102; 1H NMR (400 MHz, CDCl3) δ = 3.04 (bs, 
1H, OH-4), 3.71 (s, 1H, CH3 COOMe), 3.87 (dd, 1H, J = 8.0 Hz, J = 3.4 Hz, H-3), 3.95 (t, 1H, J = 3.4 Hz, H-2), 
4.31 (dq, J = 7.9 Hz, J = 2.1 Hz, H-4), 4,60 (d, 1H, J = 7.9 Hz, H-5), 4.72 (d, 1H, J = 11.6 Hz, CHHPh), 4.78 (d, 
1H, J = 11.6 Hz, CHHPh), 5.52 (d, 1H, J = 1.4 Hz, H-1), 7.24 – 7.51 (m, 10H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 52.6 (CH3 COOMe), 61.0 (C-2), 68.3 (C-4), 72.9 (C-5), 73.2 (CH2 Bn), 77.9 (C-3), 85.4 (C-1), 127.9 
– 131.9 (CH Arom), 137.1 (Cq Bn), 169.8 (C=O COOMe); HRMS: [M+NH4]+ calcd for C20H25O5N4S 
433.15457, found 433.15418. 
 
Methyl (phenyl 4-acetyl-2-azido-3-O-benzyl-2-deoxy-1-thio-α-D-mannopyranoside) uronate 
(8): Compound 7 (245 mg, 0.6 mmol) was treated with 3 mL pyridine/Ac2O (3:1) solution for 
8h followed by the addition of 2 mL MeOH. The reaction mixture was taken up in EtOAc and 
washed with 2M HCl and saturated NaHCO3. The organic phase is dried (MgSO4), filtered and concentrated 
under reduced pressure. Flash column chromatography (EtOAc/PE) afforded the title compound 8 (274 mg, 0.6 
mmol, quant.) as a colorless oil. TLC: 50% EtOAc/PE (5% AcOH); [α]D22: +37° (c = 1, CHCl3); IR (neat, cm-1): 
740, 1001, 1118, 1218, 1373, 1747, 2102; 1H NMR (500 MHz, CDCl3) δ = 2.05 (s, 3H, CH3 Ac), 3.85 (bs, 4H, 
H-2, CH3 COOMe), 3.95 (t, 1H, J = 3.5 Hz, H-3), 4.56 (d, 1H, J = 2.5, H-5), 4.62 (d, 1H, J = 11.5 Hz, CHHPh), 
4.65 (d, 1H, J = 11.5 Hz, CHHPh), 5.54 (t, 1H, J = 3.5 Hz, J = 2.5 Hz, H-4), 5.72 (d, 1H, J = 9.0 Hz, H-1), 7.25 
– 7.66 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.2 (CH3 COOMe), 57.7 (C-2), 
68.2 (C-4), 72.9 (CH2 Bn), 73.2 (C-5), 74.8 (C-3), 80.7 (C-1), 127.8 – 132.2 (CH Arom), 131.7 (Cq SPh), 136.3 
(Cq Bn), 167.9 (C=O COOMe or Ac), 169.5 (C=O Ac or COOMe); HRMS: [M+H]+ calcd for C22H24O6N3S 
458.13803, found 458.13934. 
 
Methyl (2,3,4-tri-O-benzyl-6-O-(4,6-di-O-acetyl-2-azido-3-O-benzyl-2-deoxy-
α/β-D-mannopyranosyl)-α-D-glucopyranoside (10): Disaccharide 10 was 
obtained from donor 5 and acceptor 9 according to the general procedure for 
glycosidations using the Ph2SO/Tf2O activator system. TLC: 30% EtOAc/PE; α-
anomer: 1H NMR (500 MHz, CDCl3) δ = 2.00 (s, 3H, CH3 Ac), 2.03 (s, 3H, CH3 Ac), 3.33 (s, 3H, CH3 
COOMe), 3.39 (t, 1H, J = 9.0 Hz, H-4), 3.49 (dd, 1H, J = 10.0 Hz, J = 4.0 Hz, H-2), 3.61 (d, 1H, J = 11.5 Hz, H-
6), 3.67 – 3.74 (m, 2H, H-5, H-5’), 3.78 (dd, 1H, J = 11.5 Hz, J = 4.5 Hz, H-6), 3.86 (dd, 1H, J = 9.5 Hz, J = 3.5 
Hz, H-3’), 3.89 (d, 1H, J = 1.5 Hz, H-2’), 3.95 (dd, 1H, J = 12.0 Hz, J = 2.5 Hz, H-6’), 3.99 (t, 1H, J = 9.0 Hz, 
H-3), 4.03 (dd, 1H, J = 12.0 Hz, J = 4.5 Hz, H-6’), 4.45 (d, 1H, J = 11.0 Hz, CHHPh), 4.53 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.61 (d, 1H, J = 3.5 Hz, H-1), 4.64 (d, 1H, J = 12.0 Hz, CHHPh), 4.67 (d, 1H, J = 11.5 Hz, CHHPh), 
4.80 (d, 2H, J = 11.0 Hz, CHHPh, CHHPh), 4.85 (s, 1H, H-1’), 4.92 (d, 1H, J = 11.5 Hz, CHHPh), 5.02 (d, 1H, J 
= 11.0 Hz, CHHPh), 5.23 (t, 1H, J = 9.5 Hz, H-4’), 7.21 – 7.40 (m, 20H, H Arom); 13C NMR (125 MHz, CDCl3) 
δ = 20.7 (CH3 Ac), 20.8 (CH3 Ac), 55.2 (CH3 OMe), 60.6 (C-2’), 62.1 (C-6’), 66.8 (C-6), 67.2 (C-4’), 68.9 (C-
5’), 68.6 (C-5), 71.9 (CH2 Bn), 73.2 (CH2 Bn), 74.9 (CH2 Bn), 75.7 (C-3’), 75.8 (CH2 Bn), 77.6 (C-4), 79.9 (C-
2), 82.0 (C-3), 97.9 (C-1), 98.4 (C-1’), 127.3 – 128.6 (CH Arom), 137.2 (Cq Bn), 137.9 (Cq Bn), 138.1 (Cq Bn), 
138.6 (Cq Bn), 169.4 (C=O Ac), 170.7 (C=O Ac); 13C-GATED (125 MHz, CDCl3): 97.9 (JC1,H1 = 171 Hz, C-1), 




























[α]D22: -17° (c = 0.8, CHCl3); IR (neat, cm-1): 698, 738, 754, 1004, 1039, 1068, 1132, 1240, 1367, 1743, 2104; 
1H NMR (400 MHz, CDCl3) δ = 2.01 (s, 3H, CH3 Ac), 2.03 (s, 3H, CH3 Ac), 3.34 (s, 3H, CH3 OMe), 3.36 (t, 
1H, J = 9.2 Hz, H-4), 3.38 – 3.41 (m, 1H, H-5’), 3.46 (dd, 1H, J = 9.6 Hz, J = 4.5 Hz, H-3), 3.49 (d, 1H, J = 8.0 
Hz, H-2), 3.51 (m, 1H, J = 3.6 Hz, H-6), 3.75 (d, 1H, J = 4.5 Hz, H-2), 4.00 (t, 1H, J = 9.2 Hz, H-3), 4.07 – 4.11 
(m, 2H, H-6, H-6’), 4.17 (dd, 1H, J = 12.0 Hz, J = 5.2 Hz, H-6’), 4.26 (s, 1H, H-1’), 4.53 (d, 1H, J = 11.6 Hz, 
CHHPh), 4.55 (d, 1H, J = 12.4 Hz, CHHPh), 4.56 (s, 1H, H-1), 4.62 (d, 1H, J = 12.0 Hz, CHHPh), 4.67 (d, 1H, J 
= 12.4 Hz, CHHPh), 4.77 (d, 1H, J = 12.0 Hz, CHHPh), 4.80 (d, 1H, J = 10.8 Hz, CHHPh), 4.87 (d, 1H, J = 11.6 
Hz, CHHPh), 5.00 (d, 1H, J = 10.8 Hz, CHHPh), 5.15 (t, 1H, J = 9.6 Hz, H-4’), 7.23 – 7.36 (m, 20H, H Arom); 
13C NMR (100 MHz, CDCl3) δ = 20.7 (CH3 Ac), 20.7 (CH3 Ac), 55.1 (CH3 OMe), 61.3 (C-2’), 62.6 (C-6’), 67.3 
(C-4’), 68.7 (C-6), 69.5 (C-5), 71.8 (CH2 Bn), 72.4 (C-5’), 73.4 (CH2 Bn), 74.6 (CH2 Bn), 75.7 (CH2 Bn), 77.2 
(C-3’), 77.6 (C-4), 79.8 (C-2), 81.9 (C-3), 97.8 (C-1), 99.8 (C-1’), 127.3 – 128.6 (CH Arom), 137.2 (Cq Bn), 
138.0 (Cq Bn), 138.2 (Cq Bn), 138.6 (Cq Bn), 169.3 (C=O Ac), 170.8 (C=O Ac); 13C-GATED (100 MHz, 
CDCl3): 97.8 (JC1,H1 = 171 Hz, C-1), 99.8 (JC1’,H1’ = 158 Hz, C-1’); HRMS: [M+Na]+ calcd for C45H51O12N3Na 




(13): Disaccharide 13 was obtained from donor 5 and acceptor 12 according to 
the general procedure for glycosidations using the Ph2SO/Tf2O activator 
system. TLC: 30% EtOAc/PE; β-anomer: IR (neat, cm-1): 696, 1028, 1035, 
1217, 1506, 1733, 2102; 1H NMR (400 MHz, CDCl3) δ = 1.98 (s, 3H, CH3 Ac), 2.05 (s, 3H, CH3 Ac), 3.27 (dd, 
1H, J = 9.5 Hz, J = 3.6 Hz, H-3’), 3.51 (s, 1H, H-5), 3.68 (d, 1H, J = 9.8 Hz, H-5’), 3.71 (s, 3H, CH3 OMe pMP), 
3.76 (bs, 1H, H-2’), 3.89 (dd, 1H, J = 10.0 Hz, J = 3.4 Hz, H-3), 4.07 (dd, 1H, J = 12.5 Hz, J = 1.2 Hz, H-6), 
4.17 (dd, 1H, J = 10.0 Hz, J = 7.8 Hz, H-2), 4.20 (d, 1H, J = 13.2 Hz, H-6), 4.36 (s, 1H, H-4), 4.43 (d, 1H, J = 
12.2 Hz, CHHPh), 4.56 (d, 1H, J = 12.2 Hz, CHHPh), 4.66 (d, 1H, J = 11.7 Hz, CHHPh), 4.88 (s, 1H, H-1’), 
4.90 (d, 1H, J = 7.8 Hz, H-1), 5.07 (d, 1H, J = 11.7 Hz, CHHPh), 5.23 (t, 1H, J = 9.6 Hz, H-4’), 5.59 (s, 1H, 
CHPh), 6.81 (d, 1H, J = 9.1 Hz, 2xCH pMP), 7.05 (d, 1H, J = 9.1 Hz, 2xCH pMP), 7.25 – 7.59 (m, 15H, H 
Arom); 13C NMR (100 MHz, CDCl3) δ = 20.8 (CH3 Ac), 20.9 (CH3 Ac), 55.6 (CH3 OMe pMP), 60.9 (C-2’), 
66.7 (C-5), 68.1 (C-4), 68.8 (C-6), 72.2 (CH2 Bn), 72.9 (C-5’), 75.3 (CH2 Bn), 75.6 (C-4), 77.1 (C-3), 77.3 (C-
3’), 78.9 (C-2), 100.4 (C-1’), 100.7 (CHPh), 103.2 (C-1), 114.4 (CH Arom pMP), 118.8 (CH Arom pMP), 126.4 
– 128.9 (CH Arom), 137.2 (Cq Bn), 137.7 (Cq Bn), 151.3 (Cq pMP), 155.4 (Cq pMP), 167.4 (C=O Ac or 
COOMe), 169.3 (C=O Ac or COOMe); 13C-GATED (100 MHz, CDCl3): 100.4 (JC1’,H1’ = 161 Hz, C-1’), 103.2 




pyranosyl)-α-D-glucopyranoside (14): Disaccharide 14 was obtained from donor 2 
and acceptor 9 according to the general procedure for glycosidations using the 
Ph2SO/Tf2O activator system. TLC: 30% EtOAc/PE; IR (neat, cm-1): 698, 734, 819, 
999, 1026, 1101, 1132, 1217, 1506, 1747, 2106; 1H NMR (400 MHz, CDCl3) δ = 
2.06 (s, 3H, CH3 Ac), 2.07 (s, 3H, CH3 Ac), 2.13 (s, 3H, CH3 Ac), 3.83 (s, 3H, CH3 OMe), 3.45 (t, 1H, J = 9.2 
Hz, H-4), 3.53 (dd, 1H, J = 9.6 Hz, J = 3.6 Hz, H-3), 3.64 (d, 1H, J = 9.6 Hz, H-6), 3.76 - 3.80 (m, 1H, H-5), 
3.81 (dd, 1H, J = 9.6 Hz, J = 4.0 Hz, H-6), 3,82 – 3.86 (m, 1H, H-5'), 3.97 – 4.03 (m, 3H, H-3, H-2' and H-6'), 
4.09 (dd, 1H, J = 12.0 Hz, J = 4.8 Hz, H-6'), 4.58 (d, 1H, J = 3.6 Hz, H-1), 4 59 (d, 1H, J = 11.2 Hz, CHHPh), 






























(d, 1H, J = 1.6 Hz, H-1'), 4.97 (d, 1H, J = 11.2 Hz, CHHPh), 4.99 (d, 1H, J = 10.8 Hz, CHHPh), 5.25 (t, 1H, J = 
10.0 Hz, H-4'), 5.31 (t, 1H, J = 10.0 Hz, H-3'), 7.30 – 7.43 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 
20.5 (CH3 Ac), 20.6 (CH3 Ac), 20.7 (CH3 Ac), 55.2 (CH3 OMe), 60.5 (C-2'), 61.8 (C-6'), 65.8 (C-4'), 66.5 (C-6), 
68.5 (C-5'), 69.9 (C-5), 70.9 (C-3'), 73.3 (CH2 Bn), 75.2 (CH2 Bn), 75.8 (CH2 Bn), 80.0 (C-4), 81.1 (C-2), 82.1 
(C-3), 97.9 (C-1), 98.2 (C-1'), 127.5 – 128.5 (CH Arom), 138.0 (Cq Bn), 138.1 (Cq Bn), 138.5 (Cq Bn), 169.5 
(C=O Ac), 169.8 (C=O Ac), 170.6 (C=O Ac); 13C-GATED (100 MHz, CDCl3): 97.9 (JC1,H1 = 164 Hz, C-1), 98.2 
(JC1’,H1’ = 174 Hz, C-1’); HRMS: [M+NH4]+ calcd for C40H51O13N4 795.34471, found 795.34144. 
 
3-O-(3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranosyl)-1,2;5,6-di-O-isopropyl-
idene-α-D-glucofuranose (16): Disaccharide 16 was obtained from donor 2 and acceptor 
15 according to the general procedure for glycosidations using the Ph2SO/Tf2O activator 
system. TLC: 30% EtOAc/PE; IR (neat, cm-1): 698, 734, 819, 999, 1026, 1101, 1132, 
1217, 1506, 1747, 2106; 1H NMR (400 MHz, CDCl3) δ = 1.27 (s, 3H, CH3 isoprop), 
1.32 (s, 3H, CH3 isoprop), 1.37 (s, 3H, CH3 isoprop), 1.41 (s, 3H, CH3 isoprop), 2.06 (s, 
3H, CH3 Ac), 2.10 (s, 3H, CH3 Ac), 2.12 (s, 3H, CH3 Ac), 3.97 – 4.05 (m, 2H, H-5', H-
6'), 4.06 (dd, 1H, J = 3.0 Hz, J = 1.0 Hz, H-2'), 4.07 (dd, 1H, J = 8.5 Hz, J = 2.5 Hz, H-4), 4.12 – 4.17 (m, 3H, 
H-6, H-5' and H-6'), 4.25 (dd, 1H, J = 12.0 Hz, J = 5.5 Hz, H-6), 4.28 (d, 1H, J = 3.0 Hz, H-3), 4.57 (d, 1H, J = 
3.5 Hz, H-2), 5.19 (d, 1H, J = 1.0 Hz, H-1'), 5.28 (t, 1H, J = 9.5 Hz, H-4'), 5.23 (dd, 1H, J = 10.0 Hz, J - 4.0 Hz, 
H-3'), 5.91 (d, 1H, J = 3.5 Hz, H-1); 13C NMR (100 MHz, CDCl3) δ = 20.5 (CH3 Ac), 20.6 (CH3 Ac), 20.7 (CH3 
Ac), 25.2 (CH3 isoprop), 26.2 (CH3 isoprop), 26.8 (2xCH3 isoprop), 61.2 (C-2'), 62.3 (C-6), 66.0 (C-3'), 67.9 (C-
6'), 69.3 (C-5'), 70.4 (C-4'), 72.5 (C-5), 81.3 (C-4), 81.7 (C-3), 83.9 (C-2), 99.1 (C-1'), 105.3 (C-1), 109.5 (Cq 
isoprop), 112.1 (Cq isoprop), 169.5 (C=O Ac), 169.9 (C=O Ac), 170.7 (C=O Ac); 13C-GATED (100 MHz, 
CDCl3): 99.1 (JC1',H1' = 171 Hz,    C-1'), 105.3 (JC1,H1 = 181 Hz, C-1’); HRMS: [M+Na]+ calcd for 
C24H35O13N3Na 596.20621, found 596.20586. 
 
para-Methoxyphenyl (2-O-benzyl-4,6-O-benzylidene-3-O-(3,4,6-tri-O-acetyl-2-
azido-2-deoxy-α-D-mannopyranosyl)-β-D-galactopyranoside (17): Disaccharide 
17 was obtained from donor 2 and acceptor 12 according to the general procedure 
for glycosidations using the Ph2SO/Tf2O activator system. TLC: 30% EtOAc/PE; 
IR (neat, cm-1): 698, 734, 819, 999, 1026, 1101, 1132, 1217, 1506, 1747, 2106; 
1H NMR (400 MHz, CDCl3) δ = 1.97 (s, 3H, CH3 Ac), 2.03 (s, 3H, CH3 Ac), 2.09 (s, 3H, CH3 Ac), 3.49 (s, 1H,    
H-5), 3.78 (s, 3H, CH3 OMe pMP), 3.86 (dd, 1H, J = 10.0 Hz, J = 3.6 Hz, H-3), 3.93 (d, 1H, J = 3.2 Hz, H-6'), 
4.03 – 4.06 (m, 2H, H-2, H-2'), 4.08 (dt, 1H, J = 11.6 Hz, J = 1.6 Hz, H-6), 4.14 (dq, 1H, J = 10.4 Hz, J = 2.8 
Hz, H-5'), 4.32 (s, 1H, J = 3.2 Hz, H-4), 4.37 (dd, 1H, J = 12.4 Hz, J = 1.2 Hz, H-6), 4.78 (d, 1H, J = 10.4 Hz, 
CHHPh), 4.90 (d, 1H, J = 8.0 Hz, H-1), 5.05 (d, 1H, J = 1.2 Hz, H-1'), 5.06 (d, 1H, J = 10.4 Hz, CHHPh), 5.32 
(t, 1H, J = 10.0 Hz, H-4'), 5.47 (dd, 1H, J = 10.0 Hz, J = 4.0 Hz, H-3'), 5.56 (s, 1H, CHPh), 6.82 (d, 1H, J = 9.1 
Hz, CH Arom pMP), 7.05 (d, 1H, J = 9.1 Hz, CH Arom pMP), 7.25 – 7.59 (m, 15H, H Arom); 13C NMR (100 
MHz, CDCl3) δ = 20.5 (CH3 Ac), 20.7 (CH3 Ac), 20.7 (CH Ac), 55.6 (CH3 pMP), 61.5 (C-2'), 61.6 (CH2 Bn), 
65.6 (C-4'), 66.3 (C-5), 68.5 (C-5'), 69.2 (C-6), 71.0 (C-3'), 71.1 (C-4), 74.3 (C-3), 76.3 (C-2), 93.8 (C-1'), 101.1 
(CHPh), 103.3 (C-1), 114.5 (CH Arom pMP), 118.9 (CH Arom pMP), 126.4 - 129.1 (CH Arom), 137.5 (Cq Bn), 
138.0 (Cq Bn), 151.4 (Cq pMP), 155.5 (Cq pMP), 169.4 (C=O Ac), 169.7 (C=O Ac), 170.6 (C=O Ac); 13C-
GATED (100 MHz, CDCl3): 93.8 (JC1’,H1’ = 172 Hz, C-1’), 103.3 (JC1,H1 = 158 Hz, C-1); HRMS: [M+NH4]+ 

































deoxy-β-D-mannopyranosyluronate)-α-D-glucopyranoside (18): Disaccharide 18 
was obtained from donor 8 and acceptor 9 according to the general procedure for 
glycosidations using the Ph2SO/Tf2O activator system. TLC: 30% EtOAc/PE; 
[α]D22: -16° (c = 1, CHCl3); IR (neat, cm-1): 698, 736, 754, 1033, 1070, 1105, 1180, 1224, 2113; 1H NMR (500 
MHz, CDCl3) δ = 2.04 (s, 3H, CH3 Ac), 3.31 (s, 3H, CH3 OMe), 3.35 (t, 1H, J = 9.5 Hz, H-4), 3.44 (dd, 1H, J = 
10.5 Hz, J = 6.5 Hz, H-6), 3.48 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, H-2), 3.55 (dd, 1H, J = 9.0 Hz, J = 3.5 Hz, H-
3’), 3.69 (s, 4H, H-2 and CH3 COOMe), 3.73 (d, 1H, J = 9.5 Hz, H-5’), 3.79 (m, 1H, J = 8.0 Hz, J = 6.5 Hz, J = 
1.5 Hz, H-5), 4.00 (t, 1H, J = 9.5 Hz, H-3), 4.10 (dd, 1H, J = 8.0 Hz, J = 1.5 Hz, H-6), 4.28 (s, 1H, H-1’), 4.53 
(d, 1H, J = 11.0 Hz, CHHPh), 4.54 (s, 1H, H-1), 4.61 (d, 1H, J = 11.0 Hz, CHHPh), 4.62 (d, 1H, J = 11.0 Hz, 
CHHPh), 4.66 (d, 1H, J = 11.0 Hz, CHHPh), 4.76 (d, 1H, J = 11.0 Hz, CHHPh), 4.79 (d, 1H, J = 11.0 Hz, 
CHHPh), 4.86 (d, 1H, J = 11.0 Hz, CHHPh), 4.98 (d, 1H, J = 11.0 Hz, CHHPh), 5.31 (t, 1H, J = 9.0 Hz, H-4’), 
7.23 – 7.37 (m, 20H, H Arom); 13C NMR (125 MHz, CDCl3) δ = 20.7 (CH3 Ac), 52.7 (CH3 COOMe), 55.1 (CH3 
OMe), 68.2 (C-4’), 68.8 (C-6), 69.6 (C-5), 72.2 (CH2 Bn), 73.2 (C-5’), 73.4 (CH2 Bn), 74.6 (CH2 Bn), 75.7 (CH2 
Bn), 75.7 (C-3’), 77.6 (C-4), 79.8 (C-2), 81.9 (C-3), 97.6 (C-1), 99.7 (C-1’), 127.6 – 128.6 (CH Arom), 137.1 
(Cq Bn), 138.0 (Cq Bn), 138.3 (Cq Bn), 138.4 (Cq Bn), 138.6 (Cq Bn), 167.5 (C=O Ac or COOMe), 169.3 (C=O 
Ac or COOMe); 13C-GATED (125 MHz, CDCl3): 97.8 (JC1,H1 = 170 Hz, C-1), 99.7 (JC1,H1 = 160 Hz, C-1’); 




(19): A solution of 41 mg donor 8 (0.09 mmol) and 70 mg acceptor 12 (0.15 
mmol, 1.5 equiv.) in 3 mL DCM was stirred over activated MS3Å for 30min 
before 29 mg N-iodosuccinimide (0.13 mmol, 1.3 equiv.) was added. The mixture 
was cooled to -40°C and 5 µL TMSOTf (cat.) was added. Stirring was continued and the reaction mixture was 
allowed to warm to rT. When TLC-analysis indicated complete conversion, 0.2 mL triethylamine was added. 
The reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was extracted twice 
with EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. 
Flash chromatography (EtOAc/PE) and removal of the eluent afforded 40 mg of the title compound 19 (0.048 
mmol, 53%, (α/β=1/2) as a colorless oil. TLC: 30% EtOAc/PE; IR (neat, cm-1): 696, 734, 746, 819, 1045, 1083, 
1220, 1365, 1506, 1743, 2108; β-anomer: 1H NMR (400 MHz, CDCl3) δ = 2.04 (s, 3H, CH3 Ac), 3.28 (dd, 1H, J 
= 9.5 Hz, J = 3.6 Hz, H-3’), 3.51 (bs, 1H, H-5), 3.65 (d, 1H, J = 9.8 Hz, H-5’), 3.71 (s, 3H, CH3 pMP or 
COOMe), 3.75 (d, 1H, J = 3.6 Hz, H-2’), 3.77 (s, 3H, CH3 COOMe or pMP), 3.89 (dd, 1H, J = 10.0 Hz, J = 3.4 
Hz, H-3), 4.03 – 4.08 (m, 1H, H-6), 4.18 (dd, 1H, J = 10.0 Hz, J = 7.8 Hz, H-2), 4.34 (d, 1H, J = 13.2 Hz, H-6), 
4.37 (s, 1H, H-4), 4.45 (d, 1H, J = 12.2 Hz, CHHPh), 4.58 (d, 1H, J = 12.2 Hz, CHHPh), 4.66 (d, 1H, J = 11.7 
Hz, CHHPh), 4.88 (s, 1H, H-1’), 4.90 (d, 1H, J = 7.8 Hz, H-1), 5.08 (d, 1H, J = 11.7 Hz, CHHPh), 5.21 (t, 1H, J 
= 9.6 Hz, H-4’), 5.60 (s, 1H, CHPh), 6.82 (d, 1H, J = 9.1 Hz, CH Arom pMP), 7.05 (d, 1H, J = 9.1 Hz, CH 
Arom pMP), 7.25 – 7.59 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 20.6 (CH3 Ac), 52.7 (CH3 pMP or 
COOMe), 55.6 (CH3 COOMe or pMP), 60.9 (C-2’), 66.7 (C-5), 68.2 (C-5), 68.8 (C-6), 72.1 (CH2 Bn), 73.2 (C-
5’), 75.3 (CH2 Bn), 75.6 (C-4), 77.1 (C-3), 77.3 (C-3’), 78.9 (C-2), 100.4 (C-1’), 100.7 (CHPh), 103.2 (C-1), 
114.4 (CH Arom pMP), 118.7 (CH Arom pMP), 126.4 – 128.9 (CH Arom), 137.2 (Cq Bn), 137.7 (Cq Bn), 138.6 
(Cq Bn), 151.4 (Cq pMP), 155.4 (Cq pMP), 167.5 (C=O COOMe or Ac), 169.3 (C=O Ac or COOMe); 13C-
GATED (100 MHz, CDCl3): 100.4 (JC1’,H1’ = 163 Hz, C-1’), 103.2 (JC1,H1 = 161 Hz, C-1); α-anomer: 13C-
GATED (100 MHz, CDCl3): 93.0 (JC1’,H1’ = 170 Hz, C-1’), 101.0 (JC1,H1 = 161 Hz, C-1); HRMS: [M+Na]+ calcd 




























4-Azido-2,3-di-O-benzyl-4-deoxy-α/β-D-fucopyranose (21): To a vigorously stirred solution 
of 119 mg compound 2040 (0.26 mmol) in 1 mL DCM/H2O (10/1 v/v) was added 58 mg NIS 
(0.26 mmol, 1 equiv.) and 20 µL TFA (0.26 mmol, 1 equiv.). The mixture was stirred for 
15min. before 10 mL Na2S2O3 (10% in H2O) and 10 mL NaHCO3 (sat. aq.) were added. The biphasic mixture 
was diluted with 50 mL EtOAc and extracted. The aqueous phase was extracted twice with 25 mL EtOAc. The 
combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column 
chromatography using (EtOAc/PE) afforded 69 mg of the title compound 21 (0.19 mmol, 73%) as a colorless oil. 
TLC: 50% EtOAc/PE; IR (neat, cm-1): 609, 1041, 1091, 1222, 2098; α-anomer: 1H NMR (500 MHz, CDCl3) δ = 
1.24 (d, 3H, J = 6.5 Hz, H-6), 3.26 (bs, 1H, OH-1), 3.74 (d, 1H, J = 3.5 Hz, H-4), 3.86 (dd, 1H, J = 9.5 Hz, J = 
3.5 Hz, H-2), 4.03 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, H-3), 4.18 (q, 1H, J = 6.5 Hz, H-5), 4.70 (d, 1H, J = 11.5 Hz, 
CHHPh), 4.77 (d, 1H, J = 11.5 Hz, CHHPh), 4.80 (d, 1H, J = 11.5 Hz, CHHPh), 4.84 (d, 1H, J = 11.5 Hz, 
CHHPh), 5.18 (d, 1H, J = 3.5 Hz, H-1), 7.29 – 7.42 (m, 10H, H Arom); 13C NMR (125 MHz, CDCl3) δ = 17.3 
(C-6), 64.5 (C-4), 64.6 (C-5), 72.8 (CH2 Bn), 73.7 (CH2 Bn), 76.0 (C-2), 77.8 (C-3), 91.6 (C-1), 127.7 – 128.4 
(CH Arom), 137.8 (Cq Bn), 137.9 (Cq Bn); β-anomer: 1H NMR (500 MHz, CDCl3) δ = 1.31 (d, 3H, J = 6.5 Hz, 
H-6), 3.55 (q, 1H, J = 6.5 Hz, H-5), 3.61 (t, 1H, J = 9.5 Hz, J = 8.5, H-2), 3.64 (d, 1H, J = 3.5 Hz, H-4), 3.68 
(dd, 1H, J = 9.5 Hz, J = 3.5 Hz, H-3), 3.70 (bs, 1H, OH-1), 4.57 (bd, 1H, J = 8.5 Hz, H-1), 4.76 (d, 1H, J = 11.5 
Hz, CHHPh), 4.82 (d, 1H, J = 11.5 Hz, CHHPh), 4.83 (d, 1H, J = 11.5 Hz, CHHPh), 4.91 (d, 1H, J = 11.5 Hz, 
CHHPh), 7.29 – 7.42 (m, 10H, H Arom); 13C NMR (125 MHz, CDCl3) δ = 17.4 (C-6), 63.6 (C-4), 69.2 (C-5), 
72.9 (CH2 Bn), 75.2 (CH2 Bn), 80.2 (C-2), 81.1 (C-3), 97.5 (C-1), 127.7 – 128.4 (CH Arom), 137.7 (Cq Bn), 
138.3 (Cq Bn); HRMS: [M+Na]+ calcd for C20H23O4N3Na 392.15808, found 392.15813. 
 
Methyl (phenyl 2-azido-3-O-benzyl-2-deoxy-4-O-(4-azido-2,3-di-O-benzyl-4-
deoxy-α-D-fucopyranosyl)-α-D-mannopyranoside) uronate (22): Chemoselective 
glycosyl-ation: Disaccharide 22 was obtained from donor 20 and acceptor 7 
according to the general procedure for glycosidations using the Ph2SO/Tf2O 
activator system. Orthogonal glycosylation: A solution of 55 mg of donor 21 (0.15 
mmol), 85 mg diphenylsulfoxide (0.42 mmol, 2.8 equiv.) and 112 mg tri-tert-butylpyrimidine (0.45 mmol, 3 
equiv.) in 3 mL DCM was stirred over activated 100 mg MS3Å for 30min. The mixture was cooled to -60°C and 
33 µL Tf2O (0.20 mmol, 1.3 equiv.) was added. The mixture was allowed to warm to -40°C in 1h followed by 
addition of  78 mg acceptor 9 (0.17 mmol, 1.1 eq) in 1 mL DCM. Stirring was continued and the reaction 
mixture was allowed to warm to 0°C. The reaction mixture was taken up in 25 mL EtOAc and washed with 
water. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash 
chromatography (10% EtOAc/PE) and removal of the eluent afforded 73 mg of the title compound 22 (0.095 
mmol, 67%) as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: +3° (c = 0.3, CHCl3); IR (neat, cm-1): 609, 1041, 
1091, 1222, 1710, 2098; 1H NMR (400 MHz, CDCl3) δ = 1.21 (d, 1H, J = 6.5 Hz, C-6’), 3.45 (dd, 1H, J = 10.0 
Hz, J = 3.5 Hz, H-4), 3.47 (s, 3H, CH3 COOMe), 3.67 – 3.69 (m, 1H, H-3’, H-4’), 3.77 (dd, 1H, J = 9.5 Hz, J = 
3.5 Hz, H-2’), 3.83 (q, 1H, J = 6.5 Hz, H-5’), 3.93 (t, 1H, J = 3.5 Hz, H-3), 4.23 (dd, 1H, J = 4.3 Hz, J = 2.0 Hz, 
H-2), 4.51 (d, 2H, J = 11.5 Hz, 2xCHHPh), 4.56 (d, 1H, J = 11.5 Hz, CHHPh), 4.61 (d, 1H, J = 2.0 Hz, H-1), 
4.68 (d, 1H, J = 11.5 Hz, CHHPh), 4.75 (d, 1H, J = 11.5 Hz, CHHPh), 4.76 (d, 1H, J = 11.5 Hz, CHHPh), 4.77 
(d, 1H, J = 3.5 Hz, H-1’), 5.62 (d, 1H, J = 10.0 Hz, H-5), 7.25 – 7.67 (m, 20H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 17.3 (C-6’), 52.1 (CH3 COOMe), 57.1 (C-4), 64.4 (C-3’or C-4’), 65.3 (C-5’), 72.9 (CH2 Bn), 73.1 
(CH2 Bn), 73.8 (CH2 Bn), 75.0 (C-1), 75.3 (C-2), 75.9 (C-2’), 76.1 (C-3), 77.8 (C-4’ or C-3’), 79.6 (C-5), 99.7 
(C-1’), 124.7 – 134.1 (CH Arom), 130.9 (Cq SPh), 136.6 (Cq Bn), 137.9 (Cq Bn), 138.2 (Cq Bn), 168.9 (C=O 
COOMe); 13C-GATED (100 MHz, CDCl3): 75.0 (JC1,H1 = could not be determined), 96.1 (JC1’,H1’ = 166 Hz, C-




































fucopyranosyl)-α/β-D-mannopyranosyluronate)-2-deoxy-β-D-1,6-anhydroglucose (24): A solution of 38 mg 
donor 22 (0.050 mmol) and 21 mg acceptor 23 (0.075 mmol, 1.5 equiv.) in 2 mL DCM was stirred over 
activated MS3Å for 30min before 17 mg N-iodosuccinimide (0.075 mmol, 1.5 equiv.) was added. The mixture 
was cooled to -40°C and 2 µL TMSOTf (cat.) was added. Stirring was continued and the reaction mixture was 
allowed to warm to rT. When TLC-analysis indicated complete reaction, 0.2 mL triethylamine was added. The 
reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was extracted twice with 
EtOAc. The combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. 
Flash chromatography (EtOAc/PE) and removal of the eluent afforded 32 mg of the title compound 24 (0.032 
mmol, 65%, α/β=1/2) as a colorless oil. TLC: 30% EtOAc/PE; α-anomer: 1H NMR (400 MHz, CDCl3) δ = 1.20 
(d, 1H, J = 6.4 Hz, H-6’’), 3.23 (s, 1H, H-2), 3.51 (s, 3H, CH3 COOMe), 3.72 (s, 1H, H-3), 3.74 – 3.82 (m, 4H, 
H-6, H-4’, H-5’ and H-2’’), 3.90 – 3.92 (m, 2H, H-4, H-2’), 3.91 (t, 1H, J = 3.2 Hz, H-3’’), 4.00 (dd, 1H, J = 
10.0 Hz, J = 3.6 Hz, H-3’), 4.13 (d, 1H, J = 7.2 Hz, H-6), 4.19 (t, 1H, J = 4.0 Hz, H-4’’), 4.50 (d, 1H, J = 12.0 
Hz, CHHPh), 4.56 (d, 1H, J = 12.0 Hz, CHHPh), 4.63 (d, 1H, J = 2.4 Hz, H-5’’), 4.66 (d, 1H, J = 12.0 Hz, 
CHHPh), 4.74 (d, 1H, J = 12.0 Hz, CHHPh), 4.76 (d, 1H, J = 11.6 Hz, CHHPh), 4.80 (d, 1H, J = 11.6 Hz, 
CHHPh), 4.81 (bs, 1H, H-1’), 4.81 – 4.83 (m, 4H, 2xCH2 Bn), 4.93 (d, 1H, J = 5.6 Hz, H-5), 5.32 (d, 1H, J = 7.6 
Hz, H-1’’), 5.51 (s, 1H, H-1), 7.22 – 7.41 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 17.3 (C-6’’), 
52.7 (CH3 COOMe), 59.5 (C-2 or C-2’’), 60.0 (C-2 or C-2’’), 64.5 (C-5’ or C-4’), 65.4 (C-6), 65.6 (C-4’ or C-
5’), 72.6 (CH2 Bn), 72.9 (CH2 Bn), 73.2 (CH2 Bn), 73.9 (CH2 Bn), 74.1 (C-5’’), 74.9 (C-4’’), 75.5, 75.9 (C-3’’, 
C-4 or C-2’), 76.3 (C-5), 77.5 (C-3’), 77.7 (C-3), 77.8 (C-2’ or C-4), 97.8 (C-1’’), 99.8 (C-1’), 100.6 (C-1), 
129.0 – 130.5 (CH Arom), 137.0 (Cq Bn), 137.2 (Cq Bn), 137.9 (Cq Bn), 138.3 (Cq Bn), 169.3 (C=O COOMe); 
13C-GATED (100 MHz, CDCl3): 97.8 (JC1’’,H1’’ = 166 Hz, C-1’’), 99.8 (JC1’,H1’ = 167 Hz, C-1’), 100.6 (JC1,H1 = 
168 Hz, C-1); β-anomer: [α]D22: +2° (c = 0.3, CHCl3); IR (neat, cm-1): 609, 1041, 1091, 1222, 1710, 2098; 1H 
NMR (400 MHz, CDCl3) δ = 1.19 (d, 3H, J = 6.4 Hz, H-6’’), 3.17 (s, 1H, H-2), 3.67 (dd, 1H, J = 8.7 Hz, J = 3.5 
Hz, H-3’), 3.73 (s, 3H, CH3 COOMe), 3.74 – 3.77 (m, 2H, H-4’’, H-5’’), 3.78 – 3.81 (m, 2H, H-3, H-6), 3.82 (d, 
1H, J = 3.8 Hz, H-2’’), 3.89 (d, 1H, J = 9.3 Hz, H-5’), 3.93 (d, 1H, J = 3.8 Hz, H-3’’), 3.96 (s, 1H, H-4), 3.98 (d, 
1H, J = 3.5 Hz, H-2’), 4.15 (d, 1H, J = 7.3 Hz, H-6), 4.32 (t, 1H, J = 9.0 Hz, H-4’), 4.56 – 4.61 (m, 5H, 
2xCHHPh, 3x CHHPh), 4.63 (d, 1H, J = 2.5 Hz, H-5), 4.68 (d, 1H, J = 11.8 Hz, CHHPh), 4.72 (d, 1H, J = 11.9 
Hz, CHHPh), 4.79 (d, 1H, J = 11.9 Hz, CHHPh), 4.81 (s, 1H, H-1’), 5.35 (d, 1H, J = 3.8 Hz, H-1’’), 5.51 (s, 1H, 
H-1), 7.25 – 7.36 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 17.2 (C-6’’), 52.7 (CH3 COOMe), 58.9 
(C-2), 60.6 (C-2’), 64.7 (C-4’’ or C-5’’), 64.8 (C-6), 65.2 (C-5’’ or C-4’’), 71.5 (C-5), 72.0 (CH2 Bn), 72.5 (C-
3’’), 72.6 (CH2 Bn), 72.8 (CH2 Bn), 73.1 (C-4’), 73.4 (CH2 Bn), 75.5 (C-2’’), 75.9 (C-5’), 77.6 (C-4), 77.8 (C-3), 
79.7 (C-3’), 96.1 (C-1’), 98.2 (C-1’’), 100.9 (C-1), 127.4 – 128.5 (CH Arom), 137.2 (Cq Bn), 137.9 (Cq Bn), 
138.1 (Cq Bn) 167.8 (C=O COOMe); 13C-GATED (100 MHz, CDCl3): 96.1 (JC1’,H1’ = 160 Hz, C-1’), 98.2 
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Abstract: A tethered nucleophilic substitution strategy for the stereoselective introduction of axially 
oriented amino functions on various gluco- and mannopyranosides is presented. The resulting 4-amino 
functionalized monosaccharide building blocks have, after some manipulations, found application in 






The broad variety of naturally occurring carbohydrate structures originates not only from 
the large number of possible interglycosidic linkages, but also from the wide diversity in 
monosaccharide constituents. Aminosugars,2 hexapyranoses functionalized by amino groups 
at different positions, represent an important category of carbohydrate units found in 
numerous oligosaccharides and glycoconjugates. For instance, aminosugars are not only 
important as essential components of bacterial capsular polysaccharides,3 but also as 
structural elements of aminoglycoside antibiotics.4 The biological importance of natural 
products containing aminosugars demands the development of efficient synthesis routes to 
these monosaccharides. This Chapter focuses on the stereoselective introduction of a C4 








A convenient route to the regio- and stereoselective introduction of nitrogen substituents 
involves the use of tethered nitrogen nucleophiles.6 For example, allylic trichloroacetimidates 
have been employed in the Overman rearrangement to provide the corresponding allylic 
trichloroacetamides.7 Alternatively, o-iodoxybenzoic acid (IBX)8 or N-iodosuccinimide 
(NIS)-mediated9 cyclization of allylic trichloroacetimidates gives the corresponding trans-
disposed iodo-oxazolines. In an extension to these methods, this Chapter describes a novel, 
straightforward synthesis of orthogonally protected 4-amino glycosides. Key element in this 
strategy is the selective introduction of a trichloroacetimidate moiety at the C6-OH of 
partially protected gluco- and mannopyranosides. The hydroxyl at C4 is transformed into a 
suitable leaving group amenable to base-induced substitution by the tethered imidate moiety 
to provide the corresponding oxazine. Furthermore, after hydrolysis and suitable protection, 
these aminoglycosides can be readily applied as building blocks in oligosaccharide synthesis. 
 
Results and Discussion 
 
As a first example, the transformation of methyl 2,3-di-O-benzyl-α-D-glucopyranoside (1)10 
into methyl 4-acetamido-6-O-acetyl-2,3-di-O-benzyl-4-deoxy-α-D-galactopyranoside (5) was 
investigated (Scheme 1). Treatment of 1 with trichloroacetonitrile (Cl3CCN) in the presence 
of a catalytic amount of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) led to the selective 
formation of 6-O-acetimidate 2 in a yield of 89%. Installation of the 4-O-triflate (Tf2O, 
pyridine) followed by base-mediated cyclization of resulting 3 gave oxazine 4 (80% yield, 2 
steps), the structure of which was fully confirmed by spectroscopic analysis. Transformation 
of 1 via a three-step one-pot procedure afforded oxazine 4 in slightly improved yield (89% 
over 3 steps). Acidic hydrolysis of 4 and acetylation of the intermediate aminoalcohol gave 
methyl 4-acetamido-6-O-acetyl-2,3-di-O-benzyl-4-deoxy-α-D-galactopyranoside (5) in a 
yield of 89%. 
 
Scheme 1. 
2: R = H


































Reagents and conditions: (a) Cl3CCN, DBU, DCM, 0°C, 89% (b) Tf2O, pyridine, DCM (c) DiPEA, DCM, 80% 
(over 2 steps) (d) 1) 80% AcOH in H2O, 60°C, 2) Ac2O, pyridine, 89% (over 2 steps). 
 
Next, diversely functionalized manno- and glucopyranosides were employed in the tethered 







O-benzyl-α-D-mannopyranoside (6)11 to the three-step one pot procedure afforded oxazine 7, 
albeit in a moderate yield (entry 1). Closer inspection of the sequence of reactions revealed 
that the first two steps, which entailed installation of the 6-O-imidate and 4-O-triflate 
functions, proceeded with equal efficiency as observed for the synthesis of its glucopyranose 
congener 3 from diol 1 (Scheme 1). Arguably, the axially oriented 2-O-benzyl group in 
mannopyranoside 6 may cause 1,3-diaxial strain in the transition state hampering the 
formation of oxazine 7. Hydrolysis and acetylation of 7 gave fully protected 4-deoxy-4-
aminotaloside 8. The next objective was application of the developed protocol on protected 
thioglycosides, representing useful building blocks in the assembly of oligosaccharides 
(entries 2-4).12 Gratifyingly, ethyl 2,3-O-isopropylidene-1-thio-α-D-mannopyranoside 913 was 
readily transformed into oxazine 10 (entry 2). Unmasking of the oxazine ring in 10 proceeded 
with concomitant partial hydrolysis of the isopropylidene protective group. Acetylation and 
ensuing purification of the crude reaction mixture led to the isolation of 4-deoxy-4-
aminotalosides 11 and 12 in a combined yield of 61%. An unexpected difference in efficiency 
in the outcome of the three-step oxazine synthesis was observed in the case of ethyl  
 
Table 1. 














































11: R = isoprop
12: R = Ac  
R = isoprop : 40%




13: R = Bn










15: R = Bn
16: R = Bz
R = Bn: 21%

































a 1) Cl3CCN, DBU, DCM, 0°C, 2) Tf2O, pyridine, DCM, 0°C, 3) DiPEA. b 1) 80% AcOH in H2O, 2) Ac2O, 







thioglucosides 1314 and 1415 (entry 3). In both cases, selective installation of the primary 
trichloroacetimidate proceeded well. However, treatment of the intermediate 6-O-acetimidate 
in 13 with triflic anhydride and pyridine followed by DiPEA-mediated cyclization afforded 
oxazine 15 in a rather poor yield. This probably results from the high nucleophilic nature of 
the anomeric thio-function. Indeed, decreasing the nucleophilicity16 of the 1-thio group by 
replacing the C2 benzyl protective group for a benzoyl (14), led to formation of oxazine 16 in 
a satisfactory yield. Analogously, application of the sequence of reactions to phenyl 2-azido-
3-O-benzyl-2-deoxy-1-thio-α-D-glycoside (18),17 bearing an electron withdrawing azide at 
C2, provided the 2,4-diamino derivative 19 in a good yield (entry 4). Both oxazines 16 and 19 
were readily hydrolyzed and acetylated leading to the 4-acetamidogalactosides 17 and 20 in 
61% and 94% yield, respectively. 
Orthogonally protected oxazine 19 was selected as a model compound to be used both as 
donor and acceptor in ensuing glycosylation reactions. Diaminogalactosides possessing 
differently functionalized amino functions are frequently encountered in natural products. For 
instance as 2-acetamido-4-amino-2,4,6-trideoxy-galactopyranosides present in the capsular 
zwitterionic polysaccharides of Bacteroides fragilis.3 The group of Van Boom and Van der 
Marel recently demonstrated18 that partially protected thioglycosides can be effectively 
employed as acceptor glycosides in the dehydrative condensation procedure developed by Gin 
and coworkers.19 Aglycon 21 was readily obtained by acidic hydrolysis of oxazine 19 and 
subsequent selective reaction of the amine with N-(benzyloxycarbonyl-oxy)succinimide 
(Scheme 2). Dehydrative condensation was accomplished by activating 2,3,4,6-tetra-O-
benzyl-α/β-D-galactopyranose (23)20 under the influence of diphenylsulfonium bistriflate, 
followed by addition of acceptor 21 to afford the α-linked thiodisaccharide 24 in 65% yield. 
This excellent anomeric selectivity is surprising as reactive donors in combination with 
primary alcohol acceptors usually give anomeric mixtures.21 Next, the fully orthogonally 
protected thiodonor 22 was prepared by acetylation of compound 21. Activation of this 
disarmed16 donor 22 was accomplished by treatment with diphenylsulfoxide (Ph2SO)/triflic 
anhydride (Tf2O),22 which was shown to be a more potent thiophilic promoter system than the 
analogous benzenesulfinyl piperidine (BSP)/Tf2O23 combination recently developed by the 
Crich-laboratory. Addition of methyl glucoside 25,24 to the activated donor, smoothly 




This Chapter describes a new, straightforward synthesis procedure for the construction of 4-
amino-4-deoxyglycosides, and their application as donor and acceptor in condensation 
reactions towards disaccharides. It was found that nucleophilic inversion of C4 in the gluco-







likely, 1,3-diaxial interaction hampers the incoming nucleophile leading to a reduced yield. 
Retention of configuration was not observed in the presented cases. Furthermore, diamino-
galactoside 22 showed promise as a valuable building block in the Ph2SO/Tf2O-mediated 





















21: R = H
























Reagents and conditions: (a) 1) 80% AcOH in H2O, 60°C, 2) CbzOSu, pyridine, 95% (over 2 steps) (b) Ac2O, 
pyridine, quant. (c) 23, Ph2SO, Tf2O, TTBP, DCM, -60°C then 21, 65% (d) 22, Ph2SO, Tf2O, DCM, -60°C then 




General procedure 1H and 13C NMR spectra were recorded on a Jeol JNM-FX-200 (200/50.1 MHz) and a 
Bruker AV-400 (400/100 MHz) spectrometer. Chemical shifts are given in ppm (δ) relative to tetramethylsilane 
as internal standard. Coupling constants are given in Hz. All given 13C spectra are proton decoupled. Mass 
spectra were recorded with PE/SCIEX API 165 with electronspray interface and Q-Star Applied Biosystems Q-
TOF (TOF-section). Optical rotations were measured on a Propol automatic polarimeter. Traces of water in the 
donor and acceptor glycosides, diphenylsulfoxide and TTBP were removed by co-evaporation with toluene. 
TTBP was synthesized as described by Crich and coworkers.26 Dichloromethane (DCM, Baker p.a.) was boiled 
under reflux over P2O5 for 2h and distilled immediately prior to use. Solvents used for flash chromatography and 
TLC were of technical grade and distilled before use. Flash chromatography was performed on Baker silica gel 
(0.063 – 0.200 mm). TLC-analysis was conducted on DC-fertigfolien (Schleicher & Schuell, F1500, LS254) 
with detection by UV-absorption (254 nm) where applicable and by spraying with 20% sulfuric acid in ethanol 
followed by charring at ~150°C or by spraying with a solution of (NH4)6Mo7O24·H2O (25 g/L) and 
(NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulphuric acid followed by charring at ~150°C. Free amine functions 
were detected by spraying with a ninhydrine-solution in EtOH followed by charring at ~150°C.  
 
Oxazine 4: A solution of methyl 2,3-di-O-benzyl-α-D-glucopyranoside (1) (0.5 g; 1 mmol) in 
5 mL DCM was cooled to 0°C under an Ar-atmosphere. Subsequently, 0.1 mL 
trichloroacetonitrile (1.05 mmol, 1.05 equiv.) and 3 µL 1,8-diazabicyclo[5.4.0]undec-7-ene 
(0.01 mmol, 0.01 equiv.) were added to the solution. According to TLC-analysis, all starting 
material was consumed after 5min. Subsequent treatment of the reaction mixture with 0.4 
mL pyridine (5 mmol, 5 equiv.) and 0.24 mL trifluoromethanesulfonic anhydride (1.5 mmol, 1.5 equiv.) afforded 
the triflated product in 5min at 0°C. Base-induced cyclization was accomplished by addition of 1.0 mL  














by flash chromatography (20% EtOAc/PE). Removal of the eluent gave 0.40 g of the title compound 4 (0.80 
mmol, 80%) as a yellow oil. TLC: 35% EtOAc in PE; [α]D22: +63° (c = 1, CHCl3); IR (cm-1): 1001, 1028, 1043, 
1089, 1195, 1220, 1352, 1454, 1496, 1510, 1679, 1718; 1H NMR (400 MHz, CDCl3): δ = 3.37 (s, 3H, CH3 
OMe), 3.62 (dd, 1H, J = 3.5 Hz, J = 10.1 Hz, H-2), 3.94 (m, 1H, H-4), 4.04 (bd, 1H, J = 2.0 Hz, H-5), 4.13 (dd, 
1H, J = 10.1 Hz, J = 4.4 Hz, H-3), 4.29 (d, 1H, J = 11.8 Hz, H-6), 4.42 (dd, 1H, J = 11.8, J = 1.3 Hz, H-6), 4.60 
(d, 1H, J = 3.5 Hz, H-1), 4.65 (d, 1H, J = 11.8 Hz, CHHPh); 4.77 – 4.88 (m, 3H, CHHPh, CH2 Bn), 7.25 – 7.47 
(m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 54.1 (C-4), 55.7 (Me), 60.4 (C-5), 69.2 (C-6), 71.8 (CH2 
Bn), 73.8 (CH2 Bn), 75.2 (C-3), 75.6 (C-2), 99.5 (C-1), 127.4 – 128.3 (CH Arom), 138.3 (Cq Bn), 138.9 (Cq Bn), 
153.0 (C=NH); ESI-MS: 500.0 [M+H]+. 
 
Methyl 4-acetamido-6-O-acetyl-2,3-di-O-benzyl-4-deoxy-α-D-galactopyranose (5): A solution 
of 0.44 g oxazine 4 (0.89 mmol) in 5 mL 80% AcOH/H2O was stirred for 30min at ambient 
temperature. After removal of the solvent under reduced pressure, the residue was co-
evaporated several times with toluene. The crude product was subsequently dissolved in 4 mL pyridine and 
treated with 1 mL Ac2O. Stirring was continued for 8h before the solvent was removed in vacuo. After co-
evaporation with toluene the crude mixture was purified by flash chromatography (30% EtOAc/PE). Removal of 
the eluent gave 0.49 g of the title compound 5 (0.79 mmol, 89%) as a yellow oil. TLC: 35% EtOAc/PE; [α]D22: 
+2° (c = 1, CHCl3); IR: 1028, 1099, 1155, 1195, 1232, 1369, 1651, 1739; 1H NMR (400 MHz, CDCl3): δ = 2.04 
(s, 3H, CH3 Ac), 2.06 (s, 3H, CH3 Ac), 3.38 (s, 3H, CH3 OMe), 3.45 – 3.49 (dd, 1H, J = 4.0 Hz, J = 10.1 Hz, H-
2), 3.96 – 4.00 (dd, 1H, J = 10.7 Hz, J = 4.7 Hz, H-3), 4.08 – 4.15 (m, 3H, H-5, H-6, H-6), 4.52 (d, 1H, J = 11.1 
Hz, CHHPh), 4.64 (d, 1H, J = 4.0 Hz, H-1), 4.65 (d, 1H, J = 12.2 Hz, CHHPh), 4.77 (t, 1H, J = 4.4 Hz, H-4), 
4.78 (d, 1H, J = 11.1 Hz, CHHPh), 4.86 (d, 1H, J = 12.2 Hz, CHHPh), 5.60 (d, 1H, J = 10.1 Hz, NH), 7.26 – 
7.39 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 20.8 (CH3 Ac), 23.5 (CH3 Ac), 47.6 (C-4), 55.4 (CH3 
OMe), 63.2 (C-6), 66.7 (C-5), 71.7 (CH2 Bn), 73.6 (CH2 Bn), 75.3 (C-2), 76.0 (C-3), 98.6 (C-1), 127.7 – 128.4 
(CH Arom), 137.9 (Cq Bn), 138.2 (Cq Bn), 170.5 (C=O); HRMS: [M+H]+ calcd for C15H34NO7 458.2101, found 
458.2097. 
 
Methyl 2,3-di-O-benzyl-6-O-trichloroacetimidate-α-D-glucopyranoside (2): To a stirred 
solution of 1.79 g compound 1 (5 mmol) in 25 mL DCM at 0°C was added 0.5 mL 
trichloroacetonitrile (5 mmol, 1 equiv.) and 5 µL 1,8-diazabicyclo[5.4.0]undec-7-ene (0.05 
mmol, 0.05 equiv.). Stirring was allowed for 45min after which the reaction mixture was 
concentrated (waterbath ~30°C). Flash chromatography (20% EtOAc/PE) and removal of the 
eluent gave 2.23 g. of the title compound 2 (4.31 mmol, 89%) as a colorless oil. TLC: 50% EtOAc/PE. 1H NMR 
(400 MHz, CDCl3): δ = 3.39 (s, 3H, CH3 OMe), 3.46 (dd, 1H, J = 9.0 Hz, H-4), 3.50 (dd, 1H, J = 9.6 Hz, J = 3.6 
Hz, H-2), 3.82 (t, 1H, J = 9.2 Hz, H-3), 3.87 (m, 1H, J = 10.1 Hz, J = 5.0 Hz, H-5), 4.48 (d, 1H, J = 11.8 Hz, H-
6), 4.60 (d, 1H, J = 3.4 Hz, H-1), 4.61 (dd, 1H, J = 11.9 Hz, J = 5.0 Hz, H-6), 4.64 (d, 1H, J = 11.9 Hz, CHHPh), 
4.76 (d, 2H, J = 11.6 Hz, 2xCHHPh), 4.97 (d, 1H, J = 11.3 Hz, CHHPh), 7.29 – 7.37 (m, 10H, H Arom), 8.23 
(bs, 1H, NH); 13C NMR (100 MHz, CDCl3): δ = 55.1 (CH3 OMe), 68.5 (C-6), 69.6 (C-5), 70.0 (C-4), 73.2 (CH2 
Bn), 75.6 (CH2 Bn), 79.6 (C-2), 81.0 (C-3), 98.1 (C-1), 127.8 – 128.5 (CH Arom), 137.9 (Cq Bn), 138.6 (Cq Bn); 
ESI: 518.1 [M+H]+, 540.0 [M+Na]+. 
 
Oxazine 7: Oxazine 7 was obtained from compound 6 via the same procedure as described 
for the conversion of compound 1 into 4. The reaction mixture was purified by flash 
chromatography (15% EtOAc/PE). Removal of the eluent gave 75 mg of the title compound 



























OMe), 3.66 (t, 1H, J = 2.6 Hz, H-2), 4.01 (m, 2H, J = 2.6 Hz, J = 4.7 Hz, H-4, H-5), 4.06 (dd, 1H, J = 4.6 Hz, J 
= 2.6 Hz, H-3), 4.28 (d, 1H, J = 11.2 Hz, H-6), 4.54 (dd, 1H, J = 11.5 Hz, J = 2.6 Hz, H-6), 4.66 (d, 2H, J = 12.3 
Hz, 2xCHHPh), 4.78 (d, 1H, J = 12.0 Hz, CHHPh), 4.85 (d, 1H, J = 2.7 Hz, H-1), 4.86 (d, 1H, J = 12.5 Hz, 
CHHPh), 7.31 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 52.4 (C-4), 55.4 (CH3 OMe), 61.4 (C-5), 
68.7 (C-6), 70.9 (CH2 Bn), 72.7 (CH2 Bn), 74.1 (C-2, C-3), 101.0 (C-1), 127.6 – 128.4 (CH Arom), 138.3 (Cq 
Bn), 138.9 (Cq Bn), 151.8 (C=N); ESI-MS: 500.0 [M+H]+, 522.1 [M+Na]+. 
 
Methyl 4-acetamido-6-O-acetyl-2,3-di-O-benzyl-4-deoxy-α-D-talopyranoside (8): Compound 8 
was prepared from oxazine 7 via the same procedure as described for the conversion of 
compound 4 into 5. The reaction mixture was purified by flash chromatography (20% 
EtOAc/PE). Removal of the eluent gave 43 mg of the title compound 8 (0.096 mmol, 64%) as a 
yellow oil. TLC: 40% EtOAc/PE; [α]D22: +36° (c = 0.66, CHCl3); IR (cm-1): 1041, 1114, 1230, 1369, 1454, 
1515, 1670, 1739; 1H NMR (400 MHz, CDCl3): δ = 1.81 (s, 3H, NHAc), 2.06 (s, 3H, CH3 Ac), 3.34 (s, 3H, CH3 
OMe), 3.76 (m, 1H, J = 1.6 Hz, H-2), 3.81 (dd, 1H, J = 4.2 Hz, J = 3.1 Hz, H-3), 3.97 (m, 1H, H-5), 4.12 (dd, 
1H, J = 8.0 Hz, J = 3.6 Hz, H-6), 4.24 (dd, 1H, J = 11.7 Hz, J = 4.2 Hz, H-6), 4.43 (d, 1H, J = 11.6 Hz, CHHPh), 
4.66 (m, 1H, H-4), 4.68 (d, 2H, J = 11.2 Hz, 2xCHHPh), 4.76 (d, 1H, J = 11.0 Hz, CHHPh), 4.81 (d, 1H, J = 1.2 
Hz, H-1), 6.95 (d, 1H, J = 9.3 Hz, NH), 7.30 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 20.8 (CH3 
Ac), 23.2 (CH3 Ac), 46.5 (C-4), 54.8 (CH3 OMe), 64.0 (C-6), 68.2 (C-5), 69.9 (CH2 Bn), 72.1 (C-3), 74.1 (CH2 
Bn), 76.2 (C-2), 99.9 (C-1), 127.5 – 128.4 (CH Arom), 137.6 (Cq Bn), 137.8 (Cq Bn), 170.7 (C=O); ; HRMS: 
[M+H]+ calcd for C15H34NO7 458.2101, found 458.2174. 
 
Oxazine 10: Oxazine 10 was obtained from compound 9 via the same procedure as described 
for the conversion of compound 1 into 4. The reaction mixture was purified by flash 
chromatography (10% EtOAc/PE). Removal of the eluent gave 216 mg of the title compound 
10 (0.55 mmol, 54%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 1.23 (t, 3H, J = 7.4 
Hz, CH3 SEt), 1.27 (s, 3H, CH3 isoprop), 1.47 (s, 3H, CH3 isoprop), 2.62 (m, 2H, CH2 SEt), 4.19 (d, 1H, J = 7.2 
Hz, H-2), 4.23 (m, 1H, H-4), 4.27 (s, 1H, H-5), 4.28 (m, 1H, H-6), 4.35 (m, 1H, H-6), 4.67 (dd, 1H, J = 7.2 Hz, J 
= 3.7 Hz, H-3), 5.07 (s, 1H, H-1); 13C NMR (100 MHz, CDCl3): δ = 14.7 (CH3 SEt), 24.9 (CH3 isoprop), 25.4 
(CH2 SEt), 26.1 (CH3 isoprop), 49.5 (C-4), 61.1 (C-5), 67.2 (C-6), 72.0 (C-2), 76.0 (C-3), 81.4 (C-1), 110.4 (Cq 
isoprop), 154.1 (C=N); ESI-MS: 390 [M+H]+, 412 [M+Na]+. 
 
Ethyl 4-acetamido-6-O-acetyl-4-deoxy-2,3-O-isopropylidene-1-thio-α-D-talopyranoside (11): 
Compound 11 was prepared from oxazine 10 via the same procedure as described for the 
conversion of compound 4 into 5. The reaction mixture was purified by column chromatography 
(EtOAc). Removal of the eluent gave 77 mg of the title compound 11 (0.22 mmol, 40%) as a 
yellow oil, together with 50 mg ethyl 4-acetamido-2,3,6-tri-O-acetyl-4-deoxy-1-thio-α-D-talopyranoside 12 
(0.13 mmol, 21%). TLC: 40% EtOAc/PE; [α]D22: +142° (c = 1); IR (cm-1): 1002, 1037, 1083, 1211, 1235, 1373, 
1519, 1666, 1739; 1H NMR (400 MHz, CDCl3): δ = 1.32 (t, 3H, J = 7.4 Hz, CH3 SEt), 1.34 (s, 3H, CH3 isoprop), 
1.50 (s, 3H, CH3 isoprop), 2.04 (s, 3H, CH3 Ac), 2.06 (s, 3H, CH3 Ac), 2.57 (m, 1H, CHH SEt), 2.74 (m, 1H, 
CHH SEt), 4.05 (dd, 1H, J = 5.9 Hz, J = 1.0 Hz, H-2), 4.10 (dd, 1H, J = 11.8 Hz, J = 4.1 Hz, H-6), 4.23 (d, 1H, J 
= 11.8 Hz, H-6), 4.34 (t, 1H, J = 5.9 Hz, H-3), 4.38 (m, 1H, H-5), 4.47 (m, 1H, H-4), 5.52 (s, 1H, H-1), 5.86 (d, 
1H, J = 9.9 Hz, NH); 13C NMR (100 MHz, CDCl3): δ = 15.1 (CH3 SEt), 21.6 (CH3 Ac), 24.3 (CH3 Ac), 24.8 
(CH2 SEt), 26.2 (CH3 isoprop), 27.1 (CH3 isoprop), 46.5 (C-4), 64.1 (C-6), 67.5 (C-5), 72.2 (C-3), 74.6 (C-2), 
80.1 (C-1), 110.0 (Cq isoprop), 170.5 (C=O), 171.3 (C=O); HRMS: [M+H]+ calcd for C15H27NO6S 348.1403, 


























EtOAc/PE. 1H NMR (400 MHz, CDCl3): δ = 1.30 (t, 3H, J = 7.4 Hz, CH3 SEt), 2.00 (s, 3H, CH3 Ac), 2.04 (s, 
3H, CH3 Ac), 2.07 (s, 3H, CH3 Ac), 2.20 (s, 3H, CH3 Ac), 2.66 (m, 2H, CH2 SEt), 4.12 (dd, 1H, J = 11.8 Hz, J = 
4.6 Hz, H-6), 4.22 (dd, 1H, J = 11.7 Hz, J = 7.7 Hz, H-6), 4.59 (dd, 1H, J = 10.3 Hz, J = 3.6 Hz, H-4), 4.65, (m, 
1H, H-5), 5.17 (t, 1H, J = 3.6 Hz, H-3), 5.21 (m, 1H, J = 3.5 Hz, H-2), 5.31 (s, 1H, H-1), 6.19 (d, 1H, J = 10.1 
Hz, NH), 13C NMR (100 MHz, CDCl3): δ = 14.5 (CH3 SEt), 20.5 (CH3 Ac), 20.6 (CH3 Ac), 21.0 (CH3 Ac), 23.2 
(CH3 Ac), 24.9 (CH2 SEt), 46.9 (C-4), 62.8 (C-6), 65.7 (C-2), 68.2 (C-5), 70.6 (C-3), 82.5 (C-1), 168.7 (C=O), 
169.3 (C=O), 169.9 (C=O), 170.3 (C=O); ESI-MS: 414 [M+Na]+. 
 
Oxazine 15: Oxazine 15 was obtained from compound 13 via the same procedure as 
described for the conversion of compound 1 into 4. The reaction mixture was purified by 
flash chromatography (20% EtOAc/PE). Removal of the eluent gave 63 mg of the title 
compound 15 (0.12 mmol, 21%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 1.23 (t, 
3H, J = 7.6 Hz, CH3 SEt), 2.60 – 2.70 (m, 2H, J = 7.5 Hz, CH2 SEt), 3.55 (t, 1H, J = 9.2 Hz, H-2), 3.75 (dd, 1H, 
J = 8.9 Hz, J = 4.3 Hz, H-3), 3.83 (bs, 1H, H-5), 3.93 (bs, 1H, H-4), 4.32 (d, 1H, J = 11.7 Hz, H-6), 4.39 (d, 1H, 
J = 9.4 Hz, H-1), 4.55 (d, 1H, J = 10.2 Hz, H-6), 4.78 – 4.89 (m, 4H, 2xCH2 Bn), 7.25 – 7.44 (m, 10H, H Arom); 
13C NMR (100 MHz, CDCl3): δ = 15.0 (CH3 SEt), 22.9 (CH2 SEt), 53.3 (C-4), 67.4 (C-5), 67.4 (C-6), 69.4 (CH2 
Bn), 71.6 (CH2 Bn), 76.6 (C-2), 80.3 (C-3), 83.9 (C-1), 127.6 – 133.0 (CH Arom), 138.1 (Cq Bn), 138.2 (Cq Bn), 
154.4 (C=N); ESI-MS: 532.1 [M+H]+, 554.1 [M+Na]+. 
 
Oxazine 16: Oxazine 16 was obtained from compound 14 via the same procedure as 
described for the conversion of compound 1 into 4. The reaction mixture was purified by 
flash chromatography (20% EtOAc/PE). Removal of the eluent gave 63 mg of the title 
compound 16 (0.12 mmol, 64%) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ = 1.19 (t, 
3H, J = 7.5 Hz, CH3 SEt), 2.67 – 2.75 (m, 2H, J = 7.5 Hz, CH2 SEt), 3.90 – 3.93 (dd, 1H, J = 9.4 Hz, J = 4.2 Hz, 
H-3), 3.96 (d, 1H, J = 2.1 Hz, H-5), 4.06 (bs, 1H, H-4), 4.37 (d, 1H, J = 11.7 Hz, H-6), 4.52 (d, 1H, J1,2 = 9.5 Hz, 
H-1), 4.62 (dd, 1H, J = 11.7 Hz, J = 1.6 Hz, H-6), 4.70 – 4.80 (dd, 2H, J = 12.8 Hz, CH2Ph), 5.40 (t, 1H, J = 9.5 
Hz, J = 9.4 Hz, H-3), 7.18 – 8.03 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 14.7 (CH3 SEt), 22.1 
(CH2 SEt), 53.1 (C-4), 67.8 (C-5), 68.7 (C-2), 69.3 (C-6), 70.9 (CH2 Bn), 77.3 (C-3), 82.5 (C-1), 127.6 – 133.0 
(CH Arom), 129.9 (Cq Bz), 137.7 (Cq Bn), 165.0 (C=N); ESI: 544.1 [M+H]+. 
 
Ethyl 4-acetamido-6-O-acetyl-2-O-benzoyl-3-O-benzyl-4-deoxy-1-thio-β-D-galactopyran-
oside (17): Compound 17 was prepared from oxazine 16 via the same procedure as described 
for the conversion of compound 4 into 5. The reaction mixture was purified by flash 
chromatography (45% EtOAc/PE). Removal of the eluent gave 33 mg of the title compound 17 (0.066 mmol, 
61%) as a yellow oil. TLC: 35% EtOAc/PE; [α]D22: +14° (c = 0.42, CHCl3); IR (cm-1): 1242, 1369, 1454, 1550, 
1647, 1720; 1H NMR (400 MHz, CDCl3): δ = 1.24 (t, 3H, J = 7.4 Hz, CH3 SEt), 2.07 (s, 3H, CH3 Ac), 2.08 (s, 
3H, CH3 Ac), 2.65 – 2.71 (m, 2H, J = 7.4 Hz, CH2 SEt), 3.74 (dd, 1H, J = 9.7 Hz, J = 4.6 Hz, H-3), 3.86 (dd, 1H, 
J = 6.3 Hz, J = 1.2 Hz, H-5), 4.21 (d, 2H, J = 6.3 Hz, H-6), 4.46 (d, 1H, J = 12.6 Hz, CHHPh), 4.56 (d, 1H, J = 
10.1 Hz, H-1), 4.70 (d, 1H, J = 12.6 Hz, CHHPh), 4.89 – 4.92 (m, 1H, H-4), 5.22 (t, 1H., J = 9.9 Hz, H-2), 5.96 
(d, 1H, J = 10.1 Hz, NH), 7.09 – 8.01 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 14.9 (CH3 SEt), 
20.8 (CH3 Ac), 23.3 (CH3 Ac), 25.2 (CH2 SEt), 46.6 (C-4), 63.0 (C-6), 69.9 (C-2), 70.4 (CH2 Bn), 76.0 (C-5), 
76.6 (C-3), 84.8 (C-1), 127.6 – 133.2 (CH Arom), 129.5 (Cq Bz), 137.2 (Cq Bn), 170.4 (C=O), 170.7 (C=O); 





























Oxazine 19: Oxazine 19 was obtained from compound 18 via the same procedure as 
described for the conversion of compound 1 into 4. The reaction mixture was purified by 
flash chromatography (30% EtOAc/PE). Removal of the eluent gave 4.16 g of the title 
compound 19 (8.2 mmol, 74%) as a yellow oil. TLC: 40% EtOAc/PE; [α]D22: +46° (c = 1, 
CHCl3); IR (cm-1): 1172, 1226, 1678, 2110; 1H NMR (400 MHz, CDCl3): δ = 3.37 (t, 1H, J = 9.8 Hz, H-2), 3.62 
(dd, 1H, J = 9.6 Hz, J = 4.4 Hz, H-3), 3.83 (dd, 1H, J = 3.7 Hz, J = 1.5 Hz, H-5), 3.88 (d, 1H, J = 4.1 Hz, H-4), 
4.35 (m, 2H, J = 10.0 Hz, H-1, H-6), 4.62 (dd, 1H, J = 12.16 Hz, H-6), 4.72 (d, 1H, J = 12.1 Hz, CHHPh), 4.80 
(d, 1H, J = 12.1 Hz, CHHPh), 7.26 – 7.55 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3): δ = 51.8 (C-4), 60.0 
(C-5), 68.0 (C-2), 69.4 (C-6), 71.2 (CH2 Bn), 79.1 (C-3), 85.4 (C-1), 127.9 – 134.2 (CH Arom), 129.5 (Cq SPh), 
137.4 (Cq Bn), 153.7 (C=N); ; ESI-MS: 513.4 [M+H]+, 535.0 [M+Na]+. 
 
Phenyl 4-acetamido-6-O-acetyl-2-azido-3-O-benzyl-2,4-dideoxy-1-thio-β-D-galactopyranoside 
(20): Compound 20 was prepared from oxazine 19 via the same procedure as described for the 
conversion of compound 4 into 5. The reaction mixture was purified by flash chromatography 
(45% EtOAc/PE). Removal of the eluent gave 1.06 g of the title compound 20 (2.27 mmol, 94%) as a yellow oil. 
TLC: 40% EtOAc/PE; [α]D22: -22° (c = 0.24, CHCl3); IR (cm-1): 1037, 1103, 1230, 1365, 1438, 1535, 1654, 
1739, 2110; 1H NMR (400 MHz, CDCl3): δ = 1.96 (s, 3H, CH3 Ac), 2.06 (s, 3H, CH3 Ac), 3.27 (1H, t, J = 10.0 
Hz, H-2), 3.53 (dd, 1H, J = 9.7 Hz, J = 4.2 Hz, H-3), 3.74 (dd, 1H, J = 7.0 Hz, J = 5.0 Hz, H-5), 4.09 – 4.23 (m, 
2H, H-6), 4.38 (d, 1H, J = 10.3 Hz, H-1), 4.50 (d, 1H, J = 10.8 Hz, CHHPh), 4.75 (d, 1H, J = 6.9 Hz, H-4), 4.78 
(d, 1H, J = 10.8 Hz, CHHPh), 5.43 (d, 1H, J = 10.1 Hz, NH), 7.30 – 7.59 (m, 10H, H Arom); 13C NMR (100 
MHz, CDCl3): δ = 20.7 (CH3 Ac), 23.3 (CH3 Ac), 45.7 (C-4), 61.2 (C-2), 62.8 (C-6), 71.4 (CH2 Bn), 75.7 (C-5), 
79.4 (C-3), 86.1 (C-1), 128.1 – 133.8 (CH Arom), 130.9 (Cq SPh), 136.6 (Cq Bn), 170.3 (C=O); HRMS: [M+H]+ 
calcd for C23H28N4O5S 471.1624, found 471.1745. 
 
Phenyl 4-(N-benzyloxycarbonyl)-amino-2-azido-3-O-benzyl-2,4-dideoxy-1-thio-β-D-galacto-
pyranoside (21): Oxazine 19 (0.81 g, 1.58 mmol) was stirred in 5 mL 80% AcOH in H2O at 
ambient temperature. After 15min, the clear solution was diluted with toluene, concentrated 
and co-evaporated several times with toluene. The crude oil was dissolved in 5 mL DCM followed by addition 
of 0.26 mL NEt3 (2.0 mmol, 1.25 equiv.) and 0.4 g CbzOSu (1.6 mmol, 1.01 equiv.). The reaction mixture was 
stirred for 8h at room temperature before EtOAc was added. The mixture was washed with 50 mL 1M HCl. The 
water-layer was extracted twice with 50 mL EtOAc. The combined organic layers were dried (MgSO4), filtered 
en concentrated in vacuo. Flash chromatography (50% EtOAc/PE) and removal of the eluent afforded 844 mg of 
the title compound 21 (1.50 mmol, 95%) as a colorless oil. TLC: 50 % EtOAc/PE; [α]D22: -6° (c = 1, CHCl3); IR 
(cm-1): 1056, 1215, 1257, 1512, 1705, 2110; 1H NMR (200 MHz, CDCl3): δ = 3.01 (bs, 1H, OH), 3.24 (t, 1H, J = 
9.9 Hz, H-2), 3.57 (m, 3H, H-3, H-6), 3.72 (m, 1H, H-5), 4.36 (m, 2H, J = 10.2 Hz, H-1, H-4), 4.50 (d, 1H J = 
10.9 Hz, CHHPh), 4.68 (d, 1H, J = 11.3 Hz, CHHPh), 4.83 (d, 1H, J = 7.8 Hz, NH), 5.12 (s, 2H, CH2 Cbz), 13C 
NMR (50.4 MHz, CDCl3): δ = 47.5 (C-4), 60.5 (C-6), 61.1 (C-2), 67.0 (CH2 Cbz), 70.8 (CH2 Bn), 77.9 (C-5), 
78.8 (C-3), 86.1 (C-1), 127.6 – 132.6 (CH Arom), 131.3 (Cq SPh), 135.8 (Cq Cbz), 136.6 (Cq Bn), 157.3 (C=O); 
HRMS: [M+H]+ calcd for C27H30N4O5S 521.1780, found 521.1829. 
 
Phenyl 6-O-acetyl-4-(N-benzyloxycarbonyl)-amino-2-azido-3-O-benzyl-2,4-dideoxy-1-
thio-β-D-galactopyranoside (22): Compound 21 (593 mg, 1.14 mmol) was dissolved in 5 
mL pyridine followed by the addition of 2.5 mL Ac2O. The reaction mixture was stirred for 
2h at room temperature. The mixture was concentrated and co-evaporated several times with toluene. After flash 






























quant.) was obtained as a colorless oil. TLC: 50 % EtOAc/PE; [α]D22: -13° (c = 1, CHCl3); IR (cm-1): 1037, 1103, 
1226, 1365, 1454, 1510, 1716, 2110; 1H NMR (200 MHz, CDCl3): δ = 2.04 (s, 3H, CH3 Ac), 3.27 (t, 1H, J = 
10.2 Hz, J = 9.7 Hz, H-2), 3.51 (dd, 1H, J = 9.9 Hz, J = 4.3 Hz, H-3), 3.71 (t, 1H, J = 5.8 Hz, H-5), 4.20 (m, 2H, 
J = 5.1 Hz, H-6), 4.34 (d, 1H, J = 10.2 Hz, CHHPh), 4.42 (m, 1H, H-4), 4.52 (d, 1H, J = 11.0 Hz, CHHPh), 4.83 
(d, 2H, J = 10.6 Hz, H-1, NH), 5.08 (s, 2H, CH2 Cbz), 7.25 – 7.54 (m, 10H, H Arom); 13C NMR (50.4 MHz, 
CDCl3): δ = 20.7 (Ac), 48.0 (C-4), 61.2 (C-2), 62.9 (C-6), 67.2 (CH2 Cbz), 71.4 (CH2 Bn), 75.6 (C-5), 79.6 (C-
3), 86.3 (C-1), 127.9 – 133.4 (CH Arom), 131.1 (Cq SPh), 136.0 (Cq Cbz), 136.7 (Cq Bn), 156.2 (C=O Cbz), 
170.5 (C=O Ac); ESI-MS: 563.3 [M+H]+, 585.0 [M+Na]+. 
 
Phenyl 4-(N-benzyloxycarbonyl)-amino-2-azido-3-O-benzyl-6-O-(2,3,4,6-tetra-O-ben-
zyl-α-D-galactopyranosyl)-2,4-dideoxy-1-thio-β-D-galactopyranoside (24): A solution of  
54 mg donor 23 (0.1 mmol), 40 mg Ph2SO (0.2 mmol, 2 equiv.) and 74 mg tri-tert-
butylpyrimidine (0.3 mmol, 3 equiv.) in 4 mL DCM was stirred over 100 mg activated 
MS4Å for 30min The mixture was cooled to -78°C and 26 µL triflic acid anhydride 
(0.15 mmol, 1.5 equiv.) was added. The mixture was allowed to warm to -40°C in 1h followed by addition of 52 
mg acceptor 21 (0.1 mmol, 1 equiv.) in 1 mL DCM. Stirring was continued and the reaction mixture was 
allowed to warm to 0°C. Subsequently, 0.16 mL NEt3 (2 mmol, 20 equiv.) was added. Flash chromatography 
(20% EtOAc/PE) and removal of the eluent afforded 66 mg of the title compound 24 (65 µmol, 65%) as a yellow 
oil. TLC: 50% EtOAc/PE; [α]D22: +13° (c = 1, CHCl3); IR (cm-1): 1030, 1096, 1215, 1454, 1496, 1716, 2110; 1H 
NMR (400 MHz, CDCl3): δ = 3.18 (t, 1H, J = 10.0 Hz, H-2’), 3.45 (m, 2H, J = 6.7 Hz, J = 9.7 Hz, H-3, H-6), 
3.53 (dd, 1H, J = 9.3 Hz, J = 6.4 Hz, H-6), 3.59 (q, 1H, J = 5.9 Hz, H-6’), 3.75 (m, 2H, H-5’, H-6’), 3.83 (dd, 
1H, J = 10.0 Hz, J = 2.7 Hz, H-3), 3.89 (s, 1H, H-4), 3.95 (t, 1H, J = 6.3 Hz, H-5), 4.02 (dd, 1H, J = 10.1 Hz, J = 
3.6 Hz, H-2), 4.32 (d, 1H, J = 10.0 Hz, H-1’), 4.38 (s, 1H, H-4’), 4.40 (m 2H, CH2 Bn), 4.56 (d, 1H, J = 11.4 Hz, 
CHHPh), 4.69 (t, 2H, J = 13.0 Hz, CH2 Bn), 4.80 (m, 3H, CHHPh), CH2 Bn), 4.81 (d, 1H, J = 3.2 Hz, H-1’), 
4.92 (d, 1H, J = 11.4 Hz, CHHPh), 5.06 (dd, 2H, J = 12.2 Hz, CH2 Cbz), 7.20 – 7.37 (m, 35H, H Arom); 13C 
NMR (100 MHz, CDCl3): δ = 48.5 (C-4’), 61.2 (C-3’), 67.0 (CH2 Cbz), 67.6 (C-6’), 69.1 (C-6), 69.4 (C-5’), 
71.3 (CH2 Bn), 73.1 (CH2 Bn), 73.4 (CH2 Bn), 73.5 (CH2 Bn), 74.7 (CH2 Bn), 74.9 (C-4), 76.5 (C-2), 76.7 (C-5), 
78.9 (C-3), 79.8 (C-2’), 86.2 (C-1’), 98.2 (C-1), 124.7 – 133.2 (CH Arom), 131.5 (Cq SPh), 136.1 – 138.7 (Cq 




(26): A solution of 53 mg donor 22 (0.1 mmol) and 25 mg Ph2SO (0.12 mmol, 1.2 
equiv.) in 3 mL DCM was stirred over 100 mg activated MS4Å for 30min The 
mixture was cooled to -78°C before 22 µL triflic acid anhydride (0.13 mmol, 1.3 equiv.) was added. The mixture 
was stirred for 5min followed by addition of 75 mg acceptor 25 (0.1 mmol, 1 equiv.) in 1 mL DCM. The mixture 
was allowed to warm to 0°C. Subsequently, 0.16 mL NEt3 (2 mmol, 20 equiv.) was added. Flash 
chromatography (30% EtOAc/PE) and removal of the eluent afforded 92 mg of the title compound 26 (95 µmol, 
95%) as a colorless oil. TLC: 50% EtOAc/PE; IR (cm-1): 1026, 1091, 1245, 1450, 1519, 1724, 2110; 1H NMR 
(400 MHz, CDCl3): δ = 4.27 (d, J = 8.0 Hz, H-1’ β-anomer), 4.90 (d, J = 3.4 Hz, H-1’ α-anomer), 4.27 (d, J = 
3.5 Hz, H-1); 13C NMR (100,8 MHz, CDCl3): δ = 96.8 (C-1), 97.9 (C-1’ α-anomer), 102.5 (C-1’ β-anomer); 
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Abstract: This Chapter describes a convergent route of synthesis for the protected repeating unit 
trisaccharide structure 2 of the zwitterionic polysaccharide Sp1, using 1-hydroxyl and 1-thio 
functionalized donor and acceptor building blocks. Furthermore, a new synthesis approach for the 







Capsular polysaccharides (CPs) are major components of the bacterial cell wall and 
represent the virulence factors of many pathogens.1 Most of these CPs are neutral or 
negatively charged and are, in general, considered as T-cell independent antigens.2 
Interestingly, the groups of Kasper and Tzianabos reported that CPs with a zwitterionic 
charge motif, show CD4+ T cell responses.3 One example is the polysaccharide found on the 
cell wall of the Streptococcus pneumoniae species, which plays a key role in the development 
of intraabdominal sepsis.4 The repeating unit of this zwitterionic CP, called Sp1, has one 
positive and two negatively charged groups per repeating unit (1, Figure 1).5 Structure-
function studies revealed that the dual charge motif on the carbohydrate core is at the basis of 
this unusual immunological activity.6,7  
In this Chapter the chemical synthesis of the protected repeating unit structure 2 of the 







combination with the diphenylsulfoxide (Ph2SO)/triflic anhydride (Tf2O) activator system 
(Figure 1). The target trisaccharide structure 2 comprises two galacturonic acid moieties (3 
and 5)10 and the uncommon, orthogonally functionalized 2,4-diamino fucose residue 4. A new 
route of synthesis for residue 4 was examined using the tethered nucleophilic inversion 
approach described in Chapter 6.11 Lönn and Lönngren previously reported on the synthesis 



























































Results and Discussion 
 
The galacturonic acid building blocks 3 and 5 were obtained starting from 4,6-diol 7 and 
3,6-diol 9 (Scheme 1). Diol 7 was prepared from thcompound 6 using literature procedures.13 
Diol 9 was efficiently synthesized from the known galactoside 814 in a three-step/one-pot 
procedure. Regioselective silylation15 of both C3 and C6 using TBDMSCl and imidazole in 
dichloromethane was followed by benzylation of the residual C2 and C4 hydroxyl groups. 
TLC-analysis of the reaction mixture only showed minor side-product formation indicating 
negligible silyl migration.16 Acidic removal of the silyl protection afforded the desired 
building block 9 in a yield of 53% over the 3 steps. In the next step, diols 7 and 9 were 
chemo- and regioselectively oxidized using the TEMPO/BAIB reagent combination to afford 
galacturonic acid 1010 and lactone 3.17 Treatment of the crude acid 10 with freshly prepared 
diazomethane afforded terminal acceptor species 5 in a yield of 57% over the 2 steps. The 
formation of lactone derivative 3 can be rationalized by initial formation of lactol derivative 
11 followed by further oxidation towards lactone 3. 
Several procedures to 2,4-diamino fucose derivatives, in which both amino groups are 
protected in the same manner, have been published.18,19 Methods dealing with the synthesis of 
orthogonally protected 2,4-diamino fucose residues commence with regioselective de-









































7: R1=β-OMe, R2=R3=Bn, R4=R5=H
8: R1=β-SPh, R2=R3=R4=R5=H




Reagents and conditions: (a) see ref. 13 (b) 1) TBDMSCl, Imidazole, DMF, 2) BnBr, NaH, DMF, 0°C, 3) TsOH, 
MeOH, reflux, 53% (over 3 steps) (c) TEMPO, BAIB, DCM, H2O, 75% (for 3) (d) 1) TEMPO, BAIB, 
DCM/H2O (2/1), 2) CH2N2, DMF, 57% (over 2 steps). 
 
ensuing nucleophilic displacement of the equatorially oriented OH4 by an azide nucleophile. 
The presence of a C2 participating group in these derivatives prevents their use as α-selective 
donor glycosides and therefore a different approach to suitably protected derivative 4 was 
devised starting from 2-azido glucose 1322 (Scheme 2).23 The first goal to be addressed is the 
regioselective de-oxygenation of the C6 position of compound 13, which was easily obtained 
from glucosamine hydrochloride 12,22 in the presence of the sensitive azide functionality. So, 
regioselective tosylation of compound 13 afforded compound 14 in a yield of 80% along with 
minor formation of 3,6-di-O-tosylated by-product. Displacement of the C6 tosyl functionality 
by reaction with NaI in refluxing butanone (Finkelstein conditions) led to the isolation of diol 
15 in excellent yield. Sodium borohydride reduction of the intermediate C6 iodo-function 
proceeded selectively and gave quinovosamine derivate 16 in a yield of 76%, with almost no 
products arising from azide reduction. Attempts to directly reduce the C6 tosyl function in 
compound 14 using NaBH4 resulted in prolonged reaction times and decreased reaction 
efficiencies compared to iodinated compound 15. In the next step, the regioselective 
introduction of the axially oriented C4 amino function was addressed by means of a one-pot 
tethered nucleophilic inversion approach presented in Chapter 6.11 Treatment of compound 16 
with an equimolar amount of trichloroacetonitrile (Cl3CCN) and a catalytic amount of DBU 
resulted in the predominant formation of the 3-O-trichloroacetimidate intermediate. After 
triflation of OH4, excess DiPEA was added to afford the labile oxazoline derivative 17. Mild 





























13: R = OH
14: R = OTos
15: R = I






Reagents and conditions: (a) see ref. 22 (b) TsCl, pyridine, 80% (c) NaI, butanone, reflux, 96% (d) NaBH4, 
DMSO, 76% (e) Cl3CCN, DBU, DCM, 0°C then Tf2O, pyridine then DiPEA (f) Amberlite IR120 H+, MeOH, 







compound 17 yielded the 4-N-trichloroacetamide target compound 4. Two-dimensional 1H 
NMR spectroscopy nicely confirmed the inverted chirality at the C4 position. 
The assembly of the target trisaccharide 22 started at the non-reducing end using lactone 
building block 3 as donor (Scheme 3). Pre-activation of lactone 3 using in situ generated 
diphenylsulfonium bistriflate and subsequent treatment with partially protected acceptor 4 
yielded α-coupled disaccharide 18 in 74% yield.24 Liberation of the anomeric hydroxyl group 
was accomplished by treatment of disaccharide 18 with NEt3·3HF in THF giving hemiacetal 
donor 19. Disarmed disaccharide 19 was then condensed with uronate acceptor 5 under 
influence of the Ph2SO/Tf2O activation system to give trisaccharide 20, fully α-
stereoselective. For purification reasons, trisaccharide 20 was processed further by acid-




18: R = β-OTBS






































Reagents and conditions: (a) 3, Ph2SO, Tf2O, TTBP, DCM, -60°C then 4, 74% (b) NEt3·3HF, THF, 99% (c) 19, 
Ph2SO, Tf2O, DCM, -40°C then 5 (d) cat. H2SO4, MeOH, 58% (over 2 steps). 
 
With the trisaccharide 2 in hand, a global deprotection strategy was investigated as outlined 
in Figure 2. The most challenging goal in this respect is maintaining orthogonality between 
both amine functionalities at the middle fucose residue. The first attempt involves initial 
cleavage of all base labile groups (methyl esters and trichloroacetamide), followed by 
reprotection of the liberated C4’ amine with a tert-butyloxycarbonyl (Boc) group. It was 
found that base treatment proceeded well using KOH in aqueous THF. However, ensuing re-
protection of the C4’ amine group went troublesome and only a minor amount of Boc-
protected amine was detected, most probably due to steric hindrance. In the next attempt, the 




H2, Pd/C then Ac2O
then H+
1) KOH, THF/H2O
2) Boc2O, NaHCO3, 
    H2O/dioxane
1) AcSH (neat)












followed by basic hydrolysis of both methyl ester and trichloroacetamide groups.25 
Unfortunately, base treatment resulted predominantly in smaller fragments with minor methyl 
ester cleavage. These smaller fragments most probably originate from C4-C5 (β-)elimination 




This Chapter describes the synthesis of the protected trisaccharide repeating unit of the 
zwitterionic polysaccharide Sp1 using 1-thio and 1-hydroxyl glycosides in combination with 
the Ph2SO/Tf2O activator system. A new route of synthesis towards the demanding, 
orthogonally protected 2,4-diamino fucose residue is presented. Furthermore, 1-
thiogalacturonic acid ester and its corresponding lactone are efficiently employed in the 
synthesis. It became clear that the combination of galacto-configured uronic acid derivatives 
and sterically encumbered N-trichloroacetamides should be circumvented in future research to 
minimize unwanted side-reactions during deprotection. Changing the 2,4-diamino fucose to 
the terminal position and/or replacing the N-trichloroacetyl protection for a N-
benzyloxycarbonyl group will probably prevent these problems. On the other hand, the 
application of lactone functionalized donor glycosides reduces the number of synthetic steps 
at the monosaccharide and oligosaccharide level. Cleavage of the lactone bridge in 
trisaccharide 20 forms a rapid entry into larger oligosaccharide constructs enabling future 




General Procedures: 1H and 13C NMR spectra were recorded on a Brüker DMX-400 and a Brüker AV-400 
(400/100 MHz), Brüker AV500 (500/125 MHz) and a Brüker DMX-600 (600/150 MHz) spectrometer. Chemical 
shifts (δ) are given in ppm relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. 
All given 13C spectra are proton decoupled. Mass spectra were recorded with PE/SCIEX API 165 with 
electronspray interface and Q-Star Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured 
on a Propol automatic polarimeter. IR-spectra were recorded on a Shimadzu FTIR-8300. Traces of water in the 
donor and acceptor glycosides, diphenylsulfoxide and TTBP were removed by co-evaporation with toluene. 
TTBP was synthesized as described by Crich et al.27 Dichloromethane (DCM, Baker p.a.) was boiled under 
reflux over P2O5 for 2h and distilled prior to use. Trifluoromethanesulfonic anhydride was distilled from P2O5. 
Molecular sieves 3Å were flame dried before use. Solvents used for flash chromatography were of pro analysi 
quality. Flash chromatography was performed on Fluka silica gel 60 (0.04 – 0.063 mm). TLC-analysis was 
conducted on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm) where 
applicable and by spraying with 20% sulfuric acid in ethanol followed by charring at ~150°C or by spraying with 







followed by charring at ~150°C. All reactions were performed under an inert atmosphere of Argon unless stated 
otherwise. 
 
Phenyl 2,4-di-O-benzyl-1-thio-β-D-galactopyranoside (9): To a cooled (0°C) solution of 2.72 g 
compound 814 (10.0 mmol) in 50 mL DMF was added 3.24 g TBSCl (21.5 mmol, 2.15 equiv.) 
and 3.18 g imidazole (21.5 mmol, 2.15 equiv.). The mixture was allowed to warm to room 
temperature. After stirring for 8h the reaction was quenched with MeOH, taken up in EtOAc and washed with 
H2O. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
product was filtered through a plug of silica gel using (10% EtOAc/PE) as the eluent. After evaporation of the 
solvent, the crude product was dissolved in 50 mL DMF and cooled to 0°C before 3 mL BnBr (25 mmol, 2.5 
equiv.) and 1 g NaH (60% in min. oil, 25 mmol, 2.5 equiv.) were added. The mixture was allowed to stir for 12 h 
before the reaction was quenched by addition of MeOH, taken up in Et2O and washed with H2O. The organic 
phase was dried (MgSO4), filtered and concentrated under reduced pressure. The oily substance was suspended 
in 50 mL MeOH and a catalytic amount of TsOH was added. The mixture was refluxed until TLC indicated 
complete conversion. After addition of 5 mL NEt3 the reaction mixture was concentrated under reduced pressure. 
Flash chromatography afforded 2.39 g of the title compound 9 (5.26 mmol, 53%) as a colorless oil. TLC: 50% 
EtOAc/PE; [α]D22: +1° (c = 1.4, CHCl3); IR (neat, cm-1): 694, 640, 732, 871, 1018, 1049, 1311; 1H NMR (500 
MHz, CDCl3) δ = 1.86 (bs, 1H, OH), 2.33 (bs, 1H, OH), 3.49 (t, 1H, J = 6.5 Hz, J = 5.5 Hz, H-5), 3.56 – 3.58 
(m, 1H, H-6), 3.71 (bs, 1H, H-3), 3.74 (t, 1H, J = 9.5 Hz, H-2), 3.79 (s, 1H, H-4), 3.85 (dd, 1H, J = 11.5 Hz, J = 
7.0, H-6), 4.61 (d, 1H, J = 9.5 Hz, H-1), 4.62 (d, 1H, J = 12.0 Hz, CHHPh), 4.64 (d, 1H, J = 11.0 Hz, CHHPh), 
4.77 (d, 1H, J = 12.0 Hz, CHHPh), 4.92 (d, 1H, J = 11.0 Hz, CHHPh), 7.27 – 7.37 (m, 15H, H Arom); 13C NMR 
(125 MHz, CDCl3) δ = 62.2 (C-6), 74.8 (CH2 Bn), 75.3 (CH2 Bn), 75.7 (C-4), 75.9 (C-3), 78.2 (C-2), 79.0 (C-5), 
98.3 (C-1), 127.2 – 128.5 (CH Arom), 133.8 (Cq SPh), 137.9 (Cq Bn), 138.1 (Cq Bn); HRMS: [M+Na]+ calcd for 
C26H28O5SNa 475.15497, found 475.15567. 
 
Phenyl 2,4-di-O-benzyl-1-thio-β-D-galactopyranosidurono-6,3-lactone (3): To a vigorously 
stirred solution of 1.19 g compound 9 (2.63 mmol) in 10 mL DCM and 3 mL H2O was added 
82 mg TEMPO (0.5 mmol, 0.2 equiv.) and 2.12 g BAIB (6.58 mmol, 2.5 equiv.). Stirring was 
allowed until TLC indicated complete conversion of the starting material to a higher running 
spot (~15min). The reaction mixture was quenched by the addition of 50 mL Na2S2O3 solution (10% in H2O). 
The mixture was then extracted twice with EtOAc (100 mL) and the combined organic phase was dried 
(MgSO4), filtered and concentrated. Flash column chromatography using EtOAc/petroleum ether afforded 883 
mg of the title compound 3 (1.97 mmol, 75%) as a colorless oil. TLC: 20% EtOAc/PE; [α]D22: -95° (c = 0.5, 
CHCl3); IR (neat, cm-1): 979, 1026, 1060, 1097, 1151, 1365, 1454, 1799, 2869, 3030; 1H NMR (400 MHz, 
CDCl3) δ = 4.02 (s, 1H, H-4), 4.23 (d, 1H, J = 4.8 Hz, H-2), 4.36 (s, 1H, H-5), 4.48 (d, 1H, J = 11.8 Hz, 
CHHPh), 4.51 (s, 2H, CH2 Bn), 4.56 (d, 1H, J = 11.8 Hz, CHHPh), 4.79 (d, 1H, J = 4.4 Hz, H-3), 5.40 (s, 1H, H-
1), 7.14 – 7.43 (m, 15H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 70.6 (C-4), 71.1 (CH2 Bn), 72.7 (CH2 Bn), 
75.7 (C-5), 78.4 (C-2), 78.6 (C-3), 85.6 (C-1), 127.6 – 132.4 (CH Arom), 133.5 (Cq SPh), 136.4 (Cq Bn), 136.5 
(Cq Bn), 172.5 (C=O); HRMS: [M+NH4]+ calcd for C26H28O5SN 466.16882, found 466.16946. 
 
Methyl (methyl 2,3-di-O-benzyl-β-D-galactopyranoside) uronate (5): Compound 5 was 
obtained from known methyl 2,3-di-O-benzyl galactopyranoside 713 following a two-step 
procedure. First, acid 10 was obtained in the same way as described for the conversion of 
diol 9 into lactone 3. This intermediate free acid 10 was directly processed further by treatment with freshly 
























mmol, 57% over 2 steps) as white, amorphous crystals. TLC: 25% EtOAc/PE; IR (neat, cm-1): 694, 732, 894, 
1041, 1080, 1265, 1357, 1442, 1720, 2947; 1H NMR (400 MHz, CDCl3) δ = 2.55 (bs, 1H, OH-4), 3.56 (dd, 1H, J 
= 9.2 Hz, J = 3.2 Hz, H-3), 3.60 (s, 3H, CH3 OMe), 3.67 (dd, 1H, J = 9.2 Hz, J = 7.6 Hz, H-2), 3.83 (s, 3H, CH3 
COOMe), 4.06 (d, 1H, J = 1.2 Hz, H-5), 4.28 (d, 1H, J = 7.6 Hz, H-1), 4.32 (dd, 1H, J = 3.2 Hz, J = 1.2 Hz, H-
4), 4.69 (d, 1H, J = 12.0 Hz, CHHPh), 4.71 (d, 1H, J = 11.2 Hz, CHHPh), 4.76 (d, 1H, J = 12.0 Hz, CHHPh), 
4.88 (d, 1H, J = 11.2 Hz, CHHPh), 7.26 – 8.01 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 52.6 (CH3 
COOMe), 57.2 (CH3 OMe), 67.9 (C-4), 72.5 (CH2 Bn), 73.6 (C-5), 75.1 (CH2 Bn), 78.2 (C-2), 79.7 (C-3), 104.5 
(C-1), 127.6 – 128.5 (CH Arom), 137.5 (Cq Bn), 138.4 (Cq Bn), 168.4 (C=O); HRMS: [M+Na]+ calcd for 
C22H26O7Na 425.15545, found 425.15707. 
 
Tert-butyldimethylsilyl 2-azido-2-deoxy-6-O-tosyl-β-D-glucopyranoside (14): A solution 
of 3.8 g of compound 13 (13.1 mmol) in 65 mL anhydrous pyridine was cooled to 0˚C 
followed by the addition of 3.0 g tosylchloride (16 mmol, 1.2 equiv). The reaction mixture 
was stirred for 5h under Ar-atmosphere at room temperature. The reaction was quenched by addition of ice-cold 
MeOH. The mixture was diluted with 100 mL EtOAc and washed with 50 mL aq. 1M HCl solution and 50 mL 
sat. aq. NaHCO3 solution. The organic phase was dried (MgSO4), filtered and concentrated under reduced 
pressure. Flash column chromatography using ethyl acetate/petroleum ether afforded 4.7 g of the title compound 
14 (10.4 mmol, 80%) as a colorless oil. TLC: 70% EtOAc/PE; IR (neat, cm-1): 686, 779, 833, 1072, 1180, 1249, 
1369, 2106; 1H NMR (500 MHz, CDCl3) δ = 0.13 (s, 3H, CH3 TBDMS), 0.15 (s, 3H, CH3 TBDMS), 0.91 (s, 
9H, tBu, TBDMS), 2.45 (s, 3H, CH3 Ts), 3.17 (bs, 2H, 2xOH), 3.19 (dd, 1H, J = 10.0 Hz, J = 7.6 Hz, H-2), 3.31 
(dd, 1H, J = 10.0 Hz, J = 7.6 Hz, H-3), 3.42 – 3.50 (m, 2H, H-4 and H-5), 4.21 (dd, 1H, J = 10.8 Hz, J = 4.4 Hz, 
H-6), 4.27 (d, 1H, J = 10.0 Hz, H-6), 4.53 (d, 1H, J = 7.6 Hz, H-1), 7.33 (d, 2H, J = 8.0 Hz, 2H Arom), 7.79 (d, 
2H, J = 8.0 Hz, 2H Arom); 13C NMR (100 MHz, CDCl3) δ = -5.41 (CH3 TBDMS), -4.47 (CH3 TBDMS), 17.8 
(Cq tBu TBDMS), 21.5 (CH3 Ts), 25.4 (tBu TBDMS), 68.7 (C-6), 67.8, 69.6, 73.2, 74.2 (C-2, C-3, C-4 and C-5), 
96.9 (C-1), 127.8, 129.8 (CH Arom), 132.4 (Cq Ts), 144.9 (Cq Ts); HRMS: [M+Na]+ calcd for C19H31O7N3SiNa 
496.15442, found 496.15455. 
 
Tert-butyldimethylsilyl 2-azido-2,6-dideoxy-6-iodo-β-D-glucopyranoside (15): Compound 
14 (3.7 g, 8.9 mmol) was dissolved in 50 mL butanone before 3.0 g NaI (20 mmol, 2.2 
equiv.) was added. The mixture was refluxed for 5h. The reaction mixture was cooled to 
ambient temperature, diluted with 100 mL EtOAc and washed with 50 mL aq. 1M Na2S2O3 solution and 50 mL 
H2O. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column 
chromatography using ethyl acetate/petroleum ether afforded 3.7 g of the title compound 15 (8.5 mmol, 96%) as 
a yellow oil. TLC: 70% EtOAc/PE; [α]D22: +45° (c = 1.5, CHCl3); IR (neat, cm-1): 686, 779, 833, 1072, 1180, 
1249, 2106; 1H NMR (400 MHz, CDCl3) δ = 0.21 (s, 3H, CH3 TBDMS), 0.23 (s, 3H, CH3 TBDMS), 0.95 (s, 
9H, tBu TBDMS), 3.19 (m, 1H, H-5), 3.23 (t, 1H, J = 8.8 Hz, J = 8.0 Hz, H-2), 3.31 (dd, 1H, J = 10.8 Hz, J = 
2.4 Hz, H-6), 3.34 – 3.39 (m, 2H, J = 8.8 Hz, J = 6.8 Hz, H-3 and H-4), 3.57 (dd, 1H, J = 10.8 Hz, J = 2.0 Hz, H-
6), 3.83 (bs, 2H, 2xOH), 4.64 (d, 1H, J = 7.2 Hz, H-1); 13C NMR (100 MHz, CDCl3) δ = -5.2 (CH3 TBDMS), -
3.9 (CH3 TBDMS), 5.0 (C-6), 17.8 (Cq tBu TBDMS), 25.6 (tBu TBDMS), 68.4 (C-2), 73.8 (C-3 or C-4), 74.1 
(C-4 or C-3), 74.9 (C-5), 97.0 (C-1); HRMS: [M+NH4]+ calcd for C12H28N4O4SiI 447.09190, found 447.09271. 
 
Tert-butyldimethylsilyl 2-azido-2,6-dideoxy-β-D-glucopyranoside (16): To a stirred 
solution of 3.7 g compound 15 (8.6 mmol) in 100 mL DMSO was added 1.9 g NaBH4 (50 
mmol, 5.8 equiv.). The reaction mixture was stirred for 2h, quenched by MeOH and 
























pressure. The crude oil was redissolved in 75 mL DMSO and 0.5 g NaBH4 (13.1 mmol, 1.5 equiv.) was added. 
Stirring was continued for 6h followed by addition of excess methanol. The mixture was diluted with 100 mL 
EtOAc and washed with 50 mL aq. 1M HCl solution and 50 mL sat. aq. NaHCO3 solution. The organic phase 
was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography using ethyl 
acetate/petroleum ether afforded 2.0 g of the title compound 16 (6.6 mmol, 76%) as a colorless oil. TLC: 70% 
EtOAc/PE; [α]D22: +35° (c = 2.8 CHCl3); IR (neat, cm-1): 686, 779, 833, 1010, 1064, 1180, 1249, 2106; 1H NMR 
(400 MHz, CDCl3) δ = 0.14 (s, 6H, 2xCH3 TBDMS), 0.93 (s, 9H, tBu TBDMS), 1.32 (d, 1H, J = 6.1 Hz, H-6), 
2.71 (bs, 2H, 2xOH), 3.22 – 3.34 (m, 4H, H-2, H-3, H-4, H-5), 4.56 (d, 1H, J = 7.0 Hz, H-1); 13C NMR (100 
MHz, CDCl3) δ = -5.22 (CH3 TBDMS), -4.32 (CH3 TBDMS), 17.6 (C-6), 17.9 (Cq tBu TBDMS), 25.6 (tBu 
TBDMS), 69.6, 71.6, 74.3, 74.7 (C-2, C-3, C-4 and C-5), 96.9 (C-1); HRMS: [M+NH4]+ calcd for C12H29O4N4Si 
321.19526, found 321.19549. 
 
Tert-butyldimethylsilyl 4-trichloracetamido-2-azido-2,4,6-trideoxy-β-D-galactopyranoside 
(4): Diol 16 (151 mg, 0.5 mmol) and 60 µL Cl3CCN (0.6 mmol, 1.2 equiv.) were dissolved 
in 4 mL DCM, stirred over MS3Ǻ and cooled to -13°C. Subsequently a catalytic amount 
of DBU was added. The reaction mixture was allowed to stir for 1h and cooled down to -30°C. Then 0.2 mL 
pyridine (2.5 mmol, 5 equiv.) and 99 µL triflic anhydride (0.6 mmol, 1.2 equiv.) were added. The reaction 
mixture was allowed to warm to room temperature and stirred for 30min. followed by the addition of 0.8 mL 
DiPEA (5 mmol, 10 equiv.). After 4h the reaction mixture was diluted with 100 mL EtOAc and successively 
washed with 1M HCl (50 mL) and sat. aq. NaHCO3 (50 mL). The organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure. The crude dark red oil [oxazoline 17: TLC: 30% EtOAc/PE; ESI-MS: 
429.0 [M+Na]+; HRMS: [M+H]+ calcd for C14H23O3N4Cl3Si 429.06778, found 429.06811.] was suspended in 2.5 
mL MeOH and Amberlite IR120 H+-resin was added until pH = 5. Stirring was continued for 15min. before the 
reaction mixture was filtered and concentrated under reduced pressure. Flash column chromatography using 
ethyl acetate/petroleum ether afforded 84 mg (0.19 mmol, 38% over 4 steps) compound 4 as a yellow oil. TLC: 
30% EtOAc/PE; [α]D22: -11° (c = 0.4 CHCl3); IR (neat, cm-1): 678, 779, 825, 1049, 1110, 1180, 1257, 1512, 
1712, 2113; 1H NMR (400 MHz, CDCl3) δ = 0.16 (s, 6H, 2xCH3 TBDMS), 0.96 (s, 9H, tBu TBDMS), 1.24 (d, 
3H, J = 6.4 Hz, C-6), 3.16 (bs, 1H, OH-3), 3.18 (dd, 1H, J = 10.6 Hz, J = 7.6 Hz, H-2), 3.72 (dd, 1H, J = 10.4 
Hz, J = 4.4 Hz, H-3), 3.77 (dq, 1H, J = 7.2 Hz, J = 6.4 Hz, J = 1.2 Hz, H-5), 4.23 (ddd, 1H, J = 9.4 Hz, J = 4.4 
Hz, J = 1.2 Hz, H-4), 4.53 (d, 1H, J = 8.0 Hz, H-1), 6.89 (d, 1H, J = 9.2 Hz, NH-4); 13C NMR (100 MHz, 
CDCl3) δ = -5.1 (CH3 TBDMS), -4.4 (CH3 TBDMS), 16.6 (C-6), 17.9 (Cq tBu TBDMS), 25.5 (tBu TBDMS), 
55.0 (C-4), 66.5 (C-2), 69.3 (C-5), 71.4 (C-3), 92.4 (Cq CCl3), 97.4 (C-1), 163.5 (C=O TCA); HRMS: [M+H]+ 




(18): A solution of 314 mg lactone 3 (0.7 mmol), 202 mg diphenylsulfoxide 
(1.0 mmol, 1.4 equiv.) and 521 mg tri-tert-butylpyrimidine (2.1 mmol, 3 
equiv.) in 10 mL DCM was stirred over activated MS3Å for 30min. The mixture was cooled to -60°C before 166 
µL triflic acid anhydride (1.0 mmol, 1.4 equiv.) was added. The mixture was allowed to warm to -50°C in 15min 
followed by addition of 290 mg acceptor 4 (0.65 mmol, 0.9 equiv.) in 5 mL DCM. Stirring was continued and 
the reaction mixture was allowed to warm to -10°C. The reaction mixture was diluted with 50 mL EtOAc and 
washed with water (50 mL). The aqueous phase was extracted twice with EtOAc. The combined organic phase 
was dried (MgSO4), filtered and concentrated under reduced pressure. Flash chromatography (EtOAc/PE) and 






















15% EtOAc/PE; [α]D22: -10° (c = 1, CHCl3); IR (neat, cm-1): 1047, 1147, 1253, 1447, 1508, 1647, 1717, 1795, 
2112, 2857; 1H NMR (400 MHz, CDCl3) δ = 0.15 (s, 3H, CH3 TBDMS), 0.16 (s, 3H, CH3 TBDMS), 0.93 (s, 
9H, tBu TBDMS), 1.15 (d, 1H, J = 6.3 Hz, H-6), 3.22 (dd, 1H, J = 10.5 Hz, J = 7.7 Hz, H-2), 3.72 (q, J = 6.0 
Hz, H-5), 3.88 (dd, 1H, J = 10.5 Hz, J = 3.8 Hz, H-3), 4.15 (dd, 1H, J = 5.1 Hz, J = 2.2 Hz, H-2’), 4.22 (s, 1H, 
H-4’), 4.25 (d, 1H, J = 3.8 Hz. H-4), 4.40 (d, 1H, J = 11.6 Hz, CHHPh), 4.49 (d, 1H, J = 7.7 Hz, H-1), 4.54 (s, 
1H, H-5’), 4.55 (d, 1H, J = 11.9 Hz, CHHPh), 4.58 (d, 1H, J = 11.9 Hz, CHHPh), 4.71 (dd, 1H, J = 5.2 Hz, J = 
1.6 Hz, H-3’), 4.86 (d, 1H, J = 11.6 Hz, CHHPh), 5.14 (d, 1H, J = 2.2 Hz, H-1’), 6.82 (d, 1H, J = 9.1 Hz, NH-4), 
7.25 – 7.64 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = -5.1 (CH3 TBDMS), -4.5 (CH3 TBDMS), 16.8 
(C-6), 18.0 (Cq tBu TBDMS), 25.6 (tBu TBDMS), 51.4 (C-4), 64.5 (C-2), 68.8 (C-5), 71.5 (CH2 Bn), 72.3 (C-
4’), 74.8 (CH2 Bn), 75.4 (C-2’), 75.6 (C-5’), 76.5 (C-3), 80.3 (C-3’), 92.5 (Cq CCl3), 95.7 (C-1’), 97.2 (C-1), 
127.4 – 131.0 (CH Arom), 136.7 (Cq Bn), 137.9 (Cq Bn), 171.9 (C=O); 13C-GATED NMR (100 MHz, CDCl3) δ 
= 95.7 (J = 157 Hz, C-1’), 97.2 (J = 156Hz, C-1); ESI-MS: 785.2 [M+H]+. 
 
2-Azido-3-O-(2,4-di-O-benzyl-α-D-galactopyranosylurono-6,3-lactone)-4-trichlor-
acetamido-2,4,6-trideoxy-D-galactopyranose (19): To a stirred solution of 253 mg 
compound 18 in 3 mL THF was added 0.09 mL NEt3·3HF (0.6 mmol, 2 equiv.). 
After TLC-analysis indicated complete conversion of starting material the reaction 
mixture was directly applied on a silica column. Flash chromatography using ethyl acetate/petroleum ether 
afforded 195 mg of the title compound 19 (0.29 mmol, 99%) as a colorless oil. TLC: 35% EtOAc/PE; IR (neat, 
cm-1): 696, 729, 817, 906, 1028, 1056, 1109, 1163, 1269, 1508, 1714, 1791, 2113, 2905; α-anomer: 1H NMR 
(400 MHz, CDCl3) δ = 1.17 (d, 1H, J = 6.3 Hz, H-6), 3.26 (bs 1H, OH-1), 3.41 (dd, 1H, J = 10.6 Hz, J = 3.7 Hz, 
H-2), 4.16 (dd, 1H, J = 5.2 Hz, J = 2.2 Hz, H-2’), 4.23 (s, 1H, H-4’), 4.33 (dd, 1H, J = 8.9 Hz, J = 3.0 Hz, H-4), 
4.40 (d, 1H, J = 11.8 Hz, CHHPh), 4.42 (d, 1H, J = 11.9 Hz, CHHPh), 4.46 (dd, 1H, J = 5.2 Hz, J = 3.6 Hz, H-
3’), 4.48 (q, 1H, J = 6.4 Hz, H-5), 4.49 (s, 1H, H-5’), 4.68 (dd, 1H, J = 5.2 Hz, J = 1.7 Hz, H-3’), 4.86 (d, 1H, J 
= 11.8 Hz, CHHPh), 4.87 (d, 1H, J = 11.9 Hz, CHHPh), 5.17 (d, 1H, J = 2.2 Hz, H-1’), 5.31 (d, 1H, J = 3.6 Hz, 
H-1), 6.79 (d, 1H, J = 9.2 Hz, NH-4), 7.25 – 7.35 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 16.6 (C-
6), 52.4 (C-4), 59.2 (C-2), 64.2 (C-5), 71.5 (CH2 Bn), 72.2 (C-4’), 74.0 (C-3), 74.8 (CH2 Bn), 75.1 (C-2’), 75.6 
(C-5’), 80.3 (C-3’), 92.0 (C-1), 92.6 (Cq CCl3), 95.7 (C-1’), 127.4 – 128.5 (CH Arom), 137.8 (Cq Bn), 137.9 (Cq 
Bn), 162.7 (C=O TCA), 171.9 (C=O lactone); 13C GATED NMR (100 MHz, CDCl3): δ = 92.0 (J = 172 Hz, C-
1), 95.7 (J = 161 Hz, H-1’); β-anomer: 1H NMR (400 MHz, CDCl3) δ = 1.28 (d, 1H, J = 6.3 Hz, H-6), 3.32 (dd, 
1H, J = 10.4 Hz, J = 8.1 Hz, H-2), 3.78 (q, 1H, J = 6.4 Hz, H-5), 4.00 (dd, 1H, J = 10.3 Hz, J = 3.8 Hz. H-3), 
4.01 (bs, 1H, OH-1), 4.16 (dd, 1H, J = 5.2 Hz, J = 2.2 Hz, H-2’), 4.23 (s, 1H, H-4’), 4.27 (dd, 1H, J = 9.1 Hz, J = 
3.5 Hz, H-4), 4.51 (s, 1H, H-5’), 4.56 (s, 4H, 2xCH2 Bn), 4.59 (d, 1H, J = 8.0 Hz, H-1), 4.68 (dd, 1H, J = 5.2 Hz, 
J = 1.7 Hz, H-3’), 5.14 (d, 1H, J = 2.2 Hz, H-1’), 6.86 (d, 1H, J = 9.2 Hz, NH-4), 7.25 – 7.35 (m, 10H, H Arom); 
13C NMR (100 MHz, CDCl3) δ = 16.7 (C-6), 51.4 (C-4), 63.0 (C-2), 69.0 (C-5), 71.5 (CH2 Bn), 72.3 (C-4’), 74.8 
(CH2 Bn), 75.2 (C-2’), 75.7 (C-5’), 77.3 (C-3), 80.4 (C-3’), 92.5 (Cq CCl3), 95.8 (C-1’), 96.2 (C-1), 127.4 – 
128.5 (CH Arom), 136.7 (2xCq Bn), 162.8 (C=O TCA), 172.0 (C=O lactone); 13C GATED NMR (100 MHz, 
CDCl3): δ = 95.8 (J = 161 Hz, C-1’), 96.2 (J = 159 Hz, H-1); HRMS: [M+Na]+ calcd for C28H29O9N4Cl3Na 



































2,4,6-trideoxy-D-galactopyranosyl]-β-D-galactopyranoside uronate 2: A solution of 120 mg compound (19) (0.18 
mmol), 91 mg diphenylsulfoxide (0.45 mmol, 2.5 equiv.) and 52 mg tri-tert-butylpyrimidine (0.21 mmol, 1.2 
equiv.) in 5 mL DCM was stirred over 100 mg activated MS3Å for 30min. The mixture was cooled to -60°C 
before 35 µL triflic acid anhydride (0.21 mmol, 1.2 eq) was added. The mixture was allowed to warm to -40°C 
in 1h followed by addition of 121 mg acceptor 5 (0.3 mmol, 1.7 equiv,) in 1 mL DCM. Stirring was continued 
and the reaction mixture was allowed to warm to 0°C. The reaction mixture was then treated with 1 mL pyridine 
and 0.5 mL Ac2O for 10h followed by addition of 2 mL MeOH. The reaction mixture was diluted with EtOAc 
and washed subsequently with 2M HCl and sat. NaHCO3 solution. Short filtration over a plug of silica gel 
afforded the intermediate lactone 20 which was dissolved in MeOH and treated with 2 µL H2SO4 for 12h. The 
reaction mixture was neutralized upon addition of Et3N followed by concentration under reduced pressure. Flash 
chromatography (30% EtOAc/hexane) and removal of the eluent afforded the 95 mg of the title compound 2 (0.1 
mmol, 58%) as a colorless oil. TLC: 40% EtOAc/PE; [α]D22: +64° (c = 0.6, CHCl3); IR (neat, cm-1): 696, 729, 
817, 906, 1028, 1056, 1109, 1163, 1269, 1508, 1714, 1791, 2113, 2905; 1H NMR (500 MHz, CDCl3) δ = 0.91 
(d, 1H, J = 6.5 Hz, H-6’), 1.95 (d, 1H, J = 4.0 Hz, OH-3’’), 3.38 – 3.42 (m, 2H, J = 4.0 Hz, J = 3.0 Hz, H-3 and 
H-2’), 3.58 (s, 3H, CH3 OMe), 3.62 (t, 1H, J = 9.5 Hz, H-2), 3.71 (s, 3H, CH3 COOMe), 3.81 (s, 3H, CH3 
COOMe), 3.90 (dd, 1H, J = 10.0 Hz, J = 3.5 Hz, H-2’’), 3.96 (s, 1H, H-5), 4.15 – 4.20 (m, 2H, H-3’ and H-3’’), 
4.21 (s, 1H, J = 8.0 Hz, H-1), 4.27 (s, 1H, H-4’’), 4.36 (s, 1H, H-4), 4.49 (d, 1H, J = 12.5 Hz, CHHPh), 4.50 (s, 
1H, H-5’), 4.51 (s, 1H, H-4’), 4.54 (d, 1H, J = 11.5 Hz, CHHPh), 4.58 (s, 1H, H-5’’), 4.70 (d, 1H, J = 11.5 Hz, 
CHHPh), 4.74 (d, 1H, J = 11.0 Hz, CHHPh), 4.76 (s, 1H, CH2 Bn), 4.85 (d, 1H, J = 13.0 Hz, CHHPh), 4.90 (d, 
1H, J = 11.0 Hz, CHHPh), 5.05 (d, 1H, J = 3.5 Hz, H-1’), 5.61 (d, 1H, J = 2.5 Hz, H-1’’), 6.70 (d, 1H, J = 10.0 
Hz, NH-4’), 7.16 – 7.46 (m, 20H, H Arom); 13C NMR (150 MHz, CDCl3) δ = 16.1 (C-6’), 51.4 (C-4’), 52.2 
(CH3 COOMe), 52.6 (CH3 COOMe), 57.5 CH3 OMe), 60.1 (C-2’), 65.6 (C-5’), 69.2 (C-3’’), 70.1 (C-3’), 70.9 
(C-5’’), 72.7 (CH2 Bn), 73.4 (CH2 Bn and C-5), 74.6 (C-2’’), 74.9 (CH2 Bn), 75.2 (CH2 Bn), 76.2 (C-4), 77.8 (C-
4’’), 78.1 (C-2), 78.8 (C-3), 92.7 (Cq CCl3), 92.9 (C-1’’), 97.1 (C-1’), 105.1 (C-1), 127.6 – 131.0 (CH Arom), 
137.9 (Cq Bn), 138.0 (Cq Bn), 138.2 (Cq Bn), 138.3 (Cq Bn), 162.6 (C=O TCA), 168.4 (C=O COOMe), 168.7 
(C=O COOMe); 13C GATED NMR (150 MHz, CDCl3): δ = 92.9 (J = 171 Hz, C-1’’), 97.1 (J = 168 Hz, C-1’), 
105.1 (J = 159 Hz, C-1); HRMS: [M+H]+ calcd for C51H58O16N4Cl3 1086.28351, found 1087.29438. 
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Abstract: A synthetic study towards the protected tetrasaccharide repeating unit of zwitterionic 
polysaccharide PSA1 using 1-thio, 1-seleno and 1-hydroxyl functionalized donor glycosides is 








Zwitterionic polysaccharide A1 (PSA1), isolated from capsules of the anaerobic bacterium 
Bacteriodes fragilis, is thought to be the key pathogenic substance responsible for the 
development of intraabdominal sepsis.2,3 In contrast to what is found for the majority of 
pathogenic polysaccharides,4 the immune response elicited by PSA1 is mediated by T-
lymphocytes.5 This unusual immunologic property of PSA1 is likely caused by its 
zwitterionic character. Neutralization of either the positively charged amino groups or the 
negatively charged carboxyl groups resulted in a strongly reduced biological activity as 
compared to the unmodified polysaccharide construct.6,7 The repeating unit of PSA1 (1) is 
depicted in Figure 1. The positive charge is situated at the amino group of the rare 2-
acetamido-4-amino fucose moiety and the negative charge resides in the carboxylate of the 







Retrosynthetic analysis indicates that the protected tetrasaccharide repeating unit 2 can be 
assembled from protected monosaccharides 3-8 following the sequence of glycosylation 
events depicted in Figure 1. The lengthy synthetic route to suitably protected 2,4-diamino 
2,4,6-trideoxygalactose building blocks 7 or 8 dictates that this residue is best introduced at a 
late stage (i.e. the third glycosylation in Figure 1). The construction of the protected 
trisaccharide (ABC) that follows from this reasoning was investigated using orthogonal and 
chemoselective glycosylation strategies in combination with Ph2SO/Tf2O as activator system.8 
The orthogonal strategy9 required the availability of furanoside 3,10 1-seleno galactosazide 411 
and terminal pyruvate residue 6, while for the chemoselective strategy12 the availability of 












































































4: R = α-SePh
5: R = α/β-OH
7: R1 = β-SPh, R2 = Cbz






Results and Discussion 
 
Pyruvate derivative 6 was synthesized as depicted in Scheme 1. Acidolysis of the 4,6-O-
benzylidene in known thiogalactopyranoside 914 gave diol 10. The pyruvate ketal was 
introduced according to the procedure developed by Ziegler and coworkers.15 Treatment of 10 
with equimolar amounts of methyl pyruvate and borontrifluoride diethyletherate (BF3·OEt2) 
in acetonitrile gave pyruvated galactopyranoside 11. Conclusive evidence for the predicted 
(R)-stereochemistry at the pyruvate ketal came from the X-ray structure of 11 (Scheme 1). 
The iso-propyl group was installed at the anomeric centre via a Ph2SO/Tf2O-mediated 
glycosylation to give 12. Although the use of tri-tert-butylpyrimidine (TTBP)16 in this 
condensation was omitted to prevent ortho-ester formation, no deterioration of the putative 
acid labile pyruvate acetal was observed. In the last step, hydrogenolysis of the C3 benzyl 



























12: R = Bn








        
Reagents and Conditions: (a) TsOH, MeOH, 97% (b) methyl pyruvate, BF3·OEt2, ACN, 74% (c) Ph2SO, Tf2O,   
-60°C then iso-propanol, 77% (d) H2, Pd/C, MeOH, 81%.  
 
The synthesis of trisaccharide 15 was investigated employing first an orthogonal 
glycosylation approach, in which a hemiacetal donor is condensed with a 1-seleno acceptor 
(Scheme 2A).9 Pre-activation of galactofuranoside 310 using the Ph2SO/Tf2O17,18 reagent 
combination at -40°C and subsequent addition of 1.5 equivalents of partially protected 1-
selenogalactoside 4 afforded β-linked digalactoside 13 in a yield of 56%.9 Although the 
anomeric seleno-function was stable according to TLC-analysis, the yield of this condensation 
could not be further improved. In the next glycosylation event, 1-selenodisaccharide 13 was 
successfully activated with the Ph2SO/Tf2O reagent combination. However, addition of 
acceptor 6 did not afford the expected trisaccharide 15. The same outcome was observed 
employing the BSP/Tf2O activator system.19 Previous experiences have shown that 
NIS/TMSOTf is a useful alternative when sulfonium ion-mediated glycosidation of 
thioglycosides is unproductive.20 Indeed, when a mixture of disaccharide 13 and acceptor 6 
was treated with the NIS/TMSOTf 21 in DCM at 0°C trisaccharide 15 was obtained in 65% 
yield as the single stereoisomer.22 Most likely, the use of only a catalytic amount of TMSOTf 
is at the basis of this favorable result.20  
With the objective to assemble trimer 15 via a one-pot glycosylation procedure, the 
chemoselective dehydrative glycosylation strategy (Scheme 2A) was investigated.12 Pre-
activation of 1-hydroxyl donor 3 with Ph2SO/Tf2O for 1h at -40°C was followed by addition 
of a solution of diol 5 in DCM/1,4-dioxane23 (10/1) to give, upon warming of the reaction 
mixture, disaccharide 14 in 60% yield. Analogously, Ph2SO/Tf2O-mediated dehydrative 
coupling of dimer 14 with acceptor 6 afforded target trisaccharide 15 in 52% yield. Next, 
attention was focused on adapting these results in a one-pot iterative dehydrative 
glycosylation strategy (Scheme 2B). Pre-activation of donor 3 and addition of acceptor 5 
X-ray crystal structure of 







afforded hemiacetal donor 14 with concomitant regeneration of Ph2SO. The reaction mixture 
was warmed to room temperature, kept overnight and then cooled down to -60°C. Activation 
of the newly formed hemiacetal disaccharide 14 was accomplished with the addition of a 
fresh amount of Tf2O and stirring was continued for 1h at -40°C. Addition of 1.5 equivalent 
of acceptor 6 and TTBP followed by overnight warming to room temperature produced 
trisaccharide 15 in 62% yield. Removal of all the protective groups in 15 was accomplished 
by: 1) conversion of the azide functionality into the acetamido group, 2) acidic cleavage of the 
4,6-O-benzylidene acetal, and 3) alkaline hydrolysis of all ester functions gave unprotected 










































































Reagents and conditions: (a) 3, Ph2SO, Tf2O, TTBP, -40°C, DCM then 4, 56% (b) 3, Ph2SO, Tf2O, TTBP,  
-40°C, DCM/dioxane (10/1) then 5, 60% (c) 13, 6, NIS, TMSOTf, DCM, 65% (d) 14, Ph2SO, Tf2O, TTBP,  
-40°C, DCM then 6, 52% (e) 1) 1M Me3P in toluene, THF/H2O (4/1), 2) Ac2O, pyridine, 3) TsOH, MeOH, 4) 
KOH, THF/H2O, 50% (over 4 steps). 
 
Now the stage was set to study the construction of the fully protected tetrameric repeating 
unit. First, the glycosylation of trisaccharide 26 with donor 7 was investigated (Scheme 4). 
Synthesis of compound 7 started from known key intermediate 17,24 which was obtained after 
a lengthy route from commercially available glucosamine hydrochloride (Scheme 3.).25 
Following a classical sequence of reactions, C6 de-oxygenated derivative 20 was obtained. 
First, cleavage of the benzylidene function (18) followed by regioselective tosylation and 







Zn/AcOH gave quinovosamine derivative 20 in good overall yield. Inversion at OH4 was 
accomplished by first triflation under standard conditions followed by treatment with sodium 
azide giving orthogonally functionalized 21 in 88%. The last part of the synthesis consisted of 
amine protective group interchanges in order to introduce an azide at the C2 position, which 
should ensure α-selectivity during glycosylation. The 3-O-acetyl group was first exchanged 
for a 3-O-tert-butyldimethylsilyl group (22) preventing an intra-molecular aza-Wittig reaction 
during azide reduction. Treatment of compound 22 with trimethylphosphine (Me3P) in a 
THF/water mixture and subsequent re-protection of the free amine as a Cbz-group gave 
compound 23 in 94% yield. One-pot removal of the N-phthaloyl protection using 
ethylenediamine and diazotransfer on the liberated amine function afforded compound 24 in 
84% yield. Exchange of the acid labile C3 silyl protection for an acetyl delivered target 

















21: R = Ac
22: R = TBS
24: R = TBS





19: R = I

















Reagents and conditions: (a) 80% AcOH, H2O, 80°C, 95% (b) 1) TsCl, pyridine, 2) NaI, 2-butanone, reflux, 
88% (over 2 steps) (c) Zn, AcOH, DCM, 73% (d) 1) Tf2O, pyridine, 0°C, 2) NaN3, DMF, 88% (e) 1) KOtBu, 
MeOH, 2) TBDMSCl, imidazole, 81% (f) 1) 1M Me3P in toluene, toluene/H2O (100/5), 2) CbzOSu, Et3N, DCM, 
94% (over 2 steps) (g) 1) (CH2NH2)2, n-BuOH, 2) TfN3, K2CO3, CuSO4, DCM/H2O/MeOH, 84% (over 2 steps) 
(h) 1) TBAF, THF, 2) Ac2O, pyridine, 90% (over 2 steps). 
 
Compound 26 was obtained after reductive opening of the benzylidene functionality in 
compound 15 using the triethylsilane/triflic acid reagent combination (Scheme 4).26 Although 
activation of thio donor 7 with Ph2SO/Tf2O proceeded smoothly at -60°C, addition of 
trisaccharide acceptor 17 did not lead to a productive coupling. Changing the activator to the 
NIS/TMSOTf system was also unsuccessful because donor 7 could not be activated under 
these conditions. Next, attention turned to Gin’s dehydrative glycosylation procedure using 
donor 8 obtained in a straightforward manner from compound 3027 (Scheme 4). Activation of 
hemiacetal donor 8 using the Ph2SO/Tf2O reagent combination and addition of trisaccharide 
17 afforded tetrasaccharide 2 in 17% yield. Trisaccharide 17 was recovered in 53%, whereas 




























































7: R1=β-SPh, R2=Ac, R3=Cbz
25: R1=β-OTBS, R2=H, R3=TCA
8: R1=α/β-OH, R2=Ac, R3=TCA  
Reagents and conditions: (a) 1) Ac2O, pyridine, 2) TBAF, AcOH, THF, 77% (over 2 steps) (b) Et3SiH, TfOH, 





This Chapter describes the synthesis of the protected tetrasaccharide corresponding to the 
repeating unit of the zwitterionic polysaccharide PSA1. Current efforts are directed to 
overcoming the poor yield in the final glycosylation step. Possibly, the difficulty in 
introducing the 2,4-diaminofucose at this stage results from a combination of the steric bias in 
the trimeric acceptor 26 and the intrinsic low reactivity of the protected 2,4-diaminofucose 
donors 7 and 8. On the positive side, comparative studies towards the construction of the 
protected trisaccharide 15 demonstrated the effectiveness of the dehydrative glycosylation 
procedure and led to the development of a one-pot iterative protocol that is characterized by 




General Procedures: 1H and 13C NMR spectra were recorded on a Jeol JNM-FX-200 (200/50.1 MHz), a Brüker 
AV-400 (400/100 MHz) and a Brüker DMX-600 (600/150 MHz) spectrometer. Chemical shifts are given in ppm 
(δ) relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. All given 13C spectra 
are proton decoupled. Mass spectra were recorded with PE/SCIEX API 165 with electronspray interface and Q-
Star Applied Biosystems Q-TOF (TOF-section). Optical rotations were measured on a Propol automatic 
polarimeter. IR-spectra were recorded on a Shimadzu FTIR-8300. Melting points were measured on a Büchi 
Schmelzpunktbestimmungsapparat nach dr. Tottoli (+ pat 320.388) and were uncorrected. Traces of water in the 
donor and acceptor glycosides, diphenylsulfoxide, benzenesulfinylpiperidine and TTBP where removed by co-
evaporation with toluene. Benzenesulfinylpiperidine19 and TTBP16 were synthesized as described by Crich et al. 
Dichloromethane (DCM, Baker p.a.) was boiled under reflux over P2O5 for 2h and distilled immediately prior to 
use. Trifluoromethanesulfonic anhydride was distilled from P2O5. Molecular sieves 3Å were flame dried before 
use. Solvents used for flash chromatography and TLC were of technical grade and distilled before use. Flash 







fertigfolien (Schleicher & Schuell, F1500, LS254) with detection by UV-absorption (254 nm) where applicable 
and by spraying with 20% sulfuric acid in ethanol followed by charring at ~150°C or by spraying with a solution 
of (NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10g/L) in 10% sulfuric acid in water followed by 
charring at ~150°C.  
 
Phenyl 2-O-benzoyl-3-O-benzyl-1-thio-β-D-galactopyranoside (10): Known compound 928 
(100 mg, 0.18 mmol) was suspended in 5 mL MeOH and cat. TsOH was added. The 
reaction mixture was stirred until TLC indicated complete conversion of starting material 
into a lower running product. The reaction mixture was neutralized by the addition of 0.5 mL NEt3 and 
concentrated under reduced pressure. Flash column chromatography using ethyl acetate/petroleum ether afforded 
81 mg of the title compound 15 (0.18 mmol, quant.) as a colorless oil. TLC: 30% EtOAc/PE; [α]D22: +41° (c = 1, 
CHCl3); IR (neat, cm-1): 694, 995, 1056, 1257, 1720, 2923; 1H NMR (200 MHz, CDCl3) δ = 3.16 (bs, 2H, OH-4, 
OH-6), 3.67 – 3.73 (m, 2H, H-3, H-5), 3.84 – 4.06 (m, 2H, H-6), 4.22 (d, 1H, J = 2.6 Hz, H-4), 4.65 (d, 1H, J = 
12.0 Hz, CHHPh), 4.71 (d, 1H, J = 12.0 Hz, CHHPh), 4.78 (d, 1H, J = 10.2 Hz, H-1), 5.56 (t, 1H, J = 9.5 Hz, H-
2), 7.15 – 8.05 (m, 15H, H Arom); 13C NMR (50 MHz, CDCl3) δ = 62.0 (C-6), 66.3, 69.6, 78.4, 79.2 (C-2, C-3, 
C-4, C-5) 71.1 (CH2 Bn), 86.5 (C-1) 127.6 – 133.1 (CH Arom), 134.1 (Cq, SPh), 136.9 (Cq Bn) 165.3 (C=O Bz); 
HRMS: [M+Na]+ calcd for C26H26O6SNa 489.13423, found 489.13465. 
 
Phenyl 2-O-benzoyl-3-O-benzyl-4,6-O-[1-(R)-(methoxycarbonyl)-ethylidene]-1-thio-β-
D-galactopyranoside (11): To a solution of 4.66 g compound 10 (10 mmol) in 50 mL 
ACN were added 1.84 mL methylpyruvate (20 mmol, 2.0 equiv.) and 2.50 mL BF3·Et2O 
(20 mmol, 2.0 equiv.). The reaction mixture was stirred for 3h at ambient temperature 
under Ar-atmosphere, followed by the addition of 1 mL Et3N and 250 mL EtOAc. 
Subsequently, the mixture was washed with sat. aq. NaHCO3-solution (3x150 mL). The organic phase was dried 
(MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography using ethyl 
acetate/petroleum ether afforded 3.43 g of compound 11 (7.4 mmol, 74%) as a yellow oil. To determine the 
crystal structure, the product 11 was recrystallized from boiling ethanol. TLC: 30% EtOAc/PE; [α]D22: +1° (c = 
1, CHCl3); IR (neat, cm-1): 694, 748, 979, 1072, 1203, 1257, 1458, 1519, 1712; 1H NMR (400 MHz, CDCl3) δ = 
1.58 (s, 3H, CH3 Me), 3.39 (s, 1H, H-5), 3.67 (dd, 1H, J = 9.2 Hz, J = 3.2 Hz, H-3), 3.81 (s, 3H, Me COOMe), 
3.92 (d, 1H, J = 12.8 Hz, H-6), 4.09 (d, 1H, J = 12.8 Hz, H-6), 4.37 (s, 1H, H-4), 4.55 (d, 1H, J = 12.8 Hz, 
CHHPh), 4.75 (d, 2H, J = 11.6 Hz, H-1, CHHPh), 5.53 (t, 1H, J = 9.6 Hz, H-2), 7.13 – 8.05 (m, 15H, H Arom); 
13C NMR (100 MHz, CDCl3) δ = 25.4 (CH3 Me), 52.2 (CH3 COOMe), 65.3 (C-6), 67.6 (C-4), 68.5 (C-2), 68.7 
(C-3), 69.4 (CH2 Bn), 76.9 (C-5), 85.4 (C-1), 98.3 (Cq pyruvate), 127.0 – 132.9 (CH Arom), 129.9 (Cq SPh), 
131.7 (Cq Bz), 137.2 (Cq Bn), 164.7 (C=O COOMe), 170.2 (C=O Bz); HRMS: [M+Na]+ calcd for C30H30O8SNa 
573.15536, found 573.15443. 
 
Isopropyl 2-O-benzoyl-3-O-benzyl-4,6-O-[1-(R)-(methoxycarbonyl)-ethylidene]-1-
thio-β-D-galactopyranoside (12): A solution of 2.20 g donor 11 (1 equiv.), 1.2 g 
Ph2SO (5.8 mmol, 1.5 equiv.) in 60 mL DCM was stirred over activated MS3Å for 
30min. The mixture was cooled to -60°C before 0.9 mL triflic acid anhydride (5.4 
mmol, 1.4 equiv.) was added. The mixture was allowed to warm to -40°C over 15min 
at which time 3.82 mL iso-propanol (50 mmol, 13 equiv.) was added. Stirring was continued and the reaction 
mixture was allowed to warm to -20°C. The reaction mixture was neutralized with 2.5 mL NEt3, diluted with 
EtOAc and washed with water. The aqueous phase was extracted twice with 100 mL EtOAc. The combined 




























(EtOAc/PE) and removal of the eluent afforded 1.54 g of the title compound 12 (3.1 mmol, 77%) as a white 
solid. TLC: 20% EtOAc/PE; [α]D22: +10° (c = 1, CHCl3); IR (neat, cm-1): 694, 748, 979, 1072, 1203, 1257, 1458, 
1519, 1712; 1H NMR (400 MHz, CDCl3) δ = 1.00 (d, 1H, J = 6.2 Hz, CH3 isoprop), 1.18 (d, 1H, J = 6.2 Hz, CH3 
isoprop), 1.67 (s, 3H, CH3 Me), 3.30 (s, 1H, H-5), 3.62 (dd, 1H, J = 10.0 Hz, J = 4.0 Hz, H-3), 3.86 (s, 3H, CH3 
COOMe), 3.89 (m, 1H, J = 6.2 Hz, CH isoprop), 3.97 (dd, 1H, J = 12.6 Hz, J = 1.6 Hz, H-6), 4.10 (dd, 1H, J = 
12.6 Hz, J = 1.6 Hz, H-6), 4.32 (d, 1H, J = 3.6 Hz, H-4), 4.54 (d, 1H, J = 8.0 Hz, H-1), 4.58 (d, 1H, J = 12.8 Hz, 
CHHPh), 4.80 (d, 1H, J = 12.8 Hz, CHHPh), 5.49 (dd, 1H, J = 10.0 Hz, J = 8.0 Hz, H-2), 7.18 – 8.05 (m, 10H, H 
Arom); 13C NMR (100 MHz, CDCl3) δ = 21.9 (CH3 isoprop), 23.2 (CH3 isoprop), 25.8 (CH3 Me), 52.5 (CH3 
COOMe), 65.5 (C-6), 65.7 (C-5), 67.8 (C-4), 69.5 (CH2 Bn), 70.8 (C-2), 72.2 (CH isoprop), 75.9 (C-3), 98.7 (Cq 
pyruvate) 99.9 (C-1), 127.5 – 132.7 (CH Arom), 130.4 (Cq Bz), 137.6 (Cq Bn), 165.0 (C=O COOMe), 170.7 
(C=O Bz); HRMS: [M+Na]+ calcd for C27H32O9Na 523.19385, found 523.19360. 
 
Isopropyl 2-O-benzoyl-4,6-O-[1-(R)-(methoxycarbonyl)-ethylidene]-1-thio-β-D-
galactopyranoside (6): To a solution of 3.09 g compound 12 (5.47 mmol) in 20 mL 
MeOH was added 0.61 g of Pd/C (10%). The mixture was stirred for 12h at ambient 
temperature under an atmosphere of H2 gas followed by filtration over Hyflo and 
concentration under reduced pressure. Flash column chromatography using ethyl 
acetate/petroleum ether afforded 1.65 g of compound 6 (4.0 mmol, 81%) as a white solid. TLC: 40% EtOAc/PE; 
[α]D22: +39° (c = 1, CHCl3); IR (neat, cm-1): 694, 748, 979, 1072, 1203, 1257, 1458, 1519, 1712; 1H NMR (400 
MHz, CDCl3) δ = 1.06 (d, 1H, J = 6.4 Hz, CH3 isoprop), 1.20 (d, 1H, J = 6.4 Hz, CH3 isoprop), 1.64 (s, 3H, CH3 
Me), 2.73 (bs, 1H, OH-3), 3.30 (d, 1H, J = 1.2 Hz, H-5), 3.82 (s, 3H, CH3 COOMe), 3.62 (dd, 1H, J = 10.0 Hz, J 
= 4.0 Hz, H-3), 3.89 (m, 1H, J = 6.2 Hz, CH isoprop), 3.97 (dd, 1H, J = 12.6 Hz, J = 1.6 Hz, H-6), 4.10 (dd, 1H, 
J = 12.6 Hz, J = 1.6 Hz, H-6), 4.32 (d, 1H, J = 3.6 Hz, H-4), 4.54 (d, 1H, J = 8.0 Hz, H-1), 4.58 (d, 1H, J = 12.8 
Hz, CHHPh), 4.80 (d, 1H, J = 12.8 Hz, CHHPh), 5.49 (dd, 1H, J = 10.0 Hz, J = 8.0 Hz, H-2), 7.18 – 8.05 (m, 
10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 21.9 (CH3 isoprop), 23.2 (CH3 isoprop), 25.8 (CH3 Me), 52.5 
(CH3 COOMe), 65.5 (C-6), 65.7 (C-5), 67.8 (C-4), 69.5 (CH2 Bn), 70.8 (C-2), 72.2 (CH isoprop), 75.9 (C-3), 
98.7 (Cq pyruvate) 99.9 (C-1), 127.5 – 132.7 (CH Arom), 130.4 (Cq Bz), 137.6 (Cq Bn), 165.0 (C=O COOMe), 
170.7 (C=O Bz); HRMS: [M+Na]+ calcd for C20H26O9Na 433.14690, found 433.14559. 
 
Phenyl 3-O-acetyl-2-phthalimido-2-deoxy-1-thio-β-D-glucopyranoside (18): Known 
compound 1724 (100 mg, 0.19 mmol) was suspended in 5 mL MeOH and cat. TsOH was 
added. The reaction mixture was stirred until TLC indicated complete conversion of starting 
material into a lower running product. The reaction mixture was neutralized by the addition of 0.5 mL NEt3 and 
concentrated under reduced pressure. Flash column chromatography using ethyl acetate/petroleum ether afforded 
83 mg of the title compound 18 (0.19 mmol, quant.) as a colorless oil. TLC: 20% EtOAc/PE; [α]D22: +20° (c = 1, 
CHCl3); IR (neat, cm-1): 709, 1110, 1257, 1380, 1712; 1H NMR (200 MHz, CDCl3) δ = 1.91 (s, 3H, CH3 Ac), 
2.23 (s, 1H, OH-6), 3.06 (s, 1H, OH-4), 3.66 – 4.01 (m, 4H, H-4, H-5, H-6, H-6’), 4.29 (t, 1H, J = 10.2 Hz, H-2), 
4.34 (d, 1H, J = 10.6 Hz, H-1), 5.68 (t, 1H, J = 8.8 Hz, H-3), 7.24 – 7.91 (m, 9H, H Arom); 13C NMR (50 MHz, 
CDCl3) δ = 20.6 (CH3 Ac), 53.7 (C-2), 62.3 (C-6), 69.6, 74.4, 79.6 (C-3, C-4, C-5), 83.0 (C-1), 123.6 – 134.2 
(CH Arom), 131.4 (Cq SPh), 167.1 (C=O NPhth), 167.9 (C=O NPhth), 171.2 (C=O Ac); HRMS: [M+Na]+ calcd 
for C22H21O7NSNa 466.09309, found 466.09249. 
 
Phenyl 3-O-acetyl-6-iodo-2-phthalimido-2,6-dideoxy-1-thio-β-D-glucopyranoside (19): A 
solution of 44.3 g compound 18 (100 mmol) in 500 mL anhydrous pyridine was cooled to 



























was stirred for 12h under Ar-atmosphere at 0˚C. The reaction was quenched by addition of ice cold MeOH. The 
mixture was diluted with 1 L EtOAc and washed twice with 400 mL 1M HCl solution and 400mL NaHCO3 (sat. 
aq.). The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The crude oil was 
dissolved in 500 mL 2-butanone and 21 g NaI (140 mmol, 1.4 equiv.) was added. The mixture was refluxed for 4 
days at 90˚C. The reaction mixture was cooled to ambient temperature, diluted with 1 L EtOAc and washed 
twice with 400 mL 1M Na2S2O3 and 300 mL H2O. The organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure. Flash column chromatography using ethyl acetate/petroleum ether yielded 
49.0 g compound 19 (88 mmol, 88%) as a yellow solid. TLC: 20% EtOAc/PE; IR (neat, cm-1): 709, 1110, 1257, 
1380, 1712; 1H NMR (200 MHz, CDCl3) δ = 1.89 (s, 3H, CH3 Ac), 3.03 (d, 1H, J = 5.4 Hz, OH-4), 3.39 – 3.69 
(m, 4H, H-4, H-5, 2xH-6), 4.27 (t, 1H, J = 10.2 Hz, H-2), 5.70 (t, 1H, J = 8.4 Hz, H-3), 5.79 (d, 1H, J = 10.6 Hz, 
H-1), 7.23 – 7.77 (m, 9H H Arom); 13C NMR (50 MHz, CDCl3) δ = 6.0 (C-6), 20.6 (CH3 Ac), 53.5, 73.6, 74.1, 
78.3, 82.6, 86.7 (C-1, C-2, C-3, C-4, C-5), 123.6 – 134.4 (CH Arom), 130.7 (Cq NPhth), 130.9 (Cq NPhth), 167.0 
(C=O Nphth), 167.8 (C=O NPhth), 171.3 (C=O Ac); HRMS: [M+Na]+ calcd for C22H20O6NISNa 575.99482, 
found 575.99487. 
 
Phenyl 3-O-acetyl-2-phthalimido-2,6-dideoxy-1-thio-β-D-glucopyranoside (20): To a 
solution of 49 g compound 19 (88 mmol) in 440 mL DCM and 43 mL AcOH (740 mmol, 
8.4 equiv.) was added 127 g Zn-powder (1936 mmol, 22 equiv.). The mixture was stirred 
for 6h at ambient temperature under Ar-atmosphere. The reaction mixture was filtered and concentrated under 
reduced pressure. Flash column chromatography using ethylacetate/petroleum ether afforded 27.4 g of 
compound 20 (64 mmol, 73%) as a white solid. TLC: 30% EtOAc/PE; [α]D22: +74° (c = 2.5, CHCl3); IR (neat, 
cm-1): 709, 1110, 1257, 1380, 1712; 1H NMR (200 MHz, CDCl3) δ = 1.43 (d, 3H, J = 6.2 Hz, C-6), 1.91 (s, 3H, 
CH3 Ac), 2.57 (s, 1H, OH-4), 3.42 (t, 1H, J = 9.2 Hz, H-4), 3.62 – 3.69 (m, 1H, H-5), 4.27 – 4.33 (m, 1H, H-2), 
5.60 (t, 1H, J = 9.6 Hz, H-3), 5.70 (d, 1H J = 10.8 Hz, H-1), 7.24 – 7.74 (m, 9H, H Arom); 13C NMR (50 MHz, 
CDCl3) δ = 17.8 (C-6), 20.4 (CH3 Ac), 53.9, 74.2, 76.2, 82.5 (C-1, C-2, C-3, C-4, C-5), 123.3 – 133.9 (CH 
Arom), 130.8 (Cq SPh or NPhth), 131.3 (Cq SPh or NPhth), 131.6 (Cq SPh or NPhth), 167.0 (C=O NPhth), 167.7 
(C=O NPhth), 171.1 (C=O Ac); HRMS: [M+Na]+ calcd for C22H21O6NSNa 450.09818, found 450.09792. 
 
Phenyl 3-O-acetyl-4-azido-2-phthalimido-2,4,6-trideoxy-1-thio-β-D-galactopyranoside (21): 
A solution of 27.4 g compound 20 (64 mmol) in 320 mL DCM and 25.8 mL pyridine (320 
mmol, 5 equiv.) was cooled to -78˚C. Then 15.9 mL Tf2O (96 mmol, 1.5 equiv.) was added. 
The reaction mixture was kept at -40°C for 2h and allowed to warm to room temperature over a period of 12h. 
The reaction was quenched by addition of 50 mL MeOH. The mixture was diluted with 800 mL Et2O and 
washed 4 times with 100 mL H2O, twice with 200 mL sat. CuSO4 and 200 mL brine. The organic phase was 
dried (MgSO4), filtered and concentrated under reduced pressure. Co-evaporation with toluene afforded the 
crude triflate intermediate as a colorless oil. The crude triflate was dissolved in 320 mL DMF, followed by the 
addition of 83.2 g NaN3 (1280 mmol, 20 equiv.) was added. The mixture was stirred at room temperature for 
1.5h. The mixture was diluted with 800 mL EtOAc and washed three times with 200 mL H2O. The organic phase 
was dried (MgSO4), filtered and concentrated under reduced pressure. Flash column chromatography using ethyl 
acetate/petroleum ether afforded 25.5 g compound 21 (56.3 mmol, 88%) as a white solid. TLC: 20% EtOAc/PE; 
[α]D22: -4° (c = 1, CHCl3); IR (neat, cm-1): 709, 864, 1049, 1126, 1272, 1380, 1581, 1705, 2113, 2931; 1H NMR 
(400 MHz, CDCl3) δ = 1.40 (d, 3H, J = 6.0 Hz, C-6), 1.95 (s, 3H, CH3 Ac), 3.91 – 3.96 (m, 1H, H-5), 3.97 (d, 
1H, J = 3.2 Hz, H-4), 4.62 (t, 1H, J = 10.8 Hz, H-2), 5.60 (d, 1H, J = 10.4 Hz, H-1), 5.83 (t, 1H, J = 6.8 Hz, H-
3), 7.23 – 7.90 (m, 9H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 17.8 (C-6), 20.3 (CH3 Ac), 50.0 (C-2), 63.5 

















(Cq NPhth), 167.0 (C=O NPhth), 168.0 (C=O NPhth), 169.94 (C=O Ac); HRMS: [M+NH4]+ calcd for 
C22H24O5N5S 470.14927, found 470.14810. 
 
Phenyl 4-azido-2-phthalimido-3-O-tert-butyldimethylsilyl-2,4,6-trideoxy-1-thio-β-D-
galactopyranoside (22): To a solution of 25.5 g compound 21 (56.3 mmol) in 300 mL 
MeOH was added Amberlite IR120 H+-resin. After 4 days stirring under reflux, the reaction 
mixture was filtered over Hyflo and concentrated under reduced pressure. The crude oil was dissolved in 250 mL 
DMF followed by the addition of 16.6 g TBDMSCl (110 mmol, 2.0 equiv.) and 7.48 g imidazole (110 mmol, 2.0 
equiv.). The mixture was stirred at ambient temperature for 4 days. The reaction was quenched by the addition of 
5 mL MeOH. The mixture was diluted with 500 mL EtOAc and washed with 250 mL 1M HCl and 250 mL sat. 
aq. NaHCO3. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. 
Crystallization from boiling ethyl acetate afforded 19.3 g of compound 22 (40 mmol, 66%) as white, amorphous 
crystals. TLC: 20% EtOAc/PE; [α]D22: +14° (c = 1.8, CHCl3); IR (neat, cm-1): 709, 864, 1049, 1126, 1272, 1380, 
1581, 1705, 2113, 2931; 1H NMR (200 MHz, CDCl3) δ = -0.25 (s, 3H, CH3 TBDMS), 0.00 (s, 3H, CH3 
TBDMS), 0.71 (s, 9H, tBu TBDMS), 1.38 (d, 3H, J = 6.2 Hz, C-6), 3.64 (d, 1H, J = 2.8 Hz, H-3), 3.80 – 3.89 
(m, 1H, H-5), 4.55 (t, 1H, J = 10.2 Hz, H-4), 4.71 (t, 1H, J = 10.2 Hz, H-2), 5.52 (d, 1H, J = 10.6 Hz, H-1), 7.20 
– 7.75 (m, 9H, H Arom); 13C NMR (50 MHz, CDCl3) δ = -4.8 (CH3 TBDMS), 17.4 (C-6), 18.0 (Cq tBu 
TBDMS), 25.2 (tBu TBDMS), 52.6 (C-4), 66.7, 71.5, 73.3, 83.6 (C-1, C-2, C-3, C-5), 123.0 – 128.7 (CH Arom), 
131.6 (Cq SPh), 132.0 (Cq NPhth), 132.6 (Cq NPhth), 167.3 (C=O, NPhth), 168.4 (C=O, NPhth); HRMS: 
[M+Na]+ calcd for C26H32O4N4SSiNa 547.18057, found 547.17974. 
 
Phenyl 4-(N-benzyloxycarbonyl)-amino-2-phthalimido-3-O-tert-butyldimethylsilyl-2,4,6-
trideoxy-1-thio-β-D-galactopyranoside (23): To a solution of 19.37 g compound 22 (40 
mmol) in 120 mL toluene was added 80 mL of 1M Me3P solution in toluene (80 mmol, 2.0 
equiv.) and 5 mL of H2O. The mixture was stirred overnight at ambient temperature. The mixture was 
concentrated under reduced pressure and traces of H2O where removed by co-evaporation with toluene. The 
crude oil was dissolved in 200 mL DCM and 14.9 g of N-(benzyloxycarbonyloxy)succinimide (60 mmol, 1.5 
equiv.) and 6.63 mL of NEt3 (50 mmol, 1.25 equiv.) were added. The mixture was stirred for 5h at ambient 
temperature. The reaction was quenched upon addition of 50 mL MeOH followed by concentration of the 
reaction mixture under reduced pressure. Flash column chromatography using ethyl acetate/petroleum ether 
afforded 22.8 g of compound 23 (35.2 mmol, 88%) as a white solid. TLC: 20% EtOAc/PE; [α]D22: +80° (c = 1, 
CHCl3); IR (neat, cm-1): 694, 864, 1018, 1103, 1242, 1380, 1527, 1689, 2090, 2947; 1H NMR (400 MHz, 
CDCl3) δ = -0.43 (s, 3H, CH3 TBDMS), 0.04 (s, 3H, CH3 TBDMS), 0.63 (s, 9H, tBu TBDMS), 1.28 (d, 3H, J = 
6 Hz, C-6), 3.89 (td, 1H, J = 6.4 Hz, H-5), 4.03 (t, 1H, J = 5.6 Hz, H-4), 4.11 (t, 1H, J = 10.4 Hz, H-2), 4.64 (t, 
1H, J = 5.2 Hz, H-3), 5.04 – 5.15 (m, 3H, CH2 and NH Cbz), 5.57 (d, 1H, J = 10.8 Hz, H-1), 7.22 – 7.86 (m, 9H 
H Arom); 13C NMR (100 MHz, CDCl3) δ = -5.6 (CH3 TBDMS), -4.8 (CH3 TBDMS), 17.3 (Cq tBu TBDMS), 
19.1 (C-6), 25.2 (tBu TBDMS), 53.8 (C-4), 55.7 (C-2), 66.8 (CH2 Cbz), 68.8, 74.5, 83,4 (C-1, C-3, C-5), 123.0 – 
134.3 (CH Arom), 131.5 (Cq NPhth), 131.7 (Cq NPhth), 132.4 (Cq SPh), 136.4 (Cq Cbz), 156.8 (C=O Cbz), 167.3 
(C=O NPhth), 168.4 (C=O NPhth); HRMS: [M+H]+ calcd for C34H41O6N2SSi 633.24491, found 633.24481. 
 
Phenyl 4-(N-benzyloxycarbonyl)-amino-2-azido-3-O-tert-butyldimethylsilyl-2,4,6-tri-deoxy-1-thio-β-D-
galactopyranoside (24): To a solution of 22.8 g compound 23 (35.2 mmol) in 800 mL n-
butanol was added 280 mL of ethylenediamine (4.2 mol, 120.0 equiv.). The mixture was 
heated overnight at 70˚C followed by concentration under reduced pressure. The crude oil 






















131 mL H2O followed by the addition of 7.2 g K2CO3 (72.7 mmol, 2 equiv.) and 55 mg CuSO4 (0.34 mmol, 
cat.). The reaction mixture was treated with a freshly prepared solution of triflyl azide in DCM [20.4 mL Tf2O 
(123 mmol) was added dropwise to a vigorously stirred biphasic mixture of 40 g NaN3 (615 mmol) in 154 mL 
H2O and 260 mL DCM at 0°C. The organic phase was separated and added to the reaction mixture mentioned 
above.] The mixture was stirred overnight at ambient temperature, diluted with 250 mL EtOAc and washed 
twice with 150 mL H2O The organic phase was dried (MgSO4), filtered and concentrated under reduced 
pressure. Flash column chromatography using ethyl acetate/petroleum ether afforded 22.8 g of compound 24 
(35.2 mmol, 88%) as a yellow oil. TLC: 20% EtOAc/PE; [α]D22: +1° (c = 1, CHCl3); IR (neat, cm-1): 694, 864, 
1018, 1103, 1242, 1380, 1527, 1689, 2090, 2947; 1H NMR (400 MHz, CDCl3) δ = 0.12 (s, 3H, CH3 TBDMS), 
0.15 (s, 3H, CH3 TBDMS), 0.87 (s, 9H, tBu TBDMS), 1.23 (d, 3H, J = 6.4 Hz, C-6), 3.07 (t, 1H, J = 9.6 Hz, H-
2), 3.58 – 3.63 (m, 2H, H-3, H-5), 3.89 (t, 1H, J = 6 Hz, H-4), 4.35 (d, 1H, J = 10.0 Hz, H-1), 4.73 (d, 1H, J = 
10.4 Hz, NH Cbz), 5.07 (s, 2H, CH2 Cbz), 7.25 – 7.57 (m, 10H, H Arom); 13C NMR (100 MHz, CDCl3) δ = -5.6 
(CH3 TBDMS),      -4.8 (CH3 TBDMS), 16.7 (C-6), 17.9 (Cq tBu TBDMS), 25.6 (tBu TBDMS), 55.3 (C-4), 64.3 
(C-2), 67.0 (CH2 Cbz), 74.0, 74.4, 86.6 (C-1, C-3, C-5), 127.6 – 133.1 (CH Arom), 131.9 (Cq SPh), 136.4 (Cq 
Cbz), 156.6 (C=O Cbz); HRMS: [M+H]+ calcd for C26H37O4N4SSi 529.22993, found 529.22874. 
 
Phenyl 3-O-acetyl-4-(N-benzyloxycarbonyl)-amino-2-azido-2,4,6-trideoxy-1-thio-β-D-
galactopyranoside (7): To a mixture of 22.8 g of compound 24 (35 mmol) was added 175 
mL MeOH and a catalytical amount of KOtBu. The mixture was stirred for 2h, neutralized 
by Amberlite IR120 H+-resin and filtered. The reaction mixture was concentrated under 
reduced pressure. The crude oil was dissolved in 130 mL pyridine and 45 mL Ac2O. The mixture was stirred for 
5h and quenched with MeOH. The solvents were removed under reduced pressure followed by flash column 
chromatography using ethyl acetate/petroleum ether affording 14.3 g of compound 7 (31.5 mmol, 90%) as a 
yellow oil. TLC: 20% EtOAc/PE; [α]D22: -22° (c = 1, CHCl3); IR (neat, cm-1): 1041, 1072, 1222, 1514, 1702, 
1747, 2111; 1H NMR (400 MHz, CDCl3) δ = 1.25 (d, 3H, J = 6.0 Hz, H-6), 1.98 (s, 3H, CH3 Ac), 3.45 (t, 1H, J 
= 10.4 Hz, H-2), 3.73 (m, 1H, J = 10.0 Hz, J = 6.0 Hz, H-5), 4.18 (dd, 1H, J = 10.0 Hz, J = 3.6 Hz, H-4), 4.48 (d, 
1H, J = 10.4 Hz, H-1), 4.83 (dd, 1H, J = 10.4 Hz, J = 3.6 Hz, H-3), 5.04 (d, 1H, J = 10.0 Hz, NH), 5.08 (d, 1H, J 
= 12.4 Hz, CHHPh), 5.16 (d, 1H, J = 12.4 Hz, CHHPh), 7.28 – 7.60 (m, 10H, H Arom); 13C NMR (100 MHz, 
CDCl3) δ = 16.6 (C-6), 20.4 (CH3 Ac), 51.8 (C-4), 59.5 (C-2), 66.7 (CH2 Cbz), 73.5 (C-5), 74.4 (C-3), 86.4 (C-
1), 127.6 – 136.2 (CH Arom), 131.2 (Cq SPh), 136.2 (Cq Cbz), 156.3 (C=O Cbz), 169.8 (C=O Ac); HRMS: 
[M+H]+ calcd for C22H25O5N4S 457.15402, found 457.15353. 
 
2-Azido-4,6-O-benzylidene-3-O-(2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl)-
2-deoxy-α/β-D-galactopyranoside (14): A solution of 117 mg donor 3 (0.2 
mmol), 113 mg Ph2SO (0.56 mmol, 2.8 equiv.) and 150 mg TTBP (0.6 mmol, 3 
equiv.) in 7 mL DCM was stirred over 100 mg activated MS3Å for 30min. The 
mixture was cooled to -60°C before 46 µL triflic acid anhydride (0.28 mmol, 1.4 
equiv.) was added. The mixture was allowed to warm to -40°C in 1h followed by 
addition of 59 mg acceptor 5 (0.2 mmol, 1 equiv.) in 1 mL DCM. Stirring was continued and the reaction 
mixture was allowed to warm to room temperature over a period of 16h. The reaction mixture was diluted with 
25 mL EtOAc and washed with 15 mL water. The organic phase was dried (MgSO4), filtered and concentrated 
under reduced pressure. Flash chromatography using ethyl acetate/petroleum ether afforded 104 mg of the title 
compound 14 (0.12 mmol, 60%) as a colorless oil. TLC: 20% EtOAc/PE. IR (neat, cm-1): 702, 979, 1041, 1095, 
1257, 1720, 2113, 2939; α-anomer: 1H NMR (600 MHz, CDCl3): 3.79 (s, 1H, H-5), 3.83 (dd, 1H, J = 12.6 Hz, J 
























(dd, 1H, J = 10.8 Hz, J = 2.4 Hz, H-3), 4.39 (d, 1H, J = 2.4 Hz, H-4), 4.60 – 4.63 (m, 2H, H-5’, H-6’), 4.67 (dd, 
1H, J = 5.4 Hz, J = 3.0 Hz, H-4’), 5.32 (d, 1H, J = 3.6 Hz, H-1), 5.42 (s, 1H, CHPh), 5.56 (s, 1H, H-1’), 5.97 – 
6.01 (m, 2H, H-2’, H-3’), 7.19 – 7.90 (m, 20H, H Arom); 13C NMR (100 MHz, CDCl3) δ = 59.2 (C-2), 62.5 (C-
5), 63.5 (C-6’), 69.1 (C-6), 70.1 (C-2’ and C-3’), 75.6 (C-4), 75.8 (C-3), 82.0, 82.3 (C-4’, C-5’), 92.4 (C-1), 
100.3 (CHPh), 107.4 (C-1’), 125.7 – 133.4 (CH Arom), 128.7 (Cq Bz), 128.8 (Cq Bz), 129.1 (Cq Bz), 129.3 (Cq 
Bz), 137.3 (Cq benzylidene), 165.6 (2xC=O, Bz), 165.7 (C=O Bz), 166.2 (C=O Bz); HRMS: [M+Na]+ calcd for 






















deoxy-α-D-galactopyranosyl)-4,6-O-[1-(R)-(methoxycarbonyl)-ethylidene]-β-D-galactopyranoside (15): One-pot 
approach: A solution of 89 mg donor 3 (0.15 mmol), 71 mg Ph2SO (0.35 mmol, 2.3 equiv.) and 74 mg TTBP 
(0.3 mmol, 2 equiv.) in 5 mL DCM was stirred over 100 mg activated MS3Å for 30min. The mixture was cooled 
to     -60°C before 30 µL triflic acid anhydride (0.18 mmol, 1.2 equiv.) was added. The mixture was allowed to 
warm to -40°C in 1h followed by addition of 44 mg acceptor 5 (0.15 mmol, 1 equiv.) in 1 mL DCM/dioxane 
(10/1). Stirring was continued and the reaction mixture was allowed to warm to room temperature over a period 
of 16h. Subsequently the reaction was cooled back to -60°C followed by the addition of 35 µL triflic acid 
anhydride (0.2 mmol, 1.3 equiv.). The mixture was allowed to warm to -40°C in 1h followed by addition of 103 
mg acceptor 6 (0.25 mmol, 1.7 equiv.) and 74 mg TTBP (0.3 mmol, 2 equiv.) in 1 mL DCM. Stirring was 
continued and the reaction mixture was allowed to warm to room temperature over a period of 16h. The reaction 
mixture was diluted with 25 mL EtOAc and washed with 15 mL water. The organic phase was dried (MgSO4), 
filtered and concentrated under reduced pressure. Flash chromatography using ethyl acetate/petroleum ether 
afforded 118 mg of the title compound 15 (0.93 mmol, 62%) as a colorless oil. NIS/TMSOTf: A solution of 51 
mg donor 1329 (0.05 mmol), 21 mg acceptor 6 (0.08 mmol, 1.5 equiv.) and 11 mg NIS (0.05 mmol, 1 equiv.) in 
0.3 mL DCM was stirred over 10 mg MS4Å for 30min. The mixture was cooled to 0ºC before 2 µL TMSOTf 
(cat.) was added. The mixture was allowed to warm to ambient temperature over 1h. The reaction was quenched 
by adding 0.1 mL NEt3, diluted with 20 mL EtOAc and washed with 5 mL 1M Na2S2O4. The organic phase was 
dried (MgSO4), filtered and concentrated under reduced pressure. Flash chromatography using ethyl 
acetate/petroleum ether afforded 41 mg of the pure trisaccharide 15 (0.032 mmol, 65%) as a colorless oil. 
Sequential approach: Trisaccharide 15 was obtained from disaccharide 14 and acceptor 6 according to the 
procedure described for the conversion of donor 3 and acceptor 5 into disaccharide 14. TLC: 20% 
EtOAc/toluene; [α]D22: +80° (c = 1, CHCl3); IR (neat, cm-1): 702, 979, 1041, 1095, 1257, 1720, 2113, 2939; 1H 
NMR (600 MHz, CDCl3) δ = 1.05 (d, 3H, J = 6.0 Hz, CH3 isoprop), 1.21 (d, 3H, CH3 isoprop), 1.67 (s, 3H, 
CH3), 3.86 (d, 1H, J = 12.0 Hz, H-6), 3.39 (s, 1H, H-5’), 3.47 (s, 1H, H-5), 3.82 (s, 3H, CH3 COOMe), 3.83 – 
3.85 (m, 2H, J = 12.0 Hz, J = 10.2 Hz, J = 3.0 Hz, H-2’, H-6), 3.92 – 3.98 (m, 2H, H-3, CH isoprop), 4.03 (d, 
1H, J = 13.8 Hz, H-6’), 4.09 (d, 1H, J = 13.8 Hz, H-6’), 4.14 (d, 1H, J = 3.6 Hz, H-4’), 4.20 (dd, 1H, J = 10.8 
Hz, J = 3.0 Hz, H-3’), 4.35 (d, 1H, J = 3.6 Hz, H-4), 4.57 – 4.62 (m, 3H, H-4’’, 2xH-6’’), 4.63 – 4.67 (m, 2H, H-
1, H-3’’), 5.18 (d, 1H, J = 3.6 Hz, H-1’), 5.29 (s, 1H, CHPh), 5.55 (t, 1H, J = 9.6 Hz, J = 8.4 Hz, H-2), 5.61 (d, 







(150 MHz, CDCl3) δ = 21.8 (CH3 isoprop), 23.2 (CH3 isoprop), 25.5 (CH3), 52.6 (CH3 COOMe), 57.8 (C-2’), 
62.8 (C-5), 63.4 (C-6’’), 65.2 (C-6’), 65.6 (C-5’), 67.6 (C-4), 68.9 (C-6), 69.9 (C-2), 72.2 (CH isoprop), 74.7 (C-
3’), 75.5 (C-4’), 75.8 (C-3), 77.2 (C-2’’), 81.8 (C-3’’), 81.9 (C-4’’), 96.6 (C-1’), 98.7 (Cq pyruvate), 99.6 (C-1), 
100.1 (CHPh), 107.5 (C-1’’), 127.9 – 133.5 (CH Arom), 128.6 (Cq Bz), 128.7 (Cq Bz), 128.8 (Cq Bz), 129.0 (Cq 
Bz), 129.1 (Cq Bz), 137.2 (Cq benzylidene), 164.8 (C=O Bz), 164.9 (C=O Bz), 165.0 (C=O Bz), 165.5 (C=O 
Bz), 165.9 (C=O Bz), 170.3 (C=O COOMe); 13C-GATED NMR (150 MHz, CDCl3) δ = 96.6 (JC1’,H1’ = 172 Hz, 
C-1’), 99.6 (JC1,H1 = 156 Hz, C-1), 107.5 (JC1’’,H1’’ = 179 Hz, C-1’’); HRMS: [M+Na]+ calcd for C67H65O22N3Na 





















(carbonyl)-ethylidene]-β-D-galactopyranoside (16): Trisaccharide 15 (40 mg, 0.032 mmol) was dissolved in 0.5 
mL of a 1M solution of Me3P in toluene (0.5 mmol, 15 equiv.) and 50 µL water. The solution was stirred for 16h 
and concentrated under reduced pressure. The residual oil was dissolved in 0.4 mL pyridine and 0.1 mL Ac2O 
and stirred for another 16h. The reaction mixture was diluted with 10 mL EtOAc and washed subsequently with 
10 mL HCl (1M) and 10 mL sat. aq. NaHCO3. The organic phase was dried (MgSO4), filtered and concentrated 
under reduced pressure. The residual oil was suspended in MeOH and treated with a catalytic amount of TsOH 
(~1mg). Stirring was allowed for 16h followed by the addition of 0.1 mL NEt3. The reaction mixture was 
concentrated under reduced pressure and filtered over a short plug of silica gel using ethyl acetate/light 
petroleum. The combinaed product-containing fractions were evaporated to dryness and dissolved in 0.2 mL 
H2O and 0.2 mL THF. This mixture was treated with 1.5 mL of a solution of 0.2M KOH in H2O until all ester 
groups were cleaved (checked by LCMS). The reaction mixture was acidified to pH = 5 using AcOH and 
concentrated under reduced pressure. Gel filtration (HW-40, 0.15M Et4NOAc in H2O) of the residual oil 
afforded the desired trisaccharide 16 (10 mg, 16 µmol, 50% over 4 steps) as a white foam. TLC: 20% 
EtOAc/toluene; 1H NMR (600 MHz, CDCl3) δ = 1.15 (d, 3H, J = 6.0 Hz, CH3 isoprop), 1.24 (d, 3H, J = 6.0 Hz, 
CH3 isoprop), 1.67 (s, 3H, CH3), 2.00 (s, 3H, CH3 NHAc), 3.51 (s, 1H, H-5), 3.58 (dd, 1H, J = 11.4 Hz, J = 4.0 
Hz, H-6’’), 3.61 – 3.65 (m, 2H, J = 4.2 Hz, J = 4.0 Hz, H-2, H-6’’), 3.68 (m, 2H, H-6’), 3.72 (dd, 1H, J = 9.6 Hz, 
J = 4.0 Hz, H-3), 3.73 – 3.76 (m, 1H, H-5’’), 3.88 (d, 1H, J = 13.2 Hz, H-6), 3.95 (d, 1H, J = 13.2 Hz, H-6), 3.96 
(s, 2H, H-3’’, H-4’’), 3.99 (s, 1H, H-2’’), 4.02 (dd, 1H, J = 10.8 Hz, J = 2.8 Hz, H-3’), 4.05 – 4.11 (m, 3H, H-4’, 
H-5’, CH isoprop), 4.35 (dd, 1H, J = 11.4 Hz, J = 2.4 Hz, H-2’), 4.38 (d, 1H, J = 3.6 Hz, H-4), 4.51 (d, 1H, J = 
7.8 Hz, H-1), 5.03 (d, 1H, J = 1.8 Hz, H-1’’), 5.23 (d, 1H, J = 3.6 Hz, H-1’); 13C NMR (150 MHz, CDCl3) δ = 
21.8 (CH3 isoprop), 23.2 (2xCH3 isoprop and NHAc), 26.0 (CH3 pyruvate), 49.1 (C-2’), 61.9 (C-6’), 63.6 (C-
6’’), 65.9 (C-6), 66.9 (C-5), 68.3 (C-4), 69.6 (C-5’), 69.8 (C-2), 71.7 (C-5’’), 71.8 (C-4’), 73.8 (CH isoprop), 
76.1 (C-3), 76.7 (C-3’), 77.9 (C-4’’), 82.4 (C-2’’), 83.7 (C-3’’), 94.9 (C-1’), 95.1 (Cq pyruvate), 101.2 (C-1), 
110.1 (C-1’’); 13C-GATED NMR (150 MHz, CDCl3) δ = 94.9 (JC1’,H1’ = 174 Hz, C-1’), 101.2 (JC1,H1 = 156 Hz, 


























α-D-galactopyranosyl)-4,6-O-[1-(R)-(methoxycarbonyl)-ethylidene]-β-D-galactopyranoside (26): Compound 15 
(100 mg, 0.08 mmol) and 68 µL Et3SiH (0.43 mmol, 5 equiv.) were dissolved in 2 mL DCM and stirred over 50 
mg activated MS3Ǻ. The mixture was cooled to -78°C and 30 µL triflic acid (0.34 mmol, 4 equiv.) was added. 
The reaction mixture was allowed to warm to -50°C until TLC indicated complete conversion (30min). The 
reaction was subsequently quenched by adding 0.4 mL MeOH and 0.3 mL NEt3 (in this order!), diluted with 15 
mL EtOAc and washed with H2O. The organic phase was dried (MgSO4), filtered and concentrated under 
reduced pressure. Flash chromatography using ethyl acetate/petroleum ether afforded 93 mg of trisaccharide 26 
(0.074 mmol, 92%) as a colorless oil. TLC: 40% EtOAc/PE; [α]D22: +44° (c = 1, CHCl3); IR (neat, cm-1): 709, 
1049, 1103, 1265, 1450, 1720, 2113, 2877; 1H NMR (600 MHz, CDCl3) δ = 1.04 (d, 1H, J = 6.6 Hz, CH3 
isoprop), 1.20 (d, 1H, J = 6.6 Hz, CH3 isoprop), 1.64 (s, 3H, CH3), 2.74 (bs, 1H, OH-4’), 3.33 (d, 1H, J = 0.6 Hz, 
H-5), 3.37 (dd, 1H, J = 10.8 Hz, J = 4.0 Hz, H-6’), 3.48 (dd, 1H, J = 10.2 Hz, J = 6.6 Hz, H-6’), 3.70 (dd, 1H, J 
= 10.2 Hz, J = 3.6 Hz, H-2’), 3.74 (bs, 1H, H-4’), 3.79 (s, 3H, CH3 COOMe), 3.82 – 3.86 (m, 1H, J = 7.2 Hz, J = 
6.0 Hz, H-5’), 3.92 – 4.00 (m, 4H, H-3, H-6, H-3’, CH isoprop), 4.12 (dd, 1H, J = 13.2 Hz, J = 1.2 Hz, H-6), 
4.36 (d, 1H, J = 4.2 Hz, H-4), 4.40 (d, 1H, J = 12.0 Hz, CHHPh), 4.45 (d, 1H, J = 12.0 Hz, CHHPh), 4.52 (d, 
1H, J = 12.0 Hz, J = 6.6 Hz, H-6’’), 4.57 (d, 1H, J = 8.4 Hz, H-1), 4.60 – 4.64 (m, 1H, J = 12.0 Hz, J = 4.2 Hz, 
H-4’’, H-6’’), 5.29 (d, 1H, J = 3.0 Hz, H-1’), 5.55 (dd, 1H, J = 12.6 Hz, J = 8.4 Hz, H-2), 5.58 (s, 1H, H-1’’), 
5.61 – 5.65 (m, 2H, H-2’’, H-3’’), 5.94 – 5.97 (m, 1H, H-5’’),7.88 – 8.06 (m, 30H, H Arom); 13C NMR (150 
MHz, CDCl3) δ = 19.4 (CH3 isoprop), 21.8 (CH3 isoprop), 23.2 (CH3), 52.6 (CH3 COOMe), 57.9 (C-2’), 62.9 
(C-6’’), 65.4 (C-6), 65.6 (C-5), 66.5 (C-4), 68.9 (C-5’), 69.5 (C-4’),69.9 (C-6’), 70.2 (C-5’’), 70.3 (C-2), 72.3 
(CH isoprop), 73.3 (CH2 Bn), 73.4 (C-3), 75.8 (C-3’), 77.2 (C-2’’ or C-3’’), 81.7 (C-3’’ or C-2’’), 82.0 (C-4’’), 
83.9 (C-1’), 98.8 (Cq pyruvate), 99.7 (C-1), 107.2 (C-1’’), 125.6 – 133.5 (CH Arom), 129.4 (Cq Bz), 129.6 (Cq 
Bz), 129.7 (Cq Bz), 129.9 (Cq Bz), 137.9 (Cq Bn), 164.8 (C=O Bz), 165.1 (C=O Bz), 165.5 (C=O Bz), 165.9 
(C=O Bz), 170.4 (C=O COOMe); 13C-GATED NMR (150 MHz, CDCl3) δ = 83.9 (JC1’,H1’ = 171 Hz, C-1’), 99.7 



























O-[1-(R)-(methoxycarbonyl)-ethylidene]-β-D-galactopyranoside (2): A solution of 21 mg donor 8 (0.055 mmol), 
28 mg Ph2SO (0.14 mmol, 2.5 equiv.) and 17 mg tri-tert-butylpyrimidine (0.07 mmol, 1.3 equiv.) in 2.5 mL 







acid anhydride (0.07 mmol, 1.3 equiv.) was added. The mixture was allowed to warm to -40°C over 1h followed 
by addition of 60 mg trisaccharide acceptor 26 (0.047 mmol, 0.85 equiv.) Stirring was continued and the reaction 
mixture was allowed to warm to 0°C. The reaction mixture was diluted with 15 mL EtOAc and washed with 
water. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. Size exclusion 
chromatography (LH20, eluent DCM/MeOH 1/1) followed by preparative HPLC (column: Gemini C18 5µm, 
21x150mm, eluent: A: 5% ACN/H2O + 0.1% TFA, B:100% ACN, 25 mL/min, gradient: 82%-92% (10min)) 
afforded 5 mg of the title compound 2 (3 µmol, 17%; 53% recovered trisaccharide 26) as a colorless oil. TLC: 
40% EtOAc/PE; IR (neat, cm-1): 702, 979, 1041, 1095, 1257, 1720, 2113, 2939; 1H NMR (600 MHz, CDCl3) δ = 
1.04 (d, 1H, J = 6.6 Hz, CH3 isoprop), 1.20 (d, 1H, J = 6.6 Hz, CH3 isoprop), 1.24 (d, 1H, J = 6.4 Hz, H-6), 1.61 
(s, 3H, CH3), 2.05 (s, 3H, CH3 Ac), 3.13 (dd, 1H, J = 10.8 Hz, J = 3.6 Hz, H-2’’), 3.32 (bs, 1H, H-5), 3.51 – 3.53 
(m, 1H, H-6’), 3.65 (dd, 1H, J = 11.4 Hz, J = 3.3 Hz, H-2’), 3.69 (dd, 1H, J = 9.0 Hz, J = 7.8 Hz, H-6’), 3.78 (s, 
3H, CH3 COOMe), 3.90 – 3.94 (m, 1H, J = 6.0 Hz, CH isoprop), 3.95 – 3.97 (m, 3H, H-6, H-4’, H-5’), 4.01 (dd, 
1H, J = 10.2 Hz, J = 3.6 Hz, H-3), 4.09 (dd, 1H, J = 10.8 Hz, J = 2.4 Hz, H-3’), 4.11 (d, 1H, J = 12.6 Hz, H-6), 
4.33 (d, 1H, J = 11.4 Hz, CHHPh), 4.35 (d, 1H, J = 4.2 Hz, H-4), 4.35 (dd, 1H, J = 11.4 Hz, J = 4.0 Hz, H-4’’), 
4.45 (d, 1H, J = 11.4 Hz, CHHPh), 4.48 (dd, 1H, J = 11.4 Hz, J = 7.6 Hz, H-6 fur.), 4.58 (d, 1H, J = 8.4 Hz, H-
1), 4.63 (q, 1H, J = 6.6 Hz, H-5’’), 4.67 (dd, 1H, J = 12.0 Hz, J = 4.6 Hz, H-6 fur.), 4.71 (m, 1H, J = 3.0 Hz, H-4 
fur.), 4.76 (d, 1H, J = 3.6 Hz, H-1’’), 5.26 (dd, 1H, J = 11.4 Hz, J = 3.9 Hz, H-3’’), 5.35 (d, 1H, J = 3.0 Hz, H-
1’), 5.54 (dd, 1H, J = 9.6 Hz, J = 8.4 Hz, H-2), 5.61 – 5.63 (m, 2H, H-2 fur. and H-3 fur.), 5.69 (bs, 1H, H-1 
fur.), 5.94 (m, 1H, J = 3.0 Hz, H-5 fur.), 6.59 (d, 1H, J = 9.2 Hz, NH-4’’), 7.17 – 8.12 (m, 30H, H Arom); 13C 
NMR (150 MHz, CDCl3) δ = 19.4 (CH3 isoprop), 21.8 (CH3 isoprop), 23.2 (CH3), 52.7 (CH3 COOMe), 53.1 (C-
4’’), 58.3 (C-2’’), 58.7 (C-2’), 63.2 (C-6’’), 64.5 (C-5’’), 65.4 (C-6), 65.6 (C-5), 66.4 (C-4), 67.5 (C-6’), 69.6 (C-
3’’), 69.7 (C-4’or C-5’), 70.5 (C-2 and C-5 fur.), 72.4 (CH isoprop), 73.2 (CH2 Bn), 73.2 (C-3), 74.5 (C-3’), 76.8 
(C-5’or C-4’), 77.5 (C-2 fur. or C-3 fur.), 80.9 (C-4 fur.), 81.0 (C-3 fur. or C-2 fur.), 92.3 (Cq CCl3), 93.4 (C-1’), 
98.2 (C-1’’), 98.9 (Cq pyruvate), 99.7 (C-1), 107.1 (C-1 fur.), 127.7 – 135.8 (CH Arom), 128.7 (Cq Bz), 128.9 
(Cq Bz), 129.0 (Cq Bz), 129.5 (Cq Bz), 129.9 (Cq Bz), 137.8 (Cq Bn), 162.5 (C=O TCA), 164.9 (C=O Bz), 165.3 
(C=O Bz), 165.6 (C=O Bz), 165.7 (C=O Bz), 166.0 (C=O Bz), 170.0 (C=O Ac or COOMe), 170.5 (C=O 
COOMe or Ac); HRMS: [M+Na]+ calcd for C77H78Cl3N7O26Na 1644.39543 found 1644.39543. 
 
X-ray crystallographic data 
 
Purified pyruvate 11 (200 mg) was suspended in 2 ml of absolute EtOH. The mixture was heated to 70°C within 
a few minutes and kept untill almost all solids had dissolved. The sealed vial then was cooled up to 15°C (speed: 
approximately 4°C per hour). After reaching 15°C, the mixture was warmed to 50°C, kept for several minutes at 
this temperature and again cooled to 15°C (4 degrees per hour). This process was repeated several times till 
crystals of suitable size were obtained. The needle like transparent crystal of approximately 0.3 x 0.15 x 0.08 
mm size was measured on the Kappa CCD using MoKα radiation. The reflections were collected up to 2θ = 25°. 
The cell was obtained and refined from 25 frames from reflection within the same angle range using Scalepack30 
software. The data was processed using Denzo package.30 The structure was solved using direct methods 
(SHELXS9-7).31 The full matrix least-squares refined was applied using SHELXL97 program.32 All of non-H 
atoms were found on Fourier difference maps and refined anisotropically while all H atoms were included from 









Table 1. Crystal data and structure refinement for pyruvate acetal 11. 
Empirical formula  C30H30O8S 
Formula weight  550.60 
Temperature  293(2) 
Wavelength  0.71073 
Crystal system  Orthorhombic 
Space group  P 212121 






Density (calculated) 1.286 
Absorption coefficient 0.162 
F(000) 1160 
Crystal size 0.3 x 0.15 x 0.06 
Theta range for data collection 2.5 → 25 
Reflections collected 7621 
Independent reflections 4549 [Rint = 0.0755] 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4549 / 0 / 363 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0706, wR2 = 0.1485 
R indices (all data) R1 = 0.1300, wR2 = 0.1780 
Absolute structure parameter -0.12(17) 
Extinction coefficient 0.011(3) 
Largest diff. peak and hole 0.258 and -0.184 e.Å-3 
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General Conclusion and Future Prospects 
 
This Thesis reports on research aimed at the assembly of acidic and zwitterionic 
polysaccharides of bacterial origin, using suitably protected 1-thioglycoside residues. 
Thioglycosides are attractive monosaccharide building blocks because of their high stability 
towards the diverse reaction conditions used in functional group manipulations. Recently, the 
use of 1-thioglycosides has been stimulated by the advent of the 1-benzenesulfinylpiperidine 
(BSP)/triflic anhydride (Tf2O) and the diphenylsulfoxide (Ph2SO)/Tf2O activator system. 
These sulfonium ion based activators proved to be efficient promoters for glycosylations in 
which inreactive (disarmed) 1-thioglycosides are employed. Furthermore, one-pot orthogonal 
and chemoselective oligosaccharide synthesis strategies that involve the use of 1-
thioglycosides in combination with the above mentioned sulfonium based activator systems 
have proven to be feasible. Chapter 1 presents an overview of the different procedures for the 







distinguished, the first one involves introduction of the carboxylic acid function at the 
monosaccharide stage and the second introduction of the carboxylate at the oligosaccharide 
stage. Both approaches require an efficient oxidation method. Reports on the oxidation at the 
oligosaccharide level exceed in number those concerning the use of suitably protected 1-
thioglycuronic acid ester donors. The latter approach is an important component of the 
research described in this thesis. In Chapter 2 an efficient strategy for the synthesis of 1-
thioglycuronides is described. Using the TEMPO/BAIB reagent combination, a series of 
functionalized 4,6-unprotected 1-thioglycosides was in a chemo- and regioselective fashion 
converted into the corresponding 1-thioglycuronides. Despite the deactivating carboxylate 
ester present on the carbohydrate core, these 1-thioglycuronides could smoothly be activated 
using the Ph2SO/Tf2O or BSP/Tf2O reagent combination, as is exemplified in the 
chemoselective synthesis of a protected form of the trisaccharide portion present on the 
capsules of the fungus Fusarium sp. M7-1. Chapter 3 discusses the synthesis and application 
of 6,3-lactone derivatives of 1-thioglycuronides. These compounds were obtained from the 
corresponding 3,6-unprotected 1-thioglycosides via a tandem oxidation/lactonization process 
using the TEMPO/BAIB system. Furthermore, the synthesis of the [β-D-Galp-(1→3)-α-D-
GalpA-(1→4)-α-D-GlcN3-OMe] trisaccharide was achieved. The used strategy required a 
minimum number of protective group manipulations at the disaccharide stage. The central 
galacturonic acid was initially used as donor building block followed by base-mediated 
hydrolysis of the lactone at the disaccharide stage. In the next stage this acceptor disaccharide 
was coupled to the non-reducing end of a galactose building block. Chapter 4 describes the 
use of 1-thio functionalized mannuronic acid esters in oligosaccharide synthesis. Other then  
the corresponding 1-thioglucuronic and galacturonic acid esters, the mannuronic acid 
derivatives showed high to exclusive β-selectivity in the Ph2SO/Tf2O-mediated coupling 
procedure. The developed strategy was used in the first synthesis of an alginate trisaccharide. 
Chapter 5 describes the glycosylation properties of deactivated 1-thiomannosazide and 1-thio 
mannosaziduronic acid esters. Installation of an acetyl protective group at positions C4 and 
C6 of the mannosazide led to reasonable β-selectivities. Acetyl protection at C3 of these 
mannosazide donors yielded, irrespective of the protective group pattern of the donor 
glycoside, α-coupled products. Chapter 6 describes a tethered nucleophilic substitution 
approach for the synthesis of 4-amino functionalized galacto- and talopyranosides. 
Regioselective installation of a trichloroacetimidate at C6 of 4,6-unprotected gluco- and 
mannopyranosides followed by conversion of C4-OH into the triflate and base treatment 
delivered the corresponding 4-amine substituted galacto- and talopyranoside, respectively.  
Chapter 7 describes a convergent route of synthesis to a protected trisaccharide 
corresponding to the repeating unit of the zwitterionic polysaccharide Sp1 isolated from the 
cell-wall of Streptococcus pneumoniae. This type of zwitterionic polysaccharides was 
recently discovered as the main pathogen in the formation of intraabdominal abscesses. 






































































particular, unmasking the N-trichloroacetyl group did not proceed uneventfully. Changing this 
protective group for an N-benzyloxycarbonyl group may circumvent these problems. Chapter 
8 describes a synthetic study towards tetrasaccharide 4 corresponding to the repeating unit of 
the zwitterionic polysaccharide PSA1 isolated from the cell-wall of Bacteriodes fragilis. The 
ABC trisaccharide part was synthesized using an iterative one-pot dehydrative synthesis 
approach using the Ph2SO/Tf2O activator system (Figure 1). Unfortunately, the final 
condensation towards tetrasaccharide 4 proceeded in low yield most probably as a result of 
the steric environment around the acceptor nucleophile. Reversing the order of glycosylation 
events, first assembling disaccharide 2, which is then employed in the one-pot dehydrative 
glycosylation approach towards tetrasaccharide 4 may prove to be a more efficient strategy. 
 
Mechanistic Aspects and Perspective 
 
The research described in this Thesis shows that 1-thioglycuronides and sulfonium triflate 
activators are a promising combination for the assembly of complex oligosaccharides. As 
with other glycosylation procedures, the outcome of these glycosylation reactions in terms of 
yield and stereoselectivity1 can not always be predicted. Figure 2 depicts the postulated   
 







































R = piperidine (BSP)








mechanism for the pre-activation of 1-thioglycoside 5 using either the BSP/Tf2O or 
Ph2SO/Tf2O reagent combination. Initial attack of the anomeric sulfur group on in situ 
generated sulfonium bistriflate results in the formation of intermediate 6, which is believed to 
be rapidly converted into an equilibrium mixture of covalently bound α-triflate 7 and contact 
ion pair 8. Studies by the Crich laboratory indicate that the stereochemical outcome of these 
sulfonium ion-mediated glycosylations is governed by the position of this equilibrium.  
 
Table 1. 










































11: R = Bn













15: R = Bn
































































Electronic destabilization of the positive charge of the contact ion pair would shift the 
equilibrium to the α-triflate 7, thereby facilitating an SN2 type reaction with the incoming 
nucleophilic acceptor leading to higher β-selectivities in product 9.2,3,4 Another decisive factor 
on the anomeric selectivity is the reactivity of the acceptor nucleophile, which was implied 
previously by Paulsen.5 In his seminal review, it was stated that primary alcohol acceptors are 
considerably more reactive than their secondary counterparts and therefore react with less 
anomeric selectivity. 
Chapter 3 describes, amongst others, the Ph2SO/Tf2O-mediated glycosylation of phenyl 1-
thio-β-D-galacturonic acid lactones with a variety of acceptor molecules. Compared to the 
phenyl 1-thio-β-D-galacturonic acid esters described in Chapter 2, increased α-selectivities 
were observed (Table 1). Coupling methyl uronate donor 10 with acceptor 11 yielded an 
anomeric mixture of α/β = 1/2, whereas coupling of lactone donor 13 with the same acceptor 
proceeded with complete α-selectivity (entries 1 and 2). The altered steric and electronic 
environment has a beneficial effect on the α-selectivity. In a further experiment, it was 
revealed that the orientation of the thiophenyl functionality in lactone donor 17 does not 
influence the anomeric product ratio (entry 3). In order to identify the exact reactive 
intermediate in these galactosylations, pre-activation of the anomerically mixed donor 17 was 
monitored using low temperature NMR spectroscopy (Figure 3). Figure 3A depicts a detailed 
part of the spectrum of a mixture of donor 17 and Ph2SO at -55°C in CD2Cl2. Addition of 
Tf2O to the cooled NMR tube then showed conversion of the anomeric donor mixture into a 
single species (Figure 3B). Based on the altered value of the chemical shift of the anomeric 
signal (δ = 6.01 ppm) and the peak splitting pattern, β-triflate 23 is postulated as the actual 
glycosylating species. Upon addition of an acceptor nucleophile, β-triflate 23 is selectively 
displaced in an SN2-type manner leading to a α-coupled disaccharide. The predominant  
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presence of β-triflate 23 at the expense of the contact ion pair intermediate is most probably 
the result of the anomeric effect and of torsional strain preventing hybridization changes 
(favored sp3 → unfavored sp2) necessary for oxocarbenium ion formation.6 Formation of the 
α-triflate intermediate is unlikely due to the destabilizing Δ2-effect.7,8 
Despite the presented high α-selectivities, the difference in the anomeric selectivity for the 
Ph2SO/Tf2O-mediated glycosylation of donor lactone 13 with galacturonic acceptor 19 (Table 
1, entry 4) and the corresponding α-selective glucuronic acid acceptor 21 (entry 5) is still 
difficult to rationalize. It could well be that double stereodifferentation, first described by 
Spijker and Van Boeckel in the field of carbohydrate chemistry,9 is at the basis of the 
moderate anomeric selectivity obtained for galacturonic acceptor 19. Using L-galacturonic 
acid ester 24 having exactly the same 
electronic effects but different 
stereochemical preferences, when 
compared to 19, may support this theory 
(Figure 4). An alternative option may be D-

















In Chapters 4 and 5 the high β-selectivity of deactivated 1-thiomannuronic acid esters, 1-
thiomannosazides and 1-thiomannosaziduronic acid ester donors is described. It was reasoned 
that the strongly electron withdrawing carboxylate function dictates the equilibrium between 
the α-triflate and the contact ion pair to be completely shifted towards the α-triflate, favoring 
β-side attack. To investigate this, 1-thiomannuronic acid ester 26 was chosen as a model 
compound for variable temperature NMR experiments (Figure 5). Recording the 1H NMR 
spectra at +25°C and -50°C revealed the existence of a conformational mixture. On the basis  
 












26a (4C1) 26b (
1C4)
33% 67%
+25°C in CD2Cl2 














3.2 ppm3.4 3.63.84.04.24.44.64.85.0 5.2 5.4 5.6 5.8 6.0 














of the observed peak splitting patterns it was concluded that donor 26 predominantly exists in 
the uncommon 1C4 conformer 26b (67%) along with 33% of the regular 4C1 conformation 26a 
(Figure 5B).10,11 During warming of the NMR probe to +25°C the peaks of both conformers 
coalesce resulting in the average spectrum displayed in Figure 5A. In the 1C4 conformer 26b, 
the electron withdrawing C5 carboxylate and the ring O-atom benefit from their opposite 
dipole moments (Figure 6). The 4C1 conformation 26a lacks this stabilizing effect. 
Furthermore, due to the low electronegativity of the sulfur atom (2.44) compared to that of 
oxygen (3.50), the anomeric effect is less pronounced thereby allowing the C1 thiophenyl 
































This conformational equilibrium was also determined in disaccharides having a α-oriented 
thiophenyl function at their reducing end (Figure 7). An example is disaccharide 32, which 
was obtained from reaction between hemiacetal donor 30 and acceptor 31.12 Donor 30 was 
prepared from known 1-thio mannuronic acid ester 2913 via NIS/TFA-mediated hydrolysis.14 
After separation of the anomers, which was only possible by reverse-phase high performance 
liquid chromatography,15 room temperature NMR-analysis of the individual α- and the β-
anomers of disaccharide 32 revealed that the reducing end thiophenyl uronic acid residue 
exists as a stable mixture of two conformers. The exact nature of these conformers is not 
established. Furthermore, the conformational ratio present in the α-disaccharide 32α is 
different from the ratio found in the β-disaccharide 32β. Exchange of the α-thiophenyl group 
for an α-glycoside moiety shifts the conformational equilibrium completely towards the 4C1 
conformer (cf Chapter 4, compounds 14, 21, and 23). Inspection of the 1H NMR spectra of 
revealed a small coupling constant between H1 and H2 usually observed in mannopyranoside 





























32 (α/β = 13/87)31
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29 : R = α-SPh










Having established that donor 26 predominantly exists in the unexpected 1C4 conformer, 
attention was focused on the exact nature of the reactive intermediate formed after its 
activation with the Ph2SO/Tf2O reagent combination. In Figure 8 three possible reaction 
intermediates 33a, 33b and 34 are depicted. Formation of α-triflate intermediate 33b (1C4 
conformer) can, a priori, be ruled out due to the unfavorable equatorial positioning of the 
triflate substituent. Activation of donor 26b (1C4 conformer) would result in initial formation 
of phenyl sulfonium salt 34. This reactive intermediate 34 is stabilized by the reverse 
anomeric effect, first described by Lemieux and coworkers.16 In the next step, this phenyl 
sulfonium substituted intermediate 34 collapses towards the α-triflate 33a. Preliminary low 
temperature NMR experiments with donor 26 showed, amongst others, formation of two new 
carbohydrate compounds upon addition of Ph2SO and Tf2O (Figure 9). On the basis of the 
coupling constants it was concluded that one compound has the 1C4 conformation and the 
other adopts the 4C1 conformation. The anomeric signal of the 1C4 conformer resonates at δ =  
6.51 ppm with a three-bond coupling (3J1,2) of 10.0 Hz (Figure 9A). On the basis of this 
result, sulfonium species 34 is postulated to be one of the key reaction intermediates (Figure 
8). It is assumed that this intermediate 33a is displaced by the acceptor nucleophile in an SN2-
type fashion resulting in the high to exclusive β-selectivities observed. The other major new 
reactive intermediate (assigned as 1’, 2’, etc in Figure 9A and B) formed has an anomeric 
signal appearing as singlet and resonating at δ = 4.34 ppm. After addition of CD3OD to the 
reaction mixture nothing changed and it was concluded that this compound was the major 
decomposition product from reaction of donor 26 with Ph2SO and Tf2O. After purification, 
bicyclic product 36 could be assigned based on NMR- and MS-spectroscopic analysis (Figure 
9B).17 This electrophilic aromatic substitution has also been found by Crich and coworkers 
during activation of 3,4-locked mannopyranosides.18 Apparently, no evidence for triflate 
formation was found on the basis of these NMR measurements.6b,19 More insight into the 
glycosylation properties of these deactivated mannuronic acid ester donors can be obtained by 
using β-thiophenyl derivative 27 (Figure 6).20 The different orientation of the anomeric 








































Another point which still has to be addressed is the high α-selectivity in the 3-O-acetyl 







intermediate leading to full α-selectivity in the coupled disaccharides (Figure 8). Conclusive 
evidence for the 3-O-acetyl participation model could be gained by application of 3-O-
trichloroacetyl protected compound 28 (Figure 6).21 Due to the non-participating character of 
this group, complete β-selectivity is expected using this donor 28. 
 
 Figure 9. 1H NMR spectrum of activated donor 26 at -30°C (A) and -10°C (B). 
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Polysacchariden behoren tot de meest complexe klasse van biopolymeren. Dit complexe 
karakter is er mede debet aan dat de rol die polysacchariden spelen in biologische systemen 
niet goed bekend is. Studies naar structuur-activiteits relaties worden sterk gehinderd door een 
tekort aan zuivere en goed gedefinieerde verbindingen. Een oplossing voor dit probleem is het 
ontwikkelen van methodieken om fragmenten van  polysacchariden (zg. oligosacchariden) te 
synthetiseren.  
Het onderzoek dat in dit proefschrift wordt beschreven is gericht op het ontwikkelen en 
toepassen van (nieuwe) synthese methodieken ter verkrijging van zwitterionische of negatief 
geladen oligosacchariden. Een gemeenschappelijk kenmerk van deze moleculen is dat ze 
zogenaamde uronzuren bevatten. Dit zijn suikermoleculen waarvan de C5 hydroxymethyl 
groep is geoxideerd tot een carbonzuur functie. In Hoofdstuk 1 wordt een (historisch) 
overzicht gegeven van de verschillende manieren om negatief en zwitterionisch geladen 
oligosacchariden te bereiden. Er zijn twee benaderingswijzen gangbaar, namelijk 1) het 
koppelen van alle monosacchariden gevolgd door oxidatie in het stadium van oligosaccharide, 
of 2) oxidatie van de monosacchariden gevolgd door het koppelen van de uronzuren tot 
oligosacchariden. De laatste variant vereist zowel een efficiënt oxidatie reagens als een 
krachtig activator systeem voor het condenseren van de uronzuren. Hoofdstuk 2 beschrijft het 
gebruik van TEMPO als efficiënt reagens voor de chemo- en regioselectieve oxidatie van 4,6-
onbeschermde 1-thioglycosiden. Verder wordt aangetoond dat de aldus verkregen inreactive 
1-thio uronzuren gebruikt kunnen worden als bouwstenen voor de synthese van een negatief 
geladen trisaccharide. Recent ontwikkelde sulfonium activator systemen bleken krachtig 
genoeg te zijn om koppeling van deze inreactieve uronzuren te bewerkstelligen. In Hoofdstuk 
3 wordt het gebruik van 3,6-onbeschermde 1-thioglycosiden beschreven. Behandeling van 
deze verbindingen met het TEMPO reagens gaf de overeenkomstige 6,3-lactonen. Het 
koppelen van deze tricyclische donor bouwstenen verloopt in het algemeen stereospecifieker 
dan met de overeenkomstige 1-thio uronzuren beschreven in Hoofdstuk 2. De toename van 






dat de lactonen efficiënt gebruikt kunnen worden in oligosaccharide synthese. De lacton 
functie zorgt ervoor dat het aantal beschermende groep manipulaties in het disaccharide 
stadium tot een minimum beperkt kon worden. Hoofdstuk 4 behandelt de glycosylerende 
eigenschappen van 1-thiomannuronzuren. De combinatie van het grote anomere effect en de 
aanwezigheid van een C6 carboxylaat groep maakt dat de koppelingen exclusief β-selectief 
verlopen. Deze vondst maakt de eerste chemische synthese van een alginaat trisaccharide 
mogelijk. Tevens werd de invloed van andere elektronenzuigende groepen op de 
glycosylerende eigenschappen van mannose derivaten onderzocht. Hiertoe werd 1-
thiomannosazide gefunctionaliseert met verschillende deactiverende groepen. In Hoofdstuk 5 
wordt beschreven dat zelfs door de aanwezigheid van 4,6-di-acetyl bescherming al redelijke 
β-selectiviteit behaald wordt. Toepassing van 3-O-acetyl bescherming resulteerde daarentegen 
altijd in α-selectiviteit. Hoofdstuk 6 beschrijft een nieuwe synthesemethode voor het 
verkrijgen van axiaal georiënteerde C4 amino glycosiden. Met behulp van deze een-pots 
reactie werden vanuit 4,6-onbeschermd gluco- en mannopyranoside op een makkelijke manier 
4-amino gesubstitueerde galacto- en talopyranosiden gesynthetiseerd. De laatste twee 
synthese-hoofdstukken van dit proefschrift beschrijven toepassingen van de ontwikkelde 
synthesemethodieken. In Hoofdstuk 7 wordt de synthese behandeld van een beschermd 
trisaccharide dat correspondeert met de repeterende eenheid van het Sp1 zwitterionisch 
polysaccharide. Verder wordt een nieuwe syntheseroute naar een orthogonaal 
gefunctionaliseerde 2,4-diamino fucose bouwsteen beschreven. In Hoofdstuk 8 wordt de 
synthese van een beschermd tetrasaccharide beschreven. Dit is de repeterende eenheid van het 
zwitterionische polysaccharide PSA1 dat geïsoleerd is uit de celwand van een anaerobe 
bacterie. Een deel van dit tetrasaccharide werd gesynthetiseerd met behulp van een een-pots 
dehydratieve condensatiereactie. Het gebruik van deze krachtige synthesetechniek verkleinde 
het aantal reactiestappen en daarmee het verlies van waardevolle bouwstenen aanmerkelijk. 
Het bleek echter dat de laatste koppeling niet efficiënt verliep waarschijnlijk vanwege teveel 
sterische hindering in het acceptor molecuul. Het uitleidende Hoofdstuk 9 geeft naast een 
korte samenvatting een uitgebreide mechanistische beschrijving van de reactieve 
intermediairen die gevormd kunnen worden tijdens een koppelingsreactie. De beschreven 


















































































































aanvang  gemaakt  met  de  studie  Organische  Chemie  aan  de  Hogeschool  Rotterdam  en 
Omstreken  te Delft. In het kader van het afstudeeronderzoek werd van september 1999  tot 
juni  2000  onderzoek  verricht  bij  Byk Gulden  (het  latere Altana  Pharma AG)  te Konstanz 
(Dld).  Dit  onderzoek  behelsde  de  synthese  van  heterocyclische  aromaten  als  mogelijke 
tryptase  inhibitoren  die  van  belang  kunnen  zijn  voor  de  behandeling  van  astma.  De 
opleiding werd  in 2000 met goed gevolg afgerond en  in  september van dat  jaar werd  een 
aanvang gemaakt met de studie Scheikunde aan de Universiteit Leiden.  In de periode van 
september 2001 tot en met mei 2002 werd de hoofdvakstage uitgevoerd bij de vakgroep Bio‐
organische  Synthese onder  leiding van prof. dr.  J.H. van Boom  en prof. dr. G.A. van der 
Marel. De  stage was gericht op de  synthese van het α‐Gal  trisaccharide voorzien van  een 
vetstaart; dit als onderdeel van een  immunologische studie naar een mogelijk vaccin  tegen 
kanker. Het doctoraal examen werd in 2002 behaald. 
Van  september  2002  tot  september  2006  werd  als  assistent‐in‐opleiding  het  in  dit 




presentatie),  het  22nd  International  Carbohydrate  Symposium  te Glasgow,  Schotland  (Juli 
2004, poster presentatie), het CEDNETS Symposium te Krakau, Polen (Juni 2005, mondelinge 
presentatie)  en  het  23rd  International Carbohydrate  Symposium  te Whistler  (BC), Canada 
(Juli 2006, poster presentatie). 
Sinds  november  2006  wordt  in  samenwerking  met  het  biotechnologiebedrijf  Crucell 














































vele  personen  die  op  enigerlei wijze  betrokken  zijn  geweest  bij mijn  studie  en  promotie. 
Hierbij wil ik beginnen met mijn ouders die mij altijd gestimuleerd hebben om door te leren 
(“je moet  het  nu  doen;  als  je  ouder  wordt  gaat  het  niet meer”).  Verder  natuurlijk mijn 
schoonmoeder, (schoon)broers en (schoon)zussen voor het plezier en de steun die  jullie mij 
gegeven hebben toen ik studeerde en mijn promotieonderzoek uitvoerde.  








erg  prettig  met  jullie  samengewerkt  en  vele  mooie  ideeën  (al  dan  niet  succesvol) 
uitgeprobeerd. Ook Richard en Martijn de K. wil ik graag bedanken voor de gezelligheid en 
wetenschappelijke  deliberaties.  Evenals  Erwin  waar  ik  al  10  jaar  dezelfde  chemische 
interesses mee deel. Verder heb ik de contacten met Bas, Steven, Paul van S., Micha, Michiel, 
Tom,  Jimmy,  Jasper,  Gijsbert,  Mattie,  Kimberly,  Farid,  Karen,  Martijn  V.,  Peter,  Carlo, 
Henrik, Ali, Vicky, Paul G., Varsha, Martijn R., Matthijs, Rian, Martin, Christoph  en Ulrik 




Lies,  ontzettend  bedankt  voor  je  liefde  en  steun  de  afgelopen  jaren.  Je  bent  met  me 
meegegaan uit dat mooie Zeeland naar Moordrecht. Ik hoop op nog vele jaren samen met jou 
en de kindjes. 
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